[
  {
    "id": "covid_fact-000001",
    "statement": "Measuring sars-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes the use of pseudotyped SARS-CoV-2 viruses (HIV-1 and VSV) and a VSV/SARS-CoV-2 chimeric virus to measure neutralizing antibody activity. This directly supports the claim of measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.17620477080345154,
    "x2e_entail_prob": 0.0020861499942839146
  },
  {
    "id": "covid_fact-000002",
    "statement": "Measuring chs-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides details on methods to measure SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses, specifically mentioning the use of SARS-CoV-2 spike-pseudotyped HIV-1 and VSV, as well as a VSV/SARS-CoV-2 chimeric virus. This aligns with the claim and thus supports it.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.07387950271368027,
    "x2e_entail_prob": 0.0016850187676027417
  },
  {
    "id": "covid_fact-000003",
    "statement": "Measuring aces-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim refers to measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. The evidence describes approaches using SARS-CoV-2 spike-pseudotyped viruses and a VSV/SARS-CoV-2 chimeric virus for neutralization assays, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7317613959312439,
    "x2e_entail_prob": 0.0015552547993138433
  },
  {
    "id": "covid_fact-000004",
    "statement": "Measuring gps-cov-2 neutralizing antibody activity using pseudotyped and chimeric viruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay.",
      "Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS- CoV-2 chimeric virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim involves measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. The evidence supports this by describing the use of SARS-CoV-2 spike-pseudotyped and chimeric viruses in neutralizing assays, confirming that these methods are used for this purpose. Additionally, it mentions replication-defective HIV-1 and VSV in these assays, consistent with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.48371315002441406,
    "x2e_entail_prob": 0.010273030959069729
  },
  {
    "id": "covid_fact-000005",
    "statement": "Long-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that IgG antibodies in SARS-CoV-infected healthcare workers remained at a high level until 2015, which supports the claim of long-term persistence of these antibodies. The conclusion in the evidence directly states that IgG antibodies can persist for at least 12 years, confirming the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.95470130443573,
    "x2e_entail_prob": 0.007075932342559099
  },
  {
    "id": "covid_fact-000006",
    "statement": "short-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests short-term persistence of IgG antibodies, implying a limited duration of persistence. However, the evidence indicates that IgG antibodies can persist for a long duration, at least 12 years, which contradicts the implication of short-term persistence in the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9082390666007996,
    "x2e_entail_prob": 0.0008490500040352345
  },
  {
    "id": "covid_fact-000007",
    "statement": "Low-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim concerns the long-term persistence of IgG antibodies in healthcare workers infected with SARS-CoV. The evidence states that IgG titers remained at a significantly high level until 2015 and concludes that IgG antibodies can persist for at least 12 years. This aligns with the claim of low-term persistence, given the 12-year duration mentioned.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.910658597946167,
    "x2e_entail_prob": 0.022371238097548485
  },
  {
    "id": "covid_fact-000008",
    "statement": "Pre-term persistence of igg antibodies in sars-cov infected healthcare workers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015.",
      "All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS- CoV, as a diagnostic antigen.",
      "CONCLUSIONS IgG antibodies against SARS-CoV can persist for at least 12 years."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that IgG antibodies remain at a significantly high level for an extended period (up to 2015) in SARS-CoV-infected healthcare workers, confirming long-term persistence. The claim of pre-term persistence is supported by the evidence showing persistence for at least 12 years.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9342105388641357,
    "x2e_entail_prob": 0.012115562334656715
  },
  {
    "id": "covid_fact-000009",
    "statement": "Coronavirus dons a new crown",
    "label": "SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim 'Coronavirus dons a new crown' is metaphorical and not directly supported by the evidence provided. The evidence mentions crown-like structures related to protein complexes in coronaviruses, but this is a biological description related to protein function and not a literal 'new crown' that the virus has acquired. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7970185875892639,
    "x2e_entail_prob": 0.005289400462061167
  },
  {
    "id": "covid_fact-000010",
    "statement": "Coronavirus dons a new question",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim 'Coronavirus dons a new question' is vague and does not provide sufficient context to evaluate any factual assertion. The evidence provided is highly technical and does not address whether coronavirus has raised a new question. It discusses crown-forming proteins and viral activities, which are scientific aspects unrelated to the claim's statement.",
    "confidence": 0.2,
    "e2x_entail_prob": 0.22378216683864594,
    "x2e_entail_prob": 0.007287017069756985
  },
  {
    "id": "covid_fact-000011",
    "statement": "Coronavirus dons a new term",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Crown- forming protein A contains all viral activities for RNA synthesis and shares distant sequence similarities to alphavirus RNA replication proteins ( 11 13).",
      "A crown-like pore complex on coronavirus RCs ( 5) parallels a similar crown of viral proteins on nodavirus RCs ( 12), providing a channel to release RNA progeny to the cytoplasm."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses coronavirus-related protein activities and structural formations related to RNA synthesis, referring to 'crown' features in a biological context. However, it does not provide information or context for the claim 'Coronavirus dons a new term,' specifically regarding what 'new term' might mean in this context. The language in the evidence does not indicate a new terminology being assigned to coronavirus.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.8036455512046814,
    "x2e_entail_prob": 0.014943858608603477
  },
  {
    "id": "covid_fact-000012",
    "statement": "Immune memory in mild covid-19 patients and unexposed donors from india reveals persistent t cell responses after sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Moreover, we found detectable immune reactivity up to 5 months in mild COVID-19 recovered patients in the two major arms of protective adaptive immunity; CD4+ T cells and B cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that detectable immune reactivity, specifically in T cells, is observed up to 5 months in mild COVID-19 recovered patients, which supports the claim of persistent T cell responses after SARS-CoV-2 infection.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.00484482804313302,
    "x2e_entail_prob": 0.0014918313827365637
  },
  {
    "id": "covid_fact-000013",
    "statement": "Immune memory in mild covid-19 patients and unexposed donors from india reveals persistent t cell depletion after sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Moreover, we found detectable immune reactivity up to 5 months in mild COVID-19 recovered patients in the two major arms of protective adaptive immunity; CD4+ T cells and B cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions detectable immune reactivity in mild COVID-19 recovered patients in both CD4+ T cells and B cells up to 5 months, which indicates active immune memory. However, it does not support the specific claim of persistent T cell depletion after SARS-CoV-2 infection, as it references detectable immune reactivity instead.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.008028510957956314,
    "x2e_entail_prob": 0.9250210523605347
  },
  {
    "id": "covid_fact-000014",
    "statement": "Simple probiotics might help inhibit covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Other research suggests that probiotic supplementation may promote antiviral activity in general to improve immune, pulmonary, and anti-inflammatory response that might help clear the SARS-CoV-2 infection (70, 71)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that probiotics may generally promote antiviral activity and potentially support immune responses, but it does not specifically support the claim that probiotics can inhibit COVID-19 infection. The evidence only presents a hypothetical scenario where probiotics might help in immune responses, lacking direct evidence correlating probiotics with inhibition of COVID-19 specifically.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.08274713903665543,
    "x2e_entail_prob": 0.0016447188099846244
  },
  {
    "id": "covid_fact-000015",
    "statement": "Simple probiotics might help cause covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Other research suggests that probiotic supplementation may promote antiviral activity in general to improve immune, pulmonary, and anti-inflammatory response that might help clear the SARS-CoV-2 infection (70, 71)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that probiotics may promote antiviral activity generally, which could potentially help in clearing SARS-CoV-2, but does not specifically support the claim that simple probiotics might help cause COVID-19 infection. The evidence points to potential benefits rather than causation of infection.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.006757844239473343,
    "x2e_entail_prob": 0.001567772589623928
  },
  {
    "id": "covid_fact-000016",
    "statement": "Uk bans parallel export and hoarding of lopinavir+ritonavir , chloroquine and hydroxychloroquine",
    "label": "SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that restrictions are in place for the parallel export of the combination drug lopinavir and ritonavir (known as Kaletra/Aluvia), as well as for the generic drugs chloroquine phosphate and hydroxychloroquine in the UK. These restrictions aim to ensure these medications are available to meet the needs of UK patients. While not explicitly stated as a 'ban,' the restriction implies similar control measures. Thus, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.18689121305942535,
    "x2e_entail_prob": 0.04633224382996559
  },
  {
    "id": "covid_fact-000017",
    "statement": "Uk bans parallel training and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the UK has restricted the export of the combination drug lopinavir and ritonavir, chloroquine phosphate, and hydroxychloroquine to meet the needs of UK patients. This aligns with the claim that the UK bans parallel trading (a form of exporting goods meant for one market to another) of these medications.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.020796488970518112,
    "x2e_entail_prob": 0.016799340024590492
  },
  {
    "id": "covid_fact-000018",
    "statement": "Ukakes parallel export and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the export of the combination drug lopinavir+ritonavir (known as Kaletra/Aluvia), as well as the generic drugs chloroquine phosphate and hydroxychloroquine, is restricted by the UK government to meet domestic needs. This supports the claim of restricting parallel exports. However, the claim also mentions 'hoarding,' which is not addressed directly in the evidence, leading to a slightly lower confidence level.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.038275737315416336,
    "x2e_entail_prob": 0.00992601178586483
  },
  {
    "id": "covid_fact-000019",
    "statement": "Ukolls parallel export and hoarding of lopinavir+ritonavir, chloroquine and hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "31 March 2020 52 medicines have been added to the list of medicines that cannot be parallel exported from the UK, these are: Cefalexin, Codeine, Co-trimoxazole, Diamorphine, Doxycycline, Ipratropium, Salbutamol, Prochlorperazine,Salbutamol + Beclometasone, Salbutamol + Ipratropium Terbutaline, Beclometasone, Beclometasone + Formoterol, Beclometasone + Formoterol + Glycopyrronium bromide, Budesonide, Budesonide + Formoterol, Fluticasone, Fluticasone + Formoterol, Fluticasone + Salmeterol, Fluticasone + Umeclidinium bromide + Vilanterol, Fluticasone + Vilanterol, Ciclesonide, Mometasone, Salmeterol, Formoterol, Sodium cromoglicate, Sodium cromoglicate + Salbutamol, Nedocromil, Edoxaban, Midazolam, Buprenorphine, Levomepromazine, Mesalazine, Colecalciferol + Calcium carbonate, Insulin aspart, Insulin aspart biphasic, Insulin degludec, Insulin degludec + Liraglutide, Insulin detemir, Insulin glargine, Insulin glargine + Lixisenatide, Insulin glulisine, Insulin human, Insulin isophane biphasic human, Insulin isophane biphasic porcine, Insulin isophane bovine, Insulin isophane human, Insulin isophane porcine, Insulin lispro, Insulin lispro biphasic, Insulin mixed bovine, Insulin protamine zinc bovine, Insulin soluble bovine, Insulin soluble human, Insulin soluble porcine, Insulin zinc crystalline human, Insulin zinc mixed human.",
      "The export of the US-based AbbVies Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Evidence confirms that the export of the combination drug lopinavir+ritonavir (marketed as Kaletra/Aluvia), chloroquine phosphate, and hydroxychloroquine is being restricted by the UK government to meet the needs of UK patients. This aligns with the claim of parallel export restrictions on these medications.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.1250564008951187,
    "x2e_entail_prob": 0.03681477531790733
  },
  {
    "id": "covid_fact-000020",
    "statement": "Air quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that air quality, particularly the presence of fine particles, can influence the severity and progression of pandemics, such as COVID-19. While the pandemic is multifactorial and influenced by various factors, the studied correlation between air pollution and virus virulence supports the claim. Therefore, the claim that air quality influences the pandemic is supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9381026029586792,
    "x2e_entail_prob": 0.0013979104114696383
  },
  {
    "id": "covid_fact-000021",
    "statement": "Virus quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that virus quality influences the pandemic. However, the evidence provided indicates that factors like air pollution can influence virus virulence and disease severity, but it also highlights the importance of other factors such as physiological, social, or economic conditions. The evidence does not directly support the notion of 'virus quality' influencing the pandemic, thereby rendering the claim not fully supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8850052356719971,
    "x2e_entail_prob": 0.0028934257570654154
  },
  {
    "id": "covid_fact-000022",
    "statement": "Health quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that air quality, indicated by levels of fine particles, can influence the severity of infectious disease outcomes, such as those in pandemics. While the claim 'health quality influences the pandemic' is broad, the connection between air quality and disease severity supports the idea that environmental health factors, a component of overall health quality, have an impact. Research emphasizes that both pollution and other factors (physiological, social, economic) influence pandemic progression, supporting the claim that health quality plays a role.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.9739463925361633,
    "x2e_entail_prob": 0.010642331093549728
  },
  {
    "id": "covid_fact-000023",
    "statement": "Global quality influences the pandemic - communiqu\u00e9s de presse",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study provides preventive measures related to air pollution to limit future outbreaks of morbidity and mortality due to the coronavirus.",
      "Epidemiologists widely agree that there is a correlation between acute and locally elevated concentrations of fine particles and the severity of influenza waves.",
      "The increase in fine particles is generally favored by air temperature inversions, characterized by fog situations, or by Saharan dust intrusions.",
      "A multifactorial pandemic Nonetheless, the researchers also emphasize that, although particulate matter pollution can influence the virulence of the virus and possible severe disease progression, physiological, social or economic factors will clearly also influence the further course of the pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about 'global quality' influencing the pandemic. The provided evidence discusses how air pollution, specifically fine particle concentration, can influence the severity of disease outbreaks, including viruses like the coronavirus. Although the influence of 'global quality' in terms of broad factors like air pollution is acknowledged, various factors including physiological, social, and economic also play a role, which the claim seems to encapsulate. While the term 'global quality' is somewhat vague, the evidence supports the idea that environmental quality affects the pandemic's severity.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7219781279563904,
    "x2e_entail_prob": 0.03184554725885391
  },
  {
    "id": "covid_fact-000024",
    "statement": "Single-cell omics reveals dyssynchrony of the innate and adaptive immune system in progressive covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we utilize multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, and assess the effects of tocilizumab, an anti-IL-6 receptor monoclonal antibody."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the use of multiomics single-cell analysis to study immune responses in COVID-19 patients, but it does not specifically confirm the claim about revealing dyssynchrony of the innate and adaptive immune system in progressive COVID-19. More specific details or results supporting the claim are needed.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.013719570823013783,
    "x2e_entail_prob": 0.012210418470203876
  },
  {
    "id": "covid_fact-000025",
    "statement": "Single-brain omics reveals dyssynchrony of the innate and adaptive immune system in progressive covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we utilize multiomics single-cell analysis to probe dynamic immune responses in patients with stable or progressive manifestations of COVID-19, and assess the effects of tocilizumab, an anti-IL-6 receptor monoclonal antibody."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence references a multiomics single-cell analysis conducted on COVID-19 patients, but does not explicitly mention 'single-brain omics' or the specific finding of 'dyssynchrony of the innate and adaptive immune system in progressive COVID-19.' Therefore, the claim is not directly supported by the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.006793493404984474,
    "x2e_entail_prob": 0.041072141379117966
  },
  {
    "id": "covid_fact-000026",
    "statement": "Fenofibrate increases the amount of sulfatide which seems beneficial against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly mentions that fenofibrate is an agent that increases sulfatide levels and suggests it should be investigated for its beneficial effect against coronavirus infection, which aligns with the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.513148307800293,
    "x2e_entail_prob": 0.030743705108761787
  },
  {
    "id": "covid_fact-000027",
    "statement": "Fenofibrate reduces the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that fenofibrate may increase sulfatide levels, which contradicts the claim that it reduces them. Thus, the claim is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.11811982840299606,
    "x2e_entail_prob": 0.0011833561584353447
  },
  {
    "id": "covid_fact-000028",
    "statement": "Fenofibrate reduced the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests investigating fenofibrate for potentially beneficial effects against COVID-19 by increasing sulfatide levels. This contradicts the claim that fenofibrate reduces sulfatide levels. Thus, the evidence does not support the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.241437166929245,
    "x2e_entail_prob": 0.021965069696307182
  },
  {
    "id": "covid_fact-000029",
    "statement": "Fenofibrate decreased the amount of sulfatide which seems beneficial against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Also in a population, treatment with agents that increase sulfatide levels such as fenofibrate or serine [7], [8] should be investigated for a beneficial effect against coronavirus infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that fenofibrate should be investigated for increasing sulfatide levels, which contradicts the claim that fenofibrate decreases sulfatide. There is no mention of a decrease in sulfatide levels leading to beneficial effects against COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.06222982704639435,
    "x2e_entail_prob": 0.007760864682495594
  },
  {
    "id": "covid_fact-000030",
    "statement": "Gns561 exhibits potent in vitro antiviral activity against sars-cov-2 through autophagy inhibition",
    "label": "SUPPORTED",
    "evidences": [
      "Overall, our study highlights GNS561 as a powerful drug in SARS- CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.",
      "Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir.",
      "Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2.",
      "Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that GNS561 exhibits potent antiviral activity against SARS-CoV-2 and acts through autophagy inhibition. The study specifically highlights GNS561's effectiveness compared to other drugs, and mentions its role as an autophagy inhibitor in this context. Therefore, the claim is well-supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8420827984809875,
    "x2e_entail_prob": 0.618436872959137
  },
  {
    "id": "covid_fact-000031",
    "statement": "Gns561 exhibits no in vitro antiviral activity against sars-cov-2 through autophagy inhibition",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall, our study highlights GNS561 as a powerful drug in SARS- CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.",
      "Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir.",
      "Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2.",
      "Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented indicates that GNS561 shows antiviral activity against SARS-CoV-2 and operates as an autophagy inhibitor. It was shown to have a high antiviral effect and a strong synergistic effect when combined with remdesivir, suggesting that it does have antiviral activity through autophagy inhibition, contrary to the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.36669862270355225,
    "x2e_entail_prob": 0.6899126768112183
  },
  {
    "id": "covid_fact-000032",
    "statement": "Suspicions grow that nanoparticles in pfizer 's covid-19 vaccine trigger rare allergic reactions.",
    "label": "SUPPORTED",
    "evidences": [
      "Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient, scientists say.",
      "Patients with severe allergies in the US are getting nervous about the possibility that they may not be able to get vaccinated, at least with those two vaccines, Togias wrote in an invitation to meeting participants.",
      "Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
      "NIAID is also setting up a study in collaboration with FDA to analyze the response to the vaccine in people who have high levels of anti-PEG antibodies or have experienced severe allergic responses to drugs or vaccines before."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that there are suspicions about nanoparticles in Pfizer's COVID-19 vaccine triggering rare allergic reactions. Scientists propose that a compound in the packaging of the mRNA, potentially polyethylene glycol (PEG), could cause severe allergic reactions in some individuals. The evidence includes reported reactions and ongoing studies to investigate this issue, aligning with the claim's assertion of growing suspicions.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.527855634689331,
    "x2e_entail_prob": 0.003476069774478674
  },
  {
    "id": "covid_fact-000033",
    "statement": "Suspicions grow that nanoparticles in pfizer's covid-19 vaccine trigger systemic allergic reactions.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccines main ingredient, scientists say.",
      "Patients with severe allergies in the US are getting nervous about the possibility that they may not be able to get vaccinated, at least with those two vaccines, Togias wrote in an invitation to meeting participants.",
      "Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.",
      "NIAID is also setting up a study in collaboration with FDA to analyze the response to the vaccine in people who have high levels of anti-PEG antibodies or have experienced severe allergic responses to drugs or vaccines before."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that there are suspicions about nanoparticles, specifically PEG, in Pfizer's COVID-19 vaccine potentially causing allergic reactions. However, suspicions do not confirm a causal relationship, and further studies are being conducted to analyze this. The claim lacks conclusive evidence, so it is not fully supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0935802087187767,
    "x2e_entail_prob": 0.004402617923915386
  },
  {
    "id": "covid_fact-000034",
    "statement": "Berberine and obatoclax inhibit sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that both berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells, using in vitro studies. Thus, the claim is supported by the provided evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.039634399116039276,
    "x2e_entail_prob": 0.03511939197778702
  },
  {
    "id": "covid_fact-000035",
    "statement": "Berberine and obatoclax induce sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that berberine and obatoclax inhibit, rather than induce, SARS-CoV-2 replication in primary human nasal epithelial cells. This directly contradicts the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.027993442490696907,
    "x2e_entail_prob": 0.034758102148771286
  },
  {
    "id": "covid_fact-000036",
    "statement": "Berberine and obatoclax induced sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that berberine and obatoclax inhibited SARS-CoV-2 replication, rather than inducing it, in primary human nasal epithelial cells. This directly contradicts the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.012998325750231743,
    "x2e_entail_prob": 0.025146853178739548
  },
  {
    "id": "covid_fact-000037",
    "statement": "Berberine and obatoclax are sars-cov-2 replication in primary human nasal epithelial cells in vitro.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations.",
      "In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2.",
      "Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells.",
      "Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial c"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that both berberine and obatoclax were effective in inhibiting SARS-CoV-2 replication in primary human nasal epithelial cells in vitro. This directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.2650756239891052,
    "x2e_entail_prob": 0.01736213080585003
  },
  {
    "id": "covid_fact-000038",
    "statement": "Taiwan completes synthesis of potential covid-19 drug",
    "label": "SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the drug was synthesized in Taiwan, per the DCB president's statement. Although the specific mention of the drug being a 'potential covid-19 drug' is not explicitly in the evidence, the context of transferring it for mass production to fight an epidemic implies its relevance to COVID-19. Thus, the claim is mostly supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.03895226866006851,
    "x2e_entail_prob": 0.0012433264637365937
  },
  {
    "id": "covid_fact-000039",
    "statement": "Taiwan inhibits synthesis of potential covid-19 drug",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Taiwan, through the Development Center for Biotechnology (DCB), has been able to synthesize the drug quickly and is looking to mass-produce it. This contradicts the claim that Taiwan inhibits synthesis of a potential COVID-19 drug. Instead, Taiwan appears to be facilitating drug synthesis and production.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8050673007965088,
    "x2e_entail_prob": 0.0011212514946237206
  },
  {
    "id": "covid_fact-000040",
    "statement": "Taiwan requires synthesis of potential covid-19 drug",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DCB president Herbert Wu () said that the center was able to synthesize the drug in four days after acquiring its components and that the goal is to transfer the process to domestic companies so they can mass-produce a generic version to fight the epidemic, per CNA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Taiwan has synthesized a potential COVID-19 drug through the efforts of the DCB. While the claim lacks some specificity regarding whether the synthesis is a legal or policy requirement, the evidence supports the notion that Taiwan is actively involved in developing and synthesizing a potential COVID-19 treatment.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.4610641300678253,
    "x2e_entail_prob": 0.0009205780224874616
  },
  {
    "id": "covid_fact-000041",
    "statement": "25-hydroxyvitamin d concentrations are lower in patients with positive pcr for sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that in the cohort study cited, patients who tested positive for SARS-CoV-2 had significantly lower median 25-hydroxyvitamin D levels (11.1 ng/mL) compared to those who tested negative (24.6 ng/mL), with the difference being statistically significant (p = 0.004). Therefore, the claim is supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.17188946902751923,
    "x2e_entail_prob": 0.25320982933044434
  },
  {
    "id": "covid_fact-000042",
    "statement": "25-hydroxyvitamin d concentrations are elevated in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that 25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 compared to those with negative PCR. This contradicts the claim that these concentrations are elevated in patients with a positive PCR for the virus.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.013483441434800625,
    "x2e_entail_prob": 0.24689042568206787
  },
  {
    "id": "covid_fact-000043",
    "statement": "25-hydroxyvitamin d concentrations are increased in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that 25-hydroxyvitamin D concentrations are actually lower in patients with a positive PCR for SARS-CoV-2 compared to negative patients. It notes that in a Greek ICU cohort, patients positive for SARS-CoV-2 had significantly lower 25(OH)D levels. Therefore, the claim that these concentrations are increased is not supported by the provided evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2531959116458893,
    "x2e_entail_prob": 0.6443890929222107
  },
  {
    "id": "covid_fact-000044",
    "statement": "25-hydroxyvitamin d concentrations are higher in patients with positive pcr for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 ( A ) 25-hydroxyvitamin D Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by Figure 2 ( A ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by gender (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR to SARS-CoV-2; ( B ) 25-hydroxyvitamin D concentrations in the three evaluated groups divided by age (070 years vs. >70 years) (patients from 1 March to 14 April of 2019 and 2020 with a negative PCR, and of 2020 with a positive PCR for SARS-CoV-2.",
      "Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.",
      "In this cohort, significantly lower 25(OH)D levels ( p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years.",
      "Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence specifically states that 25-hydroxyvitamin D levels were significantly lower in patients with a positive PCR for SARS-CoV-2 compared to those with a negative PCR. This contradicts the claim that concentrations are higher in patients with a positive PCR. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.025659997016191483,
    "x2e_entail_prob": 0.3290328085422516
  },
  {
    "id": "covid_fact-000045",
    "statement": "Us racial inequality may be as deadly as covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that racial inequality in the US is compared in severity to the impact of COVID-19 on mortality. The statement that COVID-19 would need to erase two to three decades of mortality progress for Whites to match the impact of racial inequality implies a significant and deadly consequence of racial inequality, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.2871913015842438,
    "x2e_entail_prob": 0.8687283992767334
  },
  {
    "id": "covid_fact-000046",
    "statement": "Us racial inequality may be as useful as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that racial inequality may have as significant an impact on mortality as COVID-19, but it does not indicate that racial inequality is 'as useful' as COVID-19. The claim's language is likely incorrect as it uses 'useful' instead of 'deadly' or impactful, thus it is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.025038812309503555,
    "x2e_entail_prob": 0.037497423589229584
  },
  {
    "id": "covid_fact-000047",
    "statement": "Us racial inequality may be as effective as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence claims that racial inequality may be as deadly as Covid-19, implying a similar impact in terms of mortality. However, it also states that for Covid-19 to equal the impact of racial inequality on mortality, it would need to erase decades of progress. Thus, the claim that racial inequality may be as effective as Covid-19 is not supported by the comparison in the evidence, which emphasizes differences in impact and suggests a more severe consequence from racial inequality alone.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8681085705757141,
    "x2e_entail_prob": 0.09751848131418228
  },
  {
    "id": "covid_fact-000048",
    "statement": "Us racial transmission may be as deadly as covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Racial inequality may be as deadly as Covid-19 (replication package).",
      "For COVID-19 to raise mortality as much as racial inequality does, it would need to erase two to three decades of mortality progress for Whites."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that racial inequality may be as deadly as COVID-19. The evidence indicates that for COVID-19 to have a similar impact on mortality as racial inequality, it would need to erase two to three decades of mortality progress for Whites. This implies that racial inequality has a significant and deadly impact, comparable to that of COVID-19, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9715301394462585,
    "x2e_entail_prob": 0.295759916305542
  },
  {
    "id": "covid_fact-000049",
    "statement": "Immunity to covid-19 is probably higher than tests have shown",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by indicating that T-cell immunity to COVID-19 is more prevalent than what antibody tests alone have shown. The study mentioned suggests that T-cell immunity may be present in roughly twice as many individuals as those detected through antibody tests, aligning with the claim of higher immunity levels.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9675444960594177,
    "x2e_entail_prob": 0.0027268577832728624
  },
  {
    "id": "covid_fact-000050",
    "statement": "Immunity to covid-19 is probably less than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates the researchers have found that T-cell immunity to COVID-19 may be more widespread than antibody tests have suggested, meaning that public immunity could be higher, not lower, than what antibody tests alone have shown. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.19289132952690125,
    "x2e_entail_prob": 0.0048258644528687
  },
  {
    "id": "covid_fact-000051",
    "statement": "Immunity to covid-19 is probably lower than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that public immunity to COVID-19 is actually higher than antibody tests have shown due to the presence of T-cell immunity in more individuals, even those without detectable antibodies. Therefore, the claim that immunity is probably lower than tests have shown is contradicted by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.726422905921936,
    "x2e_entail_prob": 0.0034557911567389965
  },
  {
    "id": "covid_fact-000052",
    "statement": "Immunity to covid-19 is probably smaller than tests have shown",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Ulf Sirborn Our results indicate that public immunity to COVID-19 is probably significantly higher than antibody tests have suggested, says Professor Hans- Gustaf Ljunggren at the Center for Infectious Medicine, Karolinska Institutet, and co-senior author.",
      "One interesting observation was that it wasnt just individuals with verified COVID-19 who showed T-cell immunity but also many of their exposed asymptomatic family members, says Soo Aleman.",
      "Our results indicate that roughly twice as many people have developed T-cell immunity compared with those who we can detect antibodies in. In the present study, the researchers performed immunological analyses of samples from over 200 people, many of whom had mild or no symptoms of COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that public immunity to COVID-19 is higher than what antibody tests alone have shown, primarily due to the detection of T-cell immunity in individuals, including asymptomatic cases. The claim states the opposite, that immunity is smaller than tests have shown, which is not supported by the given evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.36137524247169495,
    "x2e_entail_prob": 0.004779673647135496
  },
  {
    "id": "covid_fact-000053",
    "statement": "A novel in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that a novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds. This directly supports the claim and mentions details consistent with it, particularly its use in evaluating the efficacy of such compounds in diagnostics departments.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1625591218471527,
    "x2e_entail_prob": 0.028264110907912254
  },
  {
    "id": "covid_fact-000054",
    "statement": "A standard in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that a novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyze both neutralizing antibodies and antiviral compounds. This directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1287655085325241,
    "x2e_entail_prob": 0.051252979785203934
  },
  {
    "id": "covid_fact-000055",
    "statement": "A conventional in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that a novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds. This aligns with the claim, thus supporting it.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.18991583585739136,
    "x2e_entail_prob": 0.05229334905743599
  },
  {
    "id": "covid_fact-000056",
    "statement": "A simple in-cell elisa assay allows rapid and automated quantification of sars-cov-2 to analyze neutralizing antibodies and antiviral compounds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in- cell ELISA (icELISA) approach.",
      "A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.",
      "Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided supports the claim by describing the establishment of a novel, rapid, and automated SARS-CoV-2 neutralization assay using an in-cell ELISA (icELISA) approach. It verifies that this assay allows for the rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds, thus aligning with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8484137058258057,
    "x2e_entail_prob": 0.035502463579177856
  },
  {
    "id": "covid_fact-000057",
    "statement": "Stanford professor balaji s. srinivasan 's peer review of the santa clara seroprevalence study indicates that its high reported positive rate results may be explained by the false positive rate of the test and/or by sample recruitment issues .",
    "label": "SUPPORTED",
    "evidences": [
      "The use of such certificates may therefore increase the risks of continued transmission. One of the most well-known attempts to justify sending workers back to offices and factories based on a supposed antibody count comes from the controversial Santa Clara study, as it has come to be known.",
      "The Stanford researchers acknowledged as much in the study and used test performance weights to scale results, but Rutherford was skeptical of these weights, as well as the population weights the researchers used.",
      "In a peer review of the antibody study published to Medium, former Stanford lecturer Balaji Srinivasan, who specializes in statistics and computational biology, argued the selection methods could have overstated the prevalence of the disease in the county.",
      "Dr. Natalie E. Dean, a professor of biostatistics at the University of Florida, tweeted that she had concerns with the adjustments made for clustering (some participants brought children and other household members with them to the test) and test characteristics (researchers assume no false positives but some false negatives)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Balaji Srinivasan's peer review indeed highlights issues with the Santa Clara seroprevalence study, specifically mentioning sample recruitment methods that could overstate disease prevalence. This corresponds with the claim pointing out issues related to false positive rates and sample recruitment, which align with the review's concerns.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.10421880334615707,
    "x2e_entail_prob": 0.0068110208958387375
  },
  {
    "id": "covid_fact-000058",
    "statement": "Stanford professor balaji s. srinivasan's peer review of the santa clara seroprevalence study indicates that its high reported positive rate results cannot be explained by the false positive rate of the test and/or by sample recruitment issues.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The use of such certificates may therefore increase the risks of continued transmission. One of the most well-known attempts to justify sending workers back to offices and factories based on a supposed antibody count comes from the controversial Santa Clara study, as it has come to be known.",
      "The Stanford researchers acknowledged as much in the study and used test performance weights to scale results, but Rutherford was skeptical of these weights, as well as the population weights the researchers used.",
      "In a peer review of the antibody study published to Medium, former Stanford lecturer Balaji Srinivasan, who specializes in statistics and computational biology, argued the selection methods could have overstated the prevalence of the disease in the county.",
      "Dr. Natalie E. Dean, a professor of biostatistics at the University of Florida, tweeted that she had concerns with the adjustments made for clustering (some participants brought children and other household members with them to the test) and test characteristics (researchers assume no false positives but some false negatives)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Balaji Srinivasan argued the study's selection methods could have overstated the prevalence, which implies concerns about the sample recruitment, challenging rather than supporting the idea that results can't be explained by recruitment issues. Additionally, other experts, such as Dr. Natalie E. Dean, have raised doubts about test characteristics, including false positives, which also suggests a challenge to the claim. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.46155354380607605,
    "x2e_entail_prob": 0.004340287297964096
  },
  {
    "id": "covid_fact-000059",
    "statement": "Fda takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the FDA issued an emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine, which is considered a significant action in the fight against COVID-19, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2677309811115265,
    "x2e_entail_prob": 0.0031495196744799614
  },
  {
    "id": "covid_fact-000060",
    "statement": "Sars takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that the FDA, not 'Sars,' issued the emergency use authorization for the first COVID-19 vaccine. Therefore, the claim is not supported as 'Sars' does not play a role in the authorization process.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.10572288185358047,
    "x2e_entail_prob": 0.0013602946419268847
  },
  {
    "id": "covid_fact-000061",
    "statement": "China takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine in the U.S., not in China. There is no mention of China issuing an emergency use authorization for its first COVID-19 vaccine in the evidence given.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3981330990791321,
    "x2e_entail_prob": 0.0013802534667775035
  },
  {
    "id": "covid_fact-000062",
    "statement": "Who takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDAs authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world, said FDA Commissioner Stephen M. Hahn, M.D."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence highlights the FDA's role in granting emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine. This contradicts the claim that assigns this action to WHO. The FDA, not WHO, took this key action in the U.S.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.3481830060482025,
    "x2e_entail_prob": 0.003264667931944132
  },
  {
    "id": "covid_fact-000063",
    "statement": "Sherlock biosciences receives fda emergency use authorization for crispr sars-cov-2 rapid diagnostic",
    "label": "SUPPORTED",
    "evidences": [
      "In addition to SHERLOCK, the company is also developing its INSPECTR platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes Sherlock Biosciences Synthetic Biology platform to provide rapid detection of a genetic match of the SARS-CoV-2 virus.",
      "Cambridge, Mass., May 7, 2020  Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Sherlock Biosciences received Emergency Use Authorization (EUA) from the FDA for its Sherlock CRISPR SARS-CoV-2 kit, which is a rapid diagnostic test for detecting the virus that causes COVID-19. Therefore, the claim is supported by the provided evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1906365305185318,
    "x2e_entail_prob": 0.001390358665958047
  },
  {
    "id": "covid_fact-000064",
    "statement": "Sherlock biosciences receives no emergency use authorization for crispr sars-cov-2 rapid diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition to SHERLOCK, the company is also developing its INSPECTR platform to create an instrument-free, handheld test  similar to that of an at-home pregnancy test  that utilizes Sherlock Biosciences Synthetic Biology platform to provide rapid detection of a genetic match of the SARS-CoV-2 virus.",
      "Cambridge, Mass., May 7, 2020  Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that Sherlock Biosciences receives no Emergency Use Authorization for its CRISPR SARS-CoV-2 rapid diagnostic is contradicted by the evidence. The company has indeed received Emergency Use Authorization from the FDA for its Sherlock CRISPR SARS-CoV-2 kit.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.01762908510863781,
    "x2e_entail_prob": 0.0010548350401222706
  },
  {
    "id": "covid_fact-000065",
    "statement": "Lipoic acid helps response in g6pd population",
    "label": "SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that \u03b1-lipoic acid supplementation increases antioxidant capacity in adults with G6PD deficiency. This indicates a positive response, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.07818931341171265,
    "x2e_entail_prob": 0.41760778427124023
  },
  {
    "id": "covid_fact-000066",
    "statement": "Lipoic acid helps degradation in g6pd population",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that \u03b1-lipoic acid supplementation increases antioxidant capacity in individuals with G6PD deficiency. However, it does not specifically mention anything about aiding in 'degradation' within this population. Thus, the claim is not supported by the evidence given.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.005307561717927456,
    "x2e_entail_prob": 0.3847768306732178
  },
  {
    "id": "covid_fact-000067",
    "statement": "Lipoic acid stress response in g6pd population",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\u0391-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency.",
      "A-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim refers to the effect of lipoic acid on a G6PD deficient population, specifically suggesting a stress response. The provided evidence directly states that \u03b1-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency, implying a beneficial stress response. Thus, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7304430603981018,
    "x2e_entail_prob": 0.5595003366470337
  },
  {
    "id": "covid_fact-000068",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan",
    "label": "SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions in vitro data suggesting that iota-carrageenan could be effective against SARS-CoV-2, as it has shown similar protective effects on other respiratory viruses. This supports the claim of an inhibition of virus entry by iota-carrageenan in a neutralization assay.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.13231296837329865,
    "x2e_entail_prob": 0.003055512672290206
  },
  {
    "id": "covid_fact-000069",
    "statement": "Sars-cov-2 in-vitro neutralization assay blocked inhibition of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not discuss any in vitro neutralization assay blocking the inhibition of virus entry by iota-carrageenan. It mentions iota-carrageenan being potentially effective as a prophylaxis or treatment for SARS-CoV-2 but does not address specific assays or suggest any blocking of entry inhibition activity.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.4357122778892517,
    "x2e_entail_prob": 0.008397838100790977
  },
  {
    "id": "covid_fact-000070",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals induction of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not explicitly mention an in-vitro neutralization assay revealing induction of virus entry by iota-carrageenan for SARS-CoV-2. It mentions in-vitro data suggesting iota-carrageenan as a prophylaxis or treatment, but not the specific assay finding claimed.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1222372055053711,
    "x2e_entail_prob": 0.00682163517922163
  },
  {
    "id": "covid_fact-000071",
    "statement": "Sars-cov-2 in-vitro neutralization assay reveals enhancement of virus entry by iota-carrageenan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.",
      "Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented discusses the in vitro effectiveness of iota-carrageenan against various respiratory viruses, including the suggestion that it could be used as a treatment for SARS-CoV-2 infections. However, there is no specific evidence indicating that iota-carrageenan enhances virus entry for SARS-CoV-2. Therefore, the specific claim of enhanced virus entry by iota-carrageenan is not supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.14702630043029785,
    "x2e_entail_prob": 0.020985260605812073
  },
  {
    "id": "covid_fact-000072",
    "statement": "Two thirds of people contacted through tracing did not fully cooperate , pilot scheme finds",
    "label": "SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly supports the claim that two thirds of people contacted through tracing did not fully cooperate, as found by a pilot scheme. The BMJ report states that two thirds of contacts did not cooperate fully, which aligns with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8671619296073914,
    "x2e_entail_prob": 0.0015477717388421297
  },
  {
    "id": "covid_fact-000073",
    "statement": "Two thirds of people contacted through tracing did indeed fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that two thirds of people contacted did not fully cooperate with contact tracing, contradicting the claim. This means the claim is not supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.03575882688164711,
    "x2e_entail_prob": 0.0031341302674263716
  },
  {
    "id": "covid_fact-000074",
    "statement": "Two thirds of people contacted through tracing did it fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that two thirds of the people contacted through tracing did not fully cooperate. Therefore, the claim stating that two thirds cooperated is incorrect.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.06662711501121521,
    "x2e_entail_prob": 0.004116151947528124
  },
  {
    "id": "covid_fact-000075",
    "statement": "Two thirds of people contacted through tracing did still fully cooperate, pilot scheme finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "However, for the other 39 (two thirds) of the contacts, index cases were unable or unwilling to give their names and details.",
      "The BMJ A covid-19 contact tracing pilot scheme in Sheffield has found that two thirds of people contacted did not fully cooperate, and many of those worked in health and care settings.",
      "The Sheffield Community Contact Tracers team was created by a group of retired doctors and public health experts and began the local pilot in April after they became frustrated by the lack of government action on contact tracing.1 In a report,2 the team described the inability or unwillingness to engage by people working in health and care settings as a major challenge. They said that contact tracing may be resisted in workplaces, especially in the NHS and care homes, where contact tracing systems, social distancing of staff, and a culture supportive of self-isolation frequently does not exist. They also found that one in five of the initial patients responded to phone calls only after a physical message was hand deliveredsomething that the UK government may want to consider as it launches new NHS test and trace services."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that two thirds of people contacted did not fully cooperate with the contact tracing pilot scheme, contrary to the claim which suggests that they did fully cooperate. Thus, the claim is not supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.007429860532283783,
    "x2e_entail_prob": 0.003209279151633382
  },
  {
    "id": "covid_fact-000076",
    "statement": "The inhaled corticosteroid ciclesonide blocks coronavirus rna replication by targeting viral nsp15",
    "label": "SUPPORTED",
    "evidences": [
      "Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.",
      "After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.",
      "These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that ciclesonide, an inhaled corticosteroid, suppresses coronavirus replication and that a resistant mutation in the presence of ciclesonide involves NSP15. This suggests ciclesonide targets NSP15, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8617686629295349,
    "x2e_entail_prob": 0.0026734587736427784
  },
  {
    "id": "covid_fact-000077",
    "statement": "The inhaled corticosteroid ciclesonide support coronavirus rna replication by targeting viral nsp15",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.",
      "After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.",
      "These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that ciclesonide, an inhaled corticosteroid, suppresses coronavirus replication and may lead to mutations in NSP15, but it does not explicitly state that ciclesonide supports coronavirus RNA replication by targeting NSP15. The claim that ciclesonide supports replication is not supported by the evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.48751017451286316,
    "x2e_entail_prob": 0.017769791185855865
  },
  {
    "id": "covid_fact-000078",
    "statement": "The us doesnt have enough hospital beds for a bad coronavirus outbreak",
    "label": "SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence includes multiple sources citing concerns about the U.S. not having enough hospital beds for a major coronavirus outbreak. This includes warnings from doctors and statements by officials like New York Governor Andrew Cuomo. The consistent concerns reflect that the claim is well-supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.011484124697744846,
    "x2e_entail_prob": 0.004504915792495012
  },
  {
    "id": "covid_fact-000079",
    "statement": "The usset have enough hospital beds for a bad coronavirus outbreak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided includes statements from U.S. doctors and New York Governor Cuomo expressing concerns about the inadequacy of hospital beds for a coronavirus outbreak, indicating that the U.S. did not have enough hospital beds to handle a severe outbreak. This directly contradicts the claim that the U.S. has enough beds.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1911083161830902,
    "x2e_entail_prob": 0.01338447630405426
  },
  {
    "id": "covid_fact-000080",
    "statement": "The usert have enough hospital beds for a bad coronavirus outbreak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies.",
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that enough hospital beds are available for a bad coronavirus outbreak is not supported by the evidence. The evidence indicates warnings and statements from officials, including New York Gov. Cuomo, suggesting that the U.S. does not have enough hospital beds and medical supplies for a severe coronavirus outbreak.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3314276337623596,
    "x2e_entail_prob": 0.0037271648179739714
  },
  {
    "id": "covid_fact-000081",
    "statement": "Oncogen researchers propose personalized vaccinomics strategy for the novel china coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "The candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.",
      "Technical details of the approach used are detailed below: We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response.",
      "The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.",
      "Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.",
      "The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a strategy for designing multiepitope peptide vaccines against the novel coronavirus using a technology derived from personalized cancer vaccination methods. The approach, labeled as 'personalized vaccinomics,' uses human leukocyte antigen (HLA) allele variation to tailor vaccines to individuals or communities. This directly supports the claim that Oncogen researchers proposed a personalized vaccinomics strategy for the coronavirus vaccine.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6151624321937561,
    "x2e_entail_prob": 0.27682098746299744
  },
  {
    "id": "covid_fact-000082",
    "statement": "Oncogen researchers propose personalized vaccinomics strategy for the traditional china coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The candidate peptides were designed by applying to viral antigens a technology used for personalized vaccination in cancer, based on long neoantigen peptides, currently in clinical trials for cancer therapy.",
      "Technical details of the approach used are detailed below: We identified multiepitope peptide vaccine candidates against nCov that can potentially trigger both CD4+ and CD8+ T cell immune response.",
      "The approach that we used for designing potential peptide vaccine candidates takes a more personalized strategy, referred to as vaccinomics , which enables the selection of target viral proteins with low mutation rates, and the design of peptides tuned to the immune characteristics of the target populations, variable based on geographic location and ethnicity.",
      "Based on the human MHC (human leukocyte antigen) allele variation, the peptide vaccines can be made more relevant to a community or individual.",
      "The selection of the peptides that could act as vaccines is determined by the binding of the processed viral peptide with the major histocompatibility complex (MHC) class I and II molecules, and the relevant HLA alleles."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that researchers are applying a personalized vaccinomics strategy to design peptide vaccine candidates against the coronavirus by considering immune characteristics and MHC allele variations. This approach aligns with the personalized strategy referred to in the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8426651954650879,
    "x2e_entail_prob": 0.10100856423377991
  },
  {
    "id": "covid_fact-000083",
    "statement": "Mathematical analysis of c\u00f3rdoba calcifediol trial suggests strong role for vitamin d in reducing icu admissions of hospitalized covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).",
      "Finally, comparison with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil indicates that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. We conclude that the C\u00f3rdoba study provides sufficient evidence to warrant immediate, well-designed pivotal clinical trials of early calcifediol administration in a broader cohort of inpatients and outpatients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions a mathematical analysis of the C\u00f3rdoba calcifediol trial, which suggests a significant role of vitamin D in reducing ICU admissions for hospitalized COVID-19 patients. Furthermore, the evidence indicates that the findings from the C\u00f3rdoba study are sufficient to recommend further well-designed clinical trials, supporting the claim of a strong role for vitamin D.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0077604674734175205,
    "x2e_entail_prob": 0.06871708482503891
  },
  {
    "id": "covid_fact-000084",
    "statement": "Mathematical analysis of c\u00f3rdoba calcifediol trial suggests strong role against vitamin d in reducing icu admissions of hospitalized covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).",
      "Finally, comparison with two additional randomized clinical trials of vitamin D supplementation for COVID-19 in India and Brazil indicates that early intervention and rapid absorption may be crucial for the observed benefits of vitamin D. We conclude that the C\u00f3rdoba study provides sufficient evidence to warrant immediate, well-designed pivotal clinical trials of early calcifediol administration in a broader cohort of inpatients and outpatients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions the C\u00f3rdoba study's conclusions about the potential benefits of vitamin D (calcifediol) in reducing ICU admissions for COVID-19 patients and emphasizes the need for further well-designed trials. However, it does not directly support the claim that there was a strong role of vitamin D in the outcomes, only the suggestion of possible benefits requiring further validation.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.08895331621170044,
    "x2e_entail_prob": 0.046947818249464035
  },
  {
    "id": "covid_fact-000085",
    "statement": "Artificial intelligence model detects asymptomatic covid-19 infections through cellphone-recorded coughs",
    "label": "SUPPORTED",
    "evidences": [
      "New AI model detects asymptomatic Covid-19 infections through device-recorded coughs Vocal sentiments Prior to the pandemics onset, research groups already had been training algorithms on cellphone recordings of coughs to accurately diagnose conditions such as pneumonia and asthma.",
      "The model identified 98.5 percent of coughs from people confirmed with Covid-19, and of those, it accurately detected all of the asymptomatic coughs.",
      "When they fed the model new cough recordings, it accurately identified 98.5 percent of coughs from people who were confirmed to have Covid-19, including 100 percent of coughs from asymptomatics  who reported they did not have symptoms but had tested positive for the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that an AI model was indeed developed to detect asymptomatic Covid-19 infections through device-recorded coughs. The model accurately identified 98.5 percent of Covid-19 positive coughs and detected all asymptomatic cases. Therefore, the claim is supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.41243818402290344,
    "x2e_entail_prob": 0.0529060922563076
  },
  {
    "id": "covid_fact-000086",
    "statement": "Artificial intelligence model cannots asymptomatic covid-19 infections through cellphone-recorded coughs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "New AI model detects asymptomatic Covid-19 infections through device-recorded coughs Vocal sentiments Prior to the pandemics onset, research groups already had been training algorithms on cellphone recordings of coughs to accurately diagnose conditions such as pneumonia and asthma.",
      "The model identified 98.5 percent of coughs from people confirmed with Covid-19, and of those, it accurately detected all of the asymptomatic coughs.",
      "When they fed the model new cough recordings, it accurately identified 98.5 percent of coughs from people who were confirmed to have Covid-19, including 100 percent of coughs from asymptomatics  who reported they did not have symptoms but had tested positive for the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim contains a grammar mistake, 'cannots' instead of 'can detect,' which could lead to misunderstanding. Ignoring this, the claim would be supported since the evidence states that the AI model correctly identifies 98.5 percent of Covid-19 coughs and 100 percent of asymptomatic Covid-19 coughs from those recorded. However, given the grammatical error, it suggests a contradiction or typo.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.026881756260991096,
    "x2e_entail_prob": 0.25398513674736023
  },
  {
    "id": "covid_fact-000087",
    "statement": "Stanford researchers test 3,200 people for covid-19 antibodies",
    "label": "SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided confirms the type of antibody test used in the Stanford study but does not specify the number of people tested. Therefore, it does not support the claim that specifically 3,200 people were tested.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0035472007002681494,
    "x2e_entail_prob": 0.0009664921672083437
  },
  {
    "id": "covid_fact-000088",
    "statement": "Stanford researchers test 3,6 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide any information about the quantity of people tested for COVID-19 antibodies in the Stanford study. It mentions the use of Premier Biotech antibody tests but lacks specifics on the number of people tested, making it impossible to confirm the accuracy of '3,6' as the number mentioned in the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.015968088060617447,
    "x2e_entail_prob": 0.0011432366445660591
  },
  {
    "id": "covid_fact-000089",
    "statement": "Stanford researchers test 3,5 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specify the number of people tested in the Stanford study. The mention of '3,5 people' also seems incorrect, as it is unlikely to reflect a real testing scenario.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0023566370364278555,
    "x2e_entail_prob": 0.0014748891117051244
  },
  {
    "id": "covid_fact-000090",
    "statement": "Stanford researchers test 3,3 people for covid-19 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The antibody tests used in the Stanford study, which were supplied by Premier Biotech, require only a fingerstick of blood and test for IgM and IgG antibodies that indicate that a person either has coronavirus or had it and recovered."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that the Stanford study used antibody tests provided by Premier Biotech. However, it does not confirm the specific number of people, '3,3 people,' being tested in the study.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.004447938874363899,
    "x2e_entail_prob": 0.0010179271921515465
  },
  {
    "id": "covid_fact-000091",
    "statement": "State lab finds 90 positive covid-19 test results were false",
    "label": "SUPPORTED",
    "evidences": [
      "Of those, a total of 91 specimens from 90 people showed false positive results.",
      "The department said the state public health laboratory uncovered a flaw in one of the testing systems it uses to test for SARS-CoV-2, the virus that causes COVID-19, and 90 of 144 people tested between June 15 and July 17 received a false positive COVID test report.",
      "Accurate and timely testing for the novel coronavirus is one of the pillars supporting effective response to the COVID-19 pandemic. She said adjustments have already been made to ensure the accuracy of future test results from this platform. They said all positive results will be further analyzed by multiple laboratory scientists, and if indicated, retested using another method.",
      "The lab used another FDA-authorized test and found the false positives.",
      "Any nursing home resident who received a false positive COVID-19 test result will be retested as soon as possible, according to the Department of Health."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that a state public health laboratory found that 90 out of 144 people tested received false positive COVID-19 test results due to a flaw in the testing system. Therefore, the claim is supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.18437707424163818,
    "x2e_entail_prob": 0.0028643428813666105
  },
  {
    "id": "covid_fact-000092",
    "statement": "State lab finds 90 positive covid-19 test results were+.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Of those, a total of 91 specimens from 90 people showed false positive results.",
      "The department said the state public health laboratory uncovered a flaw in one of the testing systems it uses to test for SARS-CoV-2, the virus that causes COVID-19, and 90 of 144 people tested between June 15 and July 17 received a false positive COVID test report.",
      "Accurate and timely testing for the novel coronavirus is one of the pillars supporting effective response to the COVID-19 pandemic. She said adjustments have already been made to ensure the accuracy of future test results from this platform. They said all positive results will be further analyzed by multiple laboratory scientists, and if indicated, retested using another method.",
      "The lab used another FDA-authorized test and found the false positives.",
      "Any nursing home resident who received a false positive COVID-19 test result will be retested as soon as possible, according to the Department of Health."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a total of 91 specimens from 90 people were found to be false positives. This directly supports the claim that the state lab found 90 positive COVID-19 test results were incorrect. The evidence also mentions the flaw in the testing system, further corroborating the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.837374210357666,
    "x2e_entail_prob": 0.00400472292676568
  },
  {
    "id": "covid_fact-000093",
    "statement": "Different mutations in sars-cov-2 associate with severe and mild outcome",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that different mutations in the SARS-CoV-2 virus are correlated with clinical outcomes ranging from mild to severe. Specific mutations associated with mild and severe outcomes are identified in various viral genes, thus supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9395685195922852,
    "x2e_entail_prob": 0.1627645641565323
  },
  {
    "id": "covid_fact-000094",
    "statement": "Different mutations in sars-cov-2 associate against severe and mild outcome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that different mutations in the SARS-CoV-2 virus are associated with varying clinical outcomes, including both severe and mild outcomes. Specific mutations correlated with mild outcomes were identified in certain viral genes, while those associated with severe outcomes were found in others. This supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8144216537475586,
    "x2e_entail_prob": 0.06131074205040932
  },
  {
    "id": "covid_fact-000095",
    "statement": "Both mutations in sars-cov-2 associate with severe and mild outcome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome.",
      "Conclusions We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome.",
      "Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in the 3-to5 exonuclease, in ORF3a, NSP2 and N. Mutations leading to severe outcome with low prevalence were found in the surface (S) glycoprotein and in NSP7.",
      "Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a correlation between mutations in SARS-CoV-2 viral genes and clinical outcomes. Specific mutations are associated with mild outcomes, while others relate to severe or inferior outcomes. These findings support the claim that mutations in SARS-CoV-2 associate with both severe and mild outcomes.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.902129590511322,
    "x2e_entail_prob": 0.1378454715013504
  },
  {
    "id": "covid_fact-000096",
    "statement": "Moderna advances late-stage development of its vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "11, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced progress on late-stage development of mRNA-1273, the Companys mRNA vaccine candidate against COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Moderna announced progress on the late-stage development of its mRNA-1273 vaccine candidate against COVID-19. This supports the claim that Moderna is advancing the late-stage development of its COVID-19 vaccine.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.11273372918367386,
    "x2e_entail_prob": 0.14388014376163483
  },
  {
    "id": "covid_fact-000097",
    "statement": "Moderna advances late-stage delivery of its vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "11, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced progress on late-stage development of mRNA-1273, the Companys mRNA vaccine candidate against COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Moderna has announced progress on the late-stage development of its mRNA vaccine candidate against COVID-19, referred to as mRNA-1273. Hence, the claim about Moderna advancing late-stage delivery of its COVID-19 vaccine is supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.06461625546216965,
    "x2e_entail_prob": 0.10231335461139679
  },
  {
    "id": "covid_fact-000098",
    "statement": "Mathematical modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates the development of a mathematical model to explain the differing effects of remdesivir on SARS-CoV-2 in the lungs versus nasal passages of rhesus macaques. Early remdesivir treatment reduced viral loads in the lungs but increased them in the nasal passages, aligning with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5928893685340881,
    "x2e_entail_prob": 0.05598820000886917
  },
  {
    "id": "covid_fact-000099",
    "statement": "Phylogenetic modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a mathematical model was developed to explain the differential effect of remdesivir in lung versus nasal passages for SARS-CoV-2 in rhesus macaques. This aligns with the claim that phylogenetic modeling explains the difference in viral kinetics between these sites in remdesivir-treated macaques.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.003966685384511948,
    "x2e_entail_prob": 0.01632586121559143
  },
  {
    "id": "covid_fact-000100",
    "statement": "Mathematical depletion explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.",
      "One Sentence Summary We developed a mathematical model to explain why remdesivir has a greater antiviral effect on SARS CoV-2 in lung versus nasal passages in rhesus macaques.",
      "In rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that a mathematical model was developed to explain the differential effects of remdesivir on SARS-CoV-2 kinetics in the lung and nasal passages of rhesus macaques. The evidence notes that remdesivir had a greater antiviral effect in the lungs compared to nasal passages, supporting the claim related to mathematical depletion explaining these differences.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9233464598655701,
    "x2e_entail_prob": 0.02636616863310337
  },
  {
    "id": "covid_fact-000101",
    "statement": "Singapore , taiwan and hong kong have brought outbreaks under control",
    "label": "SUPPORTED",
    "evidences": [
      "Singapore and Taiwan were both seen as examples of how to handle the coronavirus outbreak: stanching the growth of infections, while largely keeping their economies open.",
      "The city, like Singapore and Taiwan, has made headway in containing Covid-19.Credit...Hannah Mckay/Reuters HONG KONG  While the spread of Covid-19 is picking up speed in Europe and the United States, among other regions, the outbreaks in some countries in Asia seem to be under control."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that Singapore, Taiwan, and Hong Kong have made progress in controlling Covid-19 outbreaks, as they are mentioned as examples of managing the spread of infections effectively. This aligns with the claim that they have brought outbreaks under control.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.784174919128418,
    "x2e_entail_prob": 0.01045484934002161
  },
  {
    "id": "covid_fact-000102",
    "statement": "Singapore, taiwan and hong kong have no outbreaks under control",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Singapore and Taiwan were both seen as examples of how to handle the coronavirus outbreak: stanching the growth of infections, while largely keeping their economies open.",
      "The city, like Singapore and Taiwan, has made headway in containing Covid-19.Credit...Hannah Mckay/Reuters HONG KONG  While the spread of Covid-19 is picking up speed in Europe and the United States, among other regions, the outbreaks in some countries in Asia seem to be under control."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that Singapore, Taiwan, and Hong Kong do not have outbreaks under control. However, the evidence indicates that Singapore and Taiwan have been recognized for handling their outbreaks effectively. Additionally, Hong Kong is mentioned as making headway in containing Covid-19, suggesting that the situation is under control. Therefore, the evidence contradicts the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5569128394126892,
    "x2e_entail_prob": 0.07960066199302673
  },
  {
    "id": "covid_fact-000103",
    "statement": "Fda gives eua to saliva-based test kit",
    "label": "SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the FDA has given emergency use authorization (EUA) for saliva-based COVID-19 test kits. Specifically, SalivaDirect by Yale and a molecular test by Rutgers Clinical Genomics Laboratory have received EUA for using saliva samples. Additionally, the FDA has authorized an at-home saliva specimen collection test, further supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1669246405363083,
    "x2e_entail_prob": 0.15277913212776184
  },
  {
    "id": "covid_fact-000104",
    "statement": "Pcr gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "There is no direct evidence that 'Pcr' gives EUA for a saliva-based test kit. The evidence specifically mentions that the FDA issued EUA to both Yale School of Public Health and Rutgers Clinical Genomics Laboratory for saliva-based testing, but 'Pcr' is not mentioned. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.05122533068060875,
    "x2e_entail_prob": 0.23856528103351593
  },
  {
    "id": "covid_fact-000105",
    "statement": "Data gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the FDA issued an Emergency Use Authorization (EUA) for a saliva-based test by Yale School of Public Health (SalivaDirect). Additionally, the Rutgers Clinical Genomics Laboratory also received an EUA for their test utilizing saliva samples. This supports the claim about the EUA for saliva-based test kits.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.14245454967021942,
    "x2e_entail_prob": 0.09065688401460648
  },
  {
    "id": "covid_fact-000106",
    "statement": "Table gives eua to saliva-based test kit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1.",
      "Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens 1.",
      "The FDA has authorized more than 80 COVID-19 tests and adding more options for at-home sample collection is an important advancement in diagnostic testing during this public health emergency. Todays EUA for Rutgers Clinical Genomics Laboratorys molecular test permits testing of a saliva sample collected from the patient using a designated self- collection kit.",
      "Specifically, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test (LDT), which had been previously added to the high complexity molecular- based LDT umbrella EUA, to permit testing of samples self-collected by patients at home using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the FDA has issued Emergency Use Authorizations (EUAs) for saliva-based test kits, including SalivaDirect by Yale School of Public Health and Rutgers Clinical Genomics Laboratory\u2019s test using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device. This supports the claim that EUAs have been given to saliva-based test kits.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.45323997735977173,
    "x2e_entail_prob": 0.20727437734603882
  },
  {
    "id": "covid_fact-000107",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but not associated with protection",
    "label": "SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that seasonal human coronavirus antibodies are indeed boosted upon SARS-CoV-2 infection, confirming that part of the claim. Furthermore, it mentions that these antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, which supports the second part of the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.09690380841493607,
    "x2e_entail_prob": 0.01490003988146782
  },
  {
    "id": "covid_fact-000108",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but also associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection, but it directly states that these antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations. Therefore, the claim that they are associated with protection is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.38184481859207153,
    "x2e_entail_prob": 0.04734690114855766
  },
  {
    "id": "covid_fact-000109",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but are associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but were not associated with protection against SARS-CoV-2 infections or hospitalizations. This contradicts the claim that they are associated with protection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6600241661071777,
    "x2e_entail_prob": 0.2400553971529007
  },
  {
    "id": "covid_fact-000110",
    "statement": "Seasonal human coronavirus antibodies are boosted upon sars-cov-2 infection but strongly associated with protection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but paradoxically these hCoV cross-reactive antibodies were boosted upon SARS-CoV-2 infection.",
      "We then quantified pre-pandemic antibody levels in serum from a separate cohort of 252 individuals who became PCR-confirmed infected with SARS-CoV-2.",
      "Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection, but these antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations. Thus, while the boosting part of the claim is correct, the association with protection is not supported by the evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5133755207061768,
    "x2e_entail_prob": 0.012729499489068985
  },
  {
    "id": "covid_fact-000111",
    "statement": "Preliminary results of nationwide representative screening are out",
    "label": "SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence specifies that the results of the first nationwide representative screening are expected to be released at the end of May. Since the claim states that preliminary results are already out, it contradicts the evidence suggesting that these results have not been released yet.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3376067876815796,
    "x2e_entail_prob": 0.0011340579949319363
  },
  {
    "id": "covid_fact-000112",
    "statement": "Preliminary results of nationwide representative screening are!",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the results of the first nationwide representative screening will be released at the end of May. However, it does not confirm or provide details about preliminary results being available. Thus, the claim is not supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.008451256901025772,
    "x2e_entail_prob": 0.0014341423520818353
  },
  {
    "id": "covid_fact-000113",
    "statement": "Preliminary results of nationwide representative screening are?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not supply any preliminary results of the nationwide representative screening. It only mentions the timing of when these results will be released and specifies the population included in the study. Therefore, the claim about preliminary results is not supported by the evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0018807481974363327,
    "x2e_entail_prob": 0.0008295252337120473
  },
  {
    "id": "covid_fact-000114",
    "statement": "Preliminary results of nationwide representative screening are\".",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results of the first nationwide representative screening will be released at the end of May.",
      "These preliminary results include those older than 14 who do not live in retirement homes or similar institutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is incomplete as presented. While there is evidence that preliminary results of a nationwide screening will be released, the claim provided is cut off and does not complete the statement, making it not possible to fully evaluate its support in the context provided by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.06334834545850754,
    "x2e_entail_prob": 0.0008356629405170679
  },
  {
    "id": "covid_fact-000115",
    "statement": "New self-administered coronavirus test found effective",
    "label": "SUPPORTED",
    "evidences": [
      "Self-administered COVID-19 coronavirus can be just as effective as physician- administered tests, according to a new study by UnitedHealth Group.",
      "Researchers found that self-administered swab tests accurately detected the disease in more than 90 percent of positive patients, which is consistent with physician-administered tests.",
      "Among 500 OptumCare patients in Washington state, the self-administered swabs were able to accurately detect the coronavirus that causes COVID-19 in 90% of those who are positive, a rate that's consistent with physician-administered swabs, the insurance giant announced.",
      "A new study found that self-administered tests may be as effective as those conducted by healthcare workers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that a new self-administered coronavirus test was found effective is supported by evidence from a study by UnitedHealth Group. The study states that self-administered tests accurately detected COVID-19 in over 90% of positive cases, which is consistent with the effectiveness of tests administered by healthcare professionals. This supports the claim of the effectiveness of the self-administered tests.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9869245290756226,
    "x2e_entail_prob": 0.9095394015312195
  },
  {
    "id": "covid_fact-000116",
    "statement": "No self-administered coronavirus test found effective",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Self-administered COVID-19 coronavirus can be just as effective as physician- administered tests, according to a new study by UnitedHealth Group.",
      "Researchers found that self-administered swab tests accurately detected the disease in more than 90 percent of positive patients, which is consistent with physician-administered tests.",
      "Among 500 OptumCare patients in Washington state, the self-administered swabs were able to accurately detect the coronavirus that causes COVID-19 in 90% of those who are positive, a rate that's consistent with physician-administered swabs, the insurance giant announced.",
      "A new study found that self-administered tests may be as effective as those conducted by healthcare workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that self-administered coronavirus tests can be just as effective as physician-administered tests, with a 90% accuracy rate in detecting positive cases. Therefore, the claim that no self-administered coronavirus test is found effective is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.21378542482852936,
    "x2e_entail_prob": 0.8034900426864624
  },
  {
    "id": "covid_fact-000117",
    "statement": "Electrostatic spraying will prevent the spread of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that electrostatic spraying improves coverage of disinfectant on surfaces and reduces wastage, which might impact surface contamination. However, it does not directly support the claim that it will prevent the spread of COVID-19. The prevention of virus spread involves multiple factors including airborne transmission, not just surface disinfection.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.04441675543785095,
    "x2e_entail_prob": 0.007937036454677582
  },
  {
    "id": "covid_fact-000118",
    "statement": "Electrostatic spraying will facilitate the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that electrostatic spraying improves disinfectant coverage on surfaces, which implies it could help in controlling the spread of COVID-19 rather than facilitating it. There is no direct link in the evidence provided that electrostatic spraying will facilitate the spread of COVID-19, contrasting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.10688621550798416,
    "x2e_entail_prob": 0.0034313718788325787
  },
  {
    "id": "covid_fact-000119",
    "statement": "Electrostatic spraying will enhance the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that electrostatic spraying is likely to improve disinfectant coverage and reduce wastage, but there is no information suggesting it will enhance the spread of COVID-19. The claim implies a negative outcome, while the evidence does not support this implication.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.043974436819553375,
    "x2e_entail_prob": 0.0038308154325932264
  },
  {
    "id": "covid_fact-000120",
    "statement": "Electrostatic spraying will promote the spread of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Electrostatic spraying is likely to improve coverage of disinfectant on surfaces and reduce wastage of disinfectant, but caution should be used in handling and applying the products."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that electrostatic spraying can enhance disinfectant coverage on surfaces, implying that it helps in disinfectant distribution. There is no specific evidence to support the claim that electrostatic spraying will promote the spread of COVID-19. In fact, the purpose of using disinfectants is generally to reduce the presence of pathogens, including viruses like COVID-19.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.06925491243600845,
    "x2e_entail_prob": 0.0038685875479131937
  },
  {
    "id": "covid_fact-000121",
    "statement": "Scientists trace severe covid-19 to faulty genes and autoimmune condition",
    "label": "SUPPORTED",
    "evidences": [
      "These findings provide compelling evidence that the disruption of type I interferon is often the cause of life-threatening COVID-19, says Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University and a Howard Hughes Medical Institute investigator.",
      "COVID-19 may now be the best understood acute infectious disease in terms of having a molecular and genetic explanation for nearly 15 percent of critical cases across diverse ancestries, Casanova says.",
      "Genetics of COVID-19 outliers The way SARS-CoV-2 affects people differently has been puzzling.",
      "Science Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Zhang Q. et al.",
      "Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports that severe COVID-19 cases are associated with genetic factors and autoimmune conditions. Specifically, disruptions in type I interferon due to faulty genes or auto-antibodies are highlighted as common factors among those with severe disease outcomes. These insights align with the claim that faulty genes and autoimmune conditions contribute to severe COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.963221549987793,
    "x2e_entail_prob": 0.10411056876182556
  },
  {
    "id": "covid_fact-000122",
    "statement": "Mice trace severe covid-19 to faulty genes and autoimmune condition",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These findings provide compelling evidence that the disruption of type I interferon is often the cause of life-threatening COVID-19, says Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University and a Howard Hughes Medical Institute investigator.",
      "COVID-19 may now be the best understood acute infectious disease in terms of having a molecular and genetic explanation for nearly 15 percent of critical cases across diverse ancestries, Casanova says.",
      "Genetics of COVID-19 outliers The way SARS-CoV-2 affects people differently has been puzzling.",
      "Science Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Zhang Q. et al.",
      "Whether the proteins have been neutralized by so-called auto- antibodies, or were not produced in sufficient amounts in the first place due to a faulty gene, their missing-in-action appears to be a common theme among a subgroup of COVID-19 sufferers whose disease has thus far been a mystery."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not support the specific claim that mice trace severe COVID-19 to faulty genes and autoimmune conditions. The evidence discusses human genetics and the role of type I interferon disruption in severe COVID-19 cases, but it does not mention mice, faulty genes, or autoimmune conditions in this specific context. Therefore, while genetics is discussed in relation to severe COVID-19, the role of mice is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8475726842880249,
    "x2e_entail_prob": 0.04210573807358742
  },
  {
    "id": "covid_fact-000123",
    "statement": "Uv-emitting led lights found to kill coronavirus efficiently and cheaply.",
    "label": "SUPPORTED",
    "evidences": [
      "In a recent study, researchers found that UV light-emitting diodes (LEDs) can quickly and effectively kill the human coronavirus HCoV-OC43.",
      "A new study suggests the novel coronavirus can be killed cheaply and efficiently by ultraviolet light-emitting diodes (UV-LEDs).",
      "LED lights found to kill coronavirus efficiently, quickly, and cheaply ",
      "\"We discovered that it is quite simple to kill the coronavirus using LED bulbs that radiate ultraviolet light.",
      "In the study, the researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that UV light-emitting diodes (LEDs) have been found in studies to kill coronaviruses, including the human coronavirus HCoV-OC43, effectively and efficiently. The claim regarding the efficient and cheap use of UV-LEDs to kill the coronavirus is supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9493959546089172,
    "x2e_entail_prob": 0.20275597274303436
  },
  {
    "id": "covid_fact-000124",
    "statement": "Uv-emitting bat lights found to kill coronavirus efficiently and cheaply.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a recent study, researchers found that UV light-emitting diodes (LEDs) can quickly and effectively kill the human coronavirus HCoV-OC43.",
      "A new study suggests the novel coronavirus can be killed cheaply and efficiently by ultraviolet light-emitting diodes (UV-LEDs).",
      "LED lights found to kill coronavirus efficiently, quickly, and cheaply ",
      "\"We discovered that it is quite simple to kill the coronavirus using LED bulbs that radiate ultraviolet light.",
      "In the study, the researchers found a range of wavelengths at which UV-LEDs effectively kill coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that UV light-emitting diodes (LEDs) can effectively kill human coronaviruses, including statements that this is done quickly and cheaply. The study supports the claim that UV-emitting lights can eliminate coronavirus efficiently. However, the evidence does not specify 'bat lights'; this seems to be an assumption or interpretation of the sources, but the core claim about UV-LEDs is supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.013117923401296139,
    "x2e_entail_prob": 0.17935942113399506
  },
  {
    "id": "covid_fact-000125",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol for covid-19 outpatients in saudi arabia",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the use of hydroxychloroquine within the approved protocol for COVID-19 outpatients in Saudi Arabia is safe and tolerable, supporting the claim about its safety outcomes.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.007059385534375906,
    "x2e_entail_prob": 0.5706682205200195
  },
  {
    "id": "covid_fact-000126",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol of covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that hydroxychloroquine is safe, highly tolerable, and has minimum side effects when used for COVID-19 patients in mild to moderate cases in an outpatient setting in Saudi Arabia, which supports the claim about its safety outcome within an approved therapeutic protocol.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.002810009056702256,
    "x2e_entail_prob": 0.730104923248291
  },
  {
    "id": "covid_fact-000127",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol included covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that the use of hydroxychloroquine in COVID-19 outpatients in Saudi Arabia, following approved protocols, is considered safe and tolerable, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01489972323179245,
    "x2e_entail_prob": 0.53654545545578
  },
  {
    "id": "covid_fact-000128",
    "statement": "Hydroxychloroquine safety outcome within approved therapeutic protocol is covid-19 outpatients in saudi arabia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim as it explicitly states that the use of hydroxychloroquine for COVID-19 in outpatient settings in Saudi Arabia is considered safe and highly tolerable, with minimum side effects. This aligns with the claim's assertion about safety outcomes within an approved protocol.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.056629106402397156,
    "x2e_entail_prob": 0.5830086469650269
  },
  {
    "id": "covid_fact-000129",
    "statement": "Covid-19 coronavirus spike holds infectivity details",
    "label": "SUPPORTED",
    "evidences": [
      "As a whole, details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people.",
      "This finding might help account for the efficient spread of the new coronavirus between people.",
      "The spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia are divulging how they attach, fuse and gain entry to cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the spikes of the coronavirus responsible for COVID-19 play a significant role in its infectivity and transmission between people. The details reported help explain how the virus efficiently attaches to, fuses with, and enters human cells. This aligns with the claim that the spike holds infectivity details.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8696423172950745,
    "x2e_entail_prob": 0.00842257495969534
  },
  {
    "id": "covid_fact-000130",
    "statement": "Covid-19 coronavirus genomes holds infectivity details",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "As a whole, details contained in the results reported in this weeks paper may help to explain the efficiency of the new coronavirus in delivering its viral code into human cells, and its rapid transmission among people.",
      "This finding might help account for the efficient spread of the new coronavirus between people.",
      "The spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia are divulging how they attach, fuse and gain entry to cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that details in the coronavirus genomes reveal mechanisms of how the virus attaches, fuses, and enters human cells, which is crucial to understanding its infectivity and transmission. This supports the claim that Covid-19 coronavirus genomes hold infectivity details.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.875267744064331,
    "x2e_entail_prob": 0.02766774594783783
  },
  {
    "id": "covid_fact-000131",
    "statement": "We had the covid-19 vaccine the whole time",
    "label": "SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests the COVID-19 vaccine was always available, but the evidence provides information on vaccine technology platforms and mentions Moderna's safety, which does not indicate that the COVID-19 vaccine was pre-existing or ready before the pandemic. In reality, COVID-19 vaccines were developed rapidly after the virus was identified in 2019, but not before.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.022414667531847954,
    "x2e_entail_prob": 0.001709104748442769
  },
  {
    "id": "covid_fact-000132",
    "statement": "We had the covid-19 vaccine the next time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim 'We had the covid-19 vaccine the next time' is vague and lacks clear temporal context from the evidence provided. The evidence discusses influenza vaccines and theoretical preemptive development for new pandemics but does not confirm any specific timelines or readiness of a COVID-19 vaccine in advance. Thus, the claim is not directly supported by the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.8956654071807861,
    "x2e_entail_prob": 0.0013708509504795074
  },
  {
    "id": "covid_fact-000133",
    "statement": "We had the covid-19 vaccine the following time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide specific information about the timeline for when the COVID-19 vaccine was obtained or made available. It mentions the use of technology platforms and discusses vaccine safety, but does not address the timing related to the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.31689757108688354,
    "x2e_entail_prob": 0.0027551196981221437
  },
  {
    "id": "covid_fact-000134",
    "statement": "We had the covid-19 vaccine the second time",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And then we formulate that into a vaccine using essentially the same technology platform that all the other influenza vaccines are based on. The whole process takes a few months, and utilizes a platform that we already know is basically safe.",
      "More precisely, they thought it would be possible to do all the research, development, preclinical testing, and Phase I trials for new viral pandemics before those new viruses had even emerged  to have those vaccines sitting on the shelf and ready to go when they did.",
      "The whole time, we also knew that the Moderna vaccine was essentially safe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not directly address the claim of having the COVID-19 vaccine a 'second time.' It discusses vaccine technology and development process but lacks clear support for the specific claim about receiving the COVID-19 vaccine twice.",
    "confidence": 0.5,
    "e2x_entail_prob": 0.1606522798538208,
    "x2e_entail_prob": 0.001235273783095181
  },
  {
    "id": "covid_fact-000135",
    "statement": "Quantitative assays reveal cell fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without",
    "label": "SUPPORTED",
    "evidences": [
      "Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions that cell-cell fusion was only moderately inhibited despite requiring much lower levels of S protein, which aligns with the claim regarding minimal levels. Although the evidence does not explicitly use the term 'fusion-from-without,' the overall context supports that fusion occurs at minimal levels of the spike protein.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.1257423609495163,
    "x2e_entail_prob": 0.010524271056056023
  },
  {
    "id": "covid_fact-000136",
    "statement": "Quantitative assays reveal no fusion at minimal levels of sars-cov-2 spike protein and fusion-from-without",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that quantitative assays reveal no fusion at minimal levels of SARS-CoV-2 spike protein. The evidence indicates that cell-cell fusion was moderately inhibited at very low levels of S protein, which were below the detection limit of flow cytometry and Western blot. This suggests that fusion activity was not detected at minimal levels, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5533909201622009,
    "x2e_entail_prob": 0.9568490982055664
  },
  {
    "id": "covid_fact-000137",
    "statement": "Weekly national flu and covid-19 surveillance reports published",
    "label": "SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only discusses COVID-19 hospital admission rates in the North West and mentions the increasing COVID-19 hospital and critical care admission rates. There is no information about the publishing of weekly national flu and COVID-19 surveillance reports. Therefore, the claim that such reports are published weekly is not supported by the evidence provided.",
    "confidence": 0.5,
    "e2x_entail_prob": 0.020156050100922585,
    "x2e_entail_prob": 0.11200457811355591
  },
  {
    "id": "covid_fact-000138",
    "statement": "Weekly national flu and covid-19 pandemic reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions hospital admission rates for COVID-19 but does not mention anything about weekly national flu and COVID-19 pandemic reports being published. There is insufficient information to support the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0037433162797242403,
    "x2e_entail_prob": 0.0008764933445490897
  },
  {
    "id": "covid_fact-000139",
    "statement": "Weekly national flu and covid-19 epidemic reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specifically confirm that weekly national flu and COVID-19 epidemic reports are being published. It only mentions information about COVID-19 hospital admission rates in a specific region. There is no mention of flu reports or the frequency of the reports.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.007431725040078163,
    "x2e_entail_prob": 0.0014715592842549086
  },
  {
    "id": "covid_fact-000140",
    "statement": "Weekly national flu and covid-19 infection reports published",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By NHS regions, the highest hospital admission rates for COVID-19 were observed in the North West.",
      "COVID-19 hospital and critical care admission rates continued to increase."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions COVID-19 hospital admission rates but does not reference any weekly national flu and COVID-19 infection reports, nor confirms their publication status.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.003910548985004425,
    "x2e_entail_prob": 0.0008185346378013492
  },
  {
    "id": "covid_fact-000141",
    "statement": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors",
    "label": "SUPPORTED",
    "evidences": [
      "Furthermore, the HCV replication complexes may hide the viral RNA from recognition by host sensors (43)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses HCV replication complexes hiding viral RNA from host sensors, but does not mention coronavirus endoribonuclease or its targeting of viral polyuridine sequences. Therefore, the claim is not supported by the evidence given.",
    "confidence": 0.2,
    "e2x_entail_prob": 0.0028463127091526985,
    "x2e_entail_prob": 0.03119475208222866
  },
  {
    "id": "covid_fact-000142",
    "statement": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host defense",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Furthermore, the HCV replication complexes may hide the viral RNA from recognition by host sensors (43)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention coronavirus endoribonuclease activity or its interaction with polyuridine sequences in evading host defense. It instead refers to HCV replication complexes hiding viral RNA from host sensors. This does not support the specific claim about coronavirus endoribonucleases.",
    "confidence": 0.3,
    "e2x_entail_prob": 0.02849588356912136,
    "x2e_entail_prob": 0.036856915801763535
  },
  {
    "id": "covid_fact-000143",
    "statement": "The spike glycoprotein of the new coronavirus 2019-ncov contains a furin-like cleavage site absent in cov of the same clade .",
    "label": "SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that 2019-nCoV (COVID-19) contains a unique furin-like cleavage site in its spike glycoprotein that is absent in other SARS-like coronaviruses, supporting the claim about its absence in CoVs of the same clade.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6190704703330994,
    "x2e_entail_prob": 0.4922337532043457
  },
  {
    "id": "covid_fact-000144",
    "statement": "The spike glycoprotein of the new coronavirus a-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the spike glycoprotein of the new coronavirus (2019-nCoV) contains a furin-like cleavage site that is absent in other coronaviruses of the same clade. The evidence directly supports this, pointing out a unique furin-like cleavage site (RRAR) in the 2019-nCoV that is not present in other lineage B \u03b2CoVs such as SARS-CoV.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.661723256111145,
    "x2e_entail_prob": 0.11289162188768387
  },
  {
    "id": "covid_fact-000145",
    "statement": "The spike glycoprotein of the new coronavirus s-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that the spike glycoprotein of the new coronavirus (2019-nCoV) contains a unique furin-like cleavage site that is not present in other SARS-like coronaviruses, which aligns with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3676905333995819,
    "x2e_entail_prob": 0.43294939398765564
  },
  {
    "id": "covid_fact-000146",
    "statement": "The spike glycoprotein of the new coronavirus e-ncov contains a furin-like cleavage site absent in cov of the same clade.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs.",
      "It has been speculated that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S), which is absent in other lineage B \u03b2CoVs, such as SARS-CoV, is responsible for its high infectivity and transmissibility.2 A coronavirus (CoV) infects the target cell by either cytoplasmic or endosomal membrane fusion."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the spike glycoprotein of the new coronavirus (2019-nCoV, later known as SARS-CoV-2) contains a furin-like cleavage site which is not present in other SARS-like CoVs of the same clade. This furin-like cleavage site is unique to the new coronavirus compared to others in its class, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6814165711402893,
    "x2e_entail_prob": 0.12379825115203857
  },
  {
    "id": "covid_fact-000147",
    "statement": "Breakthrough covid-19 antibody test with nearly 100 % accuracy can help reopen economy",
    "label": "SUPPORTED",
    "evidences": [
      "Scientists said Friday they found the test can determine if someone had COVID-19 with nearly 100% accuracy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the test can determine if someone had COVID-19 with nearly 100% accuracy, which supports the claim of a breakthrough test with high accuracy. However, while the test's accuracy supports the potential to aid in reopening the economy, the causal link between test accuracy and economic reopening was not directly discussed in the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.009770901873707771,
    "x2e_entail_prob": 0.001824724255129695
  },
  {
    "id": "covid_fact-000148",
    "statement": "Breakthrough covid-19 antibody test with nearly 100 % accuracy cannot help reopen economy",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Scientists said Friday they found the test can determine if someone had COVID-19 with nearly 100% accuracy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided confirms that the COVID-19 antibody test has nearly 100% accuracy in determining if someone had COVID-19. However, the claim that this accuracy 'cannot help reopen the economy' is not supported by the evidence given, which only focuses on the accuracy of the test and does not address its potential impacts on the economy. Therefore, without further evidence, the claim is not supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.04993760958313942,
    "x2e_entail_prob": 0.007740628439933062
  },
  {
    "id": "covid_fact-000149",
    "statement": "Pyridoxal 5'-phosphate to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Pyridoxal 5'-phosphate (PLP) supplementation may help mitigate COVID-19 symptoms by addressing immune dysregulation and coagulopathy. This is supported by references to PLP reducing inflammatory cytokines and improving endothelial integrity, thereby addressing both immune suppression and hypercoagulability related to COVID-19.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8963803648948669,
    "x2e_entail_prob": 0.9552417397499084
  },
  {
    "id": "covid_fact-000150",
    "statement": "Pyridoxal 5'- inability to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that Pyridoxal 5'-phosphate (PLP) supplementation can help mitigate symptoms of COVID-19, including immune dysregulation and coagulopathy, by reducing inflammation and improving endothelial integrity. This contradicts the claim that it has an inability to mitigate these issues.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4511686861515045,
    "x2e_entail_prob": 0.6810793876647949
  },
  {
    "id": "covid_fact-000151",
    "statement": "Pyridoxal 5'-phosphate to mitigate cardiac dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that pyridoxal 5'-phosphate (PLP) supplementation may help mitigate COVID-19 symptoms related to immune suppression and inflammatory cytokine secretion, and it has effects that may lead to improved endothelial integrity and prevent hypercoagulability, which relate to coagulopathy. Animal studies support its efficacy in decreasing the severity of viral pneumonia symptoms, further implying potential benefits for cardiac dysregulation and coagulopathy in COVID-19 patients.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7397724390029907,
    "x2e_entail_prob": 0.26087337732315063
  },
  {
    "id": "covid_fact-000152",
    "statement": "Pyridoxal 5'-c to mitigate immune dysregulation and coagulopathy in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Pharmacological PLP supplementation may therefore mitigate COVID-19 symptoms by alleviating both the immune suppression underlying viral spread and the pathological hypersecretion of inflammatory cytokines, as well as directly bolstering endothelial integrity and preventing hypercoagulability.",
      "In inflammatory disease, pharmacological doses of PLP decrease circulating TNF\u03b1, IL-6 and D-dimer, and animal studies demonstrate that supplemental PLP shortens the duration and severity of viral pneumonia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that pharmacological supplementation with Pyridoxal 5'-phosphate (PLP, which the claim likely refers to as Pyridoxal 5'-c) may mitigate COVID-19 symptoms by addressing immune dysregulation and hypercoagulability. It mentions PLP's effects on reducing inflammatory cytokines and improving endothelial integrity, which aligns with mitigating immune dysregulation and coagulopathy. Though the claim does not specify exact mechanisms or levels of efficacy, the general premise is supported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.07985058426856995,
    "x2e_entail_prob": 0.006652333773672581
  },
  {
    "id": "covid_fact-000153",
    "statement": "Antibodies in infants born to mothers with covid-19 pneumonia",
    "label": "SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specifically mention antibodies in infants born to mothers with COVID-19 pneumonia. It refers more generally to the assessment of maternal and neonatal SARS-CoV-2 viral load and related parameters, but does not validate the specific claim about antibodies in infants. More specific evidence would be needed to support the claim.",
    "confidence": 0.5,
    "e2x_entail_prob": 0.05643376708030701,
    "x2e_entail_prob": 0.18474581837654114
  },
  {
    "id": "covid_fact-000154",
    "statement": "Antibodies in women born to mothers with covid-19 pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions the study of viral load, antibody transfer, and placental pathology during the COVID-19 pandemic without confirming the presence of specific antibodies in women born to mothers with COVID-19 pneumonia. There is no direct evidence about the claim regarding antibodies in these women.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.045735929161310196,
    "x2e_entail_prob": 0.8335465788841248
  },
  {
    "id": "covid_fact-000155",
    "statement": "Mortality in infants born to mothers with covid-19 pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specifically address mortality rates of infants born to mothers with COVID-19 pneumonia. It only mentions studies related to viral load, antibody transfer, and placental pathology during pregnancies in the pandemic. Therefore, the claim about infant mortality is not supported by the available evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.006975950673222542,
    "x2e_entail_prob": 0.554056704044342
  },
  {
    "id": "covid_fact-000156",
    "statement": "Aggregated mobility data could help fight covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that aggregated mobility data can help fight COVID-19 by providing near real-time information on human movement patterns. This suggests that such data could be useful in refining interventions aimed at controlling the spread of the virus.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.03853217512369156,
    "x2e_entail_prob": 0.9796690344810486
  },
  {
    "id": "covid_fact-000157",
    "statement": "Aggregated mobility data could not fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that aggregated mobility data can help provide near real-time information about changes in human movement patterns, which can be used to refine interventions against COVID-19. This suggests that such data could indeed play a role in fighting the pandemic, contrary to the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0024326168932020664,
    "x2e_entail_prob": 0.9947511553764343
  },
  {
    "id": "covid_fact-000158",
    "statement": "Aggregated mobility data could help generate covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that aggregated mobility data can help refine interventions related to patterns of human movement but does not specifically mention the generation of COVID-19. The claim is likely a misunderstanding; data can help manage COVID-19 interventions but not generate the disease itself.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0047525810077786446,
    "x2e_entail_prob": 0.002331383526325226
  },
  {
    "id": "covid_fact-000159",
    "statement": "Aggregated mobility data could help study covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "When aggregated, these data can help refine interventions by providing near real-time information about changes in patterns of human movement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that aggregated mobility data can provide near real-time information about changes in human movement patterns, which can be useful for refining interventions. This supports the claim that such data could help study COVID-19 by providing insights into movement patterns and helping to implement or adjust public health measures.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.03102716989815235,
    "x2e_entail_prob": 0.994684636592865
  },
  {
    "id": "covid_fact-000160",
    "statement": "Preliminary evidence that higher temperatures are associated with lower incidence of covid-19 , for cases reported globally up to 29th february 2020",
    "label": "SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there is a strong association between higher temperatures and lower COVID-19 incidence as of February 29, 2020, after adjusting for several factors. However, it's important to note that temperature explained only a modest amount of the total variation in COVID-19 incidence, suggesting other factors were also significant.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8823934197425842,
    "x2e_entail_prob": 0.03049534000456333
  },
  {
    "id": "covid_fact-000161",
    "statement": "Preliminary evidence that lower temperatures are associated with lower incidence of covid-19, for cases reported globally up to 29th february 2020",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that higher average temperatures were associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher. This contradicts the claim that lower temperatures are associated with lower incidence. Additionally, while a modest amount of the variation is explained by temperature, it does not support the specific claim about lower temperatures leading to lower incidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7306864857673645,
    "x2e_entail_prob": 0.02186446264386177
  },
  {
    "id": "covid_fact-000162",
    "statement": "Preliminary evidence that low temperatures are associated with lower incidence of covid-19, for cases reported globally up to 29th february 2020",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using global line-list data on COVID-19 cases reported until 29th February 2020 and global gridded temperature data, and after adjusting for surveillance capacity and time since first imported case, higher average temperature was strongly associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher.",
      "However, temperature explained a relatively modest amount of the total variation in COVID-19 incidence."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that higher average temperatures, not lower temperatures, are associated with lower COVID-19 incidence for temperatures of 1\u00b0C and higher. Furthermore, temperature only explained a modest amount of the variation in COVID-19 incidence. Therefore, the claim that low temperatures are associated with lower incidence of COVID-19 is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9531890749931335,
    "x2e_entail_prob": 0.027311310172080994
  },
  {
    "id": "covid_fact-000163",
    "statement": "The fda weighs its first coronavirus vaccine",
    "label": "SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The given evidence does not specifically confirm that the FDA is weighing its first coronavirus vaccine. It only mentions the protective effect of the Moderna vaccine and anticipates FDA approval but does not explicitly state that the FDA is currently considering its first coronavirus vaccine.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.832595944404602,
    "x2e_entail_prob": 0.0937153771519661
  },
  {
    "id": "covid_fact-000164",
    "statement": "The fda weighs its new coronavirus vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the effectiveness of Moderna's coronavirus vaccine but does not confirm whether the FDA is currently weighing this vaccine specifically. Thus, the claim about the FDA's specific actions regarding this vaccine is not directly supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.14214541018009186,
    "x2e_entail_prob": 0.049237918108701706
  },
  {
    "id": "covid_fact-000165",
    "statement": "The fda weighs its sars coronavirus vaccine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "https://www.nbcnews.com/health/health-news/moderna-vaccine-appears-protect- against-coronavirus-infection-n1251237 Reply 1.",
      "So it looks like the vaccine has a very strong protective effect, and that's the first thing you'd want to know.",
      "I expect the FDA to grant that, and very soon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests the FDA is weighing or considering its SARS coronavirus vaccine, but this specific action is not explicitly mentioned or supported in the provided evidence. The evidence talks about the effectiveness of the Moderna vaccine and expects FDA approval but does not confirm the FDA's evaluation process or decision regarding a specific SARS coronavirus vaccine.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.6691102981567383,
    "x2e_entail_prob": 0.13069263100624084
  },
  {
    "id": "covid_fact-000166",
    "statement": "High incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided includes titles of studies that generally relate to venous thromboembolism in COVID-19 patients but does not explicitly support the specific claim about a high incidence in anticoagulated severe COVID-19 patients. Further detailed data or conclusions from these studies are necessary to evaluate the claim accurately.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.030184490606188774,
    "x2e_entail_prob": 0.13236133754253387
  },
  {
    "id": "covid_fact-000167",
    "statement": "Low incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides titles that suggest studies on venous thromboembolism in COVID-19 patients, but it does not present specific data or findings that confirm a low incidence of such events in anticoagulated severe COVID-19 patients. Without direct evidence from the studies showing low incidence rates, the claim cannot be considered supported.",
    "confidence": 0.4,
    "e2x_entail_prob": 0.15488623082637787,
    "x2e_entail_prob": 0.278831422328949
  },
  {
    "id": "covid_fact-000168",
    "statement": "Median incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim provides an incomplete statement without specific incidence data for venous thromboembolic events in anticoagulated severe COVID-19 patients. The given evidence titles suggest general data on thromboembolism rates in COVID-19 patients but do not address the specific claim about incidence in the subset of anticoagulated severe cases. Therefore, without specific data points or outcomes from the evidence, the claim is not supported.",
    "confidence": 0.2,
    "e2x_entail_prob": 0.5980915427207947,
    "x2e_entail_prob": 0.39719659090042114
  },
  {
    "id": "covid_fact-000169",
    "statement": "Average incidence of venous thromboembolic events in anticoagulated severe covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.",
      "Venous Thromboembolism in Hospitalized COVID-19 Patients.",
      "Incidence of thrombotic complications in critically ill ICU patients with COVID19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim requires specific numerical data or analysis regarding the average incidence rate of venous thromboembolic events in anticoagulated severe COVID-19 patients. The evidence titles suggest studies about venous thromboembolism in COVID-19 patients, but it doesn't provide direct numerical incidence rates or analyses required to support the claim. Thus, based on available information, the claim is not directly supported.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.36182329058647156,
    "x2e_entail_prob": 0.08719641715288162
  },
  {
    "id": "covid_fact-000170",
    "statement": "Epa proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the EPA proposes science restrictions, applying to various studies and reports, during the coronavirus pandemic. This proposal corresponds with the reported timeframe and breadth mentioned in the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.006044869776815176,
    "x2e_entail_prob": 0.0015345732681453228
  },
  {
    "id": "covid_fact-000171",
    "statement": "Epa proposes broad science support in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes a concern over the EPA's actions that may politicize science and compromise decision-making, rather than supporting broad science support as claimed. The evidence suggests skepticism about the proposal's intent and its impact on the EPA's scientific processes.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3932967185974121,
    "x2e_entail_prob": 0.003214457305148244
  },
  {
    "id": "covid_fact-000172",
    "statement": "Cdc proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses science restrictions proposed by the EPA, not the CDC. The claim about the CDC proposing broad science restrictions lacks supporting evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0037895774003118277,
    "x2e_entail_prob": 0.0014568885089829564
  },
  {
    "id": "covid_fact-000173",
    "statement": "Who proposes broad science restrictions in midst of coronavirus pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The EPAs Science Advisory Board initially called it a license to politicize science and said that it would compromise the agencys decision-making process.",
      "According to EPA, it would apply not only to studies behind EPA decisions about vehicle emissions, clean air standards, and clean water protections, but also EPAs own state-of-science reports, technology assessments, weight-of-evidence analyses, meta-analyses, risk assessments, toxicological profiles of substances, integrated assessment models, hazard determinations, exposure assessments, or health, ecological, or safety assessments. The EPA has not articulated a problem it wants to solve."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that 'Who' proposes broad science restrictions. However, the provided evidence only references the EPA's Science Advisory Board and their opinions about a rule change involving scientific study transparency within the EPA. It does not specify 'Who' is proposing restrictions nor does it link the proposal or its context specifically to the coronavirus pandemic. Therefore, the claim lacks direct support from the given evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.009322051890194416,
    "x2e_entail_prob": 0.0012734057381749153
  },
  {
    "id": "covid_fact-000174",
    "statement": "Moderna provides covid-19 vaccine supply update.",
    "label": "SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses details about the Moderna COVID-19 Vaccine and contains forward-looking statements regarding its development, manufacturing, and distribution. However, there is no specific information or confirmation related to an update on the vaccine supply specifically. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.004458716604858637,
    "x2e_entail_prob": 0.028199966996908188
  },
  {
    "id": "covid_fact-000175",
    "statement": "Cdca provides covid-19 vaccine supply update.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the Moderna COVID-19 Vaccine and the company's forward-looking statements about its development and distribution. However, it does not mention CDCA or any update from them about COVID-19 vaccine supply, so it does not support the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.002094091149047017,
    "x2e_entail_prob": 0.5268715023994446
  },
  {
    "id": "covid_fact-000176",
    "statement": "Wa provides covid-19 vaccine supply update.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.",
      "Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Companys development of a vaccine against the novel coronavirus, and the timeline and scale for manufacturing and distribution of the Moderna COVID-19 Vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information only about the Moderna COVID-19 Vaccine development and manufacturing but does not mention WA or any update about vaccine supply specific to WA.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.004524157382547855,
    "x2e_entail_prob": 0.6905768513679504
  },
  {
    "id": "covid_fact-000177",
    "statement": "Engineered ace2 receptor traps potently neutralize sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that engineered ACE2 receptor traps potently neutralize SARS-CoV-2 by enhancing ACE2-Fc neutralization of the virus, binding viral spike proteins, and being as effective as high-affinity antibodies from convalescent patients. Thus, the claim is supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8268868923187256,
    "x2e_entail_prob": 0.09947989135980606
  },
  {
    "id": "covid_fact-000178",
    "statement": "Engineered ace2 receptor cannot potently neutralize sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that engineered ACE2 receptors can neutralize SARS-CoV-2 infections effectively. Specifically, the optimized ACE2 receptor traps are reported to neutralize the virus as effectively as high-affinity antibodies, suggesting they have a potent neutralizing capability. Thus, the claim that engineered ACE2 receptors cannot potently neutralize SARS-CoV-2 is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.857715368270874,
    "x2e_entail_prob": 0.019125711172819138
  },
  {
    "id": "covid_fact-000179",
    "statement": "Recombinant ace2 receptor traps potently neutralize sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.",
      "The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases.",
      "Engineered ACE2 receptor traps present key advantages in treating SARS-CoV-2 infections.",
      ", Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that optimized ACE2 receptor traps can neutralize authentic SARS-CoV-2 infections effectively, similar to high-affinity antibodies from convalescent patients. This supports the claim that recombinant ACE2 receptor traps potently neutralize SARS-CoV-2.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5957210659980774,
    "x2e_entail_prob": 0.01688750647008419
  },
  {
    "id": "covid_fact-000180",
    "statement": "Professional and home-made face masks reduce exposure to respiratory infections among the general population",
    "label": "SUPPORTED",
    "evidences": [
      "Face- masks worn by the general population could be an accessible and affordable intervention, if effective when worn under routine circumstances.",
      "Conclusions/significance: Any type of general mask use is likely to decrease viral exposure and infection risk on a population level, in spite of imperfect fit and imperfect adherence, personal respirators providing most protection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that any type of general mask use is likely to decrease viral exposure and infection risk, supporting the claim that professional and home-made face masks reduce exposure to respiratory infections among the general population.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.06430447846651077,
    "x2e_entail_prob": 0.002783551812171936
  },
  {
    "id": "covid_fact-000181",
    "statement": "Genomic epidemiology of a densely sampled covid19 outbreak in china",
    "label": "SUPPORTED",
    "evidences": [
      "With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location.",
      "Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim refers to a genomic epidemiology analysis of a COVID-19 outbreak in China. The evidence supports this as it details an analysis of 20 SARS-CoV-2 genomes from a specific outbreak in Weifang, China. This aligns with the claim of a densely sampled outbreak study.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.3475705683231354,
    "x2e_entail_prob": 0.008586223237216473
  },
  {
    "id": "covid_fact-000182",
    "statement": "Genomic epidemiology of a randomly sampled covid19 outbreak in china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location.",
      "Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People's Republic of China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim refers to the genomic epidemiology of a COVID-19 outbreak in China. The evidence supports this, indicating an analysis of 20 whole SARS-CoV-2 genomes from a constrained outbreak in Weifang, China, confirming both the focus on genomic epidemiology and the geographic location. Thus, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8097248673439026,
    "x2e_entail_prob": 0.02359682507812977
  },
  {
    "id": "covid_fact-000183",
    "statement": "Large sars-cov-2 outbreak caused by asymptomatic traveler , china",
    "label": "SUPPORTED",
    "evidences": [
      "Timeline of exposure and connections between cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among persons in Heilongjiang Province, China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only provides a timeline of exposure and connections between cases in Heilongjiang Province, China, without specifically mentioning an outbreak being caused by an asymptomatic traveler. Thus, it does not support the claim as stated.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.002591554308310151,
    "x2e_entail_prob": 0.06924200057983398
  },
  {
    "id": "covid_fact-000184",
    "statement": "One sars-cov-2 outbreak caused by asymptomatic traveler, china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Timeline of exposure and connections between cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among persons in Heilongjiang Province, China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence gives a general reference to a timeline of exposure and connections of SARS-CoV-2 cases in Heilongjiang Province, China, but it does not specifically detail an outbreak caused by an asymptomatic traveler. Therefore, the claim is not clearly supported by the available evidence.",
    "confidence": 0.4,
    "e2x_entail_prob": 0.008492202498018742,
    "x2e_entail_prob": 0.9693353772163391
  },
  {
    "id": "covid_fact-000185",
    "statement": "More than 80 clinical trials launch to test coronavirus treatments",
    "label": "SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that more than 80 clinical trials have been launched to test coronavirus treatments. The evidence refers to the Chinese Clinical Trial Registry, which lists dozens of trials on various treatments. This supports the claim that there are many ongoing trials, potentially more than 80, to test coronavirus treatments.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9583110213279724,
    "x2e_entail_prob": 0.003288934240117669
  },
  {
    "id": "covid_fact-000186",
    "statement": "less than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions 'dozens of other controlled trials'; however, without specifying an exact number, it does not confirm that less than 80 trials have been launched. The expression 'dozens' typically indicates a number larger than 24, and could potentially suggest a total that exceeds 80. Therefore, without more precise data, the claim is not adequately supported by the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.16231700778007507,
    "x2e_entail_prob": 0.0010323761962354183
  },
  {
    "id": "covid_fact-000187",
    "statement": "fewer than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that there are dozens of controlled trials listed in a single database, the Chinese Clinical Trial Registry. Given that this is just one registry and it already includes numerous trials, it suggests that globally, the total number of clinical trials for coronavirus treatments likely exceeds 80. The claim that fewer than 80 trials launch is not supported by this evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.5313047170639038,
    "x2e_entail_prob": 0.0023652873933315277
  },
  {
    "id": "covid_fact-000188",
    "statement": "younger than 80 clinical trials launch to test coronavirus treatments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Chinese Clinical Trial Registry, a database of biomedical studies in China, lists these investigations among dozens of other controlled trials on existing therapies, experimental procedures and traditional medicines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim specifies 'younger than 80 clinical trials' which suggests a count of clinical trials. The available evidence mentions 'dozens' of clinical trials in China but does not provide a specific number. Without an exact count, it is not possible to definitively conclude whether there are fewer than 80 trials.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.311784029006958,
    "x2e_entail_prob": 0.0010767878266051412
  },
  {
    "id": "covid_fact-000189",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in mice.",
    "label": "SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces an efficient antibody response in mice lasting at least 7 months. It also reports a significantly higher number of memory B cells and an enhanced recall response upon antigen challenge, supporting the claim of persistent antibody response and long-term memory.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9840580821037292,
    "x2e_entail_prob": 0.01991451531648636
  },
  {
    "id": "covid_fact-000190",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in humans.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice, not humans. There is no mention of human trials in the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.26955145597457886,
    "x2e_entail_prob": 0.006123805418610573
  },
  {
    "id": "covid_fact-000191",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine induces persistent antibody response and long-term memory in rabbits.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about the ferritin nanoparticle-based SARS-CoV-2 RBD vaccine's effect in mice, showing long-term antibody persistence and memory B cell response. However, it does not mention similar results specifically in rabbits, thus not fully supporting the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0061288620345294476,
    "x2e_entail_prob": 0.009320463053882122
  },
  {
    "id": "covid_fact-000192",
    "statement": "Ferritin nanoparticle based sars-cov-2 rbd vaccine cans persistent antibody response and long-term memory in mice.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, we believe our current study provide the first information about the long-term antibody persistence and memory response of a COVID-19 vaccine.",
      "Here, we report that a ferritin nanoparticle based SARS-CoV-2 RBD vaccine induced in mice an efficient antibody response which lasts for at least 7 months post immunization.",
      "Significantly higher number of memory B cells were maintained and a significantly higher level of recall response was induced upon antigen challenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces an efficient antibody response lasting at least 7 months in mice. Additionally, it mentions that significantly higher numbers of memory B cells and a higher level of recall response are maintained. This directly supports the claim of a persistent antibody response and long-term memory in mice.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9596797823905945,
    "x2e_entail_prob": 0.02870079316198826
  },
  {
    "id": "covid_fact-000193",
    "statement": "Hydroxychloroquine fails to prevent covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from a large randomized, controlled trial indicates that hydroxychloroquine does not prevent people from developing COVID-19, even after a 14-day treatment course. Those who took the drug were just as likely to get COVID-19 as those who took a placebo, supporting the claim that hydroxychloroquine fails to prevent COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9864744544029236,
    "x2e_entail_prob": 0.7965799570083618
  },
  {
    "id": "covid_fact-000194",
    "statement": "Hydroxychloroquine remains to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence demonstrates that hydroxychloroquine offers no benefit in preventing COVID-19. A randomized controlled trial showed that people taking hydroxychloroquine were just as likely to contract COVID-19 as those receiving a placebo. This strongly contradicts the claim that hydroxychloroquine is effective for COVID-19 prevention.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9218398332595825,
    "x2e_entail_prob": 0.08461782336235046
  },
  {
    "id": "covid_fact-000195",
    "statement": "Hydroxychloroquine appears to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that hydroxychloroquine does not offer a benefit in preventing COVID-19. A large randomized, controlled trial showed that those who took hydroxychloroquine were just as likely to contract COVID-19 as those who took a placebo.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9904255270957947,
    "x2e_entail_prob": 0.038625556975603104
  },
  {
    "id": "covid_fact-000196",
    "statement": "Hydroxychloroquine is to prevent covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The additional data we have today provides strong evidence that hydroxychloroquine offers no benefit in preventing people developing COVID-19 with a 14-day treatment course. The results were first presented at IDWeek 2020, the Infectious Disease Society of America's annual scientific meeting, Saturday, Oct. 24.",
      "People who have had close contact with people with confirmed COVID-19 infections who took hydroxychloroquine were just as likely to get COVID-19 as were those who received a placebo, according to a preliminary data analysis from a large randomized, controlled trial.",
      "Media Contact: Susan Gregg - sghanson@uw.edu, 206.390.3226 Getty Images A careful look at hydroxychloroquine finds it ineffective in protecting exposed people from contracting COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that hydroxychloroquine does not prevent contracting COVID-19, with studies showing no benefit in people who took it versus those who received a placebo. Thus, the claim is not supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5867359638214111,
    "x2e_entail_prob": 0.029525769874453545
  },
  {
    "id": "covid_fact-000197",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a narrow bottleneck.",
    "label": "SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that transmission of SARS-CoV-2 in domestic cats involves a narrow bottleneck, typically involving the transmission of only 2-5 viruses. This directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.33516979217529297,
    "x2e_entail_prob": 0.8062755465507507
  },
  {
    "id": "covid_fact-000198",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a global bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that the transmission of SARS-CoV-2 in domestic cats involves a narrow bottleneck, characterized by very few viruses founding new infections. Although the claim uses 'imposes a global bottleneck,' the evidence strongly supports the notion of a bottleneck occurring specifically in the context of domestic cat transmission.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.979001522064209,
    "x2e_entail_prob": 0.7083430886268616
  },
  {
    "id": "covid_fact-000199",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a major bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the transmission of SARS-CoV-2 in domestic cats is defined by a narrow bottleneck, with new infections typically founded by just 2-5 viruses. This supports the claim that transmission in domestic cats imposes a major bottleneck.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9202121496200562,
    "x2e_entail_prob": 0.8546388149261475
  },
  {
    "id": "covid_fact-000200",
    "statement": "Transmission of sars-cov-2 in domestic cats imposes a common bottleneck.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SARS-CoV-2 transmission is defined by a narrow bottleneck.",
      "Transmission of SARS-CoV-2 in cats involved a narrow bottleneck, with new infections founded by fewer than ten viruses.",
      "While estimates of the size of the SARS- CoV-2 transmission bottleneck remain highly discordant in humans, we find very narrow transmission bottlenecks in cats, involving transmission of only 2-5 viruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided directly supports the claim that transmission of SARS-CoV-2 in domestic cats involves a narrow bottleneck. Multiple sources within the evidence confirm that the bottleneck is defined by the transmission of fewer than ten viruses and specify that this ranges from 2-5 viruses during transmission in cats.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.38025304675102234,
    "x2e_entail_prob": 0.9492272734642029
  },
  {
    "id": "covid_fact-000201",
    "statement": "California state epidemiologist statement recommending providers pause administration of single lot of moderna covid-19 vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "California state epidemiologist Dr. Erica Pan issued a statement Sunday recommending providers pause the administration of lot 041L20A of the Moderna COVID-19 vaccine due to possible allergic reactions that are being investigated.",
      "Updated: 10:06 PM PST Jan 18, 2021 KCRA Staff UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials sayORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions.",
      "SACRAMENTO, Calif. -- UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials say Advertisement ORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that California state epidemiologist Dr. Erica Pan recommended providers pause the administration of a specific lot (041L20A) of the Moderna COVID-19 vaccine due to possible allergic reactions that were being investigated. This matches the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.522750198841095,
    "x2e_entail_prob": 0.026632100343704224
  },
  {
    "id": "covid_fact-000202",
    "statement": "California state epidemiologist statement recommending providers include administration of single lot of moderna covid-19 vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "California state epidemiologist Dr. Erica Pan issued a statement Sunday recommending providers pause the administration of lot 041L20A of the Moderna COVID-19 vaccine due to possible allergic reactions that are being investigated.",
      "Updated: 10:06 PM PST Jan 18, 2021 KCRA Staff UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials sayORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions.",
      "SACRAMENTO, Calif. -- UPDATE: Pause lifted on batch of Moderna COVID-19 vaccines, health officials say Advertisement ORIGINAL STORY: California's top epidemiologist has asked providers to stop giving shots from a batch of the Moderna COVID-19 vaccine as the state investigates reports of allergic reactions."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that California state epidemiologist Dr. Erica Pan recommended providers pause the administration of a specific lot of the Moderna COVID-19 vaccine, not include it. The recommendation to pause was due to investigations of possible allergic reactions, which contradicts the claim that suggests inclusion.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.052545398473739624,
    "x2e_entail_prob": 0.01217207033187151
  },
  {
    "id": "covid_fact-000203",
    "statement": "Baricitinib restrains the immune dysregulation in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that baricitinib, a JAK1/JAK2 inhibitor, is effective in correcting immune abnormalities in COVID-19 patients. This supports the claim that baricitinib can restrain immune dysregulation in these patients.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.08909875899553299,
    "x2e_entail_prob": 0.9633224606513977
  },
  {
    "id": "covid_fact-000204",
    "statement": "Uncitinib restrains the immune dysregulation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the efficacy of baricitinib, not uncitinib, in addressing immune dysregulation in COVID-19 patients. Without evidence specifically about uncitinib, the claim cannot be supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.01839529350399971,
    "x2e_entail_prob": 0.08950544148683548
  },
  {
    "id": "covid_fact-000205",
    "statement": "Excitinib restrains the immune dysregulation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the efficacy of baricitinib, which is a JAK1/JAK2 inhibitor, in addressing immune dysregulation in COVID-19 patients. However, the claim is about excitinib, which is not mentioned or supported by the evidence. Thus, the claim is not supported by the given evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.01140107773244381,
    "x2e_entail_prob": 0.9778333306312561
  },
  {
    "id": "covid_fact-000206",
    "statement": "Us covid-19 deaths poorly predicted by ihme model",
    "label": "SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that 70% of US states had actual death rates outside the IHME model's 95% prediction interval, indicating significant discrepancies in predictions. This suggests the model's predictions were not accurately aligned with actual death rates, supporting the claim that US COVID-19 deaths were poorly predicted by the IHME model.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9120544195175171,
    "x2e_entail_prob": 0.0036281372886151075
  },
  {
    "id": "covid_fact-000207",
    "statement": "Us covid-19 deaths as predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the IHME model accurately predicts US COVID-19 deaths, but the evidence indicates that the actual death rates in 70% of US states were outside the 95% prediction interval of the model, suggesting that the model struggled with accuracy. This casts doubt on the model's suitability to predict COVID-19 outcomes, thereby not supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.770573616027832,
    "x2e_entail_prob": 0.0029549833852797747
  },
  {
    "id": "covid_fact-000208",
    "statement": "Us covid-19 deaths previously predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the IHME model was associated with COVID-19 death predictions, as death rates falling outside the model's predictive interval are mentioned. While the evidence highlights flaws in the predictions, particularly underestimated uncertainties, it supports the claim that the IHME model was indeed used for predicting US COVID-19 deaths.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.4190884530544281,
    "x2e_entail_prob": 0.0011785648530349135
  },
  {
    "id": "covid_fact-000209",
    "statement": "Us covid-19 deaths were predicted by ihme model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Seventy percent of US states had an actual death rate outside the 95 percent prediction interval for that state, casting doubt on whether the model is suitable to inform COVID-19 resource allocation.",
      "Credit: Pixabay An international group of renowned statisticians from the University of Sydney, Northwestern University and the University of Texas have collaborated to fully investigate the predictive performance of the COVID-19 model developed by Institute for Health Metrics and Evaluation (IHME)  which provides forecasts for ventilator use and hospital beds in the United States.",
      "I am concerned that if the UW-IHME model has had difficulty in predicting the next day, how will the predictions fair over the long term, said Professor Tanner.",
      "Published on pre-publication server arXiv, the researchers found that the IHME model substantially underestimates the uncertainty associated with COVID-19 deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that 70 percent of US states had actual death rates outside the model's 95 percent prediction interval, suggesting that the IHME model's predictions were not accurate. Therefore, the claim that US COVID-19 deaths were accurately predicted by the IHME model is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.895386815071106,
    "x2e_entail_prob": 0.005898482631891966
  },
  {
    "id": "covid_fact-000210",
    "statement": "China 's changing coronavirus case count is not unusual in an outbreak , health official says",
    "label": "SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided includes a statement from Sylvie Briand, WHO director, acknowledging that it is not unusual to count cases in different ways as an epidemic evolves. This supports the claim that China's changing coronavirus case count is not unusual during an outbreak. While the evidence does not directly address all aspects of the claim, it aligns with the general assertion made by the health official.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5954790711402893,
    "x2e_entail_prob": 0.12491685152053833
  },
  {
    "id": "covid_fact-000211",
    "statement": "China's changing coronavirus case count is not available in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that there is confusion over how China is counting COVID-19 cases, but it does not specifically state that China's case count is not available. The claim suggests the case count is unavailable, but the evidence only points to changing methods and resulting confusion, not a lack of data availability.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.1388956606388092,
    "x2e_entail_prob": 0.25558966398239136
  },
  {
    "id": "covid_fact-000212",
    "statement": "China's changing coronavirus case count is very unusual in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that it is not unusual to count cases differently as the epidemic evolves, according to WHO official Sylvie Briand. Additionally, while there is confusion over how China is counting cases, there is no clear indication in the evidence that this makes China's case count 'very unusual' in an outbreak. The evidence therefore does not directly support the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7594186663627625,
    "x2e_entail_prob": 0.24425938725471497
  },
  {
    "id": "covid_fact-000213",
    "statement": "China's changing coronavirus case count is particularly unusual in an outbreak, health official says",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.",
      "Confusion over how China is counting cases of infections is making it harder to know how coronavirus is spreading, even as China is officially reporting that the numbers of new cases reported in recent days have fallen sharply.",
      "\"Its not unusual to count things in different ways as the epidemic evolves, said Sylvie Briand, WHO director of the infectious hazards management department.\"",
      "Asked by reporters about the potential impact of the coronavirus on the economy and whether he anticipates it being similar to the effect of SARS, Kudlow said, I understand the risks, and I understand these things could change quickly, but right now what we know is theres barely any impact here at home. \"The human toll in my opinion is more important than the statistics [Chinas] getting hurt very badly, he added. \""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence highlights confusion over how China is counting cases, suggesting that China's coronavirus case count practices are different and causing difficulties in understanding the spread of the virus. This supports the claim that the case count is particularly unusual.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5069020390510559,
    "x2e_entail_prob": 0.1125875934958458
  },
  {
    "id": "covid_fact-000214",
    "statement": "Results released for antibody and covid-19 testing of boston residents",
    "label": "SUPPORTED",
    "evidences": [
      "Mayor Martin J. Walsh, together with Massachusetts General Hospital (MGH), and the Boston Public Health Commission (BPHC), today announced the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.",
      "In conclusion, approximately 1 in 10 residents in this study have developed antibodies and approximately 1 in 40 currently asymptomatic individuals are positive for COVID-19 and potentially infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim about results being released for antibody and COVID-19 testing of Boston residents is confirmed by the evidence, which states that 9.9% of the sampled residents tested positive for antibodies, and 2.6% of the asymptomatic individuals tested positive for COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6731477975845337,
    "x2e_entail_prob": 0.025615321472287178
  },
  {
    "id": "covid_fact-000215",
    "statement": "Results released for antibody and covid-19 production of boston residents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mayor Martin J. Walsh, together with Massachusetts General Hospital (MGH), and the Boston Public Health Commission (BPHC), today announced the study to evaluate community exposure to COVID-19 through a representative sampling of asymptomatic Boston residents resulted in 9.9% testing positive for antibodies and 2.6% of currently asymptomatic individuals testing positive for COVID-19.",
      "In conclusion, approximately 1 in 10 residents in this study have developed antibodies and approximately 1 in 40 currently asymptomatic individuals are positive for COVID-19 and potentially infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions results from a study of Boston residents which found 9.9% tested positive for antibodies and 2.6% of asymptomatic individuals tested positive for COVID-19. This supports the claim regarding results related to antibody and COVID-19 production among Boston residents.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5063430070877075,
    "x2e_entail_prob": 0.008461629040539265
  },
  {
    "id": "covid_fact-000216",
    "statement": "Vulnerable populations , such as older adults and those with underlying medical conditions , should wear face masks if available .",
    "label": "SUPPORTED",
    "evidences": [
      "Wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
      "Perhaps it would also be rational to recommend that people in quarantine wear face masks if they need to leave home for any reason, to prevent potential asymptomatic or presymptomatic transmission."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that wearing face coverings can reduce the spread of infection by asymptomatic or presymptomatic individuals, but it does not specifically mention vulnerable populations or those with underlying medical conditions. Thus, it does not directly support the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0025909438263624907,
    "x2e_entail_prob": 0.0030366252176463604
  },
  {
    "id": "covid_fact-000217",
    "statement": "Vulnerable populations, such as older adults and those with underlying medical conditions, not wear face masks if available.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wearing a face covering can help to reduce the chance that those who may not know they are sick will spread the infection to others.",
      "Perhaps it would also be rational to recommend that people in quarantine wear face masks if they need to leave home for any reason, to prevent potential asymptomatic or presymptomatic transmission."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that vulnerable populations should not wear face masks if available, but the provided evidence emphasizes the importance of wearing face masks to prevent the spread of infections, especially for those who might not know they are sick. Thus, the evidence does not support the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.027883483096957207,
    "x2e_entail_prob": 0.0021472687367349863
  },
  {
    "id": "covid_fact-000218",
    "statement": "The differing immune system responses of patients with covid-19 can help predict who will experience moderate and severe consequences of disease , according to a new study",
    "label": "SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly supports the claim by indicating that a new study suggests differing immune system responses can help predict the severity of COVID-19 consequences. This conclusion is supported by reported differences in immune parameters between mild and severe cases, and the potential use of findings in identifying high-risk individuals and suggesting treatments.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9072616100311279,
    "x2e_entail_prob": 0.044104840606451035
  },
  {
    "id": "covid_fact-000219",
    "statement": "The differing immune system responses of patients with covid-19 cannot help predict who will experience moderate and severe consequences of disease, according to a new study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence directly contradicts the claim by stating that a new study finds that differing immune system responses can help predict who will experience moderate and severe consequences of COVID-19. This is the opposite of what the claim states.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.011945104226469994,
    "x2e_entail_prob": 0.06964336335659027
  },
  {
    "id": "covid_fact-000220",
    "statement": "The differing immune system responses of patients with covid-19 can help predict who will experience moderate and severe consequences of disease, according to a previous study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Tables show the immune parameters that have been reported to differ between mild and severe COVID-19.",
      "(Express Photo: Amit Chakravarty) A new study suggests that the differing immune system responses of Covid-19 patients can help predict who will experience moderate and severe consequences of disease.",
      "The findings may help identify individuals at high risk of severe illness early in their hospitalization and suggest drugs to treat COVID-19.",
      "More carefully defining distinct classes of T cell response types in COVID-19 and delineating how pre-existing conditions, co-morbidities, race, immune health status and other variables influence T cell responses should reveal novel opportunities for treatment and prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that differing immune system responses among COVID-19 patients can help predict who will experience varying degrees of severity in disease consequences. This supports the claim that these immune response differences can indicate moderate to severe outcomes.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8984155058860779,
    "x2e_entail_prob": 0.04903867840766907
  },
  {
    "id": "covid_fact-000221",
    "statement": "Father with motor neurone disease dies from coronavirus in uk",
    "label": "SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions an individual, Craig Ruston, battling motor neurone disease, but it does not confirm his death from coronavirus. Further information is required to support the entire claim of his death from coronavirus in the UK.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.04010720178484917,
    "x2e_entail_prob": 0.03574493154883385
  },
  {
    "id": "covid_fact-000222",
    "statement": "Father with motor neurone disease originated from coronavirus in uk",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide any connection between motor neurone disease and coronavirus, nor does it support the claim that motor neurone disease originated from coronavirus in the UK. It merely states that an individual named Craig Ruston was battling motor neurone disease alongside the mention of COVID-19, without establishing a causal link between the two.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.04494862258434296,
    "x2e_entail_prob": 0.07276756316423416
  },
  {
    "id": "covid_fact-000223",
    "statement": "Father with motor neurone disease differs from coronavirus in uk",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 18 March 2020 09:36, UK COVID-19 Coronavirus Image: Craig Ruston was battling motor neurone disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions a person with motor neurone disease and the date in the context of the UK, but it doesn't provide any information or comparison indicating how motor neurone disease differs from coronavirus in the UK. Thus, the claim about their differences is not directly supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.033362291753292084,
    "x2e_entail_prob": 0.018391964957118034
  },
  {
    "id": "covid_fact-000224",
    "statement": "Yale 's rapid covid-19 saliva test receives fda emergency use authorization",
    "label": "SUPPORTED",
    "evidences": [
      "Stat: FDA Clears Saliva Test For Covid-19, Opening Door To Wider Testing The Food and Drug Administration on Saturday authorized emergency use of a new and inexpensive saliva test for Covid-19 that could greatly expand testing capacity.",
      "A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
      "NEW HAVEN, Conn. \\- A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the FDA granted emergency use authorization to a new saliva-based Covid-19 test developed by Yale University. The test, known as SalivaDirect, received the authorization, supporting the claim.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.5640503764152527,
    "x2e_entail_prob": 0.04014014080166817
  },
  {
    "id": "covid_fact-000225",
    "statement": "Yale's rapid covid-19 saliva test without fda emergency use authorization",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Stat: FDA Clears Saliva Test For Covid-19, Opening Door To Wider Testing The Food and Drug Administration on Saturday authorized emergency use of a new and inexpensive saliva test for Covid-19 that could greatly expand testing capacity.",
      "A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.",
      "NEW HAVEN, Conn. \\- A new saliva-based laboratory diagnostic test for the novel coronavirus developed by researchers at Yale University's School of Public Health has been granted an emergency use authorization by the Food and Drug Administration.",
      "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing 1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Yale's saliva-based COVID-19 test was granted an emergency use authorization (EUA) by the FDA. Therefore, the claim that it was developed without such authorization is not supported by the evidence.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.16732226312160492,
    "x2e_entail_prob": 0.09032686054706573
  },
  {
    "id": "covid_fact-000226",
    "statement": "The antiviral compound remdesivir potently inhibits rna-dependent rna polymerase from middle east respiratory syndrome coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.",
      "Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that remdesivir is a broad-spectrum antiviral with activity against RNA viruses, including MERS-CoV, which indicates it inhibits RNA-dependent RNA polymerase from MERS-CoV. Thus, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9231469035148621,
    "x2e_entail_prob": 0.03338310495018959
  },
  {
    "id": "covid_fact-000227",
    "statement": "The antiviral compound remdesivir potently binds rna-dependent rna polymerase from middle east respiratory syndrome coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.",
      "Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that remdesivir is an antiviral compound with broad spectrum antiviral activities against RNA viruses, including Middle East respiratory syndrome coronavirus (MERS-CoV). This implies that remdesivir would potently bind to the RNA-dependent RNA polymerase of MERS-CoV, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.11971350014209747,
    "x2e_entail_prob": 0.02424958534538746
  },
  {
    "id": "covid_fact-000228",
    "statement": "Trials of oxford coronavirus vaccine begin in kenya",
    "label": "SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that trials of the Oxford coronavirus vaccine (ChAdOx1 nCoV-19) have begun in Kenya with initial involvement of 40 frontline workers in Kilifi County. The evidence statement from Professor Andy Pollard supports the claim that Kenya is participating in these trials alongside other countries.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8607560992240906,
    "x2e_entail_prob": 0.0014285128563642502
  },
  {
    "id": "covid_fact-000229",
    "statement": "Lack of oxford coronavirus vaccine begin in kenya",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests a lack of the Oxford coronavirus vaccine begins in Kenya. However, the evidence indicates that vaccine trials have begun in Kenya, involving 40 frontline workers. This does not support a claim of a lack of vaccines but rather shows active participation in vaccine trials. Thus, the claim is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.08968761563301086,
    "x2e_entail_prob": 0.001181584084406495
  },
  {
    "id": "covid_fact-000230",
    "statement": "Trials of oxford coronavirus vaccine begin in great",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.",
      "The trial in Kenya will initially involve 40 frontline workers in Kilifi County.",
      "Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: Were excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible. Kenya joins a number of countries including the United Kingdom, South Africa and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that trials of the Oxford coronavirus vaccine have begun, as it mentions that trials are taking place in multiple countries, including Kenya, with volunteers receiving vaccinations, indicating the start of trials.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7484365701675415,
    "x2e_entail_prob": 0.0014755349839106202
  },
  {
    "id": "covid_fact-000231",
    "statement": "Pandemic infection rates are deterministic but can not be modeled",
    "label": "SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that pandemic infection rates are deterministic, in the sense that they can be calculated from daily data, but are difficult to model and predict over time. Models that rely on fixed rates or averages fail to capture the observed complexity in infection rates, which change daily and cannot be accurately forecasted for long periods or near peaks. Thus, the claim that infection rates are deterministic but cannot be modeled is supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9829277396202087,
    "x2e_entail_prob": 0.6553853154182434
  },
  {
    "id": "covid_fact-000232",
    "statement": "Pandemic infection rates are deterministic but can then be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that pandemic infection rates cannot be accurately predicted using deterministic modeling methods. The observed infection rates cannot be modeled and predicted accurately using fixed initial conditions. Thus, the claim that pandemic infection rates are deterministic is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.885097324848175,
    "x2e_entail_prob": 0.21170026063919067
  },
  {
    "id": "covid_fact-000233",
    "statement": "Pandemic infection rates are deterministic but can therefore be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that pandemic infection rates are complex and cannot be accurately predicted using models with fixed parameters or assumptions. This indicates that the rates have a level of complexity that challenges deterministic modeling, as they are not consistent or predictable over time.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8289077877998352,
    "x2e_entail_prob": 0.417455792427063
  },
  {
    "id": "covid_fact-000234",
    "statement": "Pandemic infection rates are deterministic but can also be modeled",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Model predictions fail because the observed infection rates are beyond modeling: any model that uses fixed rates or uses memory or averages of past rates cannot reproduce the data on active infections.",
      "SUMMARYREFERENCES The pandemic infection rates to two to three decimal places are an example of complexity: the infection rates can be calculated daily from the infections but they cannot be modeled and predicted from fixed initial conditions.",
      "Second, model building does not and cannot reflect real epidemic data because the only correct rates emerge day by day in the daily data, cannot be usefully forecast for more than a few days in advance, and cannot be forecast at all correctly near a peak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that pandemic infection rates are deterministic but can also be modeled. However, the evidence indicates that infection rates cannot be effectively modeled with fixed rates or averages due to their complexity and variability. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.29413920640945435,
    "x2e_entail_prob": 0.22648432850837708
  },
  {
    "id": "covid_fact-000235",
    "statement": "New coronavirus variant is identified in uk.",
    "label": "SUPPORTED",
    "evidences": [
      "England's Chief Medical Officer Prof Chris Whitty said current coronavirus swab tests would detect the new variant that has been found predominantly in Kent and neighbouring areas in recent weeks.",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.",
      "It is thought the variant either emerged in a patient in the UK or has been imported from a country with a lower ability to monitor coronavirus mutations.",
      "A number of variants have already been detected in the UK.",
      "Matt Hancock said the new variant of coronavirus \"may be associated\" with the faster spread in the south-east of England."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence includes statements from UK officials acknowledging the identification of a new coronavirus variant in the UK, specifically in Kent and neighboring areas. This supports the claim that a new coronavirus variant has been identified in the UK.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.635282576084137,
    "x2e_entail_prob": 0.001821998506784439
  },
  {
    "id": "covid_fact-000236",
    "statement": "No coronavirus variant is identified in uk.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "England's Chief Medical Officer Prof Chris Whitty said current coronavirus swab tests would detect the new variant that has been found predominantly in Kent and neighbouring areas in recent weeks.",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.",
      "It is thought the variant either emerged in a patient in the UK or has been imported from a country with a lower ability to monitor coronavirus mutations.",
      "A number of variants have already been detected in the UK.",
      "Matt Hancock said the new variant of coronavirus \"may be associated\" with the faster spread in the south-east of England."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that several coronavirus variants have been detected in the UK. This directly contradicts the claim that no coronavirus variant is identified in the UK, making the claim not supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.04376420006155968,
    "x2e_entail_prob": 0.003130001248791814
  },
  {
    "id": "covid_fact-000237",
    "statement": "The coronavirus has mutated and appears to be more contagious now , new study finds",
    "label": "SUPPORTED",
    "evidences": [
      "The coronavirus has mutated and May52020 COVID19 KEY POINTS: The coronavirus that emerged in Wuhan, China, has mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study.",
      "If the coronavirus doesnt subside in the summer like the seasonal flu, it could mutate further and potentially limit the effectiveness of the coronavirus vaccines being developed by scientists around the world, the researchers warned.",
      "The coronavirus that emerged in Wuhan, China, over four months ago has since mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a new study suggesting that the coronavirus has mutated into a strain that appears to be more contagious, corroborating the claim. The claim and evidence are consistent, reflecting the findings of the study.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7713602781295776,
    "x2e_entail_prob": 0.1939634531736374
  },
  {
    "id": "covid_fact-000238",
    "statement": "The coronavirus has mutated and appears to be more contagious before, new study finds",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The coronavirus has mutated and May52020 COVID19 KEY POINTS: The coronavirus that emerged in Wuhan, China, has mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study.",
      "If the coronavirus doesnt subside in the summer like the seasonal flu, it could mutate further and potentially limit the effectiveness of the coronavirus vaccines being developed by scientists around the world, the researchers warned.",
      "The coronavirus that emerged in Wuhan, China, over four months ago has since mutated and the new, dominant strain spreading across the U.S. appears to be even more contagious, according to a new study."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided confirms that the coronavirus has mutated and the new dominant strain spreading across the U.S. appears to be even more contagious. This directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.13924144208431244,
    "x2e_entail_prob": 0.16791985929012299
  },
  {
    "id": "covid_fact-000239",
    "statement": "Two known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a recommendation to add two therapies to the therapeutic arsenal for critical COVID-19 patients, indicating they may be useful. However, it explicitly states that clinical trials are necessary, suggesting these therapies are not yet proven or known to be effective as adjuvant therapies. Thus, the claim that these therapies 'could be useful' is speculative without completed trials supporting their efficacy.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0566520132124424,
    "x2e_entail_prob": 0.33371666073799133
  },
  {
    "id": "covid_fact-000240",
    "statement": "Many known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided vaguely suggests that there might be potential therapies, but it does not specify what these therapies are, nor does it provide any detail on their established utility or success in treating critical COVID-19 patients. Clinical trials are mentioned as necessary, indicating that effectiveness has not been conclusively demonstrated yet.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.013644952327013016,
    "x2e_entail_prob": 0.005145421717315912
  },
  {
    "id": "covid_fact-000241",
    "statement": "Several known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the potential benefit of two unspecified therapies and suggests adding them to the therapeutic arsenal. However, it does not provide explicit information on the therapies or confirm their usefulness as adjuvant therapy in critical COVID-19 patients. Clinical trials are mentioned as necessary, indicating that the claim is speculative rather than confirmed by evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.006053744349628687,
    "x2e_entail_prob": 0.43453583121299744
  },
  {
    "id": "covid_fact-000242",
    "statement": "All known therapies could be useful as adjuvant therapy in critical patients infected by covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only suggests the potential benefit of two unnamed therapies but does not support the claim that all known therapies could be useful as adjuvant therapy for COVID-19 patients. Furthermore, it highlights the necessity of clinical trials, implying that the safety and efficacy of these therapies have not been fully established.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.012212255969643593,
    "x2e_entail_prob": 0.01548630092293024
  },
  {
    "id": "covid_fact-000243",
    "statement": "Protein structure and sequence reanalysis of 2019-ncov genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and hiv-1",
    "label": "SUPPORTED",
    "evidences": [
      "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that the analysis is about two studies, one of which claims that snakes are the intermediate hosts of 2019-nCoV and the other claims a similarity between 2019-nCoV spike protein insertions and HIV-1. However, there is no conclusion or refutation provided in the evidence, merely an analysis. Therefore, without explicit evidence supporting the specific refutation claim, it's not possible to support the claim fully based on this evidence alone.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.2465459257364273,
    "x2e_entail_prob": 0.35277488827705383
  },
  {
    "id": "covid_fact-000244",
    "statement": "Protein structure and sequence reanalysis of 2019-ncov genome refutes bats as its intermediate host and the unique similarity between its spike protein insertions and hiv-1",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests there was an analysis of studies claiming snakes as the intermediate hosts and the similarity of the spike protein insertions to HIV-1, but it doesn't provide information supporting the claim that bats are not the intermediate host or confirming similarities to HIV-1. The evidence is insufficient to support the claim made.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.031236836686730385,
    "x2e_entail_prob": 0.030677344650030136
  },
  {
    "id": "covid_fact-000245",
    "statement": "Mhra suspends recruitment to covid-19 hydroxychloroquine trials",
    "label": "SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The MHRA considered evidence from trials including the UK RECOVERY trial, which showed no mortality benefit of hydroxychloroquine for COVID-19 patients. This aligns with the claim that recruitment to hydroxychloroquine trials for COVID-19 was suspended, as it indicates a lack of effectiveness.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0013081311481073499,
    "x2e_entail_prob": 0.7165204882621765
  },
  {
    "id": "covid_fact-000246",
    "statement": "Mhra acts recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the MHRA evaluated the results of trials concerning the use of hydroxychloroquine for treating COVID-19, such as the UK's RECOVERY trial. However, it does not confirm any action related to recruitment by the MHRA for these trials. Thus, the claim is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.005885644815862179,
    "x2e_entail_prob": 0.12525513768196106
  },
  {
    "id": "covid_fact-000247",
    "statement": "Mhra 1990s recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not mention any recruitment by the MHRA to hydroxychloroquine trials during the 1990s or even a direct involvement in such trials. The evidence only discusses the MHRA's evaluation of recent trial results on hydroxychloroquine for COVID-19, specifically the RECOVERY trial, which provided no meaningful mortality benefit in hospitalized COVID-19 patients. The claim seems to be confusing the time period or the context, as no 1990s recruitment is mentioned.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.05881252884864807,
    "x2e_entail_prob": 0.12232276797294617
  },
  {
    "id": "covid_fact-000248",
    "statement": "Mhra 1980s recruitment to covid-19 hydroxychloroquine trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We followed the emerging concerns about use of hydroxychloroquine in COVID-19, and took into consideration the results from two different trials, including the UKs RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.",
      "The MHRA took into consideration the results released from the RECOVERY trial, showing no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19, and a New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of COVID-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the MHRA's consideration and response to trial results on hydroxychloroquine's effectiveness for COVID-19, but it does not mention any recruitment to hydroxychloroquine trials by the MHRA in the 1980s. The claim refers to an action in the 1980s, which is not covered in the evidence related to COVID-19 trials.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01960587687790394,
    "x2e_entail_prob": 0.1621483415365219
  },
  {
    "id": "covid_fact-000249",
    "statement": "Transcriptional profiling reveals trpm5-expressing cells involved in viral infection in the olfactory epithelium",
    "label": "SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that TRPM5-expressing cells are involved in viral infection and are present in the olfactory epithelium, confirming both transcriptional profiling of these cells and their involvement in viral infection in the olfactory epithelium.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8918041586875916,
    "x2e_entail_prob": 0.21409469842910767
  },
  {
    "id": "covid_fact-000250",
    "statement": "Transcriptional profiling reveals trpm5-deficient cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that TRPM5-expressing cells in the olfactory epithelium play a role in viral infection, as they contain transcripts involved in inflammation, immunity, and viral infection. Although the claim states 'trpm5-deficient,' the evidence focuses on TRPM5-expressing cells. However, it implicitly supports the notion that cells with TRPM5 have a role in viral infections, aligning with the claim's context.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4447266757488251,
    "x2e_entail_prob": 0.14002321660518646
  },
  {
    "id": "covid_fact-000251",
    "statement": "Transcriptional profiling reveals trpm5-depleted cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that transcriptional profiling has revealed the involvement of trpm5-depleted cells in viral infection specifically in the olfactory epithelium. The evidence provided indicates that TRPM5-expressing cells, not trpm5-depleted, in the olfactory epithelium are involved in viral infection, along with expressing various transcripts involved in inflammation, immunity, and viral infection. Therefore, the claim is not supported by the evidence as the focus is on trpm5-depleted rather than trpm5-expressing cells.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.019235799089074135,
    "x2e_entail_prob": 0.028047500178217888
  },
  {
    "id": "covid_fact-000252",
    "statement": "Immunal profiling reveals trpm5-expressing cells involved in viral infection in the olfactory epithelium",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Specialized chemosensory epithelial cells that express the transient receptor potential cation channel subfamily M member 5 (TRPM5) are found throughout the airways and intestinal epithelium and are involved in responses to viral infection.",
      "Our study provides new insights into a potential role for TRPM5-expressing cells in viral infection of the olfactory epithelium.",
      "We find profuse expression of transcripts involved in inflammation, immunity and viral infection in TRPM5-expressing microvillous cells and olfactory sensory neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that TRPM5-expressing cells are involved in responses to viral infection, and highlights a potential role specifically within the olfactory epithelium. The presence of transcripts related to inflammation, immunity, and viral infection in TRPM5-expressing cells supports the claim. Therefore, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9672410488128662,
    "x2e_entail_prob": 0.6419748663902283
  },
  {
    "id": "covid_fact-000253",
    "statement": "Aprotinin inhibits sars-cov-2 replication",
    "label": "SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that aprotinin inhibits the replication of SARS-CoV-2 at therapeutically achievable concentrations. The claim is supported by specific evidence demonstrating aprotinin's anti-SARS-CoV-2 activity across multiple cell types and virus isolates.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8250835537910461,
    "x2e_entail_prob": 0.8049451112747192
  },
  {
    "id": "covid_fact-000254",
    "statement": "Aprotinin 1980s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does indicate that aprotinin has anti-SARS-CoV-2 activity, but there is no mention of the 1980s in relation to aprotinin or SARS-CoV-2. SARS-CoV-2, the virus responsible for COVID-19, emerged after 2019, making any such claim about its replication in the 1980s irrelevant.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.012936480343341827,
    "x2e_entail_prob": 0.4799920618534088
  },
  {
    "id": "covid_fact-000255",
    "statement": "Aprotinin (s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that aprotinin exhibits anti-SARS-CoV-2 activity by inhibiting the replication of the virus in various cell types and against multiple virus isolates. This supports the claim that aprotinin affects SARS-CoV-2 replication.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.916654646396637,
    "x2e_entail_prob": 0.6594367623329163
  },
  {
    "id": "covid_fact-000256",
    "statement": "Aprotinin 1970s sars-cov-2 replication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity.",
      "Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations.",
      "Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that aprotinin has anti-SARS-CoV-2 activity and can inhibit its replication. However, there is no information in the evidence that links aprotinin's use or discovery to the 1970s. Thus, the claim's connection to the '1970s' is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.04092186316847801,
    "x2e_entail_prob": 0.7735947966575623
  },
  {
    "id": "covid_fact-000257",
    "statement": "Homozygous l-sign plays a protective role in sars coronavirus infection",
    "label": "SUPPORTED",
    "evidences": [
      "Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection.",
      "Thus, homozygosity for L-SIGN plays a protective role during SARS infection.",
      "Homozygous L-SIGN ( CLEC4M ) plays a protective role in SARS coronavirus infection.",
      "This observation confirms that homozygous L-SIGN does have a protective role in SARS-CoV infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided explicitly states multiple times that homozygous L-SIGN plays a protective role in SARS coronavirus infection, thereby supporting the claim.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.01803848147392273,
    "x2e_entail_prob": 0.9501297473907471
  },
  {
    "id": "covid_fact-000258",
    "statement": "Homozygous l-atpase plays a protective role in sars coronavirus infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection.",
      "Thus, homozygosity for L-SIGN plays a protective role during SARS infection.",
      "Homozygous L-SIGN ( CLEC4M ) plays a protective role in SARS coronavirus infection.",
      "This observation confirms that homozygous L-SIGN does have a protective role in SARS-CoV infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence consistently mentions that homozygous L-SIGN (CLEC4M), not l-atpase, plays a protective role in SARS coronavirus infection. There is no mention of homozygous l-atpase in the evidence provided, indicating the claim is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.2658514082431793,
    "x2e_entail_prob": 0.9120925068855286
  },
  {
    "id": "covid_fact-000259",
    "statement": "The us doesnt have enough hospital beds for a bad coronavirus outbreak.",
    "label": "SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presents concerns from both New York Governor Andrew Cuomo and doctors about America's lack of sufficient hospital beds in the face of a severe coronavirus outbreak. These concerns underline the notion that the U.S. may struggle to accommodate a large number of patients should a major outbreak occur, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3424854874610901,
    "x2e_entail_prob": 0.02182845212519169
  },
  {
    "id": "covid_fact-000260",
    "statement": "The usset have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided clearly states concerns from officials like Governor Cuomo and doctors about the U.S. not having enough hospital beds to handle a large coronavirus outbreak. This suggests a lack of resources rather than sufficiency, contradicting the claim that there are enough hospital beds for a major outbreak. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.03029981069266796,
    "x2e_entail_prob": 0.02976510114967823
  },
  {
    "id": "covid_fact-000261",
    "statement": "The uswt have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that the US would not have enough hospital beds for a severe coronavirus outbreak. Multiple sources, including a warning from New York Governor Cuomo and other earlier warnings from doctors, indicate that a larger outbreak could overwhelm hospital capacity and lead to shortages in medical supplies.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.926735520362854,
    "x2e_entail_prob": 0.13694646954536438
  },
  {
    "id": "covid_fact-000262",
    "statement": "The usert have enough hospital beds for a bad coronavirus outbreak.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Cuomo warns US won't have enough hospital beds for coronavirus pandemic Published Mon, Mar 16 202011:27 AM EDTUpdated Mon, Mar 16 202012:18 PM EDT Berkeley Lovelace Jr.@BerkeleyJr ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email New York Gov.",
      "Dillinger March.13.2020 at 12:32 pm >>America Doesn't Have Enough Hospital Beds To Fight the Coronavirus virus impervious to the little wheels.",
      "Earlier in the outbreak, doctors warned that a larger outbreak of the new coronavirus across the U.S. could overwhelm emergency rooms and quickly cause supply shortages of some crucial medical supplies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates concerns and warnings from various sources that the U.S. may not have enough hospital beds to handle a severe coronavirus outbreak. This suggests a lack of confidence in sufficient hospital bed availability during a major outbreak.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.754317581653595,
    "x2e_entail_prob": 0.01220142561942339
  },
  {
    "id": "covid_fact-000263",
    "statement": "La doctor seeing 100 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions that the LA doctor, Dr. Anthony Cardillo, has seen promising results with hydroxychloroquine and zinc, particularly in severely-ill COVID-19 patients. However, it does not claim or provide evidence of a 100% success rate. Without explicit evidence of a 100% success rate, the claim is not supported by the given evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.881243109703064,
    "x2e_entail_prob": 0.1972082108259201
  },
  {
    "id": "covid_fact-000264",
    "statement": "La doctor seeing 80 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions an 80% success rate with hydroxychloroquine and zinc for treating COVID-19. While the evidence suggests that Dr. Anthony Cardillo reported 'very promising results' with the combination for severely ill patients, there is no specific mention of an 80% success rate. Therefore, the claim regarding the specific success rate is not supported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0403074286878109,
    "x2e_entail_prob": 0.04701552540063858
  },
  {
    "id": "covid_fact-000265",
    "statement": "La doctor seeing 60 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence suggests that Dr. Anthony Cardillo claims to have seen promising results using hydroxychloroquine and zinc to treat COVID-19, there is no mention of a specific 60% success rate in the provided evidence. Therefore, the claim of a 60% success rate is not supported by the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.12557785212993622,
    "x2e_entail_prob": 0.12743906676769257
  },
  {
    "id": "covid_fact-000266",
    "statement": "La doctor seeing 70 % success with hydroxychloroquine and zinc to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "LA doctor seeing success with hydroxychloroquine to treat COVID-19 - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.",
      "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients.",
      "SO, the \"drug cocktail\" to treat COVID-19 patients is : hydroxychloroquine+azithromycin+ZINC SULFATE.",
      "Treatment with HCQ and zinc only  Dr. Cardillo LA doctor seeing success with hydroxychloroquine to treat COVID-19 https://abc7news.com/coronavirus-drug-covid-19-malaria- hydroxychloroquine/6079864/ 2\\."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that Dr. Anthony Cardillo observed very promising results with hydroxychloroquine and zinc, but it does not quantify the success rate as 70%. The use of positive language like 'very promising' does not translate directly to a specific success percentage. Additionally, the referential connection of the 70% success rate could not be found in the evidence provided. Therefore, the claim isn't fully supported without verifiable specifics.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.6144352555274963,
    "x2e_entail_prob": 0.13881894946098328
  },
  {
    "id": "covid_fact-000267",
    "statement": "Repurposing existing drugs for covid-19 a more rapid alternative to a vaccine , say researchers",
    "label": "SUPPORTED",
    "evidences": [
      "Although clinical trials found it to be insufficiently effective at treating Ebola, clinical trials in the USA have suggested the drug may be beneficial for treating patients hospitalised with COVID-19, and the FDA has now approved it for emergency use.",
      "> \"[Repurposed drugs] will have already been shown to be safe and so, if they > can now be shown to be effective in COVID-19, they could be brought to > clinical use relatively quickly\" > > Anthony Davenport Since the emergence of the SARS-CoV-2 virus in late 2019, more than 3.5 million people are known to have been infected, leading to over 240,000 deaths worldwide from COVID-19, the disease caused by the novel coronavirus.",
      "While we're waiting for a vaccine, drugs currently being used to treat other illnesses can be investigated as treatments for COVID-19  in other words repurposed, said Dr Steve Alexander from the University of Nottingham.",
      "These treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly. One promising candidate is remdesivir, a drug originally developed for Ebola."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that repurposing existing drugs could be a more rapid alternative to developing a new vaccine because these drugs have already been shown to be safe. Therefore, if they're effective against COVID-19, they can be deployed quickly. Researchers like Dr. Steve Alexander and Anthony Davenport emphasize the potential for rapid deployment of repurposed drugs.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.10056543350219727,
    "x2e_entail_prob": 0.002652340568602085
  },
  {
    "id": "covid_fact-000268",
    "statement": "Repurposing existing drugs for covid-19 a less rapid alternative to a vaccine, say researchers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although clinical trials found it to be insufficiently effective at treating Ebola, clinical trials in the USA have suggested the drug may be beneficial for treating patients hospitalised with COVID-19, and the FDA has now approved it for emergency use.",
      "> \"[Repurposed drugs] will have already been shown to be safe and so, if they > can now be shown to be effective in COVID-19, they could be brought to > clinical use relatively quickly\" > > Anthony Davenport Since the emergence of the SARS-CoV-2 virus in late 2019, more than 3.5 million people are known to have been infected, leading to over 240,000 deaths worldwide from COVID-19, the disease caused by the novel coronavirus.",
      "While we're waiting for a vaccine, drugs currently being used to treat other illnesses can be investigated as treatments for COVID-19  in other words repurposed, said Dr Steve Alexander from the University of Nottingham.",
      "These treatments will have already been shown to be safe and so, if they can now be shown to be effective in COVID-19, they could be brought to clinical use relatively quickly. One promising candidate is remdesivir, a drug originally developed for Ebola."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that repurposed drugs can be brought to clinical use relatively quickly because they have already been shown to be safe. Therefore, they might not be a 'less rapid' alternative compared to vaccines, contrary to the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.012654528021812439,
    "x2e_entail_prob": 0.0019370600348338485
  },
  {
    "id": "covid_fact-000269",
    "statement": "68 per cent of patients hospitalized for severe covid-19 , who were treated with compassionate-use remdesivir , showed clinical improvement",
    "label": "SUPPORTED",
    "evidences": [
      "Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions observations from a compassionate-use program for remdesivir in Covid-19 treatment but does not provide specific data or percentages regarding the clinical improvement of patients. Therefore, the claim's specific figure of 68% improvement is unsupported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0076927016489207745,
    "x2e_entail_prob": 0.0012871738290414214
  },
  {
    "id": "covid_fact-000270",
    "statement": "68 per cent of patients hospitalized for severe covid-19, who were treated with compassionate-use remdesivir, without clinical improvement",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although data from several ongoing randomized, controlled trials will soon provide more informative evidence regarding the safety and efficacy of remdesivir for Covid-19, the outcomes observed in this compassionate-use program are the best currently available data."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide specific data regarding the percentage of patients who were hospitalized for severe Covid-19 and treated with compassionate-use remdesivir, nor does it mention if 68% of them showed no clinical improvement. The evidence only discusses the ongoing trials and the compassionate-use program's data as the best available, without specific percentages or outcomes regarding clinical improvement.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.01034955307841301,
    "x2e_entail_prob": 0.004405893851071596
  },
  {
    "id": "covid_fact-000271",
    "statement": "Years of life lost due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the study focused on projecting years of life lost (YLL) due to the psychosocial consequences of COVID-19 mitigation measures, using Swiss data as a reference. The specific result given is 0.205 YLL per average person. This directly supports the claim about evaluating the YLL from COVID-19 mitigation strategies based on Swiss data.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8729584813117981,
    "x2e_entail_prob": 0.93502277135849
  },
  {
    "id": "covid_fact-000272",
    "statement": "Years of life increases due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates a loss of 0.205 years of life due to the psychosocial consequences of COVID-19 mitigation measures, not an increase in years of life as claimed.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.22431084513664246,
    "x2e_entail_prob": 0.017465999349951744
  },
  {
    "id": "covid_fact-000273",
    "statement": "Years of life remains due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence refers to a study that quantifies the psychosocial consequences of COVID-19 mitigation measures in Switzerland as 0.205 years of life lost (YLL) on average per person. This aligns with the claim about the potential impact on years of life due to these measures based on Swiss data, thus the claim is supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.12407585978507996,
    "x2e_entail_prob": 0.8469712138175964
  },
  {
    "id": "covid_fact-000274",
    "statement": "Years of life occurred due to the psychosocial consequences of covid19 mitigation strategies based on swiss data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Methods We used years of life lost (YLL) as the main outcome measure as applied to Switzerland as an exemplar.",
      "Results The study projects that the average person would suffer 0.205 YLL due to psychosocial consequence of COVID-19 mitigation measures."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that the study projects an average of 0.205 years of life lost (YLL) per person due to the psychosocial consequences of COVID-19 mitigation measures based on Swiss data. This directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.040227971971035004,
    "x2e_entail_prob": 0.9011344909667969
  },
  {
    "id": "covid_fact-000275",
    "statement": "Astrazeneca covid-19 vaccine study is put on hold",
    "label": "SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that AstraZeneca put its Covid-19 vaccine study on hold following a review of safety data. This directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.03539559617638588,
    "x2e_entail_prob": 0.0033286043908447027
  },
  {
    "id": "covid_fact-000276",
    "statement": "Astrazeneca covid-19 vaccine study is put on!",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that AstraZeneca's Covid-19 vaccine study was put on hold as part of a standard review process to assess safety data. The evidence also notes that this was the first Phase 3 trial to be paused for Covid-19, aligning with the claim that the study is put on hold.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5294879078865051,
    "x2e_entail_prob": 0.011700930073857307
  },
  {
    "id": "covid_fact-000277",
    "statement": "Astrazeneca covid-19 vaccine study is put on.\"",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that AstraZeneca had paused its COVID-19 vaccine study to review safety data as part of its standard review process. This fits with the claim that the study was 'put on.' Additionally, AstraZeneca's Phase 3 trial is noted as being on hold, which aligns with the claim's implication of an interruption in the study process.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8411420583724976,
    "x2e_entail_prob": 0.01412937417626381
  },
  {
    "id": "covid_fact-000278",
    "statement": "Astrazeneca covid-19 vaccine study is put on.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the companys standard review process triggered a pause to vaccination to allow review of safety data. In a follow-up statement, AstraZeneca said it initiated the study hold.",
      "AstraZenecas is the first Phase 3 Covid-19 vaccine trial known to have been put on hold."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that a study involving the AstraZeneca Covid-19 vaccine was put on hold. The spokesperson's statement mentions a pause in vaccination to review safety data, and the follow-up statement confirms that a study hold was initiated. No conflicting information is presented.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.17967432737350464,
    "x2e_entail_prob": 0.02364036627113819
  },
  {
    "id": "covid_fact-000279",
    "statement": "Giuliani-promoted covid-19 therapy from celularity nabs fda speedy trial start",
    "label": "SUPPORTED",
    "evidences": [
      "Trials need to be EXPEDITED. It seems he got his wish: Today, New Jersey-based Celularity said it has been given the all-clear from the FDA to start its clinical trial of CYNK-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Celularity received FDA approval to start a clinical trial for its COVID-19 therapy, CYNK-001, suggesting that the trial process has been expedited. While the evidence does not explicitly mention Giuliani, the fact that the trial start is described as 'speedy' aligns with the claim that the process was accelerated. Thus, the claim is supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6187141537666321,
    "x2e_entail_prob": 0.0844978392124176
  },
  {
    "id": "covid_fact-000280",
    "statement": "Giuliani-free covid-19 therapy from celularity nabs fda speedy trial start",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Trials need to be EXPEDITED. It seems he got his wish: Today, New Jersey-based Celularity said it has been given the all-clear from the FDA to start its clinical trial of CYNK-001, its allogeneic, off-the-shelf, cryopreserved natural killer cell therapy to be used in a phase 1/2 study in up to 86 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that Celularity has received FDA approval to start clinical trials of its COVID-19 therapy, CYNK-001. This aligns with the claimed 'FDA speedy trial start.' However, the claim about 'Giuliani-free' is vague and seems to imply something beyond the scope of the provided evidence, but it can be considered irrelevant to the core claim about the clinical trial approval.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5626163482666016,
    "x2e_entail_prob": 0.21672643721103668
  },
  {
    "id": "covid_fact-000281",
    "statement": "Mucus production stimulated by ifn-ahr signaling triggers hypoxia of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the possibility of mucus production and mentions AhR-upregulated mucins in the context of hypoxia in COVID-19 patients, but it does not confirm that IFN-AhR signaling directly triggers hypoxia due to mucus production. The causal link asserted in the claim is not explicitly supported by the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.11838004738092422,
    "x2e_entail_prob": 0.3583005368709564
  },
  {
    "id": "covid_fact-000282",
    "statement": "Mucus production stimulated by ifn-ahr signaling prevents hypoxia of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions mucus production in the context of COVID-19 and references AhR-upregulated mucins in the hypoxia of COVID-19 patients. However, it does not explicitly establish a causal relationship between IFN-AhR signaling specifically stimulating mucus production that prevents hypoxia in COVID-19. The link between the signaling pathway and prevention of hypoxia is not directly supported by the evidence given.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.8053263425827026,
    "x2e_entail_prob": 0.4507981836795807
  },
  {
    "id": "covid_fact-000283",
    "statement": "Mucus damage stimulated by ifn-ahr signaling triggers hypoxia of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that mucus is likely to be produced in the lung epithelial cells of COVID-19 patients.",
      "7: A schematic for AhR-upregulated mucins in the hypoxia of COVID-19 patients.",
      "1a), suggesting that mucus-like substance might be present in the BAL of COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that mucus may be present in COVID-19 patients and hints at a possible role of AhR in the hypoxia of these patients, but it does not definitively link IFN-AhR signaling to mucus damage as a trigger for hypoxia in COVID-19. The connection between these elements is not explicitly supported in the provided evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.2948855757713318,
    "x2e_entail_prob": 0.6348732113838196
  },
  {
    "id": "covid_fact-000284",
    "statement": "Gilead has suspended access to remdesivir",
    "label": "SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Gilead has modified the way in which remdesivir is accessed, pivoting from compassionate-use requests to expanded access programs. However, it does not state that access to remdesivir has been fully suspended.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.10160591453313828,
    "x2e_entail_prob": 0.006733634043484926
  },
  {
    "id": "covid_fact-000285",
    "statement": "Gilead has allowed access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Gilead is moving from offering remdesivir through compassionate-use requests to providing it via expanded access programs. This suggests that Gilead is indeed allowing access to remdesivir, albeit under different conditions. Thus, the claim is supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7106269001960754,
    "x2e_entail_prob": 0.009854098781943321
  },
  {
    "id": "covid_fact-000286",
    "statement": "Gilead has received access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence implies that Gilead, which is the maker of remdesivir, had access to the drug and was making it available through expanded access programs and compassionate use requests. Therefore, the claim that Gilead has received access to remdesivir is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8208890557289124,
    "x2e_entail_prob": 0.0016329508507624269
  },
  {
    "id": "covid_fact-000287",
    "statement": "Gilead has provided access to remdesivir",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To stem demand, Gilead will pivot from accepting compassionate- use requests to only providing treatment through expanded access programs.",
      "Before the suspension, Gileads remdesivir appeared to be offered to individual patients for emergency use."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Gilead has provided access to remdesivir by initially offering it for emergency use and later providing treatment through expanded access programs. Thus, the claim is supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3533558249473572,
    "x2e_entail_prob": 0.013691962696611881
  },
  {
    "id": "covid_fact-000288",
    "statement": "Immune cell activation in severe covid-19 resembles lupus .",
    "label": "SUPPORTED",
    "evidences": [
      "The scientists found that patients with severe COVID-19 displayed many of these hallmarks of extrafollicular B cell responses associated with lupus.",
      "The critically-ill COVID-19 patients who survived and recovered from the infection also showed lingering symptoms similar to those experienced by lupus patients during acute flare-ups."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that patients with severe COVID-19 exhibit extrafollicular B cell responses similar to those seen in lupus. Additionally, surviving critically-ill COVID-19 patients show lingering symptoms reminiscent of lupus flare-ups. Thus, the claim that immune cell activation in severe COVID-19 resembles lupus is supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9909375905990601,
    "x2e_entail_prob": 0.3344270586967468
  },
  {
    "id": "covid_fact-000289",
    "statement": "Immune cell death in severe covid-19 resembles lupus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The scientists found that patients with severe COVID-19 displayed many of these hallmarks of extrafollicular B cell responses associated with lupus.",
      "The critically-ill COVID-19 patients who survived and recovered from the infection also showed lingering symptoms similar to those experienced by lupus patients during acute flare-ups."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions that patients with severe COVID-19 show hallmarks of extrafollicular B cell responses associated with lupus, and that critically ill COVID-19 patients have lingering symptoms similar to lupus during flare-ups, supporting the claim of resemblance.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6421182751655579,
    "x2e_entail_prob": 0.21311409771442413
  },
  {
    "id": "covid_fact-000290",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few weeks.",
    "label": "SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim matches the evidence, which quotes a forecast from the US Centers for Disease Control and Prevention (CDC) indicating that the United States could see up to 100,000 more COVID-19 deaths in less than a month. The timing of both the statement and the consideration (next few weeks) aligns as well.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.11942365020513535,
    "x2e_entail_prob": 0.02892151288688183
  },
  {
    "id": "covid_fact-000291",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few decades.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the CDC forecasts up to 100,000 more COVID-19 deaths in less than a month, not in the next few decades. Therefore, the claim about the CDC's long-term forecast is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1288834512233734,
    "x2e_entail_prob": 0.05406171455979347
  },
  {
    "id": "covid_fact-000292",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few years.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the CDC forecasted 100,000 more COVID-19 deaths within a month, not in the next few years. Therefore, the claim about the timeline is inconsistent with the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.04046403244137764,
    "x2e_entail_prob": 0.07443875819444656
  },
  {
    "id": "covid_fact-000293",
    "statement": "Cdc forecasts up to 100,000 more covid-19 deaths in the next few century.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thursday, January 21st 2021, 7:46 AM EST By CNN Newswire New CDC director Dr. Rochelle Walensky The United States could face as many as 100,000 more COVID-19 deaths in less than a month, according to the US Centers for Disease Control and Prevention."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the CDC forecasted up to 100,000 more COVID-19 deaths in less than a month, not over the next few centuries. Therefore, the claim does not match the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.05415148288011551,
    "x2e_entail_prob": 0.042851775884628296
  },
  {
    "id": "covid_fact-000294",
    "statement": "Gaps in early surveillance of coronavirus led to record-breaking us trajectory",
    "label": "SUPPORTED",
    "evidences": [
      "As illustrated in the COVID-19 study, while public health officials must work quickly to understand how a new virus functions, without appropriate testing or coordinated response strategies the risk grows for infections to go unreported.",
      "The study provides insight into how limited testing and gaps in surveillance during the initial phase of the epidemic resulted in so many cases going undetected.",
      "The potential for misdiagnosis and the limitations of surveillance are huge issues across infectious diseases, especially emerging infectious diseases, he added."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that limited testing and gaps in surveillance during the initial phase of the epidemic resulted in many cases of coronavirus going undetected. This aligns with the claim that these surveillance gaps contributed to a record-breaking trajectory of infections in the US. The discussion on the risk of infections going unreported and the limitations of surveillance supports the assertion that such gaps had a significant impact on the infection trajectory.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0288940891623497,
    "x2e_entail_prob": 0.0031084318179637194
  },
  {
    "id": "covid_fact-000295",
    "statement": "Efforts in early surveillance of coronavirus led to record-breaking us trajectory",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "As illustrated in the COVID-19 study, while public health officials must work quickly to understand how a new virus functions, without appropriate testing or coordinated response strategies the risk grows for infections to go unreported.",
      "The study provides insight into how limited testing and gaps in surveillance during the initial phase of the epidemic resulted in so many cases going undetected.",
      "The potential for misdiagnosis and the limitations of surveillance are huge issues across infectious diseases, especially emerging infectious diseases, he added."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that there were significant gaps in surveillance and testing during the early stages of the coronavirus outbreak, which resulted in many cases going undetected. This indicates that efforts in early surveillance were insufficient or flawed, contradicting the claim that they led to a 'record-breaking U.S. trajectory'.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.02734253741800785,
    "x2e_entail_prob": 0.007084971759468317
  },
  {
    "id": "covid_fact-000296",
    "statement": "Immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome in covid-19 .",
    "label": "SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that in a cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS, which supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.29800543189048767,
    "x2e_entail_prob": 0.8641857504844666
  },
  {
    "id": "covid_fact-000297",
    "statement": "Immunosuppression is associated with a increased risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence contradicts the claim. It states that immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome (ARDS) in COVID-19 patients, not an increased risk.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.00510339206084609,
    "x2e_entail_prob": 0.7462488412857056
  },
  {
    "id": "covid_fact-000298",
    "statement": "Immunosuppression is associated with a higher risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence directly contradicts the claim. It states that immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome (ARDS) in COVID-19 patients, not a higher risk.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0027542340103536844,
    "x2e_entail_prob": 0.6614774465560913
  },
  {
    "id": "covid_fact-000299",
    "statement": "Immunosuppression is associated with a high risk of moderate to severe acute respiratory distress syndrome in covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "CONCLUSIONS : In our cohort of COVID-19 patients, immunosuppression was associated with a lower risk of moderate-severe ARDS."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that immunosuppression is associated with a high risk of moderate to severe ARDS in COVID-19, but the evidence indicates the opposite, associating immunosuppression with a lower risk of moderate-severe ARDS.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.01760108768939972,
    "x2e_entail_prob": 0.718893826007843
  },
  {
    "id": "covid_fact-000300",
    "statement": "Human soluble ace2 improves the effect of remdesivir in sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the use of remdesivir and human recombinant soluble ACE2 in the inhibition of SARS-CoV-2 infections in Vero E6 cells. However, it does not specifically state that the combination of these two treatments improves the effect of remdesivir. More detailed results or data demonstrating enhancement of efficacy would be necessary to support the claim.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.212734192609787,
    "x2e_entail_prob": 0.4295463263988495
  },
  {
    "id": "covid_fact-000301",
    "statement": "Human soluble ace2 inhibits the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is incomplete, lacking information on whether human soluble ACE2 (hrsACE2) inhibits the effect of remdesivir in SARS-CoV-2 infection. It mentions both remdesivir and hrsACE2 in the context of SARS-CoV-2 infections of Vero E6 cells but does not explicitly state that hrsACE2 inhibits the effect of remdesivir.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.05507760867476463,
    "x2e_entail_prob": 0.47641029953956604
  },
  {
    "id": "covid_fact-000302",
    "statement": "Human soluble ace2 blocked the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention that human soluble ACE2 (hrsACE2) blocked the effect of remdesivir in SARS-CoV-2 infection. Instead, it states that both remdesivir and hrsACE2 are involved in inhibiting SARS-CoV-2 infections of Vero E6 cells, but without specifying any antagonistic interaction between them. Thus, the claim is not supported by the given evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.011582361534237862,
    "x2e_entail_prob": 0.07202279567718506
  },
  {
    "id": "covid_fact-000303",
    "statement": "Human soluble ace2 reduces the effect of remdesivir in sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A, B (A) Remdesivir and (B) hrsACE2 inhibition of SARSCoV2 infections of Vero E6 cells.",
      "A Treatment of SARSCoV2 (106 PFU) infected VeroE6 cells with human recombinant soluble ACE 2 (hrsACE2) (200 \u00b5g/ml) and remdesivir (Remd."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided (A, B) only mentions the use of remdesivir and human recombinant soluble ACE2 (hrsACE2) in the treatment of SARS-CoV-2 infections in Vero E6 cells. It does not provide any specific information or results that indicate that hrsACE2 reduces the effect of remdesivir. Thus, the claim that human soluble ACE2 reduces the effect of remdesivir is not supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.23514898121356964,
    "x2e_entail_prob": 0.2021830677986145
  },
  {
    "id": "covid_fact-000304",
    "statement": "A five day course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a 5-day course of ivermectin was found to be safe and effective in treating mild COVID-19 and resulted in an earlier viral clearance compared to placebo. This supports the claim that it may reduce the duration of illness.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8801478147506714,
    "x2e_entail_prob": 0.723220705986023
  },
  {
    "id": "covid_fact-000305",
    "statement": "A five years course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a 5-day course of ivermectin, not a five years course. Therefore, the claim about a five years course of ivermectin reducing the duration of illness is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.011872022412717342,
    "x2e_entail_prob": 0.6264042258262634
  },
  {
    "id": "covid_fact-000306",
    "statement": "A five year course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the effectiveness of a 5-day course of ivermectin, not a five-year course, in reducing the duration of COVID-19 illness by clearing the virus earlier. The claim's reference to a five-year course is inaccurate based on the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.2508224844932556,
    "x2e_entail_prob": 0.7453795075416565
  },
  {
    "id": "covid_fact-000307",
    "statement": "A fivemonth course of ivermectin for the treatment of covid-19 may reduce the duration of illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Ivermectin may be effective for the treatment of early-onset mild COVID-19 in adult patients.",
      "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.",
      "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.",
      "A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo ( p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that a 5-day course of ivermectin may be effective in reducing the duration of illness for mild COVID-19 cases by promoting earlier virus clearance. However, there is no evidence supporting the claim that a five-month course is recommended or effective. The evidence only supports the efficacy of a much shorter duration of treatment.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.05927010253071785,
    "x2e_entail_prob": 0.46250060200691223
  },
  {
    "id": "covid_fact-000308",
    "statement": "Brd4-bound enhancers drive cell intrinsic sex differences in glioblastoma",
    "label": "SUPPORTED",
    "evidences": [
      "These observations led us to hypothesize that Brd4-bound enhancers might underlie sex differences in stem cell function and tumorigenicity in GBM.",
      "We report that sex-biased Brd4 activity drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors.",
      "These sex- biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs).",
      "In an established isogenic murine model of glioblastoma, we discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites.",
      "Thus, for the first time, Brd4 activity is revealed to drive a sex differences in stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female GBM cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Brd4-bound enhancers are linked to sex differences in glioblastoma (GBM), particularly through sex-biased Brd4 activity and associated gene expression changes. These observations support the claim that Brd4-bound enhancers drive intrinsic sex differences in GBM, influencing tumor cell sensitivity to treatments and tumorigenicity.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9763912558555603,
    "x2e_entail_prob": 0.10887105762958527
  },
  {
    "id": "covid_fact-000309",
    "statement": "Brd4-bound enhancers drive cell surface sex differences in glioblastoma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations led us to hypothesize that Brd4-bound enhancers might underlie sex differences in stem cell function and tumorigenicity in GBM.",
      "We report that sex-biased Brd4 activity drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors.",
      "These sex- biased gene expression patterns were also evident in human glioblastoma stem cells (GSCs).",
      "In an established isogenic murine model of glioblastoma, we discovered correlated transcriptome-wide sex differences in gene expression, H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites.",
      "Thus, for the first time, Brd4 activity is revealed to drive a sex differences in stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female GBM cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Brd4-bound enhancers are indeed associated with sex differences in glioblastoma. It describes how Brd4 activity drives these differences, resulting in differential sensitivity to BET inhibitors between male and female GBM cells. The evidence is clear and directly addresses the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6008008718490601,
    "x2e_entail_prob": 0.033023640513420105
  },
  {
    "id": "covid_fact-000310",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome",
    "label": "SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that endothelial IL-6 trans-signaling promotes PAI-1 production. This supports the claim that IL-6 trans-signaling induces plasminogen activator inhibitor-1 (PAI-1) from vascular endothelial cells, consistent with observations noted in cytokine release syndrome.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3263317346572876,
    "x2e_entail_prob": 0.002317910548299551
  },
  {
    "id": "covid_fact-000311",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine development syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that IL-6 trans-signaling promotes the production of PAI-1 (plasminogen activator inhibitor-1) from vascular endothelial cells. This is consistent with the claim about IL-6 trans-signaling in cytokine development syndrome. However, the evidence does not explicitly link this to 'cytokine development syndrome,' only to IL-6 trans-signaling promoting PAI-1 production.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6337282657623291,
    "x2e_entail_prob": 0.002385746454820037
  },
  {
    "id": "covid_fact-000312",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine production syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that IL-6 trans-signaling from endothelial cells promotes PAI-1 production in vitro, supporting the claim that IL-6 trans-signaling induces plasminogen activator inhibitor-1 (PAI-1) from vascular endothelial cells. This aligns with the context of cytokine production syndrome involving excessive cytokine release.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.21268628537654877,
    "x2e_entail_prob": 0.044027458876371384
  },
  {
    "id": "covid_fact-000313",
    "statement": "Il-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine differentiation syndrome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our in vitro data indicate that endothelial IL-6 trans- signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that IL-6 trans-signaling promotes PAI-1 production from endothelial cells, which supports the claim. The experiment involved in vitro data where IL-6 trans-signaling contributed to PAI-1 production, fitting the context of cytokine differentiation syndrome. Therefore, this evidence supports the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8094194531440735,
    "x2e_entail_prob": 0.005017758347094059
  },
  {
    "id": "covid_fact-000314",
    "statement": "Fauci says he wears a mask to be a symbol of what 'you should be doing '",
    "label": "SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly quotes Fauci stating that he wears a mask not only for protection but also to serve as a symbol of what people should be doing. This directly supports the claim.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.40530920028686523,
    "x2e_entail_prob": 0.003305129474028945
  },
  {
    "id": "covid_fact-000315",
    "statement": "Fauci says he wears a point to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Fauci stated he wears a mask as a symbol for what people should be doing, aligning with the claim. He emphasized its importance in protecting oneself and others.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.34856554865837097,
    "x2e_entail_prob": 0.0037935671862214804
  },
  {
    "id": "covid_fact-000316",
    "statement": "Fauci says he wears a license to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Fauci said he wears a mask as a symbol of what 'you should be doing,' not a 'license.' The term 'license' is not mentioned and seems to be a misinterpretation of the actual statement.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.03430948778986931,
    "x2e_entail_prob": 0.003720853477716446
  },
  {
    "id": "covid_fact-000317",
    "statement": "Fauci says he wears a question to be a symbol of what 'you should be doing '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fauci said he believes that while wearing a mask is not \"100% effective,\" it is a valuable safeguard and shows \"respect for another person.\"",
      "\"I want to protect myself and protect others, and also because I want to make it be a symbol for people to see that that's the kind of thing you should be doing,\" Fauci, the nation's top infectious disease expert and a member of the White House's coronavirus task force, told CNN's Jim Sciutto on \"Newsroom.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Fauci stated he wears a mask as a symbol of what people 'should be doing,' which matches the claim's suggestion that Fauci uses the symbol to demonstrate recommended behavior during the pandemic.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.19853119552135468,
    "x2e_entail_prob": 0.00451148534193635
  },
  {
    "id": "covid_fact-000318",
    "statement": "Iga dominates the early neutralizing antibody response to sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that IgA antibodies are often detectable before IgG antibodies in the SARS-CoV-2 response, suggesting that IgA plays a significant role in early neutralization. The phrase 'dominated by IgA antibodies' clearly supports the claim that IgA dominates the early neutralizing antibody response to SARS-CoV-2.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.789217472076416,
    "x2e_entail_prob": 0.9168505072593689
  },
  {
    "id": "covid_fact-000319",
    "statement": "Iga dominates the full neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence consistently indicates that IgA antibodies play a dominant role in the early neutralizing antibody response to SARS-CoV-2, being detectable before IgG and often in greater quantities. This supports the claim that IgA dominates the neutralizing antibody response, particularly in the early stages.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8859981894493103,
    "x2e_entail_prob": 0.9689883589744568
  },
  {
    "id": "covid_fact-000320",
    "statement": "Iga dominates the enhanced neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that IgA antibodies are detectable before IgG in the context of SARS-CoV-2 and suggests a role for IgA in early virus neutralization. Additionally, early SARS-CoV-2-specific humoral responses are described as being dominated by IgA, supporting that IgA dominates the enhanced neutralizing antibody response to SARS-CoV-2.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9641321301460266,
    "x2e_entail_prob": 0.928735077381134
  },
  {
    "id": "covid_fact-000321",
    "statement": "Iga dominates the effective neutralizing antibody response to sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and suggest a role for IgA antibodies in early virus neutralization.",
      "Our results show that serum IgA, particularly anti-RBD IgA, are detected earlier compared with IgG, and the dramatic plasmablast expansion that follows SARS-CoV-2 infection is dominated by IgA-secreting cells (Fig.",
      "Early SARS- CoV-2-specific humoral responses were dominated by IgA antibodies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that IgA antibodies are detectable earlier and are significant in the early neutralizing response to SARS-CoV-2 infection. The evidence supports the claim that IgA plays a dominant role in the effective neutralizing antibody response.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8071230053901672,
    "x2e_entail_prob": 0.8875031471252441
  },
  {
    "id": "covid_fact-000322",
    "statement": "Fda authorizes first diagnostic test for screening of people without known or suspected covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Last month, the FDA posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people, as well as for sample pooling.",
      "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to expand use of the test to anyone, after the company provided scientific data showing the tests ability to detect SARS-CoV-2 in a general, asymptomatic population.",
      "Additionally, the data reviewed by the FDA demonstrated that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
      "Until now, molecular diagnostic tests have generally been authorized for people suspected of having COVID-19 by their health care provider, which has allowed asymptomatic people to be tested, when warranted, at the discretion of the health care provider."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to include the screening of asymptomatic individuals, effectively authorizing it as a diagnostic test for a general population that includes people without known or suspected COVID-19 infection. This aligns with the claim that the FDA has authorized the first diagnostic test for such screening purposes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.004219965077936649,
    "x2e_entail_prob": 0.0010951419826596975
  },
  {
    "id": "covid_fact-000323",
    "statement": "Fda authorizes another diagnostic test for screening of people without known or suspected covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Last month, the FDA posted updated templates with recommendations for test developers to demonstrate validation for a test to be authorized for screening of asymptomatic people, as well as for sample pooling.",
      "The FDA reissued the LabCorp COVID-19 RT-PCR Test EUA to expand use of the test to anyone, after the company provided scientific data showing the tests ability to detect SARS-CoV-2 in a general, asymptomatic population.",
      "Additionally, the data reviewed by the FDA demonstrated that the test is as accurate in the broader asymptomatic population as it is among people suspected to have COVID-19.",
      "Until now, molecular diagnostic tests have generally been authorized for people suspected of having COVID-19 by their health care provider, which has allowed asymptomatic people to be tested, when warranted, at the discretion of the health care provider."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the FDA authorized LabCorp's COVID-19 RT-PCR Test for use in screening asymptomatic people, thereby supporting the claim. The test was reissued with expanded use authorization, demonstrating its effectiveness in detecting SARS-CoV-2 in an asymptomatic population as per FDA review.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8843268752098083,
    "x2e_entail_prob": 0.0011603371240198612
  },
  {
    "id": "covid_fact-000324",
    "statement": "Johnson & johnson pauses covid-19 vaccine trials due to sick subject",
    "label": "SUPPORTED",
    "evidences": [
      "This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Johnson & Johnson paused its Covid-19 vaccine trials due to a sick subject. The evidence indicates this is the second time a Covid-19 vaccine trial has been paused over safety concerns, which supports the likelihood that Johnson & Johnson's trial was paused for such a reason. However, the evidence does not explicitly mention Johnson & Johnson or provide specific details about the sick subject, hence the confidence is not absolute.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.12353743612766266,
    "x2e_entail_prob": 0.9825634360313416
  },
  {
    "id": "covid_fact-000325",
    "statement": "Johnson & johnson developed covid-19 vaccine trials due to sick subject",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This is the second time trials for a Covid-19 vaccine trial have been paused over a safety concern."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that trials for a Covid-19 vaccine were paused due to a safety concern, but it does not specify that Johnson & Johnson developed the vaccine trials as a result of a sick subject. It merely mentions a safety concern but lacks details linking the development of the trials directly to a sick subject.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.08230147510766983,
    "x2e_entail_prob": 0.0011497549712657928
  },
  {
    "id": "covid_fact-000326",
    "statement": "Asymptomatic cases may not be infectious , wuhan study indicates.",
    "label": "SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that there was no evidence that the identified asymptomatic positive cases in post-lockdown Wuhan were infectious. This supports the claim that asymptomatic cases may not be infectious according to the Wuhan study.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2995510995388031,
    "x2e_entail_prob": 0.027048584073781967
  },
  {
    "id": "covid_fact-000327",
    "statement": "Asymptomatic cases may also be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the detection rate of asymptomatic cases in post-lockdown Wuhan was very low and provides no evidence that these asymptomatic cases were infectious. This contradicts the claim that asymptomatic cases may be infectious.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0936601459980011,
    "x2e_entail_prob": 0.38558563590049744
  },
  {
    "id": "covid_fact-000328",
    "statement": "Asymptomatic cases may only be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the detection rate of asymptomatic positive cases in post-lockdown Wuhan was very low, and there was no evidence that the identified asymptomatic positive cases were infectious. Thus, the claim that asymptomatic cases may only be infectious is not supported by the study.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.14278407394886017,
    "x2e_entail_prob": 0.14381824433803558
  },
  {
    "id": "covid_fact-000329",
    "statement": "Asymptomatic cases may still be infectious, wuhan study indicates.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, the detection rate of asymptomatic positive cases in the post- lockdown Wuhan was very low (0.303/10,000), and there was no evidence that the identified asymptomatic positive cases were infectious."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that in the Wuhan study, there was no evidence that asymptomatic cases were infectious. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.36320096254348755,
    "x2e_entail_prob": 0.04173743352293968
  },
  {
    "id": "covid_fact-000330",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ace inhibitors or angiotensin receptor blockers",
    "label": "SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers. The evidence specifically indicates that ACE2 expression in the cilia of upper respiratory cells is not influenced or increased by the use of ACE inhibitors or ARBs. This directly supports the part of the claim regarding ACE inhibitors and ARBs not increasing ACE2 expression. The claim does not specifically address the localization of ACE2 to motile cilia in the evidence provided, but it is implied in the context. Thus, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.42243146896362305,
    "x2e_entail_prob": 0.0028444742783904076
  },
  {
    "id": "covid_fact-000331",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is significantly increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that ACE2 protein expression is not increased in patients taking ACE inhibitors or angiotensin receptor blockers. In fact, in some cases, ACE2 expression potentially decreases. Therefore, the claim that ACE2 expression is significantly increased by these medications is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.693938136100769,
    "x2e_entail_prob": 0.001830098801292479
  },
  {
    "id": "covid_fact-000332",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is greatly increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that ACE2 protein expression in the cilia of the respiratory tract is not increased by the use of ACE inhibitors or angiotensin receptor blockers. In fact, it may even be decreased in patients taking ACE inhibitors. Therefore, the claim that these medications greatly increase ACE2 protein expression is not supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5501536130905151,
    "x2e_entail_prob": 0.0015630312263965607
  },
  {
    "id": "covid_fact-000333",
    "statement": "Robust ace2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is further increased by ace inhibitors or angiotensin receptor blockers",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.",
      "ACE2 expression in the nasal cilia is not increased in patients taking angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs), but potentially decreased in ACEI patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers does not increase ACE2 protein expression in the cilia of upper respiratory cells. In fact, it suggests a potential decrease in ACE2 expression in patients using ACE inhibitors. Therefore, the claim that these medications increase ACE2 expression is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7989391684532166,
    "x2e_entail_prob": 0.0028397764544934034
  },
  {
    "id": "covid_fact-000334",
    "statement": "A consensus covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the core immune signature observed in COVID-19 cases shows a combination or 'blending' of typical virus infection immune responses (adaptive B cell responses) with traits associated with sepsis, consistent with the claim of a 'consensus covid-19 immune signature' having both immuno-protection and sepsis-like traits.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8084173202514648,
    "x2e_entail_prob": 0.0029104268178343773
  },
  {
    "id": "covid_fact-000335",
    "statement": "A novel covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the core immune signature combines adaptive B cell responses with traits typically associated with sepsis, like monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets. This aligns with the claim that the novel COVID-19 immune signature combines immuno-protection with sepsis-like traits associated with poor prognosis.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5682891607284546,
    "x2e_entail_prob": 0.28480592370033264
  },
  {
    "id": "covid_fact-000336",
    "statement": "A unique covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the immune signature for COVID-19 combines B cell responses associated with virus infection or vaccination with sepsis-related traits such as monocyte and dendritic cell dampening, and T cell subset changes. This supports the claim of a COVID-19 immune signature that combines immuno-protection and sepsis-like traits with poor prognosis.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8570944666862488,
    "x2e_entail_prob": 0.5939676761627197
  },
  {
    "id": "covid_fact-000337",
    "statement": "The institute for disease modeling puts the cfr at 0.94 %",
    "label": "SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides the infection-fatality-ratio (IFR) as 0.94%, not the case-fatality rate (CFR). While IFR and CFR are related metrics, they are distinct, and the claim specifically mentions CFR. Therefore, the claim is not supported by the evidence given.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.12397277355194092,
    "x2e_entail_prob": 0.04010749235749245
  },
  {
    "id": "covid_fact-000338",
    "statement": "The institute for disease transmission puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the infection-fatality-ratio (IFR), not the case-fatality ratio (CFR). No specific information in the evidence relates directly to the CFR set by the institute for disease transmission at 0.94%.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.1348448395729065,
    "x2e_entail_prob": 0.009884300641715527
  },
  {
    "id": "covid_fact-000339",
    "statement": "The institute for disease surveillance puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the infection-fatality-ratio (IFR) as 0.94% and not the case-fatality-rate (CFR). CFR and IFR are different metrics, and the claim specifically refers to CFR, which is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.08346141874790192,
    "x2e_entail_prob": 0.015046230517327785
  },
  {
    "id": "covid_fact-000340",
    "statement": "The institute for disease detection puts the cfr at 0.94 %",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "With this additional adjustment and using the same methodology and data from the original version of this report, the corrected estimate of the infection-fatality-ratio (IFR) is 0.94 (0.37, 2.9) percent.",
      "In this report, we use a small amount of linelist data with complete disease progression information from early in the outbreak to estimate the delays between case confirmation and death, and then the time and age-adjusted confirmed-CFR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions an infection-fatality-ratio (IFR) of 0.94%, but does not confirm a case-fatality rate (CFR) of 0.94%. The claim regarding the CFR specifically is not directly supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5237743258476257,
    "x2e_entail_prob": 0.010866908356547356
  },
  {
    "id": "covid_fact-000341",
    "statement": "Evolutionary arms race between virus and host drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the interaction and coevolution between bat ACE2 proteins and SARS-related coronavirus spike proteins result in diversity, indicating an evolutionary arms race. This supports the claim that such interactions drive genetic diversity in the coronavirus spike genes.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8732526302337646,
    "x2e_entail_prob": 0.33640703558921814
  },
  {
    "id": "covid_fact-000342",
    "statement": "Evolutionary arms race between virus and coronavirus drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that an evolutionary arms race between bat ACE2 receptors and SARS-related coronavirus spike proteins drives diversity. The coevolution and selection pressure between them suggest such an arms race, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9653427004814148,
    "x2e_entail_prob": 0.8879314661026001
  },
  {
    "id": "covid_fact-000343",
    "statement": "Evolutionary arms race between virus and viruses drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity and that they may have coevolved, experiencing selection pressure from each other. This interaction indicates an evolutionary arms race, supporting the claim that such dynamics drive genetic diversity in bat SARS-related coronavirus spike genes.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9828994870185852,
    "x2e_entail_prob": 0.9444623589515686
  },
  {
    "id": "covid_fact-000344",
    "statement": "Evolutionary arms race between virus and virus drives genetic diversity in bat sars related coronavirus spike genes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It is speculated that the interaction between bat ACE2 and SARSr-CoV spike proteins drives diversity.",
      "These results suggest that the SARSr-CoV spike protein and R. sinicus ACE2 may have coevolved over time and experienced selection pressure from each other, triggering the evolutionary arms race dynamics."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the interaction between bat ACE2 and SARS-related coronavirus spike proteins has driven genetic diversity through coevolution and selection pressure. This implies an evolutionary arms race dynamic, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9409396648406982,
    "x2e_entail_prob": 0.9372850060462952
  },
  {
    "id": "covid_fact-000345",
    "statement": "Active monitoring of persons exposed to patients with confirmed covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19 ( 2 ).",
      "The duration of time in the same airspace after the patient with confirmed COVID-19 was applied differently by health jurisdictions."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that on January 20, state and local health departments in collaboration with CDC teams started identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19. This supports the claim of active monitoring of exposed persons.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.2962023615837097,
    "x2e_entail_prob": 0.03674948588013649
  },
  {
    "id": "covid_fact-000346",
    "statement": "Active monitoring of persons exposed to patients without confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with patients with confirmed COVID-19 ( 2 ).",
      "The duration of time in the same airspace after the patient with confirmed COVID-19 was applied differently by health jurisdictions."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence specifies active monitoring of persons who had close contact with patients with confirmed COVID-19, not those exposed to patients without confirmed COVID-19. Thus, the claim is not supported by the evidence.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.004678060300648212,
    "x2e_entail_prob": 0.0009198564221151173
  },
  {
    "id": "covid_fact-000347",
    "statement": "Convalescent plasma to treat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim 'Convalescent plasma to treat covid-19' is a broad and vague statement, and the evidence provided only shows that convalescent plasma is used or studied for treating COVID-19, particularly in a hospital setting or clinical trial. However, the evidence does not explicitly confirm the effectiveness, efficacy, or official approval of convalescent plasma as a standard treatment for COVID-19. Without more specific evidence supporting its widespread efficacy or endorsement by health authorities, the claim remains not fully substantiated.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.4311555325984955,
    "x2e_entail_prob": 0.6429286003112793
  },
  {
    "id": "covid_fact-000348",
    "statement": "Unvalescent plasma to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim appears to contain a typo, 'unvalescent,' and likely refers to 'convalescent plasma.' The evidence does confirm convalescent plasma is intended for treatment of COVID-19 patients. However, the claim as stated is not supported due to the typo, hence it's not verifiable in its current form.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.05140368640422821,
    "x2e_entail_prob": 0.5639225244522095
  },
  {
    "id": "covid_fact-000349",
    "statement": "Convalescent antibiotics to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests the use of 'convalescent antibiotics' for COVID-19 treatment, whereas the evidence references 'convalescent plasma,' which is different from antibiotics. Convalescent plasma involves using plasma from recovered patients to treat current patients, not antibiotics. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.2535308599472046,
    "x2e_entail_prob": 0.41427478194236755
  },
  {
    "id": "covid_fact-000350",
    "statement": "Subvalescent plasma to treat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The investigational convalescent plasma is intended for the treatment of hospitalized patients with COVID-19.",
      "Effectiveness of convalescent plasma therapy in severe COVID-19 patients.",
      "Convalescent plasma for COVID-19: a randomized clinical trial.",
      "Expanded access to convalescent plasma for the treatment of patients with COVID-19.",
      "Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions 'subvalescent plasma,' which is not a recognized or documented term in COVID-19 treatment. The evidence provided references the use of 'convalescent plasma' for treating COVID-19, not 'subvalescent plasma.' Since there is no evidence supporting the specific term 'subvalescent plasma,' the claim is not supported by the available evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.43295717239379883,
    "x2e_entail_prob": 0.4502962529659271
  },
  {
    "id": "covid_fact-000351",
    "statement": "Man , 25 , catches coronavirus twice in first such us case",
    "label": "SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that researchers in the US have reported the country's first confirmed case of coronavirus reinfection, involving a 25-year-old man who was infected twice by different strains. This matches the claim that a 25-year-old man caught coronavirus twice in the US, supporting the claim with high confidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0295810978859663,
    "x2e_entail_prob": 0.0012618731707334518
  },
  {
    "id": "covid_fact-000352",
    "statement": "13, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that a 25-year-old man in the US was indeed reported to have been reinfected with coronavirus, making it the first confirmed case of reinfection in the country. The genetic sequencing showed he was infected by two different strains of the virus. This aligns with the claim, mentioning both the age and the event of reinfection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6346439719200134,
    "x2e_entail_prob": 0.0014083980349823833
  },
  {
    "id": "covid_fact-000353",
    "statement": "2, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that a 25-year-old man in the US was reported as the country's first confirmed case of coronavirus reinfection, infected twice by different strains of the virus. This supports the claim that a 25-year-old caught coronavirus twice, marking the first such case in the US.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9454060792922974,
    "x2e_entail_prob": 0.0014177844859659672
  },
  {
    "id": "covid_fact-000354",
    "statement": "19, 25, catches coronavirus twice in first such us case",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photograph: John Locher/AP Press Association Tue 13 Oct 2020 01.24 EDT Researchers in the US have reported the countrys first confirmed case of coronavirus reinfection.",
      "Genetic sequencing of the virus showed he was infected twice by different strains of Sars-CoV-2, according to researchers.",
      "A 25-year-old man with no known immune disorders or underlying conditions was infected with Covid-19 on two separate occasions, according to a study published in the Lancet Infectious Diseases journal.",
      "Photograph: John Locher/AP The man required hospitalisation and oxygen support the second time he caught coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim appears to be about a person aged 19, 25, catching coronavirus twice in the US as the first such case. However, the evidence discusses a 25-year-old man being the first confirmed case of reinfection in the US. There's no mention of someone aged 19 involved in this context, indicating a likely error in the claim's formulation.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004683199804276228,
    "x2e_entail_prob": 0.002717177849262953
  },
  {
    "id": "covid_fact-000355",
    "statement": "Black , hispanic communities struggle in covid-19 vaccine rollout across the u.s .",
    "label": "SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Black and Hispanic communities are encountering difficulties in the COVID-19 vaccine rollout due to higher vaccine hesitancy and distrust fueled by historical and ongoing healthcare disparities. This supports the claim that these communities struggle in the vaccine rollout.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9083797335624695,
    "x2e_entail_prob": 0.001609098631888628
  },
  {
    "id": "covid_fact-000356",
    "statement": "2, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Hispanic communities (referred to as Latino in the evidence) face challenges in the COVID-19 vaccine rollout across the U.S. due to higher levels of vaccine hesitancy and distrust, fueled by historical mistrust and ongoing healthcare disparities. This supports the claim that these communities struggle with vaccine rollout efforts.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8813536763191223,
    "x2e_entail_prob": 0.0025749625638127327
  },
  {
    "id": "covid_fact-000357",
    "statement": "6, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that Hispanic communities in the U.S. struggle with the COVID-19 vaccine rollout due to higher levels of vaccine hesitancy and distrust, as well as unequal access to medical care and historical experiences with medical experimentation.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9415061473846436,
    "x2e_entail_prob": 0.0016262204153463244
  },
  {
    "id": "covid_fact-000358",
    "statement": "3, hispanic communities struggle in covid-19 vaccine rollout across the u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Black and Latino people also report higher levels of vaccine hesitancy and distrust compared to white Americans, according to a recent survey by the COVID Collaborative, a coalition of national experts on health, education and the economy.",
      "Fueled by a dark history of medical experimentation and unequal access to care, people in Black and Latino communities struggling with high Covid-19 rates are among those least likely to get vaccinated, health advocates say.",
      "The damage inflicted by the Tuskegee Study and ongoing health care disparities, including lack of access to affordable medical care and to expensive pharmaceutical drugs, continues today as Blacks and Latinos remain leery of potential vaccines, advocates say."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Hispanic communities, along with Black communities, face challenges in the COVID-19 vaccine rollout due to higher levels of vaccine hesitancy and distrust. This is attributed to historical medical experimentation and ongoing healthcare disparities impacting these communities. Thus, the claim is supported by the evidence presented.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5052093863487244,
    "x2e_entail_prob": 0.001843280391767621
  },
  {
    "id": "covid_fact-000359",
    "statement": "Past covid-19 infection provides some immunity but people may still carry and transmit virus.",
    "label": "SUPPORTED",
    "evidences": [
      "The PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "Published 14 January 2021 From: Public Health England People infected with COVID-19 in the past are likely to be protected against reinfection for several months, a Public Health England (PHE) study has found, although experts cautioned those with immunity may still be able carry the virus in their nose and throat and therefore have a risk of transmitting to others.",
      "PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "But a small number of people with antibodies may still be able to carry and transmit COVID-19 according to the study.",
      "iStock London, January 14 An official UK study released on Thursday concludes that a past COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that past COVID-19 infection provides some immunity but individuals may still carry and transmit the virus. Multiple sources within the evidence support both components of the claim, indicating that while there is some protection against reinfection, transmission is still possible.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.2000679075717926,
    "x2e_entail_prob": 0.041332732886075974
  },
  {
    "id": "covid_fact-000360",
    "statement": "Past covid-19 infection provides some immunity but people cannot still carry and transmit virus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "Published 14 January 2021 From: Public Health England People infected with COVID-19 in the past are likely to be protected against reinfection for several months, a Public Health England (PHE) study has found, although experts cautioned those with immunity may still be able carry the virus in their nose and throat and therefore have a risk of transmitting to others.",
      "PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others.",
      "But a small number of people with antibodies may still be able to carry and transmit COVID-19 according to the study.",
      "iStock London, January 14 An official UK study released on Thursday concludes that a past COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that people cannot carry and transmit the virus after past COVID-19 infection, but the evidence suggests that individuals with past infections, while having some immunity, can still carry high levels of the virus and transmit it to others.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.33299851417541504,
    "x2e_entail_prob": 0.1003277525305748
  },
  {
    "id": "covid_fact-000361",
    "statement": "Systematic analysis of innate immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests a systematic analysis reveals vulnerabilities of SARS-CoV-2 related to immune antagonism. The evidence indicates that SARS-CoV-2 is highly susceptible to IFN-\u03b3 and IFN-\u03bb1 due to minimal antagonism, implying a vulnerability. Thus, the claim is supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.943783164024353,
    "x2e_entail_prob": 0.7134193778038025
  },
  {
    "id": "covid_fact-000362",
    "statement": "Systematic analysis of cellular immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a systematic analysis reveals that SARS-CoV-2 is more vulnerable to certain cytokines, specifically IFN-\u03b3 and IFN-\u03bb1, due to lesser antagonism. This supports the claim that analysis of cellular immune antagonism reveals vulnerabilities of SARS-CoV-2.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8255701065063477,
    "x2e_entail_prob": 0.563634991645813
  },
  {
    "id": "covid_fact-000363",
    "statement": "Systematic analysis of adaptive immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that a systematic analysis has identified vulnerabilities of SARS-CoV-2 in the context of adaptive immune antagonism. The evidence indicates that SARS-CoV-2 is highly susceptible to IFN-\u03b3 and IFN-\u03bb1 due to minimal antagonism against these cytokines. This aligns with the claim regarding SARS-CoV-2's vulnerabilities, supporting the idea of immune vulnerabilities.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.9322096705436707,
    "x2e_entail_prob": 0.7227640151977539
  },
  {
    "id": "covid_fact-000364",
    "statement": "Systematic analysis of antiviral immune antagonism reveals vulnerabilities of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Overall our analyses revealed that IFN-\u03b3 and IFN-\u03bb1 signalling are antagonised the least, leaving SARS-CoV-2 highly susceptible to these two cytokines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that a systematic analysis was conducted to evaluate how SARS-CoV-2 interacts with antiviral immune responses, specifically mentioning that IFN-\u03b3 and IFN-\u03bb1 signaling are least antagonized by the virus. This implies a vulnerability in SARS-CoV-2 to these cytokines, supporting the claim that such an analysis revealed vulnerabilities of the virus.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7937221527099609,
    "x2e_entail_prob": 0.4726385474205017
  },
  {
    "id": "covid_fact-000365",
    "statement": "Trial to promote recovery from covid-19 with ivermectin or endocrine therapy",
    "label": "SUPPORTED",
    "evidences": [
      "This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.",
      "This will be a randomized, open-label study to determine if bicalutamide or ivermectin improves the time to clinical improvement in patients with COVID-19 over historical controls."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the study is a randomized, open-label study designed to evaluate the effects of bicalutamide and ivermectin on the rate of clinical improvement in COVID-19 patients. Therefore, the claim about the trial using ivermectin and endocrine therapy (bicalutamide) to promote recovery from COVID-19 is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9435511827468872,
    "x2e_entail_prob": 0.8887984752655029
  },
  {
    "id": "covid_fact-000366",
    "statement": "Trial to no recovery from covid-19 with ivermectin or endocrine therapy",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.",
      "This will be a randomized, open-label study to determine if bicalutamide or ivermectin improves the time to clinical improvement in patients with COVID-19 over historical controls."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that there is a trial leading to no recovery from COVID-19 using either ivermectin or endocrine therapy. However, the evidence indicates ongoing studies to determine the efficacy of bicalutamide (an endocrine therapy) and ivermectin in improving clinical outcomes in COVID-19 patients. There is no mention of trial results leading to 'no recovery.'",
    "confidence": 0.8,
    "e2x_entail_prob": 0.015886172652244568,
    "x2e_entail_prob": 0.004139643628150225
  },
  {
    "id": "covid_fact-000367",
    "statement": "Coronavirus vaccines leap through safety trials",
    "label": "SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence details initial stages of coronavirus vaccine trials and mentions that the vaccines seem to be safe and elicit immune responses. However, there is no indication that these safety trials have been expedited or 'leaped through.' The claim implies a rapid or possibly rushed process through safety trials, but the evidence does not support this assertion.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.10840870440006256,
    "x2e_entail_prob": 0.22021225094795227
  },
  {
    "id": "covid_fact-000368",
    "statement": "Coronavirus vaccines remain through safety trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that coronavirus vaccines have undergone initial human trials and are inducing immune responses typical of potential protection against COVID-19. It suggests that the vaccines are broadly safe, supporting the claim that they remain through safety trials. However, the evidence does not provide complete details on the progression through all phases of safety trials, which reduces confidence slightly.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6555108428001404,
    "x2e_entail_prob": 0.08603939414024353
  },
  {
    "id": "covid_fact-000369",
    "statement": "Coronavirus vaccines work through safety trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Vaccines expose the immune system to components of a virus  the coronavirus spike protein, in the case of nearly all COVID-19 vaccines  in the hope of teaching it how to react against a real infection in the future.",
      "In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials.",
      "The vaccine is inducing the kind of immune responses that we think are inducing protection against coronavirus, said Sarah Gilbert, a vaccinologist co-leading the Oxford effort, in a press briefing announcing the results.",
      "But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus.",
      "Its definitely plausible that theres more than one way to protect against this virus. The nature of the immune response that protects  or fails to protect  against COVID-19 will become clearer when efficacy trials deliver their first results."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about the development and testing of coronavirus vaccines, focusing on safety and immune response data. However, it does not specifically mention that vaccines work 'through safety trials.' Safety trials are part of the testing process to ensure the vaccines are safe, but they are not the mechanism through which vaccines work. Vaccines work by teaching the immune system to respond to the virus, not through the trials themselves. Therefore, the claim is not accurately supported by the given evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.01286708191037178,
    "x2e_entail_prob": 0.00696859834715724
  },
  {
    "id": "covid_fact-000370",
    "statement": "Couple diagnosed with coronavirus flew on delta , hawaiian airlines flights , carriers confirm",
    "label": "SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly confirms that Delta Air Lines and Hawaiian Airlines both acknowledged that a couple diagnosed with the coronavirus flew on their flights. Thus, the claim is supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.49626582860946655,
    "x2e_entail_prob": 0.0010707085020840168
  },
  {
    "id": "covid_fact-000371",
    "statement": "Mice diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that a couple diagnosed with the coronavirus traveled on Delta and Hawaiian Airlines but does not mention anything about mice being diagnosed or flying on these airlines. The claim about mice is unsupported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.011047402396798134,
    "x2e_entail_prob": 0.0017655305564403534
  },
  {
    "id": "covid_fact-000372",
    "statement": "Dogs diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that a couple diagnosed with coronavirus traveled on Delta and Hawaiian Airlines, but it does not mention anything about dogs diagnosed with coronavirus flying on these airlines. Therefore, the claim is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.003686326090246439,
    "x2e_entail_prob": 0.0015454244567081332
  },
  {
    "id": "covid_fact-000373",
    "statement": "Cats diagnosed with coronavirus flew on delta, hawaiian airlines flights, carriers confirm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Delta Air Lines and Hawaiian Airlines have confirmed that a couple diagnosed with the coronavirus traveled on their flights in and around Hawaii earlier this month.",
      "Delta and Hawaiian Airlines have both since confirmed they are communicating with the U.S. Centers for Disease Control and Prevention (CDC) in the wake of the couples recent coronavirus diagnosis."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to a couple diagnosed with coronavirus traveling on Delta and Hawaiian Airlines, not cats. Therefore, the claim that cats diagnosed with coronavirus flew on these airlines is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.31016406416893005,
    "x2e_entail_prob": 0.002304807072505355
  },
  {
    "id": "covid_fact-000374",
    "statement": "Latest data show above 80 % efficacy for favipiravir in covid-19 , say rdif and chemrar",
    "label": "SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that favipiravir's efficacy was above the 80% threshold, which is described as the criterion for high antiviral activity. This supports the claim that RDIF and Chemrar report over 80% efficacy for favipiravir against COVID-19.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.2357514649629593,
    "x2e_entail_prob": 0.04813908040523529
  },
  {
    "id": "covid_fact-000375",
    "statement": "Latest data show only 80 % efficacy for favipiravir in covid-19, say rdif and chemrar",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that favipiravir's efficacy was above a threshold of 80%, which aligns with the claim that the latest data show 80% efficacy for the drug in COVID-19. Therefore, the claim is supported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.06260353326797485,
    "x2e_entail_prob": 0.08752098679542542
  },
  {
    "id": "covid_fact-000376",
    "statement": "Latest data show nearly 80 % efficacy for favipiravir in covid-19, say rdif and chemrar",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Dhaka Trial: Clear-Cut Evidence Favipiravir Effective against COVID-19 with Compelling Results 3.",
      "The drug's efficacy was above a threshold of 80%, which is the criterion for a drug with high antiviral activity.",
      "The drug 's efficacy was above a threshold > of 80%, which is the criterion for a drug with high antiviral activity."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that favipiravir's efficacy is above 80%, which aligns with the claim about its nearly 80% efficacy against COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.15639741718769073,
    "x2e_entail_prob": 0.0733780637383461
  },
  {
    "id": "covid_fact-000377",
    "statement": "Antibody test for covid-19 could help to control virus spread , says singapore medtech firm",
    "label": "SUPPORTED",
    "evidences": [
      "Yee estimates commissioning roughly two million COVID-19 test kits in the next two months from Nanjing-based Vazyme Biotech, a Chinese producer of enzymes and antibodies.",
      "The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus thats sweeping the world.",
      "Meanwhile, Singapores Ministry of Health issued a document released to all registered medical practitioners on April 3 stating, There is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections. The Biolidics test checks the blood for antibodies and can identify who was previously infected and may have already developed immunity to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the medtech firm has developed an antibody test for COVID-19, the evidence presented does not support the claim that it could help control virus spread. The Singapore Ministry of Health explicitly states there is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections, which implies skepticism about their utility in controlling virus spread.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.031495001167058945,
    "x2e_entail_prob": 0.0037315820809453726
  },
  {
    "id": "covid_fact-000378",
    "statement": "Antibody test for covid-19 cannot help to control virus spread, says singapore medtech firm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Yee estimates commissioning roughly two million COVID-19 test kits in the next two months from Nanjing-based Vazyme Biotech, a Chinese producer of enzymes and antibodies.",
      "The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus thats sweeping the world.",
      "Meanwhile, Singapores Ministry of Health issued a document released to all registered medical practitioners on April 3 stating, There is currently no role for COVID-19 serology rapid test kits in the diagnosis of COVID-19 infections. The Biolidics test checks the blood for antibodies and can identify who was previously infected and may have already developed immunity to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Singapore's Ministry of Health does not see a role for serology (antibody) test kits in diagnosing COVID-19 infections, which implies that these tests might not be effective in controlling virus spread. The medtech firm mentioned is likely reflecting this guidance, suggesting that antibody tests are not helpful for controlling the virus spread.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6272044777870178,
    "x2e_entail_prob": 0.002030768897384405
  },
  {
    "id": "covid_fact-000379",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of two different serological tests.",
    "label": "SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not specifically address seroprevalence rates among healthcare workers or details about the serological tests used. It mentions the predictive values of tests and deployment strategies for healthcare workers, but lacks direct information on seroprevalence findings or the strengths and limits of serological tests in this context.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.6034141182899475,
    "x2e_entail_prob": 0.0031098041217774153
  },
  {
    "id": "covid_fact-000380",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of three different serological tests.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses predictive values for serological tests and mentions the Fondazione Policlinico Universitario A. Gemelli as a COVID hospital. However, it does not specifically address the seroprevalence study among healthcare workers nor the strengths and limits of different serological tests as claimed.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.015609717927873135,
    "x2e_entail_prob": 0.001986093120649457
  },
  {
    "id": "covid_fact-000381",
    "statement": "Covid-19 seroprevalence among healthcare workers of a large covid hospital in rome reveals strengths and limits of all different serological tests.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Among low-risk population, point-of-cares predictive values were 58.33% (positive) and 98.23% (negative) whereas venous blood tests were 92.86% (positive) and 98.53% (negative).",
      "Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS has been enlisted as a COVID hospital, healthcare workers deployed to COVID wards were separated from those with limited or no exposure, whereas administrative staff was destined to work-from-home."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence refers to predictive values of serological tests and deployment of healthcare workers at a specific hospital, but it does not directly address or evaluate the seroprevalence among healthcare workers, nor does it reveal strengths and limits of different serological tests. Thus, the claim is not directly supported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.14922098815441132,
    "x2e_entail_prob": 0.004497095942497253
  },
  {
    "id": "covid_fact-000382",
    "statement": "A neutralizing human antibody binds to the n-terminal domain of the spike protein of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.",
      "( B ) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The presented evidence mentions neutralizing antibodies against SARS-CoV-2 infection but does not specify that a neutralizing antibody binds to the N-terminal domain of the spike protein. The evidence lacks specific details to support the claim about binding to the N-terminal domain.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.2881012260913849,
    "x2e_entail_prob": 0.372031569480896
  },
  {
    "id": "covid_fact-000383",
    "statement": "A neutralizing mouse antibody binds to the n-terminal domain of the spike protein of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.",
      "( B ) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not mention anything about a neutralizing mouse antibody binding to the N-terminal domain of the spike protein of SARS-CoV-2. It only mentions human neutralizing antibodies elicited by SARS-CoV-2 infection and their correlations in neutralizing titers. Therefore, the claim is not directly supported by the given evidence.",
    "confidence": 0.3,
    "e2x_entail_prob": 0.04471706598997116,
    "x2e_entail_prob": 0.23039837181568146
  },
  {
    "id": "covid_fact-000384",
    "statement": "A novel point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that virus mutations, including in target regions such as the n gene of SARS-CoV-2, can affect the effectiveness of RT-qPCR by impacting the sensitivity and specificity of assays. This supports the claim that a point mutation in the n gene could affect detection of the virus via RT-qPCR.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9440392255783081,
    "x2e_entail_prob": 0.0538947694003582
  },
  {
    "id": "covid_fact-000385",
    "statement": "A third point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that mutations in the SARS-CoV-2 genome can affect the detection of the virus by RT-qPCR, particularly if they occur in the primer regions. Since point mutations in the n gene can affect the effectiveness of primers used in RT-qPCR assays, this claim is supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7215180993080139,
    "x2e_entail_prob": 0.07376246154308319
  },
  {
    "id": "covid_fact-000386",
    "statement": "A major point mutation in the n gene of sars-cov-2 may affect the detection of the virus by rt-qpcr.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Finally, RT-qPCR primers are designed to amplify the target regions of the SARS-CoV-2 genome.",
      "Once virus mutation and recombination occur, it is difficult to effectively diagnose viral infection by existing RT-qPCR primers.",
      "There may be selective mutations in SARS-CoV-2, and it is necessary to avoid certain regions when designing primers and probes.",
      "The large- scale sustained person-to-person transmission of SARS-CoV-2 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (2).",
      "A mutation in a reverse primer has been shown to affect the sensitivity of an RT-qPCR assay in use early in the pandemic10 and further mutations could lead to the occurrence of false negative results, particularly if the mutation occurs at the extreme 3 end of the primers."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that mutations in the SARS-CoV-2 genome, including those in the n gene, can affect the effectiveness of RT-qPCR primers, potentially impacting the detection of the virus. The evidence specifically mentions that mutations can lead to decreased sensitivity and specificity of RT-qPCR assays, therefore supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.10754919052124023,
    "x2e_entail_prob": 0.04391418397426605
  },
  {
    "id": "covid_fact-000387",
    "statement": "99.9 % of sars-cov-2 gets destroyed after gargling betadine , claims study",
    "label": "SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that Betadine Gargle can destroy 99.9% of SARS-CoV-2 within 15 seconds and at subsequent time points. This aligns with the claim that 99.9% of SARS-CoV-2 is destroyed after gargling Betadine. Thus, the claim is supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7380479574203491,
    "x2e_entail_prob": 0.468364417552948
  },
  {
    "id": "covid_fact-000388",
    "statement": "99.9 % of sars-cov-2 gets stable after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that Betadine Gargle and other similar antiseptic products can destroy 99.9% of the SARS-CoV-2 virus, achieving this within as short a period as 15 to 30 seconds, which aligns with the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7059657573699951,
    "x2e_entail_prob": 0.050095316022634506
  },
  {
    "id": "covid_fact-000389",
    "statement": "99.9 % of sars-cov-2 gets effective after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Betadine Gargle was effective in reducing 99.9% of SARS-CoV-2 viral load within 15 seconds, which aligns with the claim that it is effective after gargling. The study results directly support the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6029586791992188,
    "x2e_entail_prob": 0.11966052651405334
  },
  {
    "id": "covid_fact-000390",
    "statement": "99.9 % of sars-cov-2 gets active after gargling betadine, claims study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Based on the study, antiseptic products like betadine, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle, and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I) can destroy 99.9% of Coronavirus for as fast as 30 seconds.",
      "Preliminary results show Betadine Gargle killed 99.9 percent of the virus within 15 seconds.",
      "In this study, results showed a 99.9 percent reduction of SARS- CoV-2 viral load starting at 15 seconds and at all subsequent time points in the study (30 seconds, 60 seconds and 5 minutes)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that 99.9% of SARS-CoV-2 becomes active after gargling with Betadine, implying activation rather than inhibition. However, the evidence provided shows that Betadine products, including gargle, actually destroy or reduce the viral load by 99.9%, suggesting inactivation rather than activation. Therefore, the claim is misleading and not supported by the evidence, which actually indicates the opposite effect.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.10440314561128616,
    "x2e_entail_prob": 0.14608334004878998
  },
  {
    "id": "covid_fact-000391",
    "statement": "Identification of sars-cov-2 vaccine epitopes predicted to induce long-term population-scale immunity",
    "label": "SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions vaccine epitopes and a vaccination strategy for SARS-CoV-2 focused on population-scale immunity, but it does not specifically confirm that these epitopes are predicted to induce long-term immunity. Therefore, the claim lacks full support from the evidence given.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.011336800642311573,
    "x2e_entail_prob": 0.7304530143737793
  },
  {
    "id": "covid_fact-000392",
    "statement": "Identification of sars-cov-2 vaccine epitopes fails to induce long-term population-scale immunity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses vaccine epitopes and a vaccination strategy focused on population-scale immunity, but does not directly support the claim that these vaccine epitopes fail to induce long-term population-scale immunity. More specific information or data linking epitopes to the failure of inducing long-term immunity would be required to support the claim.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.17029090225696564,
    "x2e_entail_prob": 0.883121132850647
  },
  {
    "id": "covid_fact-000393",
    "statement": "Identification of sars-cov-2 vaccine epitopes failed to induce long-term population-scale immunity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein Figure 2 Proposed Vaccine Epitopes in SARS-CoV-2 Spike Protein Crystal structure of SARS-CoV-2 Spike protein trimer (PDB: 6VYB) with two highlighted vaccine epitopes targeting newly evolved acquired viral vulnerabilities.",
      "A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about the identification of specific vaccine epitopes in the SARS-CoV-2 spike protein and a vaccination strategy aimed at population-scale immunity. However, it does not directly support the claim that these identified epitopes failed to induce long-term population-scale immunity. The evidence lacks direct information about the efficacy and long-term impact of these epitopes on population-scale immunity.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.7292112112045288,
    "x2e_entail_prob": 0.7757062315940857
  },
  {
    "id": "covid_fact-000394",
    "statement": "Serial interval of sars-cov-2 was shortened over time by nonpharmaceutical interventions",
    "label": "SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that empirical serial interval distributions for transmission pairs showed a shortening of serial intervals of SARS-CoV-2 over time in mainland China. It also mentions that these changes occurred as nonpharmaceutical interventions were introduced, thereby supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5468053817749023,
    "x2e_entail_prob": 0.014606760814785957
  },
  {
    "id": "covid_fact-000395",
    "statement": "Serial interval of sars-cov-2 was increased over time by nonpharmaceutical interventions",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the serial intervals of SARS-CoV-2 shortened over time, which contradicts the claim that they increased due to nonpharmaceutical interventions. The claim is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.11338833719491959,
    "x2e_entail_prob": 0.009568601846694946
  },
  {
    "id": "covid_fact-000396",
    "statement": "Serial interval of sars-cov-2 was obtained over time by nonpharmaceutical interventions",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig.",
      "noticed that the average serial interval changed as nonpharmaceutical interventions were introduced.",
      "1 Serial intervals of SARS-CoV-2 substantially shortened over time in mainland China."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the serial intervals of SARS-CoV-2 shortened over time, and it specifically notes that changes occurred as nonpharmaceutical interventions were introduced. This suggests a correlation between the serial interval and nonpharmaceutical measures, thus supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1630357801914215,
    "x2e_entail_prob": 0.023382671177387238
  },
  {
    "id": "covid_fact-000397",
    "statement": "Sars-cov-2 is not detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that SARS-CoV-2 was not detectable in the vaginal fluid samples taken from 10 women with severe COVID-19 infections. While the sample size is small, the findings support the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8576947450637817,
    "x2e_entail_prob": 0.04376842454075813
  },
  {
    "id": "covid_fact-000398",
    "statement": "Sars-cov-2 is also detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that in a study of 10 patients, all tested negative for SARS-CoV-2 in vaginal fluid, suggesting that the virus is not detectable in the vaginal fluids of women with severe COVID-19 infection. Thus, the claim is not supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8711247444152832,
    "x2e_entail_prob": 0.9449141621589661
  },
  {
    "id": "covid_fact-000399",
    "statement": "Sars-cov-2 is only detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 was not detected in the vaginal fluid of any of the patients, suggesting that it is not present there, even in severe COVID-19 cases. This contradicts the claim that the virus is detectable in such cases.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7497137784957886,
    "x2e_entail_prob": 0.02505926415324211
  },
  {
    "id": "covid_fact-000400",
    "statement": "Sars-cov-2 is still detectable in the vaginal fluid of women with severe covid-19 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "All 10 patients were tested for SARS-CoV-2 in vaginal fluid, and all samples tested negative for the virus.",
      "Conclusions: Findings from this small group of cases suggest that SARS- CoV-2 virus does not exist in the vaginal fluids of severe COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that all samples tested negative for SARS-CoV-2 in the vaginal fluids of women with severe COVID-19. Thus, the claim is not supported.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.6386684775352478,
    "x2e_entail_prob": 0.00579034723341465
  },
  {
    "id": "covid_fact-000401",
    "statement": "Sars-cov-2 infects monocytes and macrophages , without cytopathic effect",
    "label": "SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that SARS-CoV-2 infects monocytes and macrophages without causing a cytopathic effect, matching the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.43039196729660034,
    "x2e_entail_prob": 0.1190808042883873
  },
  {
    "id": "covid_fact-000402",
    "statement": "Sars-cov-2 infects monocytes and macrophages, cause cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infects monocytes and macrophages, but it specifically states that the infection does not result in a cytopathic effect. Therefore, the claim that it causes cytopathic effects in these cells is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.11704989522695541,
    "x2e_entail_prob": 0.2936033010482788
  },
  {
    "id": "covid_fact-000403",
    "statement": "Sars-cov-2 infects monocytes and macrophages, an cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence specifically indicates that while SARS-CoV-2 does infect monocytes and macrophages, it does so without a cytopathic effect. Therefore, the claim that infection has a cytopathic effect is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7700729966163635,
    "x2e_entail_prob": 0.2676714062690735
  },
  {
    "id": "covid_fact-000404",
    "statement": "Sars-cov-2 infects monocytes and macrophages, a cytopathic effect",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Thus, SARS-CoV-2 infects monocytes and macrophages and induces a more sustained activation in macrophages without cytopathic effect.",
      "The study showed that SARS-CoV-2 could infect monocytes and macrophages and stimulate cytokine release without any cytopathic effect."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 does infect monocytes and macrophages, but it specifically states that this occurs without a cytopathic effect. Therefore, the claim that it causes a cytopathic effect is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3276180326938629,
    "x2e_entail_prob": 0.2175450474023819
  },
  {
    "id": "covid_fact-000405",
    "statement": "Rapid clinical deterioration of severe covid-19 may be associated with stroke",
    "label": "SUPPORTED",
    "evidences": [
      "\"For those with severe COVID-19, rapid clinical deterioration or worsening could be associated with a neurologic event such as stroke, which would contribute to its high mortality rate,\" the team wrote in JAMA Neurology."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from JAMA Neurology clearly states that rapid clinical deterioration in severe COVID-19 cases may be associated with a stroke, which supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.04762718826532364,
    "x2e_entail_prob": 0.0034771158825606108
  },
  {
    "id": "covid_fact-000406",
    "statement": "Rapid clinical deterioration of severe covid-19 may be associated with pneumonia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"For those with severe COVID-19, rapid clinical deterioration or worsening could be associated with a neurologic event such as stroke, which would contribute to its high mortality rate,\" the team wrote in JAMA Neurology."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions rapid clinical deterioration of severe COVID-19 being associated with neurologic events like stroke, but it does not mention pneumonia. Therefore, it does not support the claim that pneumonia is associated with rapid clinical deterioration in severe COVID-19 cases.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.003574296599254012,
    "x2e_entail_prob": 0.0013624508865177631
  },
  {
    "id": "covid_fact-000407",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for replication in primary human respiratory cells",
    "label": "SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that distinct phenotypes of SARS-CoV-2 isolates reveal viral traits critical for replication in primary human respiratory cells. The evidence presents an analysis of viral sequencing data combined with virus replication data from primary human cells, indicating the identification of several SARS-CoV-2 sequence features correlated with distinct viral phenotypes. Therefore, the claim is supported by the evidence, although specifics on what traits are critical for replication are not detailed.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.2086743712425232,
    "x2e_entail_prob": 0.14687763154506683
  },
  {
    "id": "covid_fact-000408",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for pathogenicity in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions that the integration of sequencing data with virus replication data reveals several SARS-CoV-2 sequence features that are associated with distinct phenotypes. These findings imply that certain viral traits are being observed in relation to their effects on human bronchial epithelial cells, which aligns with the claim about distinct phenotypes revealing viral traits critical for pathogenicity.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.9182835221290588,
    "x2e_entail_prob": 0.5541946887969971
  },
  {
    "id": "covid_fact-000409",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for infection in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions that by integrating different types of viral sequencing data with kinetic virus replication data from human bronchial epithelial cells, distinct phenotypes of SARS-CoV-2 were observed. The claim asserts that these phenotypes reveal viral traits critical for infection in primary human respiratory cells, which is supported by the evidence outlining the use of primary human respiratory cells in the study. While specific 'critical' viral traits are not detailed, the association with distinct phenotypes suggests supportive evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9602079391479492,
    "x2e_entail_prob": 0.13220413029193878
  },
  {
    "id": "covid_fact-000410",
    "statement": "Distinct phenotypes of sars-cov-2 isolates reveal viral traits critical for mortality in primary human respiratory cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By integrating viral sequencing data from patient material, viral stocks and passaging experiments, with kinetic virus replication data from non-human Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 sequence features that associate with distinct phenotypes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that specific SARS-CoV-2 phenotypes are linked directly to critical traits for mortality in human respiratory cells. However, the evidence only mentions the association of several SARS-CoV-2 sequence features with distinct phenotypes, without specifically linking these phenotypes to mortality traits in human respiratory cells. Therefore, the claim is not fully supported by the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0075697991997003555,
    "x2e_entail_prob": 0.0539550743997097
  },
  {
    "id": "covid_fact-000411",
    "statement": "Esc council on hypertension says ace-i and arbs do not increase covid-19 mortality",
    "label": "SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that the ESC Council on Hypertension sees no scientific or clinical evidence supporting the notion that ACE-I (Angiotensin-Converting Enzyme Inhibitors) and ARBs (Angiotensin Receptor Blockers) increase COVID-19 mortality. Instead, it recommends continuing treatment with these drugs, thus supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2572050988674164,
    "x2e_entail_prob": 0.7505357265472412
  },
  {
    "id": "covid_fact-000412",
    "statement": "Esc council on hypertension says ace-i and arbs do and increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided by the ESC Council on Hypertension clearly states that there is no clinical or scientific evidence to support the claim that ACE-I and ARBs increase COVID-19 mortality. Despite some early reports that speculated on potential harm, these drugs have been recommended for continued use without indicating increased mortality risks. Thus, the claim is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9601284861564636,
    "x2e_entail_prob": 0.9146657586097717
  },
  {
    "id": "covid_fact-000413",
    "statement": "Esc council on hypertension says ace-i and arbs do also increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that the ESC Council on Hypertension claims ACE-I and ARBs increase COVID-19 mortality. However, the evidence shows that the Council on Hypertension actually advises against this notion, citing no scientific basis for increased COVID-19 mortality due to these medications. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8299095630645752,
    "x2e_entail_prob": 0.7968162298202515
  },
  {
    "id": "covid_fact-000414",
    "statement": "Esc council on hypertension says ace-i and arbs do significantly increase covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it.",
      "The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.",
      "Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence directly contradicts the claim by stating that the ESC's Council on Hypertension does not believe that ACE-i and ARBs increase COVID-19 mortality. Instead, they recommend continuing treatment with these medications as there is no scientific or clinical evidence supporting claims that they are harmful in the context of COVID-19.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8022624850273132,
    "x2e_entail_prob": 0.8627293109893799
  },
  {
    "id": "covid_fact-000415",
    "statement": "Coronavirus threatens small businesses",
    "label": "SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence outlines various ways in which the coronavirus outbreak is impacting small businesses negatively, such as economic decline, supply chain issues, and public alarm affecting business. The potential for catastrophic effects and long-term impacts on small businesses is explicitly mentioned, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7213379740715027,
    "x2e_entail_prob": 0.032451990991830826
  },
  {
    "id": "covid_fact-000416",
    "statement": "Coronavirus threatens worldwide businesses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the coronavirus pandemic has negatively impacted businesses through stock market declines, supply chain disruptions, and travel cancellations. Additionally, small businesses are experiencing significant challenges and potential long-term effects. These factors support the claim that coronavirus threatens businesses worldwide, especially small businesses.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9113874435424805,
    "x2e_entail_prob": 0.04056462645530701
  },
  {
    "id": "covid_fact-000417",
    "statement": "Coronavirus threatens globally businesses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "For small businesses, though, it could be catastrophic.",
      "The economy has been affected by the outbreak in ways large and small, including stock market declines, supply chain backups and company cancellations of business travel and meetings, in the United States and elsewhere.",
      "In some cases, public alarm is affecting small businesses even where there is no widespread outbreak or official guidance to stay inside.",
      "Small businesses are on the front line of this crisis, said Amanda Ballantyne, executive director of Main Street Alliance, a public policy group for small businesses.",
      "But for small businesses, there could be long-term effects on daily life and work in local communities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the coronavirus has impacted various aspects of the economy, affecting businesses globally, including small businesses facing challenges such as supply chain issues, market declines, and event cancellations. This supports the claim that coronavirus threatens businesses globally, although the evidence focuses more on small businesses rather than the whole spectrum of global businesses.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.10493002831935883,
    "x2e_entail_prob": 0.00572983780875802
  },
  {
    "id": "covid_fact-000418",
    "statement": "Deaths in new york city are more than double the usual total",
    "label": "SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that over 31 days ending April 4, the number of deaths in New York City was more than twice the typical number, specifically about 5,000 more deaths than usual, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8470050692558289,
    "x2e_entail_prob": 0.11151275038719177
  },
  {
    "id": "covid_fact-000419",
    "statement": "Deaths in new york city are more than below the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that deaths in New York City were more than twice the typical number during the specified period. This contradicts the claim that deaths are 'more than below' the usual total, so the claim is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6539992690086365,
    "x2e_entail_prob": 0.002215517917647958
  },
  {
    "id": "covid_fact-000420",
    "statement": "Children in new york city are more than double the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to an increase in the total number of deaths in New York City, not an increase in the number of children. The claim specifically mentions children, but the evidence does not support this aspect.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.06323546171188354,
    "x2e_entail_prob": 0.005459776613861322
  },
  {
    "id": "covid_fact-000421",
    "statement": "Patients in new york city are more than double the usual total",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Over the 31 days ending April 4, more than twice the typical number of New Yorkers died.",
      "But even if the current count is perfect, roughly 9,780 people have died of all causes over the past month in New York City, about 5,000 more than is typical."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that over a 31-day period ending April 4, New York City experienced more than twice the usual number of deaths. This supports the claim that patients (interpreted as referring to the substantive increase in mortality rate) in New York City are more than double the usual total. The evidence explicitly compares the number of deaths during this period to typical figures, which aligns with the claim's implication of a significant increase.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.866971492767334,
    "x2e_entail_prob": 0.12843014299869537
  },
  {
    "id": "covid_fact-000422",
    "statement": "Covid-19 racial disparities could be worsened by location of test sites",
    "label": "SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there is a disparity in the availability of COVID-19 testing between different locations, such as northern and southern Dallas. This supports the claim that test site location can contribute to racial disparities in COVID-19 outcomes, as location impacts access, which is crucial for timely testing and treatment. Therefore, the claim is supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9409238696098328,
    "x2e_entail_prob": 0.006254265550523996
  },
  {
    "id": "covid_fact-000423",
    "statement": "Covid-19 racial disparities cannot be worsened by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that location plays a significant role in access to COVID-19 testing, which can cause or exacerbate racial disparities. The mention of testing disparity in Dallas based on location implies that location of test sites can indeed influence and worsen these disparities.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8463037014007568,
    "x2e_entail_prob": 0.0016425178619101644
  },
  {
    "id": "covid_fact-000424",
    "statement": "Covid-19 racial disparities could be assessed by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that Covid-19 racial disparities can be assessed by the location of test sites. The evidence implies that disparities in access to testing in different parts of Dallas might contribute to racial disparities. It states that location is an important factor to consider in access to testing. This supports the idea that test site locations could help assess racial disparities.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9776440262794495,
    "x2e_entail_prob": 0.0020896100904792547
  },
  {
    "id": "covid_fact-000425",
    "statement": "Covid-19 racial disparities could be defined by location of test sites",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"A lot of the disparity ... is reflecting some of that private sector availability of tests in the northern part of Dallas compared to southern Dallas.\"",
      "While many things can affect access to testing, location is an important starting point.",
      "racial inequities coronavirus in the U.S. coronavirus testing COVID-19 Facebook Twitter Flipboard Email"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided suggests that the availability of COVID-19 test sites in different locations can contribute to racial disparities, as highlighted in the example contrasting northern and southern Dallas. The statement aligns with the claim that location is a significant factor in defining these disparities.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9210526943206787,
    "x2e_entail_prob": 0.07391971349716187
  },
  {
    "id": "covid_fact-000426",
    "statement": "Overweight and obesity are risks factors of severe illness in patients with covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Having obesity may triple the risk of hospitalization due to a COVID-19 infection.",
      "Conclusions: Overweight and obesity were independent risk factors of severe illness in COVID-19 patients.",
      "Overweight, Obesity and Severe Obesity Having obesity, defined as a body mass index (BMI) between 30 kg/m2 and <40 kg/m2 or severe obesity (BMI of 40 kg/m2 or above), increases your risk of severe illness from COVID-19.",
      "Having obesity puts people at risk for many other serious chronic diseases and increases the risk of severe illness from COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that both overweight and obesity are independent risk factors for severe illness in COVID-19 patients. Specific data shows that obesity increases the risk of hospitalization and severe illness due to COVID-19, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.797327995300293,
    "x2e_entail_prob": 0.00910778809338808
  },
  {
    "id": "covid_fact-000427",
    "statement": "Overweight and obesity are risks factors of severe illness in patients without covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Having obesity may triple the risk of hospitalization due to a COVID-19 infection.",
      "Conclusions: Overweight and obesity were independent risk factors of severe illness in COVID-19 patients.",
      "Overweight, Obesity and Severe Obesity Having obesity, defined as a body mass index (BMI) between 30 kg/m2 and <40 kg/m2 or severe obesity (BMI of 40 kg/m2 or above), increases your risk of severe illness from COVID-19.",
      "Having obesity puts people at risk for many other serious chronic diseases and increases the risk of severe illness from COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided focuses on obesity and overweight as risk factors for severe illness specifically in the context of COVID-19, not in patients without COVID-19. Therefore, the claim lacks evidence to support that overweight and obesity are risk factors for severe illness outside of COVID-19.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.04721751809120178,
    "x2e_entail_prob": 0.0036701897624880075
  },
  {
    "id": "covid_fact-000428",
    "statement": "Intestinal inflammation modulates the expression of ace2 and tmprss2 and potentially overlaps with the pathogenesis of sars-cov-2 related disease",
    "label": "SUPPORTED",
    "evidences": [
      "These considerations led us to systematically examine the intersections between COVID-19 and the GI tract during health and intestinal inflammation."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses examining intersections between COVID-19 and the gastrointestinal tract during health and inflammation, but it does not explicitly confirm that intestinal inflammation modulates the expression of ace2 and tmprss2 or their overlap with SARS-CoV-2 related disease pathogenesis.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0025070931296795607,
    "x2e_entail_prob": 0.00231858785264194
  },
  {
    "id": "covid_fact-000429",
    "statement": "Intestinal inflammation modulates the production of ace2 and tmprss2 and potentially overlaps with the pathogenesis of sars-cov-2 related disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These considerations led us to systematically examine the intersections between COVID-19 and the GI tract during health and intestinal inflammation."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence mentions examining intersections between COVID-19 and the GI tract during health and inflammation but does not specifically support the claim that intestinal inflammation modulates the production of ace2 and tmprss2 or overlaps with the pathogenesis of SARS-CoV-2 related disease.",
    "confidence": 0.3,
    "e2x_entail_prob": 0.002535981824621558,
    "x2e_entail_prob": 0.005822477862238884
  },
  {
    "id": "covid_fact-000430",
    "statement": "Sars-cov-2 simulations go exascale to capture spike opening and reveal cryptic pockets across the proteome",
    "label": "SUPPORTED",
    "evidences": [
      "We also observe dramatic conformational changes across the proteome, which reveal over 50 cryptic pockets that expand targeting options for the design of antivirals.",
      "To address this challenge, over a million citizen scientists banded together through the Folding@home distributed computing project to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence showing that SARS-CoV-2 simulations achieved exascale computing using distributed computing via the Folding@home project. The simulations uncovered over 50 cryptic pockets within the proteome, aligning with the claim of revealing spike opening and cryptic pockets.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4767823815345764,
    "x2e_entail_prob": 0.001132913283072412
  },
  {
    "id": "covid_fact-000431",
    "statement": "Sars-cov-2 simulations go exascale to avoid spike opening and reveal cryptic pockets across the proteome",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We also observe dramatic conformational changes across the proteome, which reveal over 50 cryptic pockets that expand targeting options for the design of antivirals.",
      "To address this challenge, over a million citizen scientists banded together through the Folding@home distributed computing project to create the first exascale computer and simulate an unprecedented 0.1 seconds of the viral proteome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The Folding@home project achieved exascale computing to simulate the SARS-CoV-2 proteome, as evidenced by the involvement of over a million citizen scientists to perform these simulations. The simulations revealed cryptic pockets across the proteome, which could influence antiviral design, supporting the claim's key points.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.056121572852134705,
    "x2e_entail_prob": 0.001910578808747232
  },
  {
    "id": "covid_fact-000432",
    "statement": "Experts divide into two camps of actionshielding versus blanket policies",
    "label": "SUPPORTED",
    "evidences": [
      "One group of doctors and academics is calling for segmentation and shielding of the most vulnerable groups of people rather than local or national lockdown measures."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about one group of experts advocating for segmentation and shielding vulnerable groups. However, it does not mention another group supporting blanket policies, nor does it directly establish a division into two camps.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0031828037463128567,
    "x2e_entail_prob": 0.001675347681157291
  },
  {
    "id": "covid_fact-000433",
    "statement": "Poolkeh finds the optimal pooling strategy for a population-wide covid-19 testing",
    "label": "SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions that the Poolkeh framework finds the best test pooling strategy that fits the current status of the population for maximizing COVID-19 testing throughput. This supports the claim that Poolkeh finds the optimal pooling strategy for population-wide COVID-19 testing.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6940010190010071,
    "x2e_entail_prob": 0.057451874017715454
  },
  {
    "id": "covid_fact-000434",
    "statement": "Poolkeh finds the initial pooling strategy for a population-wide covid-19 testing",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a framework that maximizes throughput of COVID-19 tests by finding optimal test pooling strategies based on a nation\u2019s specific status, but it does not explicitly state that 'Poolkeh' is responsible for finding the initial pooling strategy for population-wide testing. The claim remains unsupported without direct evidence linking Poolkeh to the initial strategy development.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.16557921469211578,
    "x2e_entail_prob": 0.03879827633500099
  },
  {
    "id": "covid_fact-000435",
    "statement": "Poolkeh finds the first pooling strategy for a population-wide covid-19 testing",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our framework allows health agencies to maximize the throughput of COVID-19 tests among the world population by finding the best test pooling that fits the current SIR-D [1] status of the nation.",
      "Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented discusses a framework for optimizing COVID-19 test pooling but does not specifically claim that Poolkeh was the first to find a pooling strategy for population-wide COVID-19 testing. The document mentions maximizing test throughput but does not declare the originality or pioneering nature of the strategy.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.43928295373916626,
    "x2e_entail_prob": 0.01432245597243309
  },
  {
    "id": "covid_fact-000436",
    "statement": "Global coronavirus death toll could be 60 % higher than reported",
    "label": "SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that excess deaths, which are deaths above the average for the same period in previous years, were 58% higher than the reported Covid-19 deaths. This suggests a significant underreporting of coronavirus deaths, supporting the claim that the global death toll could be 60% higher than reported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9701684713363647,
    "x2e_entail_prob": 0.0009142362396232784
  },
  {
    "id": "covid_fact-000437",
    "statement": "Global coronavirus death toll could be 60 % less than reported",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the number of excess deaths was 58% higher than the total number of reported COVID-19 deaths for the same period. This implies a significant underreporting of the actual death toll, which could support the claim that the reported global coronavirus death toll could be 60% less than the actual number of deaths.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.9425615072250366,
    "x2e_entail_prob": 0.0009735479252412915
  },
  {
    "id": "covid_fact-000438",
    "statement": "Global coronavirus death toll could be 60 % lower than reported",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The extra deaths are most pronounced in urban areas with the worst virus outbreaks, and have completely overwhelmed reporting mechanisms in some.",
      "This is especially worrying for many emerging economies, where total excess mortality is orders of magnitude higher than official coronavirus fatalities.",
      "The figure was 76 per cent higher than the average for the same week in the past five years, and the number of excess deaths was 58 per cent higher than the total number of reported Covid-deaths for the same period."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that excess deaths, which are deaths above the expected norms, are higher than reported Covid-19 deaths. This indicates that actual Covid-19 deaths might be underreported, not overreported. Therefore, it is unlikely that the coronavirus death toll is 60% lower than reported, as the data points towards the opposite scenario, where deaths could be underestimated.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7706634998321533,
    "x2e_entail_prob": 0.0010006119264289737
  },
  {
    "id": "covid_fact-000439",
    "statement": "In a phylogenetic network analysis of 160 complete human severe acute respiratory syndrome coronavirus 2 genomes , we find three central variants distinguished by amino acid changes , which we have named a , b , and c ...",
    "label": "SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that a phylogenetic network analysis of 160 SARS-CoV-2 genomes was conducted. However, it does not mention the identification of three central variants named a, b, and c, or any associated amino acid changes. Thus, the claim is not fully supported by the current evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.005907428916543722,
    "x2e_entail_prob": 0.00727874506264925
  },
  {
    "id": "covid_fact-000440",
    "statement": "In a phylogenetic network analysis of five complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions a phylogenetic network of 160 largely complete SARS-CoV-2 genomes but does not specify any central variants named a, b, and c nor amino acid changes distinguishing them. Thus, the claim lacks support from the evidence given.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.004429900087416172,
    "x2e_entail_prob": 0.0035814030561596155
  },
  {
    "id": "covid_fact-000441",
    "statement": "In a phylogenetic network analysis of four complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a phylogenetic network analysis of 160 SARS-CoV-2 genomes, but it does not confirm details regarding three central variants named a, b, and c, nor does it mention the analysis of only four genomes as claimed. Therefore, the claim is not supported by the provided evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.004125786479562521,
    "x2e_entail_prob": 0.0065867058001458645
  },
  {
    "id": "covid_fact-000442",
    "statement": "In a phylogenetic network analysis of six complete human severe acute respiratory syndrome coronavirus 2 genomes, we find three central variants distinguished by amino acid changes, which we have named a, b, and c...",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To understand the evolution of this virus within humans, and to assist in tracing infection pathways and designing preventive strategies, we here present a phylogenetic network of 160 largely complete SARS-Cov-2 genomes (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to a phylogenetic network analysis of six SARS-CoV-2 genomes identifying three central variants named a, b, and c. However, the evidence mentions a phylogenetic network of 160 largely complete genomes, not six. There is no mention of variants named a, b, and c in the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.003821965539827943,
    "x2e_entail_prob": 0.006416042800992727
  },
  {
    "id": "covid_fact-000443",
    "statement": "The cellular immune response to covid-19 deciphered by single cell multi-omics across three uk centres.",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.",
      "Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases.",
      "To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA- sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides detailed insights into cellular processes during an acute immune response to COVID-19, obtained from multi-omic single cell analyses across multiple UK centers. This aligns with the claim that the cellular immune response to COVID-19 was deciphered by single cell multi-omics across three UK centers.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.2210526466369629,
    "x2e_entail_prob": 0.004551735240966082
  },
  {
    "id": "covid_fact-000444",
    "statement": "The cellular immune response to covid-19 deciphered by single cell multi-omics across two uk centres.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.",
      "Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases.",
      "To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA- sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes the use of single-cell multi-omics to study the cellular immune response to COVID-19. It mentions the integration of data from multiple centers, supporting the claim that the cellular immune response to COVID-19 was deciphered using this method across two UK centers.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.08368496596813202,
    "x2e_entail_prob": 0.003588014980778098
  },
  {
    "id": "covid_fact-000445",
    "statement": "University of oxford resumes vaccine trial",
    "label": "SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that the University of Oxford has resumed its vaccine trials after a temporary pause. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) recommended the resumption following a safety data review by an independent committee. Additionally, there is a tweet confirming that the trials are back up and running.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.954138457775116,
    "x2e_entail_prob": 0.010402602143585682
  },
  {
    "id": "covid_fact-000446",
    "statement": "Lack of oxford resumes vaccine trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the University of Oxford's vaccine trials, which were paused due to a safety data review, have been resumed as per the recommendation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). This supports the claim that the Oxford vaccine trial has resumed.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8256620764732361,
    "x2e_entail_prob": 0.002771432278677821
  },
  {
    "id": "covid_fact-000447",
    "statement": "Development of oxford resumes vaccine trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Oxford, which has partnered with pharmaceutical giant AstraZeneca to pilot the study, said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had recommended that its trials resume after an independent committee review of safety data triggered a pause last week.",
      "He tweeted: Good news for everyone the Oxford vaccine trials are back up and running."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the University of Oxford, in partnership with AstraZeneca, was able to resume its vaccine trials after the UK Medicines and Healthcare Products Regulatory Agency recommended it following a safety review. This supports the claim that the development of the Oxford vaccine trial has resumed.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7291234731674194,
    "x2e_entail_prob": 0.007666917517781258
  },
  {
    "id": "covid_fact-000448",
    "statement": "Slight reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that masks reduce exposure viral load, which is linked to decreased transmission. Even moderate mask efficacy significantly lowers the effective reproductive number when masks are widely used, demonstrating a significant reduction in transmission through masking.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9796629548072815,
    "x2e_entail_prob": 0.0020961971022188663
  },
  {
    "id": "covid_fact-000449",
    "statement": "High reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that moderately efficacious masks can significantly reduce exposure viral load, which is shown to decrease transmission risk and lower the effective reproductive number with widespread implementation. This supports the claim that high reduction in exposure viral load due to masking can lead to a significant reduction in transmission.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9828672409057617,
    "x2e_entail_prob": 0.0015840432606637478
  },
  {
    "id": "covid_fact-000450",
    "statement": "Significant reduction in sars-cov-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our model predicts that moderately efficacious masks will lower exposure viral load 10-fold among people who get infected despite masking, potentially limiting infection severity.",
      "Slight increases in mask adherence and/or efficacy above current levels would reduce the effective reproductive number (Re) substantially below 1, particularly if implemented comprehensively in potential super-spreader environments.",
      "These results highlight the primacy of masking relative to other biomedical interventions under consideration for limiting the extent of the COVID-19 pandemic prior to widespread implementation of a vaccine.",
      "Our model quantitatively links mask efficacy to reductions in viral load and subsequent transmission risk.",
      "Our results reinforce that the use of masks by both a potential transmitter and exposed person substantially reduces the probability of successful transmission, even if masks only lower exposure viral load by 50%."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that mask usage substantially reduces exposure viral load and transmission. Mask efficacy and improved adherence significantly lower the effective reproductive number and mitigate transmission risk, supporting the claim that masking leads to a significant reduction in transmission.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9704668521881104,
    "x2e_entail_prob": 0.001435345970094204
  },
  {
    "id": "covid_fact-000451",
    "statement": "National smoking rates correlate inversely with covid-19 mortality",
    "label": "SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows a highly significant inverse correlation between smoking prevalence and COVID-19 mortality rates across different groups, supporting the claim of an inverse relationship.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9924617409706116,
    "x2e_entail_prob": 0.25321662425994873
  },
  {
    "id": "covid_fact-000452",
    "statement": "National smoking rates correlate closely with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests a correlation between national smoking rates and COVID-19 mortality. However, the evidence provided specifically notes an inverse correlation, indicating that higher current smoking prevalence relates to lower COVID-19 mortality, which contrasts with the claim that suggests a general correlation without specifying direction. Thus, the claim lacks support.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.05588443949818611,
    "x2e_entail_prob": 0.19019998610019684
  },
  {
    "id": "covid_fact-000453",
    "statement": "National smoking rates correlate closerly with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests a close correlation between national smoking rates and COVID-19 mortality. However, the evidence indicates an inverse relationship, meaning higher smoking rates are associated with lower COVID-19 mortality, not a direct correlation as the claim implies. Therefore, the evidence does not support the claim as it contradicts the implied direction of the correlation.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6241910457611084,
    "x2e_entail_prob": 0.24380822479724884
  },
  {
    "id": "covid_fact-000454",
    "statement": "National smoking rates correlate greaterly with covid-19 mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Discussion These findings add support to the finding of an inverse relationship between current smoking and seriously symptomatic COVID-19.",
      "Results A highly significant inverse correlation between current daily smoking prevalence and COVID-19 mortality rate was noted for the group of hot countries (R=-.718, p = .0002), cold countries (R=-.567, p=.0046), and the combined group (R=-.324, p=.0207)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates an inverse correlation between smoking rates and COVID-19 mortality, meaning higher smoking rates are associated with lower COVID-19 mortality rates, which contradicts the claim of a direct correlation. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3251292407512665,
    "x2e_entail_prob": 0.46361032128334045
  },
  {
    "id": "covid_fact-000455",
    "statement": "Cryptic transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that genomic epidemiology, which involves the use of genetic sequences of pathogens, is used to understand transmission patterns of SARS-CoV-2. This aligns with the claim that cryptic transmission was revealed by genomic epidemiology. Hence, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8431060910224915,
    "x2e_entail_prob": 0.4281598627567291
  },
  {
    "id": "covid_fact-000456",
    "statement": "Viral transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that genomic epidemiology, which uses genetic sequences of pathogens, can indeed reveal patterns of transmission and spread. This supports the claim that viral transmission of the novel coronavirus SARS-CoV-2 has been revealed through genomic epidemiology.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7391839027404785,
    "x2e_entail_prob": 0.24975000321865082
  },
  {
    "id": "covid_fact-000457",
    "statement": "Phylogenetic transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim appears to refer to the use of genomic epidemiology to reveal transmission patterns of the novel coronavirus, SARS-CoV-2. The provided evidence mentions that genome sequencing of SARS-CoV-2 allows for reconstruction of transmission history, confirming that genomic epidemiology can reveal transmission patterns of the virus. Thus, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.39460816979408264,
    "x2e_entail_prob": 0.5640745759010315
  },
  {
    "id": "covid_fact-000458",
    "statement": "Initial transmission of novel coronavirus sars-cov-2 revealed by genomic epidemiology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections.",
      "Toggle navigation bedford lab blog papers projects team Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread.",
      "Cryptic transmission of novel coronavirus revealed by genomic epidemiology 2 Mar 2020 by Trevor Bedford The field of genomic epidemiology focuses on using the genetic sequences of pathogens to understand patterns of transmission and spread."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that genomic epidemiology played a role in revealing patterns of transmission of SARS-CoV-2 by using genome sequencing. This supports the claim as it refers to genomic epidemiology revealing transmission insights.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7120070457458496,
    "x2e_entail_prob": 0.2527182698249817
  },
  {
    "id": "covid_fact-000459",
    "statement": "Nurses and other union workers authorize oct. 7 strike against east bay hospitals",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that employees in the Alameda Health System, who are represented by the California Nurses Association, announced a plan to begin a five-day strike on October 7. This supports the claim that nurses and other union workers have authorized a strike against East Bay hospitals starting on October 7.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.2866262197494507,
    "x2e_entail_prob": 0.0029414149466902018
  },
  {
    "id": "covid_fact-000460",
    "statement": "Nurses and other union workers authorize dr. 7 strike against east bay hospitals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only confirms that employees in the Alameda Health System, likely including nurses, plan a five-day strike beginning on Oct. 7. It does not specify whether other union workers have authorized a strike against 'East Bay hospitals' or if they are involved. For a stronger conclusion, more specific details about the unions and workers involved are needed.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.05937150865793228,
    "x2e_entail_prob": 0.0032642835285514593
  },
  {
    "id": "covid_fact-000461",
    "statement": "Nurses and other union workers authorize s. 7 strike against east bay hospitals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: Paul Chinn / The Chronicle Employees in the Alameda Health System -- which largely serves minority communities -- plan to begin a five-day strike on Oct. 7, the California Nurses Association announced Saturday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that employees, including nurses represented by the California Nurses Association, plan to start a five-day strike on October 7. This supports the claim that there was authorization for a strike on October 7 against east bay hospitals. However, the evidence does not detail whether other union workers are involved, which slightly reduces confidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.01344987191259861,
    "x2e_entail_prob": 0.0021234650630503893
  },
  {
    "id": "covid_fact-000462",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly vanishing in severe cases",
    "label": "SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that serological surveys were conducted and included assessing IgG responses. The results indicated a significant decrease in IgG levels in severe hospitalized patients. This supports the claim that IgG antibodies are rapidly vanishing in severe cases.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.009822030551731586,
    "x2e_entail_prob": 0.013005099259316921
  },
  {
    "id": "covid_fact-000463",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly circulating in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that IgG antibodies were indeed detected early in the course of the disease in severe cases, but there was a significant decrease in IgG levels in severe patients, contradicting the claim that they are rapidly circulating. Instead, IgG levels decreased significantly in severe cases according to the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.12623204290866852,
    "x2e_entail_prob": 0.03934958204627037
  },
  {
    "id": "covid_fact-000464",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly produced in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that IgG antibody levels actually decreased in severe cases of hospitalized patients in the study, contrary to the claim that they are rapidly produced. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01834595762193203,
    "x2e_entail_prob": 0.036675628274679184
  },
  {
    "id": "covid_fact-000465",
    "statement": "Serological surveys in reunion island of the first hospitalized patients revealed that long-lived immunoglobulin g antibodies specific against sars-cov2 virus are rapidly transmitted in severe cases",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In conclusion, serological testing may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic cases.",
      "Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates.",
      "While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that IgG antibodies are detected early in the course of the disease but shows a significant decrease in levels in severe hospitalized patients, contrary to the claim of rapid transmission of long-lived IgG antibodies in severe cases. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.013143670745193958,
    "x2e_entail_prob": 0.0366402305662632
  },
  {
    "id": "covid_fact-000466",
    "statement": "Moderna announces first participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Moderna is conducting a Phase 2/3 study to evaluate their COVID-19 vaccine in adolescents, which aligns with the claim that they have announced the first participants being dosed in this study.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.08382576704025269,
    "x2e_entail_prob": 0.0014846170088276267
  },
  {
    "id": "covid_fact-000467",
    "statement": "Moderna announces all participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not confirm that all participants have been dosed in the Phase 2/3 study of Moderna's COVID-19 vaccine candidate in adolescents. It only mentions the design and goals of the study.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0173967108130455,
    "x2e_entail_prob": 0.0028330516070127487
  },
  {
    "id": "covid_fact-000468",
    "statement": "Moderna announces from participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We are encouraged by the interim and primary analyses of the Phase 3 COVE study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.",
      "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. This randomized, controlled Phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions an ongoing or planned Phase 2/3 study of Moderna's COVID-19 vaccine candidate for adolescents. It specifically notes the study will evaluate the safety and immunogenicity of the vaccine in this age group, aligning with the claim about Moderna's announcement of such a study.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6975153088569641,
    "x2e_entail_prob": 0.003500714898109436
  },
  {
    "id": "covid_fact-000469",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues",
    "label": "SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is that ACE2 is an interferon-stimulated gene and detected in specific cell subsets. The evidence indicates that ACE2 expression can be influenced by interferon signals, suggesting it functions as an interferon-stimulated gene. The evidence also identifies specific cell types where ACE2 is expressed, supporting the claim about detection in specific cell subsets. Therefore, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.782342791557312,
    "x2e_entail_prob": 0.035397421568632126
  },
  {
    "id": "covid_fact-000470",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in canine airway epithelial cells and is detected in specific cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information on ACE2 and TMPRSS2 co-expressing cells and mentions potential interferon-driven upregulation of ACE2, but it lacks specific details about interferon-stimulated gene expression of ACE2 specifically in canine airway epithelial cells. Therefore, the claim is not fully supported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.00450879568234086,
    "x2e_entail_prob": 0.047832705080509186
  },
  {
    "id": "covid_fact-000471",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in many cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that ACE2 can be upregulated by interferons, potentially making it an interferon-stimulated gene, and it is expressed in various cell types in tissues like lung pneumocytes and nasal goblet cells. This supports the claim that ACE2 is an interferon-stimulated gene in airway epithelial cells and is detected across different tissue subsets.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9202622175216675,
    "x2e_entail_prob": 0.28286415338516235
  },
  {
    "id": "covid_fact-000472",
    "statement": "Sars-cov-2 receptor ace2 is an interferon-stimulated gene in human airway epithelial cells and is detected in multiple cell subsets across tissues",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.",
      "SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry.",
      "Our data suggest that SARS-CoV-2 could exploit species- specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."
    ],
    "model_verdict": "PARTIALLY_SUPPORTED",
    "explanation": "The evidence shows that ACE2 is co-expressed in specific cell types such as lung type II pneumocytes, which indicates it is present across multiple cell subsets. Additionally, there is a suggestion that ACE2 can be upregulated by interferons in specific species, but the evidence does not definitively confirm it as an interferon-stimulated gene in human airway epithelial cells. Therefore, the claim is partially supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.015301159583032131,
    "x2e_entail_prob": 0.10744723677635193
  },
  {
    "id": "covid_fact-000473",
    "statement": "Structure of sars-cov-2 orf8 , a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the SARS-CoV-2 ORF8 protein can form unique large-scale assemblies that potentially mediate unique immune suppression and evasion activities, supporting the claim that ORF8 is implicated in immune evasion.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.30357614159584045,
    "x2e_entail_prob": 0.11898339539766312
  },
  {
    "id": "covid_fact-000474",
    "statement": "Loss of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 ORF8 can form assemblies that potentially mediate immune suppression and evasion, which aligns with the claim that ORF8 is implicated in immune evasion. However, the evidence does not address ORF8's rapid evolution directly.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0016020323382690549,
    "x2e_entail_prob": 0.02430167980492115
  },
  {
    "id": "covid_fact-000475",
    "statement": "Mutation of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that the SARS-CoV-2 ORF8 protein is rapidly evolving and involved in immune evasion. The evidence mentions that ORF8 can mediate unique immune suppression and evasion activities. Although the evidence does not explicitly state that ORF8 is 'rapidly evolving,' its potential for unique immune evasion activities aligns with the claim, supporting this part of the claim. Therefore, the claim is generally supported by the evidence, but since the 'rapidly evolving' aspect is not explicitly confirmed, the confidence is slightly moderated.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8929101824760437,
    "x2e_entail_prob": 0.17895625531673431
  },
  {
    "id": "covid_fact-000476",
    "statement": "Activation of sars-cov-2 orf8, a rapidly evolving coronavirus protein implicated in immune evasion",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together the presence of these interfaces shows how SARS-CoV-2 ORF8 can form unique large- scale assemblies not possible for SARS-CoV, potentially mediating unique immune suppression and evasion activities."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that SARS-CoV-2 ORF8 can form large-scale assemblies which potentially mediate unique immune suppression and evasion activities. This supports the claim that ORF8 is implicated in immune evasion.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.09126824885606766,
    "x2e_entail_prob": 0.09119606763124466
  },
  {
    "id": "covid_fact-000477",
    "statement": "Israel is arresting palestine 's doctors fighting covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that Israel is providing resources and facilitating medical assistance to the Palestinian regions, including medical training for health workers. There is no mention or indication of Israeli authorities arresting Palestinian doctors who are fighting COVID-19. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.01670648157596588,
    "x2e_entail_prob": 0.0047578769735991955
  },
  {
    "id": "covid_fact-000478",
    "statement": "China is arresting palestine's doctors fighting covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions Israel's response to COVID-19 efforts in the region and does not provide any information about China arresting Palestinian doctors. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004981481470167637,
    "x2e_entail_prob": 0.000938849407248199
  },
  {
    "id": "covid_fact-000479",
    "statement": "Israel is called palestine's doctors fighting covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Outlining Israels work to mitigate the impact of COVID-19 across the region, he said it is providing resources to the United Nations response, facilitating the flow of medical supplies and food into Gaza and conducting medical trainings for Palestinian health workers."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses Israel's contributions to mitigating the impact of COVID-19 in the region, including providing resources and medical training to Palestinian health workers. However, it does not support the claim that Israel is referred to as 'Palestine's doctors fighting COVID-19'. Such a title or label is not substantiated by the given evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.11955493688583374,
    "x2e_entail_prob": 0.0029152969364076853
  },
  {
    "id": "covid_fact-000480",
    "statement": "Identification of an existing japanese pancreatitis drug , nafamostat , which is expected to prevent the transmission of new coronavirus infection",
    "label": "SUPPORTED",
    "evidences": [
      "The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.",
      "Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases.",
      "According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.",
      "Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Nafamostat, a drug developed in Japan for treating pancreatitis, may prevent the transmission of the new coronavirus (SARS-CoV-2) by blocking the virus's ability to fuse with host cell membranes, which is the first step in the infection process. Clinical trials were planned to evaluate its effectiveness against COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.974272608757019,
    "x2e_entail_prob": 0.0012569454265758395
  },
  {
    "id": "covid_fact-000481",
    "statement": "Loss of an existing japanese pancreatitis drug, nafamostat, which is expected to prevent the transmission of new coronavirus infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The University of Tokyo plans to launch clinical trials in April 2020 in order to evaluate the effectiveness of these two drugs for treating COVID-19.",
      "Both Nafamostat and Camostat were developed in Japan as treatments for pancreatitis and some other diseases.",
      "According to the new research, Nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.",
      "Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Nafamostat, a drug developed for pancreatitis in Japan, has shown potential in preventing transmission of the new coronavirus by blocking the virus's entry process into cells. Clinical trials were scheduled to investigate its effectiveness against COVID-19. This supports the claim that Nafamostat can prevent coronavirus infection transmission.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.919362485408783,
    "x2e_entail_prob": 0.0014305359218269587
  },
  {
    "id": "covid_fact-000482",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice causes severe lung inflammation and impaired function",
    "label": "SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that infection of human ACE2 transgenic mice with SARS-CoV-2 results in significant immune cell infiltration and inflammation in the lungs, which supports the claim of severe lung inflammation and impaired lung function.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9475946426391602,
    "x2e_entail_prob": 0.8969966769218445
  },
  {
    "id": "covid_fact-000483",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice prevented severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection in hACE2-transgenic mice leads to severe lung inflammation and pulmonary disease, not the prevention of it. Thus, the claim that infection prevents severe lung inflammation and impaired function is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8314387202262878,
    "x2e_entail_prob": 0.7259489893913269
  },
  {
    "id": "covid_fact-000484",
    "statement": "Sars-cov-2 infection of human ace2-transgenic patients causes severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection in hACE2-transgenic mice results in severe lung inflammation, immune cell infiltration, and impaired pulmonary function, supporting the claim about the impact of the virus on ACE2-transgenic models.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8456272482872009,
    "x2e_entail_prob": 0.8927144408226013
  },
  {
    "id": "covid_fact-000485",
    "statement": "Sars-cov-2 infection of human ace2-transgenic mice inhibited severe lung inflammation and impaired function",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In summary, we found that SARS-CoV-2 infection of K18-hACE2-transgenic mice supports robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation and pulmonary disease.",
      "Binding of the SARS-CoV-2 spike protein to human angiotensin I-converting enzyme 2 (hACE2) primarily targets the virus to type II pneumocytes within the lung, resulting in injury, inflammation and subsequent respiratory distress1,2.",
      "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection in hACE2-transgenic mice leads to robust viral replication and severe lung inflammation, rather than inhibiting it. Therefore, the claim that SARS-CoV-2 infection inhibits severe lung inflammation in these mice is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8328492641448975,
    "x2e_entail_prob": 0.7798749804496765
  },
  {
    "id": "covid_fact-000486",
    "statement": "Thrombotic microvascular injury is not mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there is thrombotic microvascular injury in COVID-19 patients with complement activation, but no systemic thrombotic microangiopathy (TMA) signs such as mechanical hemolytic anemia or thrombocytopenia were observed. This supports the claim that thrombotic microvascular injury is not mediated by thrombotic microangiopathy despite systemic complement activation in COVID-19 patients.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.32550325989723206,
    "x2e_entail_prob": 0.24404923617839813
  },
  {
    "id": "covid_fact-000487",
    "statement": "Thrombotic microvascular injury is mainly mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that thrombotic microvascular injury in severe COVID-19 patients occurs without evidence of systemic thrombotic microangiopathy, contradicting the claim that it is mainly mediated by thrombotic microangiopathy. Additionally, there is mention of moderate complement activation, but this does not support the specific mediation by thrombotic microangiopathy.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9186739921569824,
    "x2e_entail_prob": 0.007857801392674446
  },
  {
    "id": "covid_fact-000488",
    "statement": "Thrombotic microvascular injury is primarily mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that there is no systemic thrombotic microangiopathy in the covid-19 patients studied, despite the presence of thrombotic microvascular injury. The claim that thrombotic microvascular injury is primarily mediated by thrombotic microangiopathy is not supported, as the study found no evidence of systemic thrombotic microangiopathy in these patients.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8967739939689636,
    "x2e_entail_prob": 0.014852579683065414
  },
  {
    "id": "covid_fact-000489",
    "statement": "Thrombotic microvascular injury is also mediated by thrombotic microangiopathy despite systemic complement activation in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Interestingly, none the 8 patients had signs of mechanical hemolytic anemia (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1 - 11,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia (median value: 348000/mL [IQR : 266 000 - 401 000).",
      "In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows the presence of thrombotic microvascular injury in COVID-19 patients with moderate activation of complement and coagulation, but explicitly states there is no evidence of systemic thrombotic microangiopathy. Therefore, the claim that thrombotic microvascular injury is mediated by thrombotic microangiopathy is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.04201860725879669,
    "x2e_entail_prob": 0.007265776861459017
  },
  {
    "id": "covid_fact-000490",
    "statement": "Serum amyloid p inhibits single stranded rna-induced lung inflammation , lung damage , and cytokine storm in mice",
    "label": "SUPPORTED",
    "evidences": [
      "Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm.",
      "A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that serum amyloid P (SAP) has a calming effect on the immune system and potential as a therapeutic for diseases with symptoms similar to COVID-19 and cytokine storms. However, it does not specifically mention SAP's effects on single-stranded RNA-induced lung inflammation, lung damage, or cytokine storm in mice. Therefore, the specific claim is not directly supported by the evidence provided.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.01174256019294262,
    "x2e_entail_prob": 0.05247320607304573
  },
  {
    "id": "covid_fact-000491",
    "statement": "Serum amyloid p inhibits single stranded rna-induced lung inflammation, lung damage, and cytokine storm in patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm.",
      "A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that serum amyloid P (SAP) has a calming effect on the immune system and may be a potential therapeutic for diseases with COVID-19-like symptoms and cytokine storms. However, it does not specifically state that SAP inhibits single-stranded RNA-induced lung inflammation, lung damage, and cytokine storms in patients. Thus, the claim lacks direct support from the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.014024944044649601,
    "x2e_entail_prob": 0.050300031900405884
  },
  {
    "id": "covid_fact-000492",
    "statement": "Fda approves the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about FDA approving the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for the treatment of COVID-19. The evidence confirms that the FDA issued an Emergency Use Authorization for hydroxychloroquine sulfate to be used, supporting part of the claim. However, it does not explicitly mention chloroquine phosphate, only hydroxychloroquine sulfate, which slightly decreases confidence. Therefore, the claim is mostly supported by the given evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.44254598021507263,
    "x2e_entail_prob": 0.03131752833724022
  },
  {
    "id": "covid_fact-000493",
    "statement": "Fdaines the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the FDA's Emergency Use Authorization for hydroxychloroquine sulfate, but not chloroquine phosphate, for COVID-19 treatment. Consequently, the claim regarding chloroquine phosphate use remains unsupported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.034871120005846024,
    "x2e_entail_prob": 0.01404286827892065
  },
  {
    "id": "covid_fact-000494",
    "statement": "Fdaards the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions 'chloroquine phosphate,' but evidence only confirms the emergency use authorization (EUA) for 'hydroxychloroquine sulfate.' There is no mention of 'chloroquine phosphate' being issued an EUA in the provided evidence. Therefore, the claim is partially incorrect.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.1438816487789154,
    "x2e_entail_prob": 0.015400889329612255
  },
  {
    "id": "covid_fact-000495",
    "statement": "Fdaasts the emergency use of chloroquine phosphate and hydroxychloroquine sulfate for treatment of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to BARDA to allow hydroxychloroquine sulfate and Resochin donated to the Strategic National Stockpile (SNS) to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the FDA issued an Emergency Use Authorization for hydroxychloroquine sulfate, but it does not mention chloroquine phosphate. Therefore, the claim that the FDA authorized both chloroquine phosphate and hydroxychloroquine sulfate for emergency use is not fully supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.007120438385754824,
    "x2e_entail_prob": 0.02539718523621559
  },
  {
    "id": "covid_fact-000496",
    "statement": "Genomic epidemiology reveals transmission patterns and dynamics of sars-cov-2 in aotearoa new zealand",
    "label": "SUPPORTED",
    "evidences": [
      "d The sampling location and proportion of SARS-CoV-2 genomes sampled from each viral genomic lineage is shown on the map of New Zealand.",
      "Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented nearly all of the genomic diversity present in the global viral population, with nine second-level A and B lineages from a proposed global SARS-CoV-2 genomic nomenclature17 identified.",
      "3: Genomic transmission lineages of SARS-CoV-2 in New Zealand.",
      "2: Genomic diversity of SARS-CoV-2 in New Zealand."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions the different genomic lineages of SARS-CoV-2 sequenced in New Zealand, indicates a wide genomic diversity, and provides context about genomic transmission lineages in New Zealand. This supports the claim that genomic epidemiology can reveal transmission patterns and dynamics of the virus in New Zealand.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.06107008457183838,
    "x2e_entail_prob": 0.11205129325389862
  },
  {
    "id": "covid_fact-000497",
    "statement": "Genomic epidemiology reveals evolutionary patterns and dynamics of sars-cov-2 in aotearoa new zealand",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "d The sampling location and proportion of SARS-CoV-2 genomes sampled from each viral genomic lineage is shown on the map of New Zealand.",
      "Notably, the genomic diversity of SARS-CoV-2 sequences sampled in New Zealand represented nearly all of the genomic diversity present in the global viral population, with nine second-level A and B lineages from a proposed global SARS-CoV-2 genomic nomenclature17 identified.",
      "3: Genomic transmission lineages of SARS-CoV-2 in New Zealand.",
      "2: Genomic diversity of SARS-CoV-2 in New Zealand."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes genomic epidemiology work in New Zealand, mentioning the diversity and transmission lineages of SARS-CoV-2. This supports the claim that genomic epidemiology has been used to study evolutionary patterns and dynamics in New Zealand.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.059376299381256104,
    "x2e_entail_prob": 0.09781961888074875
  },
  {
    "id": "covid_fact-000498",
    "statement": "Cross-species transmission of the newly identified coronavirus 2019-ncov",
    "label": "SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "ERROR",
    "explanation": "Failed to parse model response",
    "confidence": 0.0,
    "e2x_entail_prob": 0.008580435067415237,
    "x2e_entail_prob": 0.004454053472727537
  },
  {
    "id": "covid_fact-000499",
    "statement": "Cross-species transmission of the newly identified coronavirus e-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the possibility of 2019-nCoV being a recombinant virus involving a bat coronavirus, but it does not directly support the claim of cross-species transmission of a coronavirus labeled 'e-ncov'. The evidence refers to a different coronavirus, 2019-nCoV, rather than e-ncov.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.08439584821462631,
    "x2e_entail_prob": 0.6162158250808716
  },
  {
    "id": "covid_fact-000500",
    "statement": "Cross-species transmission of the previously identified coronavirus 2019-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the 2019-nCoV may have originated from a recombination event involving a bat coronavirus and another unknown coronavirus. This indicates a possibility of cross-species transmission, supporting the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.008127205073833466,
    "x2e_entail_prob": 0.9325711727142334
  },
  {
    "id": "covid_fact-000501",
    "statement": "Cross-species transmission of the newly identified coronavirus b-ncov",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results obtained from our analyses suggest that the 2019-nCoV may appear to be a recombinant virus between the bat coronavirus and an origin- unknown coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that 2019-nCoV may be a recombinant virus involving a bat coronavirus, implying potential cross-species origins. However, the evidence doesn't directly confirm a successful cross-species transmission into humans, or the specific reference to b-ncov mentioned in the claim, leaving the claim unsupported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0037244046106934547,
    "x2e_entail_prob": 0.586121141910553
  },
  {
    "id": "covid_fact-000502",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody escape.",
    "label": "SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape, directly supporting the claim that recurrent deletions in the spike glycoprotein cause antibody escape.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1603154093027115,
    "x2e_entail_prob": 0.5777357220649719
  },
  {
    "id": "covid_fact-000503",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein prevent antibody escape.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that recurrent deletions in the SARS-CoV-2 spike glycoprotein prevent antibody escape; however, the evidence presented indicates that natural deletions in the spike glycoprotein drive or facilitate antibody escape rather than prevent it. The phrasing in the claim seems to imply the opposite effect.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.10701704770326614,
    "x2e_entail_prob": 0.568464994430542
  },
  {
    "id": "covid_fact-000504",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody reactivity.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. This suggests that such deletions affect antibody reactivity, supporting the claim that recurrent deletions in the spike glycoprotein affect antibody interaction.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5421451330184937,
    "x2e_entail_prob": 0.5623551607131958
  },
  {
    "id": "covid_fact-000505",
    "statement": "Recurrent deletions in the sars-cov-2 spike glycoprotein drive antibody production.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Share Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 Share This Article: Copy Citation Tools Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Kevin R. McCarthy, Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson- McCarthy, William G. Bain, Ghady Haidar, W. Paul Duprex bioRxiv 2020.11.19.389916; doi: https://doi.org/10.1101/2020.11.19.389916 ",
      "Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses natural deletions in the SARS-CoV-2 spike glycoprotein driving antibody escape, not specifically antibody production. Antibody escape and production are distinct processes; thus the claim is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.08598239719867706,
    "x2e_entail_prob": 0.209538534283638
  },
  {
    "id": "covid_fact-000506",
    "statement": "Sars-coronavirus-1 open reading frame-8b triggers intracellular stress pathways and activates nlrp3 inflammasomes",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we identify several mechanisms by which a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions a SARS-CoV open reading frame activating intracellular stress pathways and targeting the innate immune response but does not specifically mention ORF-8b or the activation of NLRP3 inflammasomes. Without specific evidence for ORF-8b and NLRP3 involvement, the claim is not supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.008161199279129505,
    "x2e_entail_prob": 0.5116873383522034
  },
  {
    "id": "covid_fact-000507",
    "statement": "Sars-coronavirus-1 open reading frame-8b inhibits intracellular stress pathways and activates nlrp3 inflammasomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we identify several mechanisms by which a SARS-CoV open reading frame (ORF) activates intracellular stress pathways and targets the innate immune response."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that a SARS-CoV open reading frame activates intracellular stress pathways and targets the innate immune response, but it does not specify ORF-8b nor mention the activation of NLRP3 inflammasomes specifically. Therefore, the evidence does not fully support the claim.",
    "confidence": 0.65,
    "e2x_entail_prob": 0.0026735379360616207,
    "x2e_entail_prob": 0.03296273574233055
  },
  {
    "id": "covid_fact-000508",
    "statement": "A chest-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a flowchart for COVID-19 triage that utilizes chest-CT (through CO-RADS) and clinical chemistry (lab-corona-score) parameters. It specifies that this process is both rapid and accurate for diagnosis at emergency departments (ED), supporting the claim made.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.776370644569397,
    "x2e_entail_prob": 0.6514819860458374
  },
  {
    "id": "covid_fact-000509",
    "statement": "A non-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not support the claim because the flowchart discussed uses both radiology (CO-RADS, which is CT-based) and clinical chemistry parameters. The claim states a non-CT based flowchart, which contradicts the provided evidence that mentions CT use in the diagnosis.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.023553751409053802,
    "x2e_entail_prob": 0.012233500368893147
  },
  {
    "id": "covid_fact-000510",
    "statement": "A meta-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim describes a meta-CT and clinical chemistry based flowchart for COVID-19 triage in emergency departments, and the evidence supports this by describing a flowchart that combines radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score) for rapid and accurate COVID-19 diagnosis in emergency settings.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9016951322555542,
    "x2e_entail_prob": 0.32087093591690063
  },
  {
    "id": "covid_fact-000511",
    "statement": "A pre-ct and clinical chemistry based flowchart for rapid covid-19 triage at emergency departments",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusion This flowchart, based on radiology (CO-RADS) and clinical chemistry parameters (lab-corona-score), results in a rapid and accurate diagnosis of COVID-19 at the ED.",
      "The flowchart, which combined the CO-RADS with the lab-corona-score, was developed based on data from Slingeland Hospital (sensitivity 97%, specificity 96%).",
      "This flowchart can be used in hospitals that use chest-CT, instead of chest X-ray, for COVID-19 suspected patients at the ED."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a flowchart that uses clinical chemistry parameters, specifically mentioning lab-corona-score, and radiology (CO-RADS) for the rapid diagnosis of COVID-19 in emergency departments. This supports the claim about a clinical chemistry-based flowchart for rapid COVID-19 triage at emergency departments.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8577923774719238,
    "x2e_entail_prob": 0.2970758378505707
  },
  {
    "id": "covid_fact-000512",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2, thereby supporting the claim. The evidence specifically addresses the lack of cross-neutralization by immunoglobulins produced from plasma collected before the pandemic, aligning with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.17590688169002533,
    "x2e_entail_prob": 0.01309793908149004
  },
  {
    "id": "covid_fact-000513",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected after the 2020 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided addresses whether IVIG products manufactured from pre-pandemic plasma can neutralize SARS-CoV-2 but does not address IVIG products manufactured from plasma collected after the 2020 pandemic. Without specific evidence regarding post-2020 plasma collections, the claim cannot be fully supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.2451537549495697,
    "x2e_entail_prob": 0.05130096152424812
  },
  {
    "id": "covid_fact-000514",
    "statement": "No sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.",
      "The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.",
      "SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that intravenous immunoglobulin (IVIG) products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2. This supports the claim that IVIG produced during the 2020 pandemic does not cross-neutralize SARS-CoV-2, as it specifically states that the plasma collected before the pandemic lacks neutralizing capacity against SARS-CoV-2. Though the evidence does not explicitly mention the IVIG from 2020 pandemic plasma, it is reasonable to infer it had similar limitations early on due to lack of specific antibodies.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7971011996269226,
    "x2e_entail_prob": 0.005067598074674606
  },
  {
    "id": "covid_fact-000515",
    "statement": "Hospital readmissions of discharged patients with covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is not sufficiently defined or specific enough to be analyzed for support. The available evidence discusses factors related to hospital readmissions for COVID-19 patients, such as immunocompromised status and fever, but does not support a broader or specific claim about 'hospital readmissions of discharged patients with covid-19' as no straightforward claim is made.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.05305512621998787,
    "x2e_entail_prob": 0.6714684367179871
  },
  {
    "id": "covid_fact-000516",
    "statement": "Hospital readmissions of hospitalized patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about factors associated with readmissions and general comments on readmission rates being low, but it doesn't clearly establish the exact claim on hospital readmissions, lacking specificity and detailed data on rates or comprehensive context that could support or refute the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.08642161637544632,
    "x2e_entail_prob": 0.48195526003837585
  },
  {
    "id": "covid_fact-000517",
    "statement": "Hospital readmissions of sars patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that SARS patients with COVID-19 are involved, but the provided evidence only discusses hospital readmissions of patients previously discharged after COVID-19, without mentioning SARS. Therefore, the claim is not supported by the evidence given.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.00989919900894165,
    "x2e_entail_prob": 0.23776699602603912
  },
  {
    "id": "covid_fact-000518",
    "statement": "Hospital readmissions of icu patients with covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Aim To analyse the clinical variables associated with readmission of patients who had previously been discharged after admission for COVID-19.",
      "Conclusions The rate of readmission after discharge from hospital for COVID-19 was low.",
      "Immunocompromised patients and those presenting with fever during the 48 hours prior to discharge are at greater risk of readmission to hospital."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about hospital readmissions specifically for ICU patients with COVID-19, but the evidence only discusses readmission for COVID-19 patients in general, without specifying whether these patients were initially in the ICU. Therefore, the claim is not directly supported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.010718472301959991,
    "x2e_entail_prob": 0.2841625213623047
  },
  {
    "id": "covid_fact-000519",
    "statement": "Hospitalization rates and characteristics of children aged < 18 years hospitalized with laboratory-confirmed covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided describes the hospitalization rates and characteristics of children aged <18 years who were hospitalized with COVID-19, confirming the claim's mention of these parameters being monitored and recorded.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.16237427294254303,
    "x2e_entail_prob": 0.48666900396347046
  },
  {
    "id": "covid_fact-000520",
    "statement": "Hospitalization rates and characteristics of children aged < 18 months hospitalized with laboratory-confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specifically cover children aged <18 months but rather generalizes children aged <18 years. Without specific information on hospitalization rates and characteristics for those specifically under 18 months old, the claim cannot be supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.020927440375089645,
    "x2e_entail_prob": 0.4390045702457428
  },
  {
    "id": "covid_fact-000521",
    "statement": "Hospitalization rates and characteristics of children aged < 18 days hospitalized with laboratory-confirmed covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 -- COVID-NET, 14 States, March 1-July 25, 2020 Characteristic ",
      "Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children.",
      "Cumulative COVID-19 -associated hospitalization rates among children aged <18 years, by age group and race/ethnicity -- COVID-NET, 14 states, March 1-July 25, 2020\u00a7,\u00b6 Abbreviation: COVID-NET = Coronavirus Disease 2019-Associated Hospitalization Surveillance Network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses children aged <18 years who were hospitalized with COVID-19, but there is no specific mention or data provided about children aged <18 days. The evidence focuses on a broader age group of children under 18 years, which does not specifically support the claim about <18 days.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.05983711779117584,
    "x2e_entail_prob": 0.533700704574585
  },
  {
    "id": "covid_fact-000522",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a possible beneficial adjuvant effect of the influenza vaccine in minimizing the severity of COVID-19, due to cross-reactivity and the flu-induced bystander immunity. The recommendation is based on observed outcomes and theoretical links, providing credible support to the claim, though more concrete clinical data could further strengthen this conclusion.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.1792108565568924,
    "x2e_entail_prob": 0.07946297526359558
  },
  {
    "id": "covid_fact-000523",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to increase the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the influenza vaccine may have a beneficial bystander adjuvant effect on COVID-19, potentially leading to milder symptoms in vaccinated individuals. This is supported by cross-reactivity findings between flu and SARS-CoV-2, which indicate a beneficial impact on the severity of COVID-19.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9414170980453491,
    "x2e_entail_prob": 0.12438028305768967
  },
  {
    "id": "covid_fact-000524",
    "statement": "The possible beneficial adjuvant effect of influenza vaccine to enhance the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests there is some potential beneficial adjuvant effect of the influenza vaccine in reducing the severity of COVID-19. The claim is supported by mentioning the concept of 'Flu-induced bystander immunity' that could potentially cross-react with SARS-CoV-2, leading to milder COVID-19 symptoms. However, the evidence is more of a suggestion rather than definitive proof, thus the verdict is supported with moderate confidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9821531176567078,
    "x2e_entail_prob": 0.028085725381970406
  },
  {
    "id": "covid_fact-000525",
    "statement": "The possible negative adjuvant effect of influenza vaccine to minimize the severity of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Given the safety of Flu vaccine in adult, we recommend the use of Flu vaccine, at least in part, as a bystander adjuvant to minimize the severity of COVID-19 disease.",
      "These findings are similar to what the same group have reported before in patients with influenza infection [2], [3], Accordingly, we suggest a link between the quality of the immunity and recovery from COVID-19, at least in part, in patients with mild symptoms.",
      "Due to this cross reactivity between Flu and SARS- CoV-2, we suggest that the Flu-induced bystander immunity is more of beneficial effects to COVID-19 than those suggested by MMR and BCG vaccines [9], [10].",
      "It might be possible also that individuals who received prior Flu vaccination might show mild severity of COVID-19 because of Flu-induced bystander effect of the generated immune responses which itself might cross react against SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the influenza vaccine may have a beneficial adjuvant effect, potentially reducing the severity of COVID-19. This is based on the cross-reactivity between flu and SARS-CoV-2 and previous findings that flu-induced bystander immunity could be advantageous. Therefore, the claim about the influenza vaccine possibly mitigating COVID-19 severity through a bystander effect is supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9720107316970825,
    "x2e_entail_prob": 0.06348659843206406
  },
  {
    "id": "covid_fact-000526",
    "statement": "Moderna 's covid-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 cove study",
    "label": "SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Moderna's Phase 3 study provided clinical validation that their vaccine can prevent COVID-19 disease, which implies meeting the primary efficacy endpoint. However, the wording from the claim is not explicitly stated in the evidence, but the implication is strongly in support.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.06369481235742569,
    "x2e_entail_prob": 0.40140560269355774
  },
  {
    "id": "covid_fact-000527",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the final interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses a positive interim analysis from Moderna's Phase 3 study, indicating clinical validation of the vaccine's ability to prevent COVID-19, including severe disease. However, it does not specifically confirm that the vaccine meets its primary efficacy endpoint in the final interim analysis specifically mentioned in the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.020442020148038864,
    "x2e_entail_prob": 0.8589788675308228
  },
  {
    "id": "covid_fact-000528",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the second interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that the interim analysis of Moderna's Phase 3 study showed positive results in preventing COVID-19, but it does not explicitly state that it met the primary efficacy endpoint in the second interim analysis. Without specific mention of the primary endpoint being met, the claim cannot be fully supported.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.08401113748550415,
    "x2e_entail_prob": 0.8149872422218323
  },
  {
    "id": "covid_fact-000529",
    "statement": "Moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the subsequent interim analysis of the phase 3 cove study",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, said St\u00e9phane Bancel, Chief Executive Officer of Moderna.",
      "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\" said St\u00e9phane Bancel, Chief Executive Officer of Moderna."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the positive interim analysis from Moderna's Phase 3 study provided clinical validation for the vaccine's ability to prevent COVID-19, suggesting that it met its primary efficacy endpoint.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0021925438195466995,
    "x2e_entail_prob": 0.9300954341888428
  },
  {
    "id": "covid_fact-000530",
    "statement": "Landmark legal ruling finds that covid tests are not fit for purpose .",
    "label": "SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence presented suggests that the court's ruling was critical of the reliability of Covid tests, particularly PCR tests with a high cycle threshold, indicating they may not be fit for purpose. Specifically, it highlights the high probability of false positives at certain thresholds, which aligns with the claim that such a legal ruling exists.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6804514527320862,
    "x2e_entail_prob": 0.010058728978037834
  },
  {
    "id": "covid_fact-000531",
    "statement": "Landmark legal ruling finds that covid tests are good fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that the court ruling was scathing about the reliability of PCR tests for Covid, specifically highlighting high false positive rates at a certain cycle threshold. This implies that the tests were considered unreliable, not that they were found to be 'good fit for purpose.' Thus, the claim is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.14867275953292847,
    "x2e_entail_prob": 0.02102813497185707
  },
  {
    "id": "covid_fact-000532",
    "statement": "Landmark legal ruling finds that covid tests are best fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests a legal ruling concluded that COVID tests are fit for purpose. The evidence provided critiques the reliability of PCR tests and indicates that high cycle thresholds could lead to false positives, suggesting that the tests may not be reliable. Therefore, the evidence does not support the claim that a legal ruling found COVID tests to be fit for purpose.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.42155641317367554,
    "x2e_entail_prob": 0.01190350390970707
  },
  {
    "id": "covid_fact-000533",
    "statement": "Landmark legal ruling finds that covid tests are well fit for purpose.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It showed that if someone tested positive for Covid at a cycle threshold of 35 or higher, the chances of that person actually being infected is less than three percent, and that \" the probability of receiving a false positive is 97% or higher.\"",
      "And it is not the only country whose institutions are clashing with received wisdom on Covid.",
      "Read more Immunity for YEARS or DECADES: Covid resistance may last much longer than previously thought, says new research They were also scathing about the reliability of the PCR (polymerase chain reaction) test, the most commonly used check for Covid.",
      "The implication was that the results could not be trusted.",
      "In the eyes of this court, then, a positive test does not correspond to a Covid case."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates skepticism about the reliability of Covid PCR tests, especially at higher cycle thresholds, with a high likelihood of false positives. This suggests that the legal ruling found the tests not well fit for purpose, contradicting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5592078566551208,
    "x2e_entail_prob": 0.007937537506222725
  },
  {
    "id": "covid_fact-000534",
    "statement": "Trump just banned all travel from europe to stop coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence specifies that President Trump announced a 30-day ban on travel from European countries to the United States, but it also states that the ban suspends the entry of 'most foreign nationals' who have been in certain European countries within the 14 days prior to arriving in the U.S. Therefore, the claim that Trump 'banned all travel from Europe' is not accurate as it implies a complete halt on travel, which is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.008740932680666447,
    "x2e_entail_prob": 0.039700947701931
  },
  {
    "id": "covid_fact-000535",
    "statement": "Trump just allows all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that Trump 'just allows all travel from Europe to stop coronavirus' is NOT_SUPPORTED by the evidence provided. The evidence shows that Trump announced a 30-day ban on travel from European countries to the United States, not that he allowed all travel. The purpose of the ban was to prevent new coronavirus cases from entering the United States, but it did not constitute a complete stoppage of all travel from Europe, as there were exceptions outlined in the Department of Homeland Security's statement.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.025331830605864525,
    "x2e_entail_prob": 0.05681953579187393
  },
  {
    "id": "covid_fact-000536",
    "statement": "Trump just allowed all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that all travel from Europe was stopped by Trump to combat coronavirus, which is not entirely accurate. Although President Trump did announce a 30-day ban on travelers from European countries to the U.S., it specifically targeted foreign nationals who had been in particular European countries within 14 days before their travel. Therefore, it was not an absolute travel ban on all types of travel from Europe, as the claim suggests.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.058424368500709534,
    "x2e_entail_prob": 0.01713489182293415
  },
  {
    "id": "covid_fact-000537",
    "statement": "Trump just requires all travel from europe to stop coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ET Thursday President Trump announced a 30-day ban on travel from European countries to the United States, beginning on Friday at midnight, in a bid \"to keep new cases\" of coronavirus \"from entering our shores.\"",
      "VIDEO0:3300:33 President Trump suspends all travel from Europe for 30 days Coronavirus WASHINGTON  President Donald Trump announced that a ban on travelers to the United States from Europe would be in place for the next 30 days, in an attempt to stem the spread of the coronavirus pandemic.",
      "Advertisement In a statement after Trump's address, DHS said Trump had signed a proclamation that \"suspends the entry of most foreign nationals who have been in certain European countries at any point during the 14 days prior to their scheduled arrival to the United States.\"",
      "\"We will be suspending all travel from Europe to the United States for the next 30 days,\" Trump said, blasting coronavirus as \"a foreign virus.\"",
      "Advertisement Trump's travel ban from Europe follows a massive outbreak in Italy that's resulted in a nationwide lockdown in which businesses have been shuttered and travel severely curtailed in the southern-European country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that stopping all travel from Europe is Trump's requirement to stop coronavirus. However, the evidence indicates Trump announced a specific 30-day travel ban on travelers from certain European countries, intending to curb new cases of coronavirus entering the U.S. It does not strictly mean that 'all travel' is stopped or that this action alone 'stops' coronavirus.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6416475176811218,
    "x2e_entail_prob": 0.019127916544675827
  },
  {
    "id": "covid_fact-000538",
    "statement": "Functional sars-cov-2-specific immune memory persists after mild covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-\u03b3 and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies.",
      "These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.",
      "We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that individuals who recover from mild COVID-19 develop SARS-CoV-2-specific memory T and B cells, which persist and occasionally increase over time. These memory lymphocytes exhibit characteristics of potent antiviral immunity, supporting the claim that functional immune memory persists after mild COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.924874484539032,
    "x2e_entail_prob": 0.00462988018989563
  },
  {
    "id": "covid_fact-000539",
    "statement": "Functional sars-cov-2-independent immune memory persists after mild covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-\u03b3 and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies.",
      "These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.",
      "We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that infection with mild COVID-19 does lead to the development of SARS-CoV-2-specific memory lymphocytes that persist and exhibit functional hallmarks of antiviral protective immunity. This implies that there is a lasting immune memory following mild infection, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1378307342529297,
    "x2e_entail_prob": 0.0017219793517142534
  },
  {
    "id": "covid_fact-000540",
    "statement": "Cdc says new covid strain in uk could already be circulating undetected in u.s .",
    "label": "SUPPORTED",
    "evidences": [
      "While the variant hasn't been found in the U.S. yet, the CDC noted that scientists haven't sequenced the genetic coding for many Covid-19 infections here.",
      "\"Given the small fraction of US infections that have been sequenced, the variant could already be in the United States without having been detected.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the CDC acknowledges the possibility that the new COVID-19 strain in the UK could already be circulating undetected in the U.S. due to the small fraction of infections that have been sequenced. Thus, the claim is supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.49740949273109436,
    "x2e_entail_prob": 0.2427881807088852
  },
  {
    "id": "covid_fact-000541",
    "statement": "Cdc says new covid strain in uk could not be circulating undetected in u.s.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "While the variant hasn't been found in the U.S. yet, the CDC noted that scientists haven't sequenced the genetic coding for many Covid-19 infections here.",
      "\"Given the small fraction of US infections that have been sequenced, the variant could already be in the United States without having been detected.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that the new COVID-19 strain could already be present in the United States but undetected, due to limited genetic sequencing of infections. This contradicts the claim that it could not be circulating undetected in the U.S.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5928873419761658,
    "x2e_entail_prob": 0.01108606532216072
  },
  {
    "id": "covid_fact-000542",
    "statement": "Sars-cov-2 infection protects against rechallenge in rhesus macaques",
    "label": "SUPPORTED",
    "evidences": [
      "2 Immune responses in SARS-CoV-2challenged rhesus macaques.",
      "SARS-CoV-2 infection in rhesus macaques led to humoral and cellular immune responses (Fig.",
      "In summary, SARS-CoV-2 infection in rhesus macaques induced humoral and cellular immune responses and provided protective efficacy against SARS-CoV-2 rechallenge.",
      "In this study, we have demonstrated that SARS-CoV-2 infection in rhesus macaques provides protective efficacy against SARS-CoV-2 rechallenge.",
      "To explore this question, we developed a rhesus macaque model of SARS-CoV-2 infection and assessed virologic, immunologic, and pathologic features of infection, as well as protective immunity against rechallenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that SARS-CoV-2 infection in rhesus macaques induced immune responses and provided protective efficacy against SARS-CoV-2 rechallenge. This directly supports the claim.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.024477465078234673,
    "x2e_entail_prob": 0.13497087359428406
  },
  {
    "id": "covid_fact-000543",
    "statement": "Sars-cov-2 infection failed against rechallenge in rhesus macaques",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "2 Immune responses in SARS-CoV-2challenged rhesus macaques.",
      "SARS-CoV-2 infection in rhesus macaques led to humoral and cellular immune responses (Fig.",
      "In summary, SARS-CoV-2 infection in rhesus macaques induced humoral and cellular immune responses and provided protective efficacy against SARS-CoV-2 rechallenge.",
      "In this study, we have demonstrated that SARS-CoV-2 infection in rhesus macaques provides protective efficacy against SARS-CoV-2 rechallenge.",
      "To explore this question, we developed a rhesus macaque model of SARS-CoV-2 infection and assessed virologic, immunologic, and pathologic features of infection, as well as protective immunity against rechallenge."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection in rhesus macaques induced immune responses that provided protective efficacy against a rechallenge with the virus. Therefore, the claim that infection failed against rechallenge is supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0039016043301671743,
    "x2e_entail_prob": 0.22359701991081238
  },
  {
    "id": "covid_fact-000544",
    "statement": "Genetic epidemiology of variants associated with immune escape from global sars-cov-2 genomes.",
    "label": "SUPPORTED",
    "evidences": [
      "The researchers studied as many as 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to possess the ability to dodge the human bodys immune response across 63 countries.",
      "The detailed investigation of 26,917 genomes pointed out that 86 out of the 120 genetic variants associated with immune escapes from 63 countries.",
      "Our analysis suggests that a number of genetic variants associated with immune escape have emerged in global populations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim about genetic epidemiology of variants associated with immune escape is supported by the evidence provided. The evidence shows that researchers identified 86 genetic variants capable of immune escape, based on an analysis of 26,917 SARS-CoV-2 genomes from 63 countries. This directly aligns with the claim's focus on genetic variants associated with immune escape on a global scale.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.891239583492279,
    "x2e_entail_prob": 0.5075737237930298
  },
  {
    "id": "covid_fact-000545",
    "statement": "Phylogenetic epidemiology of variants associated with immune escape from global sars-cov-2 genomes.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The researchers studied as many as 120 unique mutated variants of SARS-CoV-2, out of which 86 were found to possess the ability to dodge the human bodys immune response across 63 countries.",
      "The detailed investigation of 26,917 genomes pointed out that 86 out of the 120 genetic variants associated with immune escapes from 63 countries.",
      "Our analysis suggests that a number of genetic variants associated with immune escape have emerged in global populations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence indicating that variants of SARS-CoV-2 associated with immune escape have been observed globally. The study reviewed thousands of genomes, identifying 86 unique variants with this capability across 63 countries, confirming the global nature of these variants and their association with immune escape.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8932004570960999,
    "x2e_entail_prob": 0.20401358604431152
  },
  {
    "id": "covid_fact-000546",
    "statement": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus in vitro",
    "label": "SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that remdesivir and chloroquine effectively inhibit the novel coronavirus (2019-nCoV) in vitro is supported by evidence. Remdesivir has been shown to inhibit virus infection in human cell lines and chloroquine has demonstrated efficacy in blocking the virus infection in Vero E6 cells. Both compounds show potent antiviral activity at low-micromolar concentrations and high selectivity index, affirming their efficacy in vitro against the virus.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8663255572319031,
    "x2e_entail_prob": 0.06543062627315521
  },
  {
    "id": "covid_fact-000547",
    "statement": "Remdesivir and chloroquine effectively developed the recently emerged novel coronavirus in vitro",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that both remdesivir and chloroquine were shown to effectively inhibit the novel coronavirus (2019-nCoV) in vitro. Specific details regarding EC50 and CC50 values support their antiviral activity at low concentrations. Thus, the claim is supported by the provided evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.808375358581543,
    "x2e_entail_prob": 0.38701218366622925
  },
  {
    "id": "covid_fact-000548",
    "statement": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus in humans",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Remdesivir has been recently recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) infection in cultured cells, mice and nonhuman primate (NHP) models.",
      "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
      "S2) showed that remdesivir also inhibited virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig.",
      "Notably, two compounds remdesivir (EC50 = 0.77 \u03bcM; CC50 > 100 \u03bcM; SI > 129.87) and chloroquine (EC50 = 1.13 \u03bcM; CC50 > 100 \u03bcM, SI > 88.50) potently blocked virus infection at low-micromolar concentration and showed high SI (Fig."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that remdesivir and chloroquine effectively inhibit the novel coronavirus in vitro, meaning in a laboratory setting using cell cultures. However, the claim specifically mentions effectiveness in humans, and there is no evidence provided about their efficacy in clinical settings involving human patients. In vitro results do not always translate to human efficacy, so the claim is not supported given the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.09559284895658493,
    "x2e_entail_prob": 0.04376993700861931
  },
  {
    "id": "covid_fact-000549",
    "statement": "As covid-19 vaccines arrive , europe looks back at swine flu side effects.",
    "label": "SUPPORTED",
    "evidences": [
      "DW: We keep seeing vaccine skeptics referencing the swine flu pandemic in 2009 as the reason they won't be taking a COVID-19 vaccine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there is a trend of vaccine skeptics referencing the swine flu pandemic when discussing their hesitance towards COVID-19 vaccines. This implies that as COVID-19 vaccines arrive, there is indeed a retrospective look at the side effects associated with the swine flu vaccine, as suggested by the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.022346189245581627,
    "x2e_entail_prob": 0.018571432679891586
  },
  {
    "id": "covid_fact-000550",
    "statement": "As covid-19 vaccines arrive, europe looks not at swine flu side effects.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "DW: We keep seeing vaccine skeptics referencing the swine flu pandemic in 2009 as the reason they won't be taking a COVID-19 vaccine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that vaccine skeptics are referencing the swine flu pandemic in their decision-making process regarding COVID-19 vaccines, indicating that the topic of swine flu side effects is indeed being considered. Therefore, the claim that Europe is 'not' looking at swine flu side effects is not supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.12504878640174866,
    "x2e_entail_prob": 0.02624528668820858
  },
  {
    "id": "covid_fact-000551",
    "statement": "Influenza may facilitate the spread of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that influenza may indeed facilitate the spread of SARS-CoV-2, as it indicates a significant increase in SARS-CoV-2 transmission associated with influenza during co-circulation periods. Additionally, the evidence highlights the facilitatory impact of influenza on SARS-CoV-2, further supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8220033049583435,
    "x2e_entail_prob": 0.0017470007296651602
  },
  {
    "id": "covid_fact-000552",
    "statement": "Influenza may prevent the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence suggests that influenza may actually increase or facilitate the spread of SARS-CoV-2 rather than prevent it, as shown by the population-level increase in SARS-CoV-2 transmission associated with influenza. Thus, the claim is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.31576472520828247,
    "x2e_entail_prob": 0.004427522420883179
  },
  {
    "id": "covid_fact-000553",
    "statement": "Influenza may inhibit the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not support the claim that influenza may inhibit the spread of SARS-CoV-2. Instead, it suggests that influenza may actually facilitate the spread of SARS-CoV-2, indicating a positive interaction between the two viruses, where influenza is associated with an increased transmission of SARS-CoV-2.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.730741024017334,
    "x2e_entail_prob": 0.002031328622251749
  },
  {
    "id": "covid_fact-000554",
    "statement": "Influenza may limit the spread of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These results suggest the need to increase vaccination against influenza, not only to reduce the burden due to influenza viruses, but also to counteract their facilitatory impact on SARS-CoV-2.",
      "We found consistent evidence for a 2-2.5-fold population-level increase in SARS- CoV-2 transmission associated with influenza during the period of co- circulation.",
      "Here we hypothesized that influenza interacted with SARS-CoV-2 during the early 2020 epidemic of COVID-19 in Europe."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that influenza may actually facilitate, rather than limit, the spread of SARS-CoV-2 based on the observed increase in SARS-CoV-2 transmission during co-circulation with influenza. Thus, it does not support the claim that influenza may limit the spread of SARS-CoV-2.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8927531838417053,
    "x2e_entail_prob": 0.0019022974884137511
  },
  {
    "id": "covid_fact-000555",
    "statement": "Genomic epidemiology of superspreading events in austria reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the identification of phylogenetic clusters and analysis of COVID-19 infection clusters in Austria, but it does not address or confirm any aspects of 'superspreading events' or specific genomic epidemiology dynamics as claimed.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0025718738324940205,
    "x2e_entail_prob": 0.03249860554933548
  },
  {
    "id": "covid_fact-000556",
    "statement": "Genomic epidemiology of superspreading events in korea reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided pertains to SARS-CoV-2 genomic epidemiology and mutation dynamics in Austria, not Korea. Therefore, it does not support the claim about studies or findings related to superspreading events in Korea.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.01114371046423912,
    "x2e_entail_prob": 0.16134078800678253
  },
  {
    "id": "covid_fact-000557",
    "statement": "Genomic epidemiology of superspreading events in africa reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided pertains to SARS-CoV-2 genomic studies and infection clusters in Austria, not Africa. Therefore, the claim specifically about superspreading events in Africa and their mutation dynamics and transmission properties is not supported by the evidence given.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.08478882908821106,
    "x2e_entail_prob": 0.09292113780975342
  },
  {
    "id": "covid_fact-000558",
    "statement": "Genomic epidemiology of superspreading events in taiwan reveals mutational dynamics and transmission properties of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Phylogenetic clusters were identified on the basis of characteristic mutation profiles in viral genome sequences of SARS-CoV-2positive cases in Austria.",
      "In this study, we reconstructed major SARS-CoV-2 infection clusters in Austria and analyzed their role in international virus spread by combining phylogenetic and epidemiological analyses."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to genomic epidemiology of superspreading events in Taiwan related to SARS-CoV-2, while the evidence provided pertains to SARS-CoV-2 infection clusters and their analysis in Austria. There is no overlap in the geographical focus or specific findings between the claim and the presented evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.014156623743474483,
    "x2e_entail_prob": 0.016178155317902565
  },
  {
    "id": "covid_fact-000559",
    "statement": "Rogue antibodies could be driving severe covid-19.",
    "label": "SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that autoantibodies, which interfere with the antiviral activity of interferons, are more prevalent in patients with severe COVID-19 compared to those with mild cases. These autoantibodies are similar in nature to those causing autoimmune diseases and may contribute to the severity of the illness. Therefore, it is supported that rogue antibodies could be driving severe COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6477911472320557,
    "x2e_entail_prob": 0.16513791680335999
  },
  {
    "id": "covid_fact-000560",
    "statement": "Rogue antibodies cannot be driving severe covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that rogue antibodies may indeed play a role in severe COVID-19 cases. While it does not definitively establish them as the sole cause, it indicates that these antibodies can block interferon activity and exacerbate the disease. Therefore, the claim that rogue antibodies cannot be driving severe COVID-19 is not supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.871951162815094,
    "x2e_entail_prob": 0.29088521003723145
  },
  {
    "id": "covid_fact-000561",
    "statement": "Rogue antibodies could be less severe covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "[2] Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.",
      "The Covid-19 patients had more antibodies that had turned on them than people with lupus, an autoimmune disease caused by similar wayward antibodies.",
      "Those antibodies, which blocked the interferons antiviral activity, werent found in people with more mild cases of COVID-19.",
      "Rather than one type of autoantibody being to blame, the scientists believe that Covid-19 is worsened when many different wayward antibodies arise in the same patient."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that rogue antibodies could make COVID-19 less severe. However, the evidence indicates that rogue antibodies worsen COVID-19 by blocking interferons' antiviral activity. These antibodies were not found in mild cases, implying that their presence correlates with more severe cases, not less severe ones.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.46788927912712097,
    "x2e_entail_prob": 0.2902756631374359
  },
  {
    "id": "covid_fact-000562",
    "statement": "Washington state group is 1st to sue fox new for calling the coronavirus a hoax",
    "label": "SUPPORTED",
    "evidences": [
      "According to the suit, Fox News violated the CPA by falsely and deceptively disseminating News via cable news contracts that the coronavirus was a hoax, and that it was otherwise not a danger to public health and safety. At least one poll has found that Fox News viewers were less likely to take precautions against the virus (including social distancing, handwashing, and other measures) seriously, and an open letter to Fox News from a group of journalism professors said misinformation that reaches the Fox News audience is a danger to public health. Based on the statements made, and the subsequent departure of Trish Regan, WASHLITE does present a cognizable theory of liability.",
      "I said it was a hoax for them to be using it as a bludgeon on Trump. Notably, he made this denial in response to criticism from 74 journalism professors who wrote an open letter to Fox claiming that coverage of the coronavirus from Fox News Channel \"is a danger to public health.\"",
      "But when you get to the point where you are endangering the community  that transcends the limits of the First Amendment. When reached by phone for comment, Catherine Clark, a Seattle attorney who volunteered to join the plaintiffs legal team after reading an initial news account, said this is a case of national importance. A supporter of First Amendment protections, she continued, When it comes to the public health, safety, and welfare, it seems to me a different set of rules apply. In a statement, Fox News general counsel Lily Fu Clafee responded to the suit by saying: Wrong on the facts, frivolous on the law."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a group from Washington state, specifically WASHLITE, did file a lawsuit against Fox News for allegedly calling the coronavirus a hoax and misleading the public about the dangers of the virus. This supports the claim that a Washington state group was the first to sue Fox News on these grounds.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3111482262611389,
    "x2e_entail_prob": 0.017493220046162605
  },
  {
    "id": "covid_fact-000563",
    "statement": "Washington state group is unable to sue fox new for calling the coronavirus a hoax",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the suit, Fox News violated the CPA by falsely and deceptively disseminating News via cable news contracts that the coronavirus was a hoax, and that it was otherwise not a danger to public health and safety. At least one poll has found that Fox News viewers were less likely to take precautions against the virus (including social distancing, handwashing, and other measures) seriously, and an open letter to Fox News from a group of journalism professors said misinformation that reaches the Fox News audience is a danger to public health. Based on the statements made, and the subsequent departure of Trish Regan, WASHLITE does present a cognizable theory of liability.",
      "I said it was a hoax for them to be using it as a bludgeon on Trump. Notably, he made this denial in response to criticism from 74 journalism professors who wrote an open letter to Fox claiming that coverage of the coronavirus from Fox News Channel \"is a danger to public health.\"",
      "But when you get to the point where you are endangering the community  that transcends the limits of the First Amendment. When reached by phone for comment, Catherine Clark, a Seattle attorney who volunteered to join the plaintiffs legal team after reading an initial news account, said this is a case of national importance. A supporter of First Amendment protections, she continued, When it comes to the public health, safety, and welfare, it seems to me a different set of rules apply. In a statement, Fox News general counsel Lily Fu Clafee responded to the suit by saying: Wrong on the facts, frivolous on the law."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that a Washington state group is unable to sue Fox News for calling the coronavirus a hoax. The evidence indicates that a lawsuit was filed against Fox News alleging it misleadingly claimed the coronavirus was a hoax. While there is mention of a cognizable theory of liability, the strong response from Fox News general counsel and public comments suggest that the lawsuit's success may be heavily contested and not straightforward, likely undermining the suit. Hence, the claim that they were unable to sue is misleading, but the overall difficulty and potential failure in legal proceedings could align with being unable to effectively sue.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.2292126715183258,
    "x2e_entail_prob": 0.11527331918478012
  },
  {
    "id": "covid_fact-000564",
    "statement": "Unfounded fears that dogs can spread covid-19 can cause harm",
    "label": "SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that there is no indication that dogs can transmit COVID-19. This unfounded fear has led to harmful actions against pets, including abandonment or euthanization. Thus, the claim that unfounded fears can cause harm is supported by the evidence indicating these negative consequences.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.46339908242225647,
    "x2e_entail_prob": 0.6538922190666199
  },
  {
    "id": "covid_fact-000565",
    "statement": "Unfounded fears that people can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that unfounded fears about the ability of pets to spread COVID-19 have resulted in harm to pets, including being abandoned or killed. Furthermore, the evidence provided by the World Organisation for Animal Health expressly advises against harming or abandoning pets due to these fears. This supports the claim that unfounded fears related to COVID-19 transmission can indeed cause harm.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.2424531877040863,
    "x2e_entail_prob": 0.4487950801849365
  },
  {
    "id": "covid_fact-000566",
    "statement": "Unfounded fears that sars can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that unfounded fears that pets can spread COVID-19 can cause harm is supported. The evidence indicates that such fears have indeed led to pets being abandoned or killed. These actions compromise the welfare of the animals based on the unsupported belief that they spread the virus, confirming the detrimental impact of these fears.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.15274390578269958,
    "x2e_entail_prob": 0.5922293066978455
  },
  {
    "id": "covid_fact-000567",
    "statement": "Unfounded fears that hiv can spread covid-19 can cause harm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, although no evidence exists to indicate that they can either transmit the virus or develop its associated coronavirus disease 2019 (COVID-19), fear among the public that pets might play a role in spreading COVID-19 has resulted in pets being abandoned or even killed.",
      "At this time, there is no evidence that companion animals play a significant role in spreading the virus that causes COVID-19; however, we are still learning about this virus.",
      "According to the World Organisation for Animal Health (OIE), there is no justification in taking measures against companion animals that may compromise their welfare, such as harming them, abandoning them, or euthanizing them based on unfounded fears over COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that baseless fears about HIV spreading COVID-19 can cause harm. The evidence provided mentions similar scenarios where unfounded fears about animals spreading COVID-19 resulted in harm to animals, such as abandonment and euthanasia. While the specific claim about HIV is not directly addressed in the evidence, the provided context sufficiently supports the idea that baseless fears about disease transmission can lead to harmful consequences. Thus, the general claim is reasonably supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.11754588037729263,
    "x2e_entail_prob": 0.010888854041695595
  },
  {
    "id": "covid_fact-000568",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in mice",
    "label": "SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium, resulting in transient olfactory dysfunction in humanized ACE2 mice.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.962312638759613,
    "x2e_entail_prob": 0.0014764651423320174
  },
  {
    "id": "covid_fact-000569",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in humans",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection leads to viral replication in the olfactory epithelium, resulting in downregulation of olfactory receptors and transient olfactory dysfunction in humanized ACE2 mice. This supports the claim that SARS-CoV-2 infection causes transient olfactory dysfunction in humans, as the findings can be extrapolated to human cases.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9264390468597412,
    "x2e_entail_prob": 0.00486807432025671
  },
  {
    "id": "covid_fact-000570",
    "statement": "Sars-cov-2 infection causes transient olfactory dysfunction in neurons",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Combined transcriptomic and proteomic analyses reveal the induction of antiviral and inflammatory responses, as well as the downregulation of olfactory receptors in OE from the infected animals.",
      "Herein we demonstrate intranasal inoculation of SARS-CoV-2 induces robust viral replication in the olfactory epithelium (OE), resulting in transient olfactory dysfunction in humanized ACE2 mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection leads to downregulation of olfactory receptors and causes transient olfactory dysfunction in the olfactory epithelium of humanized ACE2 mice. This supports the claim that SARS-CoV-2 infection can cause transient olfactory dysfunction, which is linked to neurons in the olfactory system.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.916079044342041,
    "x2e_entail_prob": 0.00608178460970521
  },
  {
    "id": "covid_fact-000571",
    "statement": "1 million pc owners combine their gpu power to fight covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence, which states that over one million personal computers have been donated to Folding@home to help fight COVID-19. Thus, the claim of 1 million PC owners combining their GPU power to address COVID-19 is accurate.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.20561949908733368,
    "x2e_entail_prob": 0.016541820019483566
  },
  {
    "id": "covid_fact-000572",
    "statement": "1 2 pc owners combine their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that over one million personal computers are contributing their processing power through Folding@home to help fight COVID-19. While the claim specifically mentions '1 2 pc owners,' this can be interpreted to mean that individual PC owners are combining their GPU power in a distributed computing effort against COVID-19. Therefore, the claim is supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5024811029434204,
    "x2e_entail_prob": 0.018185066059231758
  },
  {
    "id": "covid_fact-000573",
    "statement": "1 4 pc owners combine their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not specifically mention that 1.4 PC owners are combining their GPU power to fight COVID-19. While more than one million PC users have contributed to the Folding@Home project to fight COVID-19, it does not support the precise number claimed.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.007035326678305864,
    "x2e_entail_prob": 0.024555044248700142
  },
  {
    "id": "covid_fact-000574",
    "statement": "1 million pc owners lost their gpu power to fight covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Almost two decades after it first launched, the uniquely decentralized structure of Folding@home is bringing together more people and computing power than ever to help understand, and hopefully fight, the COVID-19 threat.",
      "Users around the world have donated processing power of over one million personal computers to help Folding@Homea distributed computing project for simulating protein dynamicsto search for new therapies for the coronavirus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that over one million personal computers have donated their processing power to the Folding@home project, which is aimed at researching COVID-19 therapies. This supports the claim that 1 million PC owners used their GPU power for this purpose.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.021263323724269867,
    "x2e_entail_prob": 0.00347292167134583
  },
  {
    "id": "covid_fact-000575",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by blocking receptor interaction",
    "label": "SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the alpaca-derived nanobody, Ty1, specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and prevents its engagement with the ACE2 receptor. This supports the claim that the nanobody neutralizes the virus by blocking receptor interaction.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.18406851589679718,
    "x2e_entail_prob": 0.6778854727745056
  },
  {
    "id": "covid_fact-000576",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by activating receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the alpaca-derived nanobody Ty1 targets the receptor binding domain of the SARS-CoV-2 spike and prevents ACE2 engagement. This means it neutralizes the virus by preventing receptor interaction, not activating it. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.02932177111506462,
    "x2e_entail_prob": 0.16768692433834076
  },
  {
    "id": "covid_fact-000577",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by its receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the alpaca-derived nanobody, Ty1, specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and directly prevents engagement with ACE2. This indicates that it neutralizes the virus by interfering with its receptor interaction, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.20428885519504547,
    "x2e_entail_prob": 0.6827840209007263
  },
  {
    "id": "covid_fact-000578",
    "statement": "An alpaca nanobody neutralizes sars-cov-2 by a receptor interaction",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that a single domain antibody fragment derived from an alpaca, named Ty1, targets the receptor binding domain of the SARS-CoV-2 spike, preventing the virus from engaging with the ACE2 receptor. This indicates that the alpaca nanobody neutralizes the virus by interfering with its receptor interaction, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8847150206565857,
    "x2e_entail_prob": 0.4576692581176758
  },
  {
    "id": "covid_fact-000579",
    "statement": "Household studies provide key insights on the transmission of , and susceptibility to , sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "The secondary attack rate for SARS-CoV-2 has been estimated to be approximately twice as high as that of SARS-CoV, 5 Lau JT Lau M Kim JH Tsui HY Tsang T Wong TW Probable secondary infections in households of SARS patients in Hong Kong."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the secondary attack rate of SARS-CoV-2 relative to SARS-CoV and mentions probable secondary infections in households, but it does not directly address the claim that household studies provide key insights into the transmission and susceptibility to SARS-CoV-2. The evidence lacks specific references to household study methodologies or findings that support the claim.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.17136502265930176,
    "x2e_entail_prob": 0.0014331405982375145
  },
  {
    "id": "covid_fact-000580",
    "statement": "Future studies provide key insights on the transmission of, and susceptibility to, sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The secondary attack rate for SARS-CoV-2 has been estimated to be approximately twice as high as that of SARS-CoV, 5 Lau JT Lau M Kim JH Tsui HY Tsang T Wong TW Probable secondary infections in households of SARS patients in Hong Kong."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide explicit insights from future studies on transmission or susceptibility to SARS-CoV-2. It only mentions the secondary attack rate estimation compared to SARS-CoV, lacking mention of insights from future studies specifically.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.07414644956588745,
    "x2e_entail_prob": 0.002117421943694353
  },
  {
    "id": "covid_fact-000581",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c damages its genome integrity seriously",
    "label": "SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that inactivating porcine coronavirus at temperatures of 56\u00b0C or higher results in substantial damage to its genome integrity, as indicated by the reduction in detectable viral templates. It has been explicitly stated that only 50.11% of viral templates are left after inactivation at 56\u00b0C for 30 minutes, and 3.36% after exposure to 92\u00b0C for 5 minutes, thus supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.016059042885899544,
    "x2e_entail_prob": 0.04510746896266937
  },
  {
    "id": "covid_fact-000582",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c increased its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that inactivating porcine coronavirus at temperatures higher than 56 \u00b0C increases its genome integrity seriously. The evidence suggests that heating the samples can degrade the viral nucleic acids, showing a loss of detectable viral templates at 56 \u00b0C and 92 \u00b0C. Therefore, this does not support the claim of increased genome integrity. Instead, the intactness of the viral genome is compromised unless specific protective solutions are used.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.008218729868531227,
    "x2e_entail_prob": 0.023072758689522743
  },
  {
    "id": "covid_fact-000583",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c increases its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that inactivating porcine coronavirus at temperatures higher than 56 \u00b0C seriously increases genome integrity. Evidence indicates that higher temperatures actually decrease the integrity of viral templates, not increase it. 50.11% of viral templates remained after inactivation at 56 \u00b0C for 30 minutes, and only 3.36% remained after inactivation at 92 \u00b0C for 5 minutes. These results show a decrease in integrity, contradicting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.013737304136157036,
    "x2e_entail_prob": 0.15486663579940796
  },
  {
    "id": "covid_fact-000584",
    "statement": "Inactivating porcine coronavirus before nuclei acid isolation with the temperature higher than 56 \u00b0c shows its genome integrity seriously",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results showed that only 50.11% of the detectable viral templates left after the inactivation of 56 \u00b0C for 30 minutes and only 3.36% left after the inactivation of 92 \u00b0C for 5 minutes when the samples were preserved by Hanks solution, one of an isotonic salt solutions currently suggested.",
      "According to The Laboratory Technical Guidelines for Detection 2019-nCoV (Fourth Edition) issued by National Health and Commission of China and The Experts Consensus on Nucleic Acid Detection of 2019-nCoV released by Chinese Society of Laboratory Medicine, the human samples must be placed under 56\u00b0C or higher to inactivate the viruses in order to keep the inspectors from virus infection before the nucleic acids were isolated as the template of qRT-PCR.",
      "We therefore highly recommend to carry out systematic investigation on the impact of high temperature inactivation on the integrity of 2019-nCoV genome and develop a sample preservation solution to protect the detectable templates of 2019-nCoV nucleic acids from high temperature inactivation damage.",
      "However, the detectable templates of viral nucleic acids can be unchanged after the samples were incubated at 56 \u00b0C or higher if the samples were preserved with an optimized solution to protect the RNA from being disrupted."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that inactivating porcine coronavirus at temperatures higher than 56 \u00b0C severely impacts genome integrity, leaving only 50.11% of viral templates after treatment at 56 \u00b0C for 30 minutes and 3.36% remaining after treatment at 92 \u00b0C for 5 minutes. This supports the claim that such treatment compromises genome integrity.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.025453312322497368,
    "x2e_entail_prob": 0.04494226723909378
  },
  {
    "id": "covid_fact-000585",
    "statement": "Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from the study indicates that therapeutic anticoagulation is associated with a significant reduction in mortality among mechanically ventilated COVID-19 patients. A Cox proportional hazard regression model showed a 79% reduction in death, and a Kaplan-Meier plot demonstrated a survival advantage. The claim is well-supported by this evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.38807156682014465,
    "x2e_entail_prob": 0.06899716705083847
  },
  {
    "id": "covid_fact-000586",
    "statement": "Therapeutic anticoagulation is associated with elevated mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that therapeutic anticoagulation is associated with a survival advantage, not elevated mortality, in mechanically ventilated COVID-19 patients. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.012709119357168674,
    "x2e_entail_prob": 0.0058521912433207035
  },
  {
    "id": "covid_fact-000587",
    "statement": "Therapeutic anticoagulation is associated with increased mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that therapeutic anticoagulation is associated with a survival advantage, not increased mortality, in mechanically ventilated COVID-19 patients. Specifically, it demonstrates a 79% reduction in death and a significant survival advantage for those receiving therapeutic anticoagulation.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8093226552009583,
    "x2e_entail_prob": 0.09526360034942627
  },
  {
    "id": "covid_fact-000588",
    "statement": "Therapeutic anticoagulation is associated with high mortality in mechanically ventilated covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001].",
      "Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course.",
      "Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that therapeutic anticoagulation is actually associated with a survival advantage, not high mortality, in mechanically ventilated COVID-19 patients. This is contrary to the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.023263053968548775,
    "x2e_entail_prob": 0.0043880087323486805
  },
  {
    "id": "covid_fact-000589",
    "statement": "Sars-cov-2 is an unrestricted bioweapon",
    "label": "SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is an assertion rather than a scientifically validated fact, lacking substantial support from the broader scientific community. While the evidence states SARS-CoV-2 meets criteria defined by a specific entity, it does not confirm a broad consensus or empirical proof that the virus is an 'unrestricted bioweapon.'",
    "confidence": 0.6,
    "e2x_entail_prob": 0.7089807391166687,
    "x2e_entail_prob": 0.0012082017492502928
  },
  {
    "id": "covid_fact-000590",
    "statement": "Sars-cov-2 is an spricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that SARS-CoV-2 is an 'unrestricted bioweapon' is supported by a specific point of view, but this assertion is not widely accepted by the scientific community or supported by the majority of evidence available. The scientific consensus indicates that SARS-CoV-2 likely originated from natural sources. The provided evidence represents a minority and speculative perspective rather than conclusive proof.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.3183797001838684,
    "x2e_entail_prob": 0.0017388849519193172
  },
  {
    "id": "covid_fact-000591",
    "statement": "Sars-cov-2 is an sricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented claims that SARS-CoV-2 is considered an 'Unrestricted Bioweapon' by the People's Liberation Army (PLA) criteria, and it follows a theory suggesting it was a product of laboratory modification. However, this remains an unsubstantiated claim within the scientific community and lacks consensus. Most scientific research concludes that the virus has a natural origin. Without broader scientific consensus or verifiable proof supporting the claim of it being a bioweapon, the claim is not sufficiently supported by the evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0321197472512722,
    "x2e_entail_prob": 0.003603386925533414
  },
  {
    "id": "covid_fact-000592",
    "statement": "Sars-cov-2 is an trricted bioweapon",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "It also strengthens our earlier assertion that SARS-CoV-2 is a product of laboratory modification, which can be created in approximately six months using a template virus owned by a laboratory of the People's Liberation Army (PLA).",
      "We therefore define SARS- CoV-2 as an Unrestricted Bioweapon and the current pandemic a result of Unrestricted Biowarfare.",
      "Importantly, while SARS-CoV-2 meets the criteria of a bioweapon specified by the PLA, its impact is well beyond what is conceived for a typical bioweapon."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that SARS-CoV-2 is a 'restricted bioweapon' (presumably intended to mean 'unrestricted bioweapon') is not fully supported by the provided evidence. The evidence suggests that an assertion was made about SARS-CoV-2 being a product of laboratory modification and meeting bioweapon criteria. However, the evidence primarily constitutes an assertion rather than scientific consensus or verified findings from credible sources. Current scientific and governmental consensus, based on investigations and studies, does not support the claim of SARS-CoV-2 being a bioweapon. Without broader acceptance in the scientific community and additional evidence, the claim remains speculative and unsubstantiated.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5290130376815796,
    "x2e_entail_prob": 0.0031364131718873978
  },
  {
    "id": "covid_fact-000593",
    "statement": "Kinetics of antibody responses dictate covid-19 outcome.",
    "label": "SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is a relationship between the kinetics of antibody responses and COVID-19 outcomes. The phrase 'Serum antibody kinetics reveals distinct COVID-19 outcomes' directly supports the claim. Other pieces of evidence indicating that neutralizing antibodies predict disease severity and survival also imply a relationship between antibody response kinetics and outcomes. Therefore, the claim is supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9527120590209961,
    "x2e_entail_prob": 0.936948835849762
  },
  {
    "id": "covid_fact-000594",
    "statement": "Standards of antibody responses dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a correlation between antibody responses and COVID-19 outcomes. Various studies show that neutralizing antibodies can predict disease severity and survival, and that there are distinct outcomes based on serum antibody kinetics. While these findings imply that antibody responses play a significant role in determining the outcome of COVID-19, the claim's absolute wording ('dictate') implies a more deterministic relationship, which might not be fully established yet. Nonetheless, the overall evidence supports the general idea that antibody responses are crucial in influencing COVID-19 outcomes.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9211935997009277,
    "x2e_entail_prob": 0.8958197832107544
  },
  {
    "id": "covid_fact-000595",
    "statement": "Kinetics of antibody production dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions multiple studies discussing the relationship between antibody kinetics and COVID-19 outcomes. These include references to antibody responses predicting disease severity and survival, as well as distinct COVID-19 outcomes being revealed by serum antibody kinetics. While these do not directly state that antibody production kinetics dictate outcomes, they strongly imply an influence, supporting the claim with moderate confidence.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.13089649379253387,
    "x2e_entail_prob": 0.6419022083282471
  },
  {
    "id": "covid_fact-000596",
    "statement": "Analysiss of antibody responses dictate covid-19 outcome.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "COVID-19 neutralizing antibodies predict disease severity and survival.",
      "Serum antibody kinetics reveals distinct COVID-19 outcomes.",
      "Viral kinetics and antibody responses in patients with COVID-19.",
      "T cell and antibody functional correlates of severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that there is a correlation between antibody responses and COVID-19 outcomes as indicated by the prediction of disease severity and survival, distinct outcomes based on serum antibody kinetics, and functional correlates of severity with T cell and antibody responses.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.927520215511322,
    "x2e_entail_prob": 0.5753159523010254
  },
  {
    "id": "covid_fact-000597",
    "statement": "Raspberry pi about to boost ventilators for coronavirus victims",
    "label": "SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the Raspberry Pi Foundation is increasing the production of its Pi Zero boards to meet the high demand for ventilators, suggesting their involvement in boosting ventilator production. While it doesn't confirm that ventilators are being produced specifically for coronavirus victims, it is reasonable to infer this given the context and timing of the statement, related to the COVID-19 pandemic situation.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.686001181602478,
    "x2e_entail_prob": 0.0043374476954340935
  },
  {
    "id": "covid_fact-000598",
    "statement": "Raspberry pi about to avoid ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Raspberry Pi is avoiding ventilators for coronavirus victims, which implies a refusal or a deliberate avoidance in connection to ventilators. However, the evidence shows that the Raspberry Pi Foundation is actually ramping up production to supply manufacturers who need them for ventilators. Thus, the evidence contradicts the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.005889249965548515,
    "x2e_entail_prob": 0.001739035127684474
  },
  {
    "id": "covid_fact-000599",
    "statement": "Raspberry pi about to take ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that Raspberry Pi is directly creating ventilators for coronavirus victims, which is not supported by the evidence. The evidence indicates that the Raspberry Pi Foundation is increasing production of Pi Zero boards to supply manufacturers, suggesting that the Pi Zero boards are components, not final ventilator products. Thus, Raspberry Pi is providing parts to assist in the production of ventilators, not directly taking ventilators themselves.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.016889411956071854,
    "x2e_entail_prob": 0.007763005793094635
  },
  {
    "id": "covid_fact-000600",
    "statement": "Raspberry pi about to receive ventilators for coronavirus victims",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Toms Hardware reports that The Raspberry Pi Foundation is ramping up production of its Pi Zero boards to help supply manufacturers with enough units to keep up with the high demand for ventilators.",
      "Another reason Raspberry Pi boards are ideal for ventilators is the companys ability to supply them quickly."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the Raspberry Pi Foundation is increasing production of Pi Zero boards to support manufacturers in meeting ventilator demand, but it does not mention Raspberry Pi directly receiving ventilators. Therefore, while the boards may be used in ventilator production, the claim about Raspberry Pi receiving ventilators is not directly supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.08111695945262909,
    "x2e_entail_prob": 0.005025706719607115
  },
  {
    "id": "covid_fact-000601",
    "statement": "Aerosol particles laden with viruses that cause covid-19 travel over 30m distance",
    "label": "SUPPORTED",
    "evidences": [
      "The results obtained demonstrate that aerosol particles generated by coughing and sneezing can travel over 30 m. Modelling of the evolution of aerosol clouds generated by coughing and sneezing enables us to evaluate the deposition dose of aerosol particles in healthy individuals.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that aerosol particles generated by coughing and sneezing can travel over 30 meters. Although it does not explicitly mention the viruses causing COVID-19, it is generally understood that aerosol particles can carry these viruses. Thus, the claim is supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.007405026350170374,
    "x2e_entail_prob": 0.028619980439543724
  },
  {
    "id": "covid_fact-000602",
    "statement": "Aerosol particles laden with viruses that cause covid-19 travel within 30m distance",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The results obtained demonstrate that aerosol particles generated by coughing and sneezing can travel over 30 m. Modelling of the evolution of aerosol clouds generated by coughing and sneezing enables us to evaluate the deposition dose of aerosol particles in healthy individuals.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that aerosol particles generated by coughing and sneezing can travel over 30 meters. Since these particles can contain viruses that cause COVID-19, the claim that aerosol particles laden with the virus can travel within a 30m distance is supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.015119251795113087,
    "x2e_entail_prob": 0.012488593347370625
  },
  {
    "id": "covid_fact-000603",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against sars-cov-2 and zoonotic coronaviruses",
    "label": "SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that mice immunized with mosaic-RBD nanoparticles elicited superior cross-reactive antibody responses compared to those from other methods, indicating that these nanoparticles can potentially elicit neutralizing antibodies against both SARS-CoV-2 and zoonotic coronaviruses. Thus, the claim is supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9593373537063599,
    "x2e_entail_prob": 0.058950163424015045
  },
  {
    "id": "covid_fact-000604",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against chs-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that mosaic RBD-nanoparticles elicit superior cross-reactive recognition of heterologous RBDs compared to other types of immunizations. This suggests that they can elicit neutralizing antibodies against both SARS-CoV-2 and zoonotic coronaviruses. Thus, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9015827178955078,
    "x2e_entail_prob": 0.058349546045064926
  },
  {
    "id": "covid_fact-000605",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against gps-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that mice immunized with mosaic RBD-nanoparticles developed antibodies with enhanced cross-reactivity compared to other forms. This implies that the mosaic RBD-nanoparticles elicit neutralizing antibodies against both SARS-CoV-2 and other zoonotic coronaviruses, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9224329590797424,
    "x2e_entail_prob": 0.12436626851558685
  },
  {
    "id": "covid_fact-000606",
    "statement": "Mosaic rbd nanoparticles elicit neutralizing antibodies against 3s-cov-2 and zoonotic coronaviruses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mice immunized with RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and neutralization responses, confirming increased immunogenicity from multimerization.",
      "Mosaic-RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous RBDs compared to sera from immunizations with homotypic SARS-CoV-2RBD-nanoparticles or antibodies from COVID-19 convalescent human plasmas.",
      "Thus, a single immunization with mosaic-RBD- nanoparticles provides a potential strategy to simultaneously protect against SARS-CoV-2 and emerging zoonotic coronaviruses."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that Mosaic RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses. Mice immunized with mosaic-RBD-nanoparticles showed superior cross-reactive recognition and neutralization compared to those immunized with homotypic SARS-CoV-2 RBD nanoparticles, suggesting increased potential for protection against both SARS-CoV-2 and emerging zoonotic coronaviruses.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.969557523727417,
    "x2e_entail_prob": 0.4676661491394043
  },
  {
    "id": "covid_fact-000607",
    "statement": "South korean city deserted due to super spreading event",
    "label": "SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Daegu, a South Korean city, was indeed deserted as a result of a super-spreading event related to COVID-19, particularly associated with a church outbreak. The deserted condition of the city is described as a notable consequence of the event.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8565962910652161,
    "x2e_entail_prob": 0.8604662418365479
  },
  {
    "id": "covid_fact-000608",
    "statement": "South korean city started due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the city of Daegu in South Korea experienced a 'super-spreading event' at a church that led to a significant outbreak of coronavirus. This outbreak resulted in deserted streets and public places, which supports the claim that the city had a significant event due to a super-spreader incident.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.906941831111908,
    "x2e_entail_prob": 0.8578436970710754
  },
  {
    "id": "covid_fact-000609",
    "statement": "South korean city remained due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Daegu, a city in South Korea, experienced a significant outbreak due to a 'super-spreading event' at a church. This outbreak led to deserted streets and community spaces as residents isolated themselves, supporting the claim that the city remained due to the super-spreading event.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8032790422439575,
    "x2e_entail_prob": 0.7841112017631531
  },
  {
    "id": "covid_fact-000610",
    "statement": "South korean city occurred due to super spreading event",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic.",
      "The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying stop from becoming a global pandemic.",
      "Updated: 20 Feb 2020, 06:04 PM IST Hyonhee Shin , Ryan Woo , AP The deserted shopping malls and cinemas of Daegu, a city of 2.5 million people, became one of the most striking images outside China of an outbreak that international authorities are trying to prevent from spreading into a global pandemic Share Via Read Full Story SEOUL/BEIJING : The streets of South Korea's fourth-largest city were abandoned on Thursday, with residents holed up indoors after dozens of people caught the coronavirus in what the authorities described as a \"super-spreading event\" at a church.",
      "South Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\".",
      "Korea's Centers for Disease Control and Prevention described the outbreak there as a \"super-spreading event\"."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Daegu, a South Korean city, experienced an outbreak described as a 'super-spreading event' by the Centers for Disease Control and Prevention (CDC) of South Korea. This aligns with the claim regarding the city being affected by a super-spreading event.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8561137318611145,
    "x2e_entail_prob": 0.9034069776535034
  },
  {
    "id": "covid_fact-000611",
    "statement": "Scientists see signs of lasting immunity , even after mild infections",
    "label": "SUPPORTED",
    "evidences": [
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys robust immune response to other viruses.",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of COVID-19, a flurry of new studies suggests.",
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells that are capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys enduring response to other viruses.",
      "Scientists see signs of lasting immunity to COVID-19, even after mild infections Share: August 18, 2020 ",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that scientists have observed strong, lasting immunity in individuals who had mild symptoms of COVID-19. This is supported by multiple studies showing the persistence of antibodies and immune cells like B cells and T cells months after infection, suggesting robust immune responses similar to those seen with other viruses.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9537732005119324,
    "x2e_entail_prob": 0.22835028171539307
  },
  {
    "id": "covid_fact-000612",
    "statement": "Scientists no signs of lasting immunity, even after mild infections",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys robust immune response to other viruses.",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of COVID-19, a flurry of new studies suggests.",
      "Disease-fighting antibodies, as well as immune cells called B cells and T cells that are capable of recognizing the virus, appear to persist months after infections have resolved  an encouraging echo of the bodys enduring response to other viruses.",
      "Scientists see signs of lasting immunity to COVID-19, even after mild infections Share: August 18, 2020 ",
      "Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that scientists are seeing encouraging signs of strong, lasting immunity to COVID-19, even in people who developed only mild symptoms. The claim states there are no signs of lasting immunity, which contradicts the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.12949900329113007,
    "x2e_entail_prob": 0.11387927830219269
  },
  {
    "id": "covid_fact-000613",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-specific viral diagnostic",
    "label": "SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the type III CRISPR-Cas system is used for a sequence-specific detection of SARS-CoV-2, which implies the ability for sequence-specific viral diagnostics. This confirms the claim of intrinsic signal amplification by type III CRISPR-Cas systems in viral diagnostics.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.09155163913965225,
    "x2e_entail_prob": 0.0011201179586350918
  },
  {
    "id": "covid_fact-000614",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-independent viral diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that type-III CRISPR-Cas systems provide sequence-independent viral diagnostics, but the evidence states the system was used for 'sensitive and sequence-specific detection' of SARS-CoV-2, which contradicts the sequence-independent aspect of the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.45539551973342896,
    "x2e_entail_prob": 0.000874727382324636
  },
  {
    "id": "covid_fact-000615",
    "statement": "Intrinsic signal amplification by type-iii crispr-cas systems provides a sequence-free viral diagnostic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that the type III CRISPR-Cas system is used for sequence-specific detection of SARS-CoV-2, which contradicts the claim that it offers sequence-free viral diagnostics. Thus, the claim is not supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3223521113395691,
    "x2e_entail_prob": 0.0009767101146280766
  },
  {
    "id": "covid_fact-000616",
    "statement": "Pet dog further tests positive for antibodies for covid-19 virus",
    "label": "SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms the presence of antibodies in the Pomeranian's blood, signifying an immune response to a previous viral infection. This supports the claim that the pet dog tested positive for antibodies to the COVID-19 virus.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.015819668769836426,
    "x2e_entail_prob": 0.9935051202774048
  },
  {
    "id": "covid_fact-000617",
    "statement": "Pet dog further tests negative for antibodies for covid-19 virus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the Pomeranian developed an immune response and had antibodies in its blood, which means it tested positive for antibodies, contradicting the claim that it tested negative for antibodies.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.011983279138803482,
    "x2e_entail_prob": 0.005802705883979797
  },
  {
    "id": "covid_fact-000618",
    "statement": "Pet dog further tests except for antibodies for covid-19 virus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This indicates that the Pomeranian had developed an immune response to the viral infection with antibodies found in the blood."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the presence of antibodies in the Pomeranian's blood, indicating an immune response to the COVID-19 virus. However, it does not provide any details about whether further tests, apart from antibody tests, were conducted on the dog. Therefore, the claim about further tests except for antibodies is not supported by the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0038333360571414232,
    "x2e_entail_prob": 0.9834148287773132
  },
  {
    "id": "covid_fact-000619",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 100 % success using hydroxychloroquine sulfate , zinc and z-pak",
    "label": "SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Dr. Vladimir Zelenko reported treating 699 coronavirus patients using a combination of hydroxychloroquine sulfate, zinc, and azithromycin (Z-Pak), with claimed '100% success,' meaning zero deaths, zero intubations, and only four hospitalizations, as per his statements. Hence, the claim is supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.27702346444129944,
    "x2e_entail_prob": 0.3560645580291748
  },
  {
    "id": "covid_fact-000620",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 10 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states a 10% success rate in treating 699 COVID-19 patients, whereas the evidence suggests a claim of 100% success. Thus, the evidence does not support the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.017682107165455818,
    "x2e_entail_prob": 0.11012911051511765
  },
  {
    "id": "covid_fact-000621",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 5 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that Dr. Vladimir Zelenko reported a 100% success rate in treating 699 coronavirus patients using hydroxychloroquine sulfate, zinc, and azithromycin (Z-Pak). However, the claim mentions a 5% success rate, which directly contradicts the evidence provided. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01804964244365692,
    "x2e_entail_prob": 0.02684244140982628
  },
  {
    "id": "covid_fact-000622",
    "statement": "Dr. vladimir zelenko has now treated 699 coronavirus patients with 20 % success using hydroxychloroquine sulfate, zinc and z-pak",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "March 31 Update : Dr. Vladimir Zelenkoprovides important update on three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) he used to effectively treat 699 coronavirus patients with 100% success 0 Shares Share On Facebook Tweet It ",
      "In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died, zero patients intubated, and four hospitalizations.",
      "Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.",
      "April 5 Update : Dr. Vladimir Zelenko said in a video interview that acocktail of Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing phenomenon results with 900 coronavirus patients treated.",
      "Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided states that Dr. Vladimir Zelenko treated 699 coronavirus patients with a drug regimen including Hydroxychloroquine Sulfate, Zinc, and Azithromycin (Z-Pak) with 100% success, implying no deaths, no intubations, and few hospitalizations. The claim of 20% success is contradicted by the evidence stating 100% success, thus the claim is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.04511770233511925,
    "x2e_entail_prob": 0.16770507395267487
  },
  {
    "id": "covid_fact-000623",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is inadequate for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the VivaDiag COVID-19 IgM/IgG Rapid Test has low sensitivity, leading to misdiagnosis in the majority of patients when used alone, and therefore is not recommended for the diagnosis of COVID-19 in acute patients in emergency settings.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7379477620124817,
    "x2e_entail_prob": 0.6480190753936768
  },
  {
    "id": "covid_fact-000624",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is useful for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the VivaDiag COVID-19 IgM/IgG Rapid Test is not recommended for diagnosing COVID-19 in acute patients in the emergency department due to low sensitivity. The test would misdiagnose the majority of patients, as it would not identify many who tested positive via RTPCR, leading to a risk of false negatives. Thus, it is not useful for this purpose, contrary to the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6421880722045898,
    "x2e_entail_prob": 0.5737213492393494
  },
  {
    "id": "covid_fact-000625",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is essential for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the VivaDiag COVID-19 IgM/IgG Rapid Test is not reliable for diagnosing COVID-19 in acute patients due to its low sensitivity. It would misdiagnose the majority of COVID-19 positive patients, which contradicts the claim that it is essential for diagnosis in emergency room settings.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.38723888993263245,
    "x2e_entail_prob": 0.5623174905776978
  },
  {
    "id": "covid_fact-000626",
    "statement": "Performance of vivadiagtm covid-19 igm/igg rapid test is suitable for diagnosis of covid-19 in acute patients referring to emergency room department",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "On the basis of our results, VivaDiag COVID19 IgM/IgG Rapid Test LFIA is not recommended for triage of patients with suspected COVID19.",
      "Indeed, the majority of patients that tested positive for COVID19 by realtime RTPCR would have been identified as negative using only the rapid serological assay, leading to a misdiagnosis of COVID19 disease in the vast majority of patients.",
      "Such low sensitivity leads to non-diagnosis of most patients, which is why the authors do not recommend the use of the COVID-19 IgM/IgG VivaDiagTM rapid test for triage of patients with suspected COVID-19 in emergency department."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that the VivaDiag COVID-19 IgM/IgG Rapid Test is not recommended for diagnosing COVID-19 in acute patients, specifically because of its low sensitivity. Therefore, the claim of its suitability for such diagnosis in emergency room settings is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7748529314994812,
    "x2e_entail_prob": 0.544489324092865
  },
  {
    "id": "covid_fact-000627",
    "statement": "Cetylpyridinium chloride-containing mouthwashes reduce in vitro sars-cov-2 infectivity.",
    "label": "SUPPORTED",
    "evidences": [
      "A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.",
      "CPC- containing mouth rinses could represent a cost-effective measure to reduce SARS-CoV-2 infectivity in saliva, aiding to reduce viral transmission from infected individuals.",
      "Here we show that Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells.",
      "\"A common compound in mouthwashes found to inhibit SARS- CoV-2 in vitro\".",
      "Antiviral activity of CPC-containing mouthwashes inhibiting SARS-CoV-2 entry."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Cetylpyridinium chloride (CPC) in mouthwashes reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells in vitro. Multiple pieces of evidence suggest that CPC-containing mouth rinses can inhibit SARS-CoV-2, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3280179500579834,
    "x2e_entail_prob": 0.7837255597114563
  },
  {
    "id": "covid_fact-000628",
    "statement": "Cetylpyridinium chloride-containing mouthwashes with in vitro sars-cov-2 infectivity.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro.",
      "CPC- containing mouth rinses could represent a cost-effective measure to reduce SARS-CoV-2 infectivity in saliva, aiding to reduce viral transmission from infected individuals.",
      "Here we show that Cetylpyridinium chloride (CPC), a quaternary ammonium compound present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by inhibiting viral fusion with target cells.",
      "\"A common compound in mouthwashes found to inhibit SARS- CoV-2 in vitro\".",
      "Antiviral activity of CPC-containing mouthwashes inhibiting SARS-CoV-2 entry."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Cetylpyridinium chloride (CPC) in mouthwashes has been found to inhibit SARS-CoV-2 in vitro by reducing viral infectivity, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.71037358045578,
    "x2e_entail_prob": 0.3527001738548279
  },
  {
    "id": "covid_fact-000629",
    "statement": "Symptom-based screening process was ineffective in detecting sars-cov-2 infection during evacuation of 126 people from wuhan , china .",
    "label": "SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that during the evacuation of 126 people from Wuhan to Frankfurt, the symptom-based screening process failed to detect SARS-CoV-2 infection in 2 individuals who were later confirmed to be infected. Additionally, the researchers explicitly concluded that the symptom-based screening process was ineffective at detecting such infections, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9156625270843506,
    "x2e_entail_prob": 0.07352850586175919
  },
  {
    "id": "covid_fact-000630",
    "statement": "Symptom-based screening process was successful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that the symptom-based screening process was deemed 'ineffective' in detecting SARS-CoV-2 infections. Specifically, it failed to detect the virus in 2 individuals during the evacuation from Wuhan. This directly contradicts the claim that the process was successful.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7636764049530029,
    "x2e_entail_prob": 0.04170357808470726
  },
  {
    "id": "covid_fact-000631",
    "statement": "Symptom-based screening process was helpful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the symptom-based screening process was deemed 'ineffective' in detecting SARS-CoV-2 infections during the evacuation of 126 people from Wuhan. Two individuals were not detected by this method but were later found to be infected. Therefore, the claim that the process was helpful is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9805450439453125,
    "x2e_entail_prob": 0.02935137040913105
  },
  {
    "id": "covid_fact-000632",
    "statement": "Symptom-based screening process was useful in detecting sars-cov-2 infection during evacuation of 126 people from wuhan, china.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In fact, the researchers noted \"epidemiologic uncertainty regarding possible transmission of the virus by asymptomatic or subclinically symptomatic infected persons\" and that it is also not clear \"whether persons who show no signs or symptoms of respiratory infections shed SARS-CoV2.\"",
      "Aside from the ineffectiveness of the screening process, the authors found that the virus could potentially be spread by those who exhibited mild symptoms: Shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection. Over 73,000 people around the world have been infected with the coronavirus, most of those cases in mainland China.",
      "Nevertheless, the researchers concluded that the symptom-based screening process was \"ineffective\" at detecting cases of SARS-CoV2 infection.",
      "In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence explicitly states that the symptom-based screening process was 'ineffective' in detecting cases of SARS-CoV-2 infection during the evacuation of 126 people from Wuhan. It mentions that individuals with mild or no symptoms could still spread the virus and that the screening process failed to detect infection in at least two persons. Therefore, the claim that the screening process was useful is not supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.46904417872428894,
    "x2e_entail_prob": 0.10707619786262512
  },
  {
    "id": "covid_fact-000633",
    "statement": "Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose",
    "label": "SUPPORTED",
    "evidences": [
      "Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance in susceptibility also affected vaccine protection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from the simulation indicates that higher pathogen challenge doses reduce vaccine efficacy, which aligns with the claim. The mention of variance in susceptibility suggests other factors affect vaccine protection, but does not contradict the claim about higher exposure doses specifically reducing efficacy.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3989071547985077,
    "x2e_entail_prob": 0.965242862701416
  },
  {
    "id": "covid_fact-000634",
    "statement": "Limited available evidence supports theoretical predictions of reduced vaccine efficacy at low exposure dose",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance in susceptibility also affected vaccine protection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that simulations show a decrease in vaccine efficacy with an increased pathogen challenge dose, and mentions variability in susceptibility affecting vaccine protection. Though the evidence focuses on increased doses, it implies a relationship between dose and efficacy, supporting the claim of reduced efficacy at low doses.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.2494320124387741,
    "x2e_entail_prob": 0.9825906157493591
  },
  {
    "id": "covid_fact-000635",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are short-lived in patients with mild illness",
    "label": "SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions that severely ill patients developed higher antibody responses compared to outpatients and asymptomatic individuals. It does not address the correlation between antibody responses and the resolution of rnaemia or the longevity of these responses in patients with mild illness.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0017221270827576518,
    "x2e_entail_prob": 0.0012191245332360268
  },
  {
    "id": "covid_fact-000636",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are long-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only discusses the comparative antibody response levels in severely ill patients, outpatients, and asymptomatic individuals. It does not address whether SARS-CoV-2 antibody responses correlate with the resolution of rnaemia or whether these responses are long-lived in patients with mild illness. Therefore, the claim cannot be supported by this evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.003257105825468898,
    "x2e_entail_prob": 0.00295040151104331
  },
  {
    "id": "covid_fact-000637",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are longer-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that severely ill patients developed higher SARS-CoV-2-specific antibody responses than those with milder illness, but it does not address the correlation between antibody responses and the resolution of RNAemia or their duration in patients with different severities of illness.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0015042850282043219,
    "x2e_entail_prob": 0.30590009689331055
  },
  {
    "id": "covid_fact-000638",
    "statement": "Sars-cov-2 antibody responses correlate with resolution of rnaemia but are over-lived in patients with mild illness",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only indicates that severely ill patients have higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. It does not address whether antibody responses correlate with the resolution of RNAemia or whether these responses are prolonged in patients with mild illness. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.005984604824334383,
    "x2e_entail_prob": 0.6905954480171204
  },
  {
    "id": "covid_fact-000639",
    "statement": "Saliva is more sensitive for sars-cov-2 detection in covid-19 patients than nasopharyngeal swabs",
    "label": "SUPPORTED",
    "evidences": [
      "Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies.",
      "When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection.",
      "Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large- scale SARS-CoV-2 testing.",
      "To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that saliva yields greater detection sensitivity and consistency throughout the course of infection compared to nasopharyngeal swabs for SARS-CoV-2. The findings demonstrate that saliva is a more sensitive alternative, thus supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9792667031288147,
    "x2e_entail_prob": 0.013141907751560211
  },
  {
    "id": "covid_fact-000640",
    "statement": "Saliva is less sensitive for sars-cov-2 detection in covid-19 patients than nasopharyngeal swabs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Saliva is a promising candidate for SARS-CoV-2 diagnostics because (1) collection is minimally invasive and can reliably be self-administered and (2) saliva has exhibited comparable sensitivity to nasopharyngeal swabs in detection of other respiratory pathogens, including endemic human coronaviruses, in previous studies.",
      "When we compared SARS-CoV-2 detection from patient-matched nasopharyngeal and saliva samples, we found that saliva yielded greater detection sensitivity and consistency throughout the course of infection.",
      "Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large- scale SARS-CoV-2 testing.",
      "To validate the use of saliva for SARS-CoV-2 detection, we tested nasopharyngeal and saliva samples from confirmed COVID-19 patients and self-collected samples from healthcare workers on COVID-19 wards."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that saliva is not less sensitive but rather more sensitive for SARS-CoV-2 detection compared to nasopharyngeal swabs. Studies show that saliva yields greater detection sensitivity and could be suitable for at-home testing. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.02657695673406124,
    "x2e_entail_prob": 0.0804491713643074
  },
  {
    "id": "covid_fact-000641",
    "statement": "Vitamin d sufficiency reduced risk for morbidity and mortality in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that vitamin D sufficiency is associated with a decreased risk of severity and mortality in COVID-19 patients. References to the anti-inflammatory effects of vitamin D and observed clinical outcomes support the claim. Therefore, the claim that vitamin D sufficiency reduces morbidity and mortality risk in COVID-19 patients is supported by the provided evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.98492830991745,
    "x2e_entail_prob": 0.06712058931589127
  },
  {
    "id": "covid_fact-000642",
    "statement": "Vitamin d sufficiency increased risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presented contradicts the claim. It suggests that vitamin D sufficiency is associated with a decreased risk of severity and mortality in COVID-19 patients, not an increased risk.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.01701163500547409,
    "x2e_entail_prob": 0.00694023072719574
  },
  {
    "id": "covid_fact-000643",
    "statement": "Vitamin d sufficiency increasing risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided suggests that vitamin D sufficiency may decrease the risk of severity and mortality in COVID-19 patients, not increase it. The evidence supports the opposite of the claim, indicating that a sufficient level of vitamin D is potentially beneficial, rather than harmful, in reducing severity and mortality risk.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5172622203826904,
    "x2e_entail_prob": 0.006843551993370056
  },
  {
    "id": "covid_fact-000644",
    "statement": "Vitamin d sufficiency greater risk for morbidity and mortality in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This anti-inflammatory effect of vitamin D might prevent cytokine storm in COVID-19 patients and may explain the decreased risk of severity and mortality observed in our patients who were vitamin D sufficient.",
      "The severity of clinical outcomes from COVID-19 and mortality were reduced in patients who were vitamin D sufficient.",
      "Conclusion: Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.",
      "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests the opposite of the claim. Vitamin D sufficiency is associated with a decreased risk of severity and mortality in COVID-19 patients, not an increased risk as the claim suggests.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.2837294638156891,
    "x2e_entail_prob": 0.00613510562106967
  },
  {
    "id": "covid_fact-000645",
    "statement": "A functional genomics approach to understand host genetic regulation of covid-19 severity",
    "label": "SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a functional genomics approach was used to understand host genetic regulation of COVID-19 severity. It identifies key genetic patterns affecting susceptibility and provides insights into genetic factors that might influence severe COVID-19 outcomes, thus supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8222554326057434,
    "x2e_entail_prob": 0.018319422379136086
  },
  {
    "id": "covid_fact-000646",
    "statement": "A functional genomics approach to understand early genetic regulation of covid-19 severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a functional genomics investigation that characterizes individuals with high genetic risk for severe COVID-19, indicating that genomics approaches are indeed being used to understand genetic regulation related to the severity of COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7225598692893982,
    "x2e_entail_prob": 0.003251828486099839
  },
  {
    "id": "covid_fact-000647",
    "statement": "A functional genomics approach to understand molecular genetic regulation of covid-19 severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A functional genomics investigation based on functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii.",
      "Here, we employed the detailed clinical, immunological and multi-omics data of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19.",
      "Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes a study utilizing functional genomics to understand the molecular genetic regulation of COVID-19 severity. It specifically addresses the genetic determinants and pathways influencing susceptibility to severe COVID-19, thereby supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8173760771751404,
    "x2e_entail_prob": 0.0038537837099283934
  },
  {
    "id": "covid_fact-000648",
    "statement": "Repeated cross-sectional sero-monitoring of sars-cov-2 in new york city",
    "label": "SUPPORTED",
    "evidences": [
      "A serological assay to detect SARS-CoV-2 seroconversion in humans."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only describes a serological assay for detecting SARS-CoV-2 seroconversion in humans and does not mention any form of repeated cross-sectional sero-monitoring in New York City. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.5,
    "e2x_entail_prob": 0.006301440764218569,
    "x2e_entail_prob": 0.9837926626205444
  },
  {
    "id": "covid_fact-000649",
    "statement": "One cross-sectional sero-monitoring of sars-cov-2 in new york city",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "A serological assay to detect SARS-CoV-2 seroconversion in humans."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions a serological assay to detect SARS-CoV-2 seroconversion in humans and does not provide specific information about a cross-sectional sero-monitoring study conducted in New York City. The claim refers to a specific type of study, which is not supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.12650881707668304,
    "x2e_entail_prob": 0.9443628191947937
  },
  {
    "id": "covid_fact-000650",
    "statement": "Patients in secret trials are successfully treated with hiv and malaria medication",
    "label": "SUPPORTED",
    "evidences": [
      "They were given HIV medication Kaletra and malaria treatment hydroxychloroquine in a secret trial.",
      "In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine.",
      "The response involved testing a litany of drugs, including a combination of ritonavir and lopinavir, antiretroviral medications used to fight HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence confirms that patients were given HIV medication (Kaletra) and malaria treatment (hydroxychloroquine) in secret trials, but it does not confirm that these patients were successfully treated. To support the claim fully, there must be evidence demonstrating successful treatment outcomes, which is currently lacking.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.03923732042312622,
    "x2e_entail_prob": 0.9251648187637329
  },
  {
    "id": "covid_fact-000651",
    "statement": "Patients in secret trials are not treated with hiv and malaria medication",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "They were given HIV medication Kaletra and malaria treatment hydroxychloroquine in a secret trial.",
      "In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine.",
      "The response involved testing a litany of drugs, including a combination of ritonavir and lopinavir, antiretroviral medications used to fight HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that the patients were given HIV medication (Kaletra, which contains ritonavir and lopinavir) and malaria treatment (hydroxychloroquine) in a secret trial. This directly contradicts the claim that they were not treated with such medications.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.03356705233454704,
    "x2e_entail_prob": 0.9736904501914978
  },
  {
    "id": "covid_fact-000652",
    "statement": "Strong link found between abnormal liver tests and poor covid-19 outcomes",
    "label": "SUPPORTED",
    "evidences": [
      "Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely a bystander affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson said.",
      "But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, a strong association was observed between abnormal liver tests and the severity of the COVID-19 cases, the researchers said.",
      "The study noted a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.",
      "We observed a strong association between the use of COVID-19 medications and abnormal liver tests, said Lim, but added that they could not confidently tease out that the abnormal tests were due to drug-induced liver injury as opposed to the disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates a strong association between abnormal liver tests and the severity of COVID-19 cases. Although the liver issues may be considered a bystander effect, the correlation between abnormal liver tests and poor COVID-19 outcomes is consistently noted in the study. This supports the claim, albeit with some nuances regarding the cause of liver issues.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9260983467102051,
    "x2e_entail_prob": 0.0065979422070086
  },
  {
    "id": "covid_fact-000653",
    "statement": "Strong link found between abnormal liver tests and normal covid-19 outcomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely a bystander affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson said.",
      "But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, a strong association was observed between abnormal liver tests and the severity of the COVID-19 cases, the researchers said.",
      "The study noted a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.",
      "We observed a strong association between the use of COVID-19 medications and abnormal liver tests, said Lim, but added that they could not confidently tease out that the abnormal tests were due to drug-induced liver injury as opposed to the disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates a strong association between abnormal liver tests and the severity of COVID-19 cases, particularly when drugs like tocilizumab are used. It does not support the claim of a link between abnormal liver tests and normal COVID-19 outcomes. This suggests the claim is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7720058560371399,
    "x2e_entail_prob": 0.009213472716510296
  },
  {
    "id": "covid_fact-000654",
    "statement": "The sars-cov-2 cytopathic effect is blocked with autophagy modulators",
    "label": "SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the cytopathic effects of SARS-CoV-2 can be blocked using autophagy modulators, specifically mentioning selective autophagy inhibitors like chloroquine and hydroxychloroquine. These inhibitors have been shown to inhibit autophagy as well as block the cytopathic effects in various tests, supporting the claim. However, some limitations due to toxicities and complexities in mechanisms are noted in the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8454081416130066,
    "x2e_entail_prob": 0.2780175805091858
  },
  {
    "id": "covid_fact-000655",
    "statement": "The sars-cov-2 cytopathic effect is compatible with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that SARS-CoV-2 cytopathic effects can be influenced by autophagy modulators, such as chloroquine and hydroxychloroquine, which inhibit autophagy. This compatibility is indicated by the correlation between autophagy inhibition and the SARS-CoV-2 cytopathic effect assay results.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9708957076072693,
    "x2e_entail_prob": 0.30046921968460083
  },
  {
    "id": "covid_fact-000656",
    "statement": "The sars-cov-2 cytopathic effect is achieved with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that selective autophagy inhibitors like chloroquine and hydroxychloroquine have been shown to block SARS-CoV-2 cytopathic effects, implying a connection to autophagy modulation. However, the evidence does not directly state that the cytopathic effect is achieved solely through autophagy modulators, as there are concerns about potential mechanisms and toxicities. Thus, the claim is tentatively supported, but with some caution.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.20217007398605347,
    "x2e_entail_prob": 0.29014068841934204
  },
  {
    "id": "covid_fact-000657",
    "statement": "The sars-cov-2 cytopathic effect is induced with autophagy modulators",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.",
      "While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19, have multiple cellular effects including inhibiting autophagy, there are also dose- limiting toxicities in patients that make clearly establishing their potential mechanisms-of-action problematic.",
      "Immunofluorescence staining for LC3B and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that SARS-CoV-2 cytopathic effects can be blocked by selective autophagy inhibitors, which implies that the cytopathic effect is influenced by autophagy. It specifically mentions the clinical benefits of chloroquine and hydroxychloroquine, which are known to inhibit autophagy, thus supporting the claim that SARS-CoV-2 cytopathic effect is related to autophagy modulation.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9567381143569946,
    "x2e_entail_prob": 0.45553821325302124
  },
  {
    "id": "covid_fact-000658",
    "statement": "Regn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence only mentions a DNA vaccine for SARS-CoV-2 in rhesus macaques and does not provide any information regarding REGN-COV2 antibodies or their effects in preventing or treating SARS-CoV-2 infection in rhesus macaques and hamsters. Thus, the claim is not supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.012141465209424496,
    "x2e_entail_prob": 0.09089453518390656
  },
  {
    "id": "covid_fact-000659",
    "statement": "Pn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided specifically mentions a DNA vaccine used for protection against SARS-CoV-2 in rhesus macaques but does not provide information about Pn-cov2 antibodies or their efficacy in preventing or treating SARS-CoV-2 in rhesus macaques or hamsters. Therefore, the claim is not supported by this particular evidence.",
    "confidence": 0.5,
    "e2x_entail_prob": 0.0055565740913152695,
    "x2e_entail_prob": 0.05276466906070709
  },
  {
    "id": "covid_fact-000660",
    "statement": "Bn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions DNA vaccine protection against SARS-CoV-2 in rhesus macaques but does not reference bn-cov2 antibodies or their specific effects on rhesus macaques and hamsters. Therefore, the claim about bn-cov2 antibodies preventing and treating SARS-CoV-2 infection in these animals is not supported by the evidence provided.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.020128246396780014,
    "x2e_entail_prob": 0.0962463766336441
  },
  {
    "id": "covid_fact-000661",
    "statement": "Hn-cov2 antibodies prevent and treat sars-cov-2 infection in rhesus macaques and hamsters",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "D. H. Barouch , DNA vaccine protection against SARS-CoV-2 in rhesus macaques."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is about a DNA vaccine protecting against SARS-CoV-2 in rhesus macaques. It does not mention Hn-cov2 antibodies or their effect on rhesus macaques and hamsters in preventing or treating SARS-CoV-2 infection. Therefore, the specific claim about Hn-cov2 antibodies cannot be evaluated based solely on this evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.014350746758282185,
    "x2e_entail_prob": 0.05344286561012268
  },
  {
    "id": "covid_fact-000662",
    "statement": "Sars-cov-2 genome evolution exposes early human adaptations",
    "label": "SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that the SARS-CoV-2 genome shows signs of evolution that indicate early adaptations to humans. The evidence mentions a study specifically designed to seek signals of evolution in the SARS-CoV-2 genome, suggesting that such adaptations may have been identified, thus supporting the claim. However, without more specific details from the study findings, the support is inferred rather than explicitly confirmed.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6156429052352905,
    "x2e_entail_prob": 0.17686530947685242
  },
  {
    "id": "covid_fact-000663",
    "statement": "Sars-cov-2 genome evolution exposes early human infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the evolution of the SARS-CoV-2 genome exposes early human infection. However, the evidence only indicates that the study sought signals of evolution to identify how the SARS-CoV-2 genome adapted early in the pandemic. There is no direct evidence provided here that links genome evolution specifically to exposing early human infection.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.03052990697324276,
    "x2e_entail_prob": 0.8262279629707336
  },
  {
    "id": "covid_fact-000664",
    "statement": "Sars-cov-2 genome evolution exposes early human infections",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates a study focused on identifying signals of evolution in the SARS-CoV-2 genome at the beginning of the COVID-19 pandemic. However, it does not explicitly state that these signals expose early human infections. Therefore, the claim is not directly supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.013765906915068626,
    "x2e_entail_prob": 0.5112411379814148
  },
  {
    "id": "covid_fact-000665",
    "statement": "Sars-cov-2 genome evolution exposes early genes adaptations",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "SUMMARY In this study we sought signals of evolution to identify how the SARS-CoV-2 genome has adapted at the outset of the COVID-19 pandemic."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is insufficient to support the claim. The claim discusses specific early gene adaptations in SARS-CoV-2 genome evolution, but the evidence only mentions a study seeking signals of evolution in the SARS-CoV-2 genome after the onset of the pandemic without providing details on early gene adaptations.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.008285106159746647,
    "x2e_entail_prob": 0.19826503098011017
  },
  {
    "id": "covid_fact-000666",
    "statement": "Research by tennessee scientists at oak ridge labs on existing drug compounds via supercomputing could combat coronavirus .",
    "label": "SUPPORTED",
    "evidences": [
      "Oak Ridge National Laboratory scientists have focused the power of the world's fastest supercomputer to search for an existing drug that can prevent the new coronavirus from penetrating human cells.",
      "The Oak Ridge National Laboratory in Tennessee (one member of the consortium) is using its supercomputers to look for compounds already on the market that might foil the virus.",
      "Oak Ridge National Laboratory, where Summit is housed, recently granted researchers emergency computation time to run through a database of existing drug compounds to see which combinations might prevent cell infection of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Evidence confirms that Tennessee scientists at Oak Ridge National Laboratory are using supercomputing to research existing drug compounds to combat COVID-19. This supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3425310254096985,
    "x2e_entail_prob": 0.023391373455524445
  },
  {
    "id": "covid_fact-000667",
    "statement": "Research by chinese scientists at oak ridge labs on existing drug compounds via supercomputing could combat coronavirus.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Oak Ridge National Laboratory scientists have focused the power of the world's fastest supercomputer to search for an existing drug that can prevent the new coronavirus from penetrating human cells.",
      "The Oak Ridge National Laboratory in Tennessee (one member of the consortium) is using its supercomputers to look for compounds already on the market that might foil the virus.",
      "Oak Ridge National Laboratory, where Summit is housed, recently granted researchers emergency computation time to run through a database of existing drug compounds to see which combinations might prevent cell infection of COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Oak Ridge National Laboratory scientists used supercomputing resources to screen existing drug compounds to find potential treatments for COVID-19. While the involvement of Chinese scientists is not directly mentioned, the primary focus of the claim\u2014that existing drug compounds are being examined via supercomputing at Oak Ridge to combat coronavirus\u2014is supported.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.023768115788698196,
    "x2e_entail_prob": 0.003928019665181637
  },
  {
    "id": "covid_fact-000668",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of ace2 in vertebrates",
    "label": "SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a broad range of mammals can potentially be infected by SARS-CoV-2 through their ACE2 proteins. Furthermore, the comparative and structural analysis of ACE2 in vertebrates is used to make predictions about the ability of these proteins to bind with SARS-CoV-2, supporting the claim of a broad host range predicted by such analysis.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8801920413970947,
    "x2e_entail_prob": 0.6453981995582581
  },
  {
    "id": "covid_fact-000669",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of fpr2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the analysis of ACE2 proteins across various mammals to predict potential SARS-CoV-2 infection, not FPR2. The claim refers to FPR2, which is different from ACE2. Thus, the claim is not supported by the evidence given.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.01903664506971836,
    "x2e_entail_prob": 0.05899384245276451
  },
  {
    "id": "covid_fact-000670",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of tmprss2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that a broad host range of SARS-CoV-2 was predicted through the analysis of TMPRSS2 in vertebrates. However, the provided evidence focuses on the analysis of ACE2, not TMPRSS2. ACE2 is the receptor involved in the entry of SARS-CoV-2 into host cells. The evidence identifies mammals potentially susceptible to SARS-CoV-2 due to ACE2, but does not address TMPRSS2, thus not supporting the specific claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.02680298127233982,
    "x2e_entail_prob": 0.20109158754348755
  },
  {
    "id": "covid_fact-000671",
    "statement": "Broad host range of sars-cov-2 predicted by comparative and structural analysis of ns2 in vertebrates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins.",
      "To identify candidate intermediate host species and species at risk for SARS-CoV-2 infection, we undertook a deep comparative genomic, evolutionary, and structural analysis of ACE2, which serves as the SARS-CoV-2 receptor in humans.",
      "Comparative analysis of ACE2 protein sequences can be used to predict their ability to bind SARS-CoV-2 S (2) and therefore may yield important insights into the biology and potential zoonotic transmission of SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the broad host range of SARS-CoV-2 is predicted by the analysis of ns2. However, the evidence provided focuses on ACE2, the receptor through which SARS-CoV-2 enters cells, rather than ns2. As the evidence does not mention ns2, it does not support the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.006364247761666775,
    "x2e_entail_prob": 0.026583777740597725
  },
  {
    "id": "covid_fact-000672",
    "statement": "Man behind sweden 's controversial virus strategy admits mistakes",
    "label": "SUPPORTED",
    "evidences": [
      "Wednesday 3 June 2020 17:07, UK COVID-19 Coronavirus Image: People walk down a high street in Stockholm in May image/svg+xml Why you can trust Sky News Sweden should have done more to combat coronavirus to prevent it having a much higher national death rate than neighbouring countries, the man behind the country's pandemic strategy has said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the individual responsible for Sweden's coronavirus strategy acknowledged that Sweden should have taken more action during the pandemic to limit deaths compared to neighboring countries. This supports the claim of admitting mistakes in the strategy.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.42291077971458435,
    "x2e_entail_prob": 0.19635765254497528
  },
  {
    "id": "covid_fact-000673",
    "statement": "Not behind sweden's controversial virus strategy admits mistakes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Wednesday 3 June 2020 17:07, UK COVID-19 Coronavirus Image: People walk down a high street in Stockholm in May image/svg+xml Why you can trust Sky News Sweden should have done more to combat coronavirus to prevent it having a much higher national death rate than neighbouring countries, the man behind the country's pandemic strategy has said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the man behind Sweden's pandemic strategy admitted that Sweden should have done more to combat coronavirus. This admission implies acknowledging mistakes in the strategy, supporting the claim that someone involved in Sweden's strategy admits to such mistakes.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7418635487556458,
    "x2e_entail_prob": 0.061479777097702026
  },
  {
    "id": "covid_fact-000674",
    "statement": "Wearing eyeglasses protects against sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing eyeglasses may reduce the chance of viral entry through the eyes and decrease hand-to-eye transmission of SARS-CoV-2. This implies a protective effect, although it only indicates a likelihood rather than certainty.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.513346254825592,
    "x2e_entail_prob": 0.5696114897727966
  },
  {
    "id": "covid_fact-000675",
    "statement": "Wearing eyeglasses protects by sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing eyeglasses may have a protective effect against SARS-CoV-2 by decreasing viral entry through the eyes and reducing hand-to-eye transmission. However, while these points indicate a potential protective effect, they don't provide direct evidence of protection, which is reflected in a less than full confidence score.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.044702425599098206,
    "x2e_entail_prob": 0.973355770111084
  },
  {
    "id": "covid_fact-000676",
    "statement": "Wearing eyeglasses exposed against sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Therefore, it is likely that wearing eyeglasses may have a protective effect by reducing the chance of viral entry through the eyes.",
      "Wearing eyeglasses prevent people from frequently touching their eyes, thereby reducing the chance of hand-to-eye transmission of SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that wearing eyeglasses can have a protective effect against SARS-CoV-2 by reducing viral entry through the eyes and discouraging hand-to-eye transmission. Therefore, the claim is supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8966166973114014,
    "x2e_entail_prob": 0.9797545075416565
  },
  {
    "id": "covid_fact-000677",
    "statement": "Butantan vaccine reaches the final stage",
    "label": "SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the clinical trial of CoronaVac, developed by Butantan Institute in partnership with Sinovac, has reached its final stage. This supports the claim that the Butantan vaccine has reached the final stage.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8748607039451599,
    "x2e_entail_prob": 0.42322784662246704
  },
  {
    "id": "covid_fact-000678",
    "statement": "Butantan vaccine reaches the first stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that the Butantan Institute's vaccine, CoronaVac, has reached its final stage of clinical trials. This contradicts the claim that it has reached the first stage.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.19395777583122253,
    "x2e_entail_prob": 0.15156784653663635
  },
  {
    "id": "covid_fact-000679",
    "statement": "Butantan vaccine reaches the challenge stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the Butantan vaccine, CoronaVac, has reached its final stage of clinical trials, not specifically 'the challenge stage.' The term 'challenge stage' is not validated in the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7989103198051453,
    "x2e_entail_prob": 0.1964380443096161
  },
  {
    "id": "covid_fact-000680",
    "statement": "Butantan vaccine reaches the second stage",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By Dorah Feliciano \\- November 24, 2020 Facebook Twitter Linkedin WhatsApp Email [uamad id=\"317182\"] RIO DE JANEIRO, BRAZIL - The clinical trial of CoronaVac, the vaccine developed by the Butantan Institute in partnership with biopharmaceutical company Sinovac Life Science, has reached its final stage.",
      "According to information from the S\u00e3o Paulo government and Butantan Institute, results should come out in the first week of December, with 46 million doses likely to be available by January 2021."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the Butantan vaccine, CoronaVac, has reached its final stage, not the second stage. Therefore, the claim about the vaccine being in the second stage is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6426016092300415,
    "x2e_entail_prob": 0.1791866272687912
  },
  {
    "id": "covid_fact-000681",
    "statement": "Adaptive immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "label": "SUPPORTED",
    "evidences": [
      "Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients.",
      "1 Characterization of T- and B-cell immune repertoires in COVID-19 convalescent patients.",
      "Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.",
      "Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.",
      "Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates the presence of SARS-CoV-2-specific T-cell and B-cell immune memory in COVID-19 convalescent patients, suggesting they retain adaptive immune responses post-recovery. References to specific humoral and cellular immunity, as well as memory T-cell immunity, support the claim of adaptive immune responses in recovered severe COVID-19 patients.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8489596843719482,
    "x2e_entail_prob": 0.25704139471054077
  },
  {
    "id": "covid_fact-000682",
    "statement": "No immune responses to sars-cov-2 in recovered severe covid-19 patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients.",
      "1 Characterization of T- and B-cell immune repertoires in COVID-19 convalescent patients.",
      "Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.",
      "Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.",
      "Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows the presence of SARS-CoV-2-specific T-cell immune memory and other immune responses in recovered COVID-19 patients. This contradicts the claim that there are no immune responses in recovered severe COVID-19 patients.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.002229812555015087,
    "x2e_entail_prob": 0.4872431755065918
  },
  {
    "id": "covid_fact-000683",
    "statement": "Estimated sars-cov-2 seroprevalence in the us",
    "label": "SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not give specific information regarding the estimated seroprevalence of SARS-CoV-2 in the U.S. as a whole. Instead, it only mentions a community prevalence study at a single medical center in Los Angeles in March 2020, which does not represent the broader US population.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.04340400919318199,
    "x2e_entail_prob": 0.05979573726654053
  },
  {
    "id": "covid_fact-000684",
    "statement": "Estimated pcvs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only refers to the community prevalence of SARS-CoV-2 in a specific medical center in Los Angeles during March 2020. It does not provide information about the estimated seroprevalence of PCVs-CoV-2 across the entire US. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.016864333301782608,
    "x2e_entail_prob": 0.012531982734799385
  },
  {
    "id": "covid_fact-000685",
    "statement": "Estimated cpvs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is specific to a single location (a Los Angeles medical center) and a specific time frame (March 2020) and does not give an overall estimate of SARS-CoV-2 seroprevalence across the entire United States. Therefore, the evidence does not support the claim related to US-wide seroprevalence.",
    "confidence": 0.4,
    "e2x_entail_prob": 0.21858961880207062,
    "x2e_entail_prob": 0.3534891605377197
  },
  {
    "id": "covid_fact-000686",
    "statement": "Estimated xs-cov-2 seroprevalence in the us",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles medical center in March 2020."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided is specific to community prevalence at a medical center in Los Angeles and in March 2020. It does not provide any information about the estimated SARS-CoV-2 seroprevalence for the entire US population, which the claim refers to.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.050845157355070114,
    "x2e_entail_prob": 0.011457255110144615
  },
  {
    "id": "covid_fact-000687",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination reduces shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the intranasal vaccination of rhesus macaques with ChAdOx1 nCoV-19 resulted in reduced shedding of SARS-CoV-2 with the D614G mutation. This aligns with the claim, supporting the idea that intranasal vaccination with the specified vaccine reduces viral shedding in the animals studied.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8385879397392273,
    "x2e_entail_prob": 0.0038561190012842417
  },
  {
    "id": "covid_fact-000688",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination increased shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that intranasal vaccination reduced shedding of SARS-CoV-2 in rhesus macaques, contrary to the claim that it increased shedding. Thus, the claim is not supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.718862771987915,
    "x2e_entail_prob": 0.013791020959615707
  },
  {
    "id": "covid_fact-000689",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination enhanced shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that intranasal ChAdOx1 nCoV-19 vaccination reduced viral shedding, contrary to the claim of enhanced shedding in rhesus macaques. Hence, the claim is not supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.11241274327039719,
    "x2e_entail_prob": 0.018442418426275253
  },
  {
    "id": "covid_fact-000690",
    "statement": "Intranasal chadox1 ncov-19/azd1222 vaccination caused shedding of sars-cov-2 d614g in rhesus macaques.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Intranasal vaccination of rhesus macaques resulted in reduced shedding and a reduction in viral load in bronchoalveolar lavage and lower respiratory tract tissue.",
      "Here we investigate whether intranasally administered ChAdOx1 nCoV-19 reduces shedding, using a SARS-CoV-2 virus with the D614G mutation in the spike protein.",
      "In conclusion, intranasal vaccination reduced shedding in two different SARS-CoV-2 animal models, justifying further investigation as a potential vaccination route for COVID-19 vaccines."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the intranasal vaccination caused shedding of SARS-CoV-2 D614G in rhesus macaques. However, the evidence indicates that the vaccination resulted in reduced shedding, not an increase or presence of it. Thus, the claim is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.011020176112651825,
    "x2e_entail_prob": 0.009139107540249825
  },
  {
    "id": "covid_fact-000691",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-free sars-cov-2 rt-qpcr",
    "label": "SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR is supported by the evidence presented. The evidence mentions that extraction-free method increases capacity for national testing programs during a pandemic, implying feasibility on a large scale.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5552067756652832,
    "x2e_entail_prob": 0.9382103085517883
  },
  {
    "id": "covid_fact-000692",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-specific sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that extraction-free SARS-CoV-2 RT-PCR testing is feasible for massive and rapid COVID-19 testing. The specific term 'extraction-specific' does not appear in the evidence, but 'extraction-free' is highlighted, suggesting feasibility in increasing testing capacity during a pandemic. Thus, the claim is likely a variation of extraction-free, supporting the notion of its feasibility for massive testing.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.860082745552063,
    "x2e_entail_prob": 0.7605044841766357
  },
  {
    "id": "covid_fact-000693",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-based sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim is about extraction-based RT-qPCR, but the evidence provided pertains to extraction-free RT-PCR. Therefore, the evidence does not support the specific claim about extraction-based RT-qPCR.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.01562577858567238,
    "x2e_entail_prob": 0.018598876893520355
  },
  {
    "id": "covid_fact-000694",
    "statement": "Massive and rapid covid-19 testing is feasible by extraction-2 sars-cov-2 rt-qpcr",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic.",
      "Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided states that massive and rapid COVID-19 testing is feasible through extraction-free SARS-CoV-2 RT-PCR. While the claim mentions extraction-2, it likely refers to the extraction-free method described, which aligns with the context of increased testing capacity. Hence, the claim is supported by the evidence given.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9498499035835266,
    "x2e_entail_prob": 0.049816202372312546
  },
  {
    "id": "covid_fact-000695",
    "statement": "Dutch scientists find new role for ace2 receptors in covid disease process",
    "label": "SUPPORTED",
    "evidences": [
      "(21,22) The protease TMPRSS2 produced by the host cells plays an important role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses the role of the protease TMPRSS2 in the priming of the spike protein to the ACE2 receptor. However, it does not mention any new role for ACE2 receptors discovered by Dutch scientists in the COVID disease process. The claim is not directly supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.005228301975876093,
    "x2e_entail_prob": 0.07082561403512955
  },
  {
    "id": "covid_fact-000696",
    "statement": "Dutch models find new role for ace2 receptors in covid disease process",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(21,22) The protease TMPRSS2 produced by the host cells plays an important role in proteolytic processing of S protein priming to the receptor ACE2 binding in human cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the role of TMPRSS2 and ACE2 in the binding process with S protein but does not mention Dutch models or a new role for ACE2 receptors in the COVID-19 disease process. Therefore, the claim is not directly supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0033236027229577303,
    "x2e_entail_prob": 0.08280090987682343
  },
  {
    "id": "covid_fact-000697",
    "statement": "Ohio health official estimates 100,000 people in state have coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that an Ohio health official, specifically Dr. Acton, stated that at least 1 percent of the population of Ohio is estimated to have the virus. Given Ohio's population is approximately 11 million, 1 percent would indeed correspond to around 100,000 people. Thus, the claim is supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1374245136976242,
    "x2e_entail_prob": 0.1769103854894638
  },
  {
    "id": "covid_fact-000698",
    "statement": "Ohio health official estimates 1,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that a health official in Ohio estimated that at least 1 percent of the state's population has the coronavirus. Given Ohio's population, this would translate to around 100,000 individuals or more, which indeed supports the claim that an estimated 1,000 people have the virus. Thus, the claim is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.744017481803894,
    "x2e_entail_prob": 0.22404831647872925
  },
  {
    "id": "covid_fact-000699",
    "statement": "Ohio health official estimates 2,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states an estimate by an Ohio health official regarding the number of people in Ohio who have coronavirus. The evidence shows that Acton, presumably a health official, estimated that at least 1% of the state's population might be carrying the virus. Given Ohio's approximate population size, 1% would indeed translate to roughly 2,000 people, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01188853569328785,
    "x2e_entail_prob": 0.12876376509666443
  },
  {
    "id": "covid_fact-000700",
    "statement": "Ohio health official estimates 15,000 people in state have coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Mike DeWineMike DeWineRepublicans eye primaries in impeachment vote Shellshocked GOP ponders future with Trump Governors respond to violence at Capitol MORE (R) that given that the virus is spreading in the community in Ohio, she estimates at least 1 percent of the population in the state has the virus.",
      "\"We know now, just the fact of community spread, says that at least 1 percent, at the very least, 1 percent of our population is carrying this virus in Ohio today,\" Acton said."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that an Ohio health official estimated 15,000 people in the state have coronavirus. The evidence provides a statement from a health official estimating that at least 1% of Ohio's population has the virus. Given Ohio's population of approximately 11.7 million, 1% would indeed be around 117,000 people. Although the specific number of 15,000 is not directly mentioned, the evidence supports the idea that a significant number of people in Ohio have the virus; however, the specific figure may be a conservative estimate. Therefore, the claim is supported by the evidence provided, as it aligns with the health official's statement.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.04537631571292877,
    "x2e_entail_prob": 0.046022020280361176
  },
  {
    "id": "covid_fact-000701",
    "statement": "Google releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that Google published COVID-19 Community Mobility Reports to show how community mobility changed in response to the pandemic, in various categories like retail, parks, and workplaces. The reports were released to help public health officials, aligning with the claim's purpose of showing local movement trends during the pandemic.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3952158987522125,
    "x2e_entail_prob": 0.006793463137000799
  },
  {
    "id": "covid_fact-000702",
    "statement": "Who releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Google is responsible for publishing the COVID-19 Community Mobility Reports, which analyze how community mobility has changed. The claim that these reports are released to show local movement trends during the pandemic is therefore supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0042678918689489365,
    "x2e_entail_prob": 0.003572377609089017
  },
  {
    "id": "covid_fact-000703",
    "statement": "China releases covid-19 community mobility reports in an effort to show local movement trends during pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The reports consist of per country, or per state, downloads (with 131 countries covered initially), further broken down into regions/counties -- with Google offering an analysis of how community mobility has changed vs a baseline average before COVID-19 arrived to change everything.",
      "In response to feedback from public health officials that data could be helpful for making critical decisions to combat COVID-19, Google has published an early release of COVID-19 Community Mobility Reports.",
      "The COVID-19 Community Mobility Reports web site will show population data trends of six categories: Retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses Google's release of COVID-19 Community Mobility Reports and their utility for public health officials but does not mention China specifically releasing these reports. Therefore, the claim that China releases COVID-19 community mobility reports is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.05128328129649162,
    "x2e_entail_prob": 0.003657660447061062
  },
  {
    "id": "covid_fact-000704",
    "statement": "Exhaled aerosol increases with covid-19 infection , and risk factors of disease symptom severity",
    "label": "SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that exhaled aerosol particles significantly increase with COVID-19 infection, supporting the claim. Additionally, the study mentions that risk factors such as aging and high BMI are associated with increases in exhaled aerosol, which directly addresses the disease symptom severity aspect of the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.004972265567630529,
    "x2e_entail_prob": 0.04748864099383354
  },
  {
    "id": "covid_fact-000705",
    "statement": "Acute aerosol increases with covid-19 infection, and risk factors of disease symptom severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that in both human and nonhuman primate subjects, exhaled aerosol particles increase with COVID-19 infection along with other factors like aging and high BMI. This supports the claim that acute aerosol increases with COVID-19 infection and with risk factors influencing disease symptom severity.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.06772894412279129,
    "x2e_entail_prob": 0.007712115533649921
  },
  {
    "id": "covid_fact-000706",
    "statement": "Chronic aerosol increases with covid-19 infection, and risk factors of disease symptom severity",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In our observational cohort study of the exhaled breath particles of 74 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected by aerosol with SARS- CoV-2, we found that exhaled aerosol particles increase one to three orders of magnitude with aging, high BMI, and COVID-19 infection.",
      "We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS- CoV-2 infection, and other changes in physiological state, translates into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that exhaled aerosol particles increase significantly with COVID-19 infection, aligning with the claim that chronic aerosol levels rise with infection. The study shows this increase across different conditions, including factors like aging and high BMI, which are risk factors for severe symptoms, supporting the claim comprehensively.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.054085299372673035,
    "x2e_entail_prob": 0.017336349934339523
  },
  {
    "id": "covid_fact-000707",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year , ignoring pandemic warning signs",
    "label": "SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence from The Washington Post and News & Guts, indicating that U.S. manufacturers shipped millions of dollars' worth of face masks to China during January and February, even as pandemic warning signs were present. The shipping was reportedly encouraged by the federal government, despite the growing awareness of the pandemic threat.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5411540269851685,
    "x2e_entail_prob": 0.003928768448531628
  },
  {
    "id": "covid_fact-000708",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, for pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from the Washington Post confirms that U.S. manufacturers indeed shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February. This action occurred despite the warning signs of the pandemic, as noted in the claim. The claim aligns with the reported economic data and government documents cited.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7028159499168396,
    "x2e_entail_prob": 0.003146656323224306
  },
  {
    "id": "covid_fact-000709",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, following pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that U.S. manufacturers sent millions of dollars worth of face masks to China early in the year, specifically in January and February, following pandemic warning signs. The evidence also indicates that the shipments were encouraged by the federal government, and highlights a substantial export of face masks and protective equipment during this period.",
    "confidence": 1,
    "e2x_entail_prob": 0.5795108079910278,
    "x2e_entail_prob": 0.0031928743701428175
  },
  {
    "id": "covid_fact-000710",
    "statement": "U.s. manufacturers sent millions of dollars of face masks to china early this year, under pandemic warning signs",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Still, Doggett was incredulous that masks desperately sought today by U.S. medical providers were provided to China by U.S. companies in large numbers through February.",
      "Washington Post: U.S. sent millions of face masks to China early this year, ignoring pandemic warning signs \"U.S. manufacturers shipped millions of dollars' worth of face masks and other protective medical equipment to China in January and February with encouragement from the federal government, a Washington Post review of economic data and internal government documents has found.",
      "Today, Chinas imports of masks and other PPE from around the world is seen by some White House officials as part of a deliberate attempt by China to corner the market as it concealed and downplayed the danger posed by the outbreak.",
      "AD While China was silent on the seriousness of the crisis, they were quietly buying up a large portion of the worlds global supply for masks and other PPE, Navarro said.",
      "Sent Millions Of Masks To China, Ignoring Warning Signs Of Pandemic By News & Guts Still life of a face mask and blue protective gloves on turquoise background Share on Facebook Share on Twitter Share on Email Manufacturers in the U.S. shipped millions of dollars worth of face masks and other equipment to China in January and February, according to an investigation by The Washington Post."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence from multiple sources, including the Washington Post, confirms that U.S. manufacturers sent millions of dollars worth of face masks to China in January and February. This was done with encouragement from the federal government, during a time when there were pandemic warning signs. Thus, the claim is well-supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.39613932371139526,
    "x2e_entail_prob": 0.0024690425489097834
  },
  {
    "id": "covid_fact-000711",
    "statement": "Fox news falls out of love with hydroxychloroquine",
    "label": "SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that Fox News has fallen out of love with hydroxychloroquine, directly supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.008324924856424332,
    "x2e_entail_prob": 0.9905802607536316
  },
  {
    "id": "covid_fact-000712",
    "statement": "Fox news falls out of patients with hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim's main idea, that Fox News has distanced itself from hydroxychloroquine, is matched by the phrasing 'fallen out of love,' which suggests a change in opinion or stance. The evidence directly supports this interpretation.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.04597822576761246,
    "x2e_entail_prob": 0.8580251336097717
  },
  {
    "id": "covid_fact-000713",
    "statement": "Fox news falls out of contacts with hydroxychloroquine",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Fox News has fallen out of love with hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Fox News has 'fallen out of love' with hydroxychloroquine, which aligns with the claim that they have fallen 'out of contacts' with it. Although the phrasing is slightly different, the meaning seems to be consistent, indicating a shift in stance or interest from Fox News regarding hydroxychloroquine.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0859728679060936,
    "x2e_entail_prob": 0.9914079308509827
  },
  {
    "id": "covid_fact-000714",
    "statement": "Autopsies show varied forms of heart damage in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that COVID-19 patients showed signs of heart damage, such as elevated troponin levels, which is a marker of muscle damage, including the heart. Additionally, macrophage inflammation in heart tissue was observed in a significant number of patients. This supports the claim that autopsies reveal varied forms of heart damage in COVID-19 patients.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0798509493470192,
    "x2e_entail_prob": 0.0018757905345410109
  },
  {
    "id": "covid_fact-000715",
    "statement": "Autopsies show common forms of heart damage in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a notable percentage of COVID-19 patients experience heart damage, as shown by elevated troponin levels and inflammation. Autopsies showed that 18 out of 21 COVID-19 patients had heart inflammation, suggesting a common occurrence. This supports the claim that common forms of heart damage occur in COVID-19 patients.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.41819918155670166,
    "x2e_entail_prob": 0.002501343609765172
  },
  {
    "id": "covid_fact-000716",
    "statement": "Autopsies show typical forms of heart damage in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Researchers had found, for example, that 8-12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction-regulating proteins called troponins--a sign of heart damage--and that these patients had an increased risk of mortality compared with those who didn't have excess troponins.",
      "Early in the pandemic, other clinicians noted that even some patients who didn't have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link.",
      "But Stone says he was surprised to see just how common these were--18 out of 21 COVID-19 patients' hearts harbored macrophages that exhibited this type of inflammation."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by evidence showing that COVID-19 patients often have elevated troponin levels, a marker of heart damage. Moreover, 18 out of 21 COVID-19 patients showed inflammation-related heart damage, indicating that heart damage is a common feature in those with COVID-19.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6014671921730042,
    "x2e_entail_prob": 0.0027906529139727354
  },
  {
    "id": "covid_fact-000717",
    "statement": "Genomic study points to natural origin of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the genomic data of the coronavirus responsible for COVID-19 supports the idea of a natural origin. The spike protein contains unique adaptations and the genomic backbone closely resembles that of a bat coronavirus, suggesting a natural zoonotic source rather than an artificial or engineered origin.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9755364656448364,
    "x2e_entail_prob": 0.7464476823806763
  },
  {
    "id": "covid_fact-000718",
    "statement": "Genomic study points to human origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the spike protein of the coronavirus that causes COVID-19 has unique adaptations, and the genome resembles a bat coronavirus. This supports a natural origin of the virus rather than a human origin. Therefore, the claim is not supported by the presented evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5630008578300476,
    "x2e_entail_prob": 0.23345085978507996
  },
  {
    "id": "covid_fact-000719",
    "statement": "Genomic study points to recent origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes genetic adaptations in the coronavirus and its resemblance to a bat coronavirus, suggesting a natural origin. However, it does not provide specific information about the timeframe of the virus's emergence, which is necessary to support the claim about its 'recent origin.' Thus, the evidence does not directly support the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.12593072652816772,
    "x2e_entail_prob": 0.03036811761558056
  },
  {
    "id": "covid_fact-000720",
    "statement": "Genomic study points to geographic origin of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The genomic data of the new coronavirus responsible for COVID-19 show that its spike protein contains some unique adaptations.",
      "This provides additional evidence that the coronavirus that causes COVID-19 almost certainly originated in nature.",
      "Their analysis showed that the backbone of the new coronaviruss genome most closely resembles that of a bat coronavirus discovered after the COVID-19 pandemic began."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the genomic analysis of the coronavirus and its similarities to a bat coronavirus, implying a natural origin. However, it does not specifically point to a geographic origin of COVID-19, which the claim suggests. Thus, the evidence does not support the specific geographic origin aspect of the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7580182552337646,
    "x2e_entail_prob": 0.00996540766209364
  },
  {
    "id": "covid_fact-000721",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the recovery trial",
    "label": "SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that colchicine is included in the RECOVERY trial with the aim to determine its effectiveness against COVID-19. This supports the claim that colchicine is being investigated as a possible treatment in the trial.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7596440315246582,
    "x2e_entail_prob": 0.21020855009555817
  },
  {
    "id": "covid_fact-000722",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the icu trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that colchicine is included in the RECOVERY trial to establish its effects on COVID-19. This implies that it is being investigated as a possible treatment, which supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.5146688222885132,
    "x2e_entail_prob": 0.11722015589475632
  },
  {
    "id": "covid_fact-000723",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the present trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that colchicine will be included in the RECOVERY trial to determine its effectiveness against COVID-19. The framework of the trial is clearly described, indicating that colchicine is indeed being investigated for this purpose. The evidence directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7349151372909546,
    "x2e_entail_prob": 0.2638764977455139
  },
  {
    "id": "covid_fact-000724",
    "statement": "Colchicine to be investigated as a possible treatment for covid-19 in the patient trial",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "By including colchicine in the RECOVERY trial, we will be able to establish whether it helps tackle the worst consequences of COVID-19. It is anticipated that at least 2500 patients recruited to the RECOVERY trial will be randomly allocated to receive colchicine plus usual standard-of-care, and results will be compared with at least 2500 patients who receive the usual standard-of-care on its own."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that colchicine is being included in the RECOVERY trial to determine its effectiveness as a treatment for COVID-19. This supports the claim that colchicine is being investigated as a possible treatment in a patient trial.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8069106936454773,
    "x2e_entail_prob": 0.19234779477119446
  },
  {
    "id": "covid_fact-000725",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in mice and nonhuman primates",
    "label": "SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions that a specific vaccine induces neutralizing antibodies in nonhuman primates. It does not confirm or deny the induction of T cell responses or the study in mice, which are crucial parts of the claim. Therefore, the claim is not fully supported by the evidence given.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.004981685429811478,
    "x2e_entail_prob": 0.00305185723118484
  },
  {
    "id": "covid_fact-000726",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in humans and nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only mentions the induction of neutralizing antibodies in nonhuman primates, with no mention of human trials or T cell responses. Therefore, the claim about the vaccine's effects in humans and its stimulation of T cell responses lacks sufficient support.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.003219917882233858,
    "x2e_entail_prob": 0.0060262251645326614
  },
  {
    "id": "covid_fact-000727",
    "statement": "An alphavirus-derived replicon rna vaccine induces sars-cov-2 neutralizing antibody and t cell responses in human and nonhuman primates",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest that a 250-\u03bcg prime-only dose or a 50-\u03bcg prime/boost immunization with the LION/repRNA-CoV2S vaccine induced concentrations of neutralizing antibodies that would be sufficient to protect nonhuman primates from infection and disease."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the LION/repRNA-CoV2S vaccine, which likely refers to an alphavirus-derived replicon RNA vaccine, induces neutralizing antibodies in nonhuman primates. While the evidence specifically mentions nonhuman primates, it does not provide direct evidence about humans. However, the implication is that similar immune responses could occur in humans, supporting the claim to some extent.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.08737695217132568,
    "x2e_entail_prob": 0.002693651709705591
  },
  {
    "id": "covid_fact-000728",
    "statement": "Coronavirus antibodies fall dramatically in first 3 months after mild cases of covid-19 according to new ucla study .",
    "label": "SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that a UCLA study found antibodies in people with mild COVID-19 cases drop sharply, decreasing by roughly half every 36 days over the first three months after infection.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.97116619348526,
    "x2e_entail_prob": 0.18449029326438904
  },
  {
    "id": "covid_fact-000729",
    "statement": "Coronavirus antibodies increased dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that antibodies in people with mild COVID-19 cases decrease sharply over the first three months. This directly contradicts the claim that antibodies increased dramatically in the same timeframe.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0012690493604168296,
    "x2e_entail_prob": 0.0015522593166679144
  },
  {
    "id": "covid_fact-000730",
    "statement": "Coronavirus antibodies increase dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that coronavirus antibodies increase dramatically in the first 3 months after mild cases of COVID-19. However, the evidence indicates that antibodies actually decrease sharply over the first three months, dropping by half every 36 days. This directly contradicts the claim, so it is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.03365669772028923,
    "x2e_entail_prob": 0.002919199410825968
  },
  {
    "id": "covid_fact-000731",
    "statement": "Coronavirus antibodies peaked dramatically in first 3 months after mild cases of covid-19 according to new ucla study.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "FINDINGS A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 36 days."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that antibodies decrease sharply over the first three months after mild COVID-19 infection, not that they peak dramatically. The claim is not supported by the evidence as it conveys the opposite of what the study finds.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.03457552194595337,
    "x2e_entail_prob": 0.0019920840859413147
  },
  {
    "id": "covid_fact-000732",
    "statement": "Coronavirus fears have led to a golden age of hand-washing psas",
    "label": "SUPPORTED",
    "evidences": [
      "His Chaplinesque performance infuses high art and physical comedy into the subject of hygiene.",
      "Some are extremely winning, like the hand-washing dance created by Vietnamese choreographer Quang \u0110\u0103ng.",
      "Because the coronavirus is a global concern, video PSAs are emerging from all corners of the globe, all at once."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there has been a surge in hand-washing PSAs globally due to coronavirus concerns. The mention of widespread video PSAs and specific creative efforts like a hand-washing dance by Quang \u0110\u0103ng suggest that there is indeed increased attention to hand-washing campaigns. This supports the notion of a 'golden age' of such PSAs.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9001637697219849,
    "x2e_entail_prob": 0.0018351594917476177
  },
  {
    "id": "covid_fact-000733",
    "statement": "Coronavirus fears have led to a golden loss of hand-washing psas",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "His Chaplinesque performance infuses high art and physical comedy into the subject of hygiene.",
      "Some are extremely winning, like the hand-washing dance created by Vietnamese choreographer Quang \u0110\u0103ng.",
      "Because the coronavirus is a global concern, video PSAs are emerging from all corners of the globe, all at once."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that there is a 'golden loss' of hand-washing PSAs due to coronavirus fears is not supported by the evidence. Instead, the evidence suggests an increase or emergence of PSAs related to hand-washing, as indicated by the global concern and various creative PSAs being made worldwide. Thus, the evidence contradicts the notion of a 'golden loss.'",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9371747374534607,
    "x2e_entail_prob": 0.005002701189368963
  },
  {
    "id": "covid_fact-000734",
    "statement": "A human neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that a human monoclonal antibody is involved in blocking SARS-CoV-2 infection, but it does not specify whether this antibody specifically targets the receptor binding site of the virus. More detailed evidence is needed to confirm the claim about targeting the receptor binding site.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.023837275803089142,
    "x2e_entail_prob": 0.9755540490150452
  },
  {
    "id": "covid_fact-000735",
    "statement": "A rabbit neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions a human monoclonal antibody blocking SARS-CoV-2, but it does not address anything about a rabbit neutralizing antibody targeting the receptor binding site of SARS-CoV-2. Therefore, there is no information to support the claim.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0039446111768484116,
    "x2e_entail_prob": 0.8497689366340637
  },
  {
    "id": "covid_fact-000736",
    "statement": "A mouse neutralizing antibody targets the receptor binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a human monoclonal antibody blocking SARS-CoV-2 infection but does not discuss a mouse neutralizing antibody, nor does it specify targeting the receptor binding site. Therefore, the claim is not directly supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.004582265391945839,
    "x2e_entail_prob": 0.9717884063720703
  },
  {
    "id": "covid_fact-000737",
    "statement": "A human neutralizing antibody targets the peptide binding site of sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      ", A human monoclonal antibody blocking SARS-CoV-2 infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only states that there is a human monoclonal antibody blocking SARS-CoV-2 infection. There is no information provided regarding it targeting the peptide binding site of SARS-CoV-2, which is a specific claim about the mechanism of action.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.013886375352740288,
    "x2e_entail_prob": 0.9822143912315369
  },
  {
    "id": "covid_fact-000738",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a human brain organoid model",
    "label": "SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim as it describes a study where SARS-CoV-2 infection leads to observable effects in human brain organoids, demonstrating the virus's neuroinvasive potential.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.011088578030467033,
    "x2e_entail_prob": 0.004962554667145014
  },
  {
    "id": "covid_fact-000739",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a canine brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided details the effects of SARS-CoV-2 infection on human brain organoids, demonstrating infection and metabolic changes, but it does not mention experiments conducted on a canine brain organoid model. Therefore, the evidence does not confirm the claim about the neuroinvasive potential of SARS-CoV-2 in a canine brain organoid model.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0042388904839754105,
    "x2e_entail_prob": 0.19569753110408783
  },
  {
    "id": "covid_fact-000740",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a rat brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that the neuroinvasive potential of SARS-CoV-2 has been revealed in a rat brain organoid model. However, the evidence provided mentions the observation of infection in human brain organoids, not rat brain organoids. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.006337251514196396,
    "x2e_entail_prob": 0.0028939738404005766
  },
  {
    "id": "covid_fact-000741",
    "statement": "Neuroinvasive potential of sars-cov-2 revealed in a mouse brain organoid model",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Following SARS-CoV-2 infection of human brain organoids, clear evidence of infection was observed, with accompanying metabolic changes in the infected and neighboring neurons."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that SARS-CoV-2 has the potential to invade neuronal tissues, demonstrated using a mouse brain organoid model. The evidence shows that SARS-CoV-2 can infect human brain organoids, which supports the neuroinvasive aspect of the virus as observed through infection and metabolic changes in neurons. Although the specific reference to a mouse brain organoid model is not mentioned, the evidence does support the neuroinvasive potential of the virus in organoids.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6194478273391724,
    "x2e_entail_prob": 0.5679982900619507
  },
  {
    "id": "covid_fact-000742",
    "statement": "Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses how the interactions with SARS-CoV-2 were studied using RNA interference and CRISPR, but does not provide information about comparative host-coronavirus protein interaction networks revealing pan-viral disease mechanisms. Thus, it does not confirm the claim.",
    "confidence": 0.5,
    "e2x_entail_prob": 0.003835895797237754,
    "x2e_entail_prob": 0.005160187371075153
  },
  {
    "id": "covid_fact-000743",
    "statement": "Comparative anti-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not confirm the claim that comparative anti-coronavirus protein interaction networks reveal pan-viral disease mechanisms. The evidence only mentions that interactions with SARS-CoV-2 were perturbed using RNA interference and CRISPR in various systems, but it does not substantiate the broader claim regarding pan-viral mechanisms.",
    "confidence": 0.5,
    "e2x_entail_prob": 0.43564385175704956,
    "x2e_entail_prob": 0.0013367957435548306
  },
  {
    "id": "covid_fact-000744",
    "statement": "Comparative non-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the integration of genetic data with protein interactions related to SARS-CoV-2 and not a comparative analysis of non-coronavirus protein interaction networks nor does it discuss pan-viral disease mechanisms as claimed. Therefore, the claim is not directly supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.035554707050323486,
    "x2e_entail_prob": 0.0013305217726156116
  },
  {
    "id": "covid_fact-000745",
    "statement": "Comparative beta-coronavirus protein interaction networks reveal pan-viral disease mechanisms",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data were integrated with genetic data where the interactions uncovered with SARS-CoV-2 were perturbed using RNA interference (RNAi) and CRISPR in different cellular systems and viral assaysan effort that functionally connected many host factors to infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the integration of genetic data and the use of RNAi and CRISPR to connect host factors to infection specific to SARS-CoV-2. However, it does not explicitly address the claim regarding comparative protein interaction networks revealing pan-viral disease mechanisms. The link to comparative analysis or pan-viral mechanisms is missing in the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.05666503682732582,
    "x2e_entail_prob": 0.11785853654146194
  },
  {
    "id": "covid_fact-000746",
    "statement": "Covid vaccine needs horseshoe crab blood but the ecosystem may suffer",
    "label": "SUPPORTED",
    "evidences": [
      "He said horseshoe crabs are vital in the process to find a coronavirus vaccine because their immune system is the most sensitive in the world.",
      "But she and other conservationists fear that without rFC or other alternatives available, the ongoing burden on horseshoe crab blood for COVID-19 vaccines and related therapeutics may imperil the crabs and the marine ecosystems that depend on them."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that horseshoe crabs are essential for the COVID-19 vaccine process due to their highly sensitive immune system. Additionally, there is concern among conservationists that reliance on horseshoe crab blood for vaccine production could threaten both the species and the marine ecosystems that rely on them. Thus, both parts of the claim are supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8538395166397095,
    "x2e_entail_prob": 0.008836565539240837
  },
  {
    "id": "covid_fact-000747",
    "statement": "Covid vaccine needs horseshoe crab blood but the ecosystem may benefit",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He said horseshoe crabs are vital in the process to find a coronavirus vaccine because their immune system is the most sensitive in the world.",
      "But she and other conservationists fear that without rFC or other alternatives available, the ongoing burden on horseshoe crab blood for COVID-19 vaccines and related therapeutics may imperil the crabs and the marine ecosystems that depend on them."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that horseshoe crab blood is indeed used in the process of developing COVID-19 vaccines due to its sensitivity. However, the evidence also indicates concerns about the impact on horseshoe crabs and the marine ecosystems that rely on them. It does not support the claim that the ecosystem may benefit from this use, as it highlights potential harm instead.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5848758220672607,
    "x2e_entail_prob": 0.001646838034503162
  },
  {
    "id": "covid_fact-000748",
    "statement": "Breakthrough needle-less vaccine could help in mass distribution",
    "label": "SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence suggests that the film's ingredients are inexpensive and the production process is simple, which could make vaccine campaigns more affordable, there is no specific mention of the breakthrough being needle-less or its potential for mass distribution. Thus, the claim that it is specifically 'needle-less' and 'could help in mass distribution' is not directly supported by the provided evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.017012104392051697,
    "x2e_entail_prob": 0.9680324196815491
  },
  {
    "id": "covid_fact-000749",
    "statement": "Breakthrough needle-specific vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that the film's ingredients and production process are inexpensive, which could make vaccine campaigns more affordable. However, it does not directly address the claim of a 'needle-specific vaccine' or clarify how this relates to mass distribution. Therefore, the claim is not fully supported by the evidence provided.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.002830114681273699,
    "x2e_entail_prob": 0.10448109358549118
  },
  {
    "id": "covid_fact-000750",
    "statement": "Breakthrough needle-driven vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the vaccine's affordability and simplicity can aid mass distribution, supporting the claim of a 'breakthrough needle-driven vaccine' helping in mass distribution.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.14895468950271606,
    "x2e_entail_prob": 0.009148300625383854
  },
  {
    "id": "covid_fact-000751",
    "statement": "Breakthrough needle-coated vaccine could help in mass distribution",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Since the ingredients to make the film are inexpensive and the process is relatively simple, it could make vaccine campaigns much more affordable."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the cost and simplicity of making the needle-coated film, but it does not clearly establish that this would help in mass distribution of vaccines. More specific information on how the film directly impacts distribution capabilities is needed to support the claim.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.006208973471075296,
    "x2e_entail_prob": 0.004630066454410553
  },
  {
    "id": "covid_fact-000752",
    "statement": "Recovery of monocyte exhaustion is associated with resolution of lung injury in covid-19 convalescence .",
    "label": "SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that changes in monocyte function, particularly the recovery from monocyte exhaustion, are associated with changes noted in convalescent COVID-19 patients, such as resolution of lung injury. This is supported by the observation of alterations in monocytes and the improvement noted in chest X-ray results. Therefore, the claim is supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9688366055488586,
    "x2e_entail_prob": 0.03966201841831207
  },
  {
    "id": "covid_fact-000753",
    "statement": "Recovery of monocyte exhaustion is associated without resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that recovery of monocyte exhaustion is associated without resolution of lung injury in COVID-19 convalescence, which suggests that despite monocyte recovery, lung injury does not resolve. However, the provided evidence indicates that the recovery of monocyte exhaustion is actually associated with the resolution of lung injury, as monocyte recovery was linked with patients having normal chest X-rays, suggesting lung recovery. Thus, the claim is not supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.17148074507713318,
    "x2e_entail_prob": 0.027981208637356758
  },
  {
    "id": "covid_fact-000754",
    "statement": "Recovery of monocyte proliferation is associated with resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that recovery of monocyte proliferation is associated with resolution of lung injury in COVID-19 convalescence. The evidence provided states that recovery of monocyte exhaustion is associated with resolution of lung injury and highlights changes in monocyte function post-recovery from COVID-19. While not specifically stating 'proliferation,' the context supports the claim as recovery is linked to lung injury resolution in convalescent patients.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.5891181230545044,
    "x2e_entail_prob": 0.07558713853359222
  },
  {
    "id": "covid_fact-000755",
    "statement": "Recovery of monocyte activation is associated with resolution of lung injury in covid-19 convalescence.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.",
      "Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 c",
      "Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray.",
      "We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that changes in monocyte function, such as recovery from exhaustion and increased expression of migration molecules, are associated with resolution of lung injury in COVID-19 convalescence. This supports the claim that recovery of monocyte activation is linked to lung injury resolution.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9341586232185364,
    "x2e_entail_prob": 0.030256662517786026
  },
  {
    "id": "covid_fact-000756",
    "statement": "Imperial college mrna vaccine technology could protect against future pandemics",
    "label": "SUPPORTED",
    "evidences": [
      "If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future.\"",
      "If these trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.\"",
      "Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.",
      "It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that Imperial College's mRNA vaccine technology has the potential to revolutionize vaccine development and enable rapid responses to emerging diseases. This implies its capability to protect against future pandemics, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.03576924279332161,
    "x2e_entail_prob": 0.19238334894180298
  },
  {
    "id": "covid_fact-000757",
    "statement": "Imperial college mrna vaccine technology cannot protect against future pandemics",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If our approach works and the vaccine provides effective protection against disease, it could revolutionise how we respond to disease outbreaks in future.\"",
      "If these trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.\"",
      "Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.",
      "It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that the mRNA vaccine technology, including Imperial College's research, holds promise for rapid response to emerging diseases and future pandemics. The claim that it cannot protect against future pandemics is contradicted by the potential and optimism expressed in the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1816309690475464,
    "x2e_entail_prob": 0.1009230986237526
  },
  {
    "id": "covid_fact-000758",
    "statement": "Dr. fauci predicts drugmakers will likely produce 1 billion covid-19 vaccines by the end of 2021",
    "label": "SUPPORTED",
    "evidences": [
      "But as we get into 2021, the manufacturers tell us that they will have hundreds of millions and likely a billion doses by the end of 2021,\" Fauci said in an interview with Reuters.",
      "Drugmakers will likely have produced a billion doses of a COVID-19 vaccine by the end of next year, Dr. Anthony Fauci, the United States' top infectious disease official, said Wednesday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that Dr. Fauci predicts drugmakers will likely produce 1 billion COVID-19 vaccines by the end of 2021. The evidence provides a direct quote from Dr. Fauci in an interview with Reuters, where he mentions that manufacturers are expected to produce hundreds of millions and likely up to a billion doses by the end of 2021. Therefore, the claim is supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8479421138763428,
    "x2e_entail_prob": 0.6250234246253967
  },
  {
    "id": "covid_fact-000759",
    "statement": "Dr. fauci predicts drugmakers will not produce 1 billion covid-19 vaccines by the end of 2021",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "But as we get into 2021, the manufacturers tell us that they will have hundreds of millions and likely a billion doses by the end of 2021,\" Fauci said in an interview with Reuters.",
      "Drugmakers will likely have produced a billion doses of a COVID-19 vaccine by the end of next year, Dr. Anthony Fauci, the United States' top infectious disease official, said Wednesday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly predicts that drugmakers are expected to produce about a billion COVID-19 vaccine doses by the end of 2021. This directly contradicts the claim that Dr. Fauci predicts they will not achieve this target.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3753818869590759,
    "x2e_entail_prob": 0.007707017008215189
  },
  {
    "id": "covid_fact-000760",
    "statement": "White house 's opening up america again guidelines",
    "label": "SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the 'Opening Up America Again' guidelines were indeed issued by the White House. These guidelines outline steps for easing restrictions and returning to normal economic activity in phases. The claim is supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.28441938757896423,
    "x2e_entail_prob": 0.11356015503406525
  },
  {
    "id": "covid_fact-000761",
    "statement": "Each house's opening up america again guidelines",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim relates to guidelines for 'Opening Up America Again,' which suggests a set of phases for reopening economic and social activities in America. The evidence indicates this is a document released by the White House, detailing recommendations for easing restrictions based on certain criteria, and is mentioned in a press conference by President Trump. Therefore, it supports the claim about the guidelines document titled 'Opening Up America Again.'",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8188844919204712,
    "x2e_entail_prob": 0.0656125396490097
  },
  {
    "id": "covid_fact-000762",
    "statement": "Any house's opening up america again guidelines",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "According to the White House, once these criteria are met, states and regions can begin returning to normal economic activity in three phases.",
      "Titled \"Opening Up America Again,\" the document lays out recommendations for easing stay-at-home restrictions for individuals, employers and organizations once a series of \"gating criteria\" are met.",
      "Learn more about the guidelines at WhiteHouse.gov/OpeningAmerica.",
      "This evening, President Trump continued his unprecedented level of access to the American people at a press conference where he presented his guidelines on the three phases of Opening Up America Again.",
      "During a virtual leadership roundtable hosted by Meeting Professionals International, held during Virtual Global Meetings Industry Day  two days before the White House released the \"Opening Up America Again\" guidelines  U.S. Travel Association CEO Roger Dow described how he and other industry leaders have started discussing specific guidelines for events once gatherings are again allowed to take place."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim 'Any house's opening up america again guidelines' is vague and lacks sufficient details to clearly match with the evidence provided. The evidence suggests guidelines titled 'Opening Up America Again' related to easing restrictions during the pandemic, but it does not address the claim about 'Any house' specifically. Without additional context or clarification about what 'Any house' refers to, the claim remains unsubstantiated by the provided evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.06173047423362732,
    "x2e_entail_prob": 0.012728346511721611
  },
  {
    "id": "covid_fact-000763",
    "statement": "Scientists are turning to existing drugs to combat covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that scientists are indeed repurposing existing drugs such as ritonavir and lopinavir, originally used for HIV, to combat COVID-19. This supports the claim that existing drugs are being considered for treatment against COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3908448815345764,
    "x2e_entail_prob": 0.0016080228378996253
  },
  {
    "id": "covid_fact-000764",
    "statement": "Scientists are turning to new drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that scientists are considering repurposing existing drugs such as ritonavir and lopinavir, originally used for HIV, to combat COVID-19. This suggests that new approaches, including new drug combinations, are being explored by scientists to address the pandemic, hence supporting the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.9289266467094421,
    "x2e_entail_prob": 0.0016706811729818583
  },
  {
    "id": "covid_fact-000765",
    "statement": "Scientists are turning to developing drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that scientists are indeed focusing on developing drugs to combat COVID-19, particularly by repurposing existing drugs and testing combinations like ritonavir and lopinavir, initially used for HIV.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8140146136283875,
    "x2e_entail_prob": 0.0031573523301631212
  },
  {
    "id": "covid_fact-000766",
    "statement": "Scientists are turning to develop drugs to combat covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "To expediate the development and approval process, many are looking at repurposing drugs to combat COVID-19.",
      "This means that it could potentially be tested sooner rather than later for patients with COVID-19.9 Other protease inhibitors that are currently being tested include the combination of ritonavir and lopinavir, drugs that were originally used for patients with HIV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that scientists are engaged in the process of repurposing existing drugs, such as ritonavir and lopinavir, to combat COVID-19. This indicates that drug development efforts are indeed being directed towards treating COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9093657732009888,
    "x2e_entail_prob": 0.0023534067440778017
  },
  {
    "id": "covid_fact-000767",
    "statement": "Indomethacin has a potent antiviral activity against sars coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions: The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.",
      "Results: Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that Indomethacin (INDO) has a potent direct antiviral activity against SARS-CoV, which supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7764149904251099,
    "x2e_entail_prob": 0.07853657007217407
  },
  {
    "id": "covid_fact-000768",
    "statement": "Indomethacin has a weak antiviral activity against sars coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions: The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.",
      "Results: Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that Indomethacin (INDO) has a potent antiviral activity against SARS coronavirus, which contradicts the claim that it has a weak antiviral activity. Therefore, the claim is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.15478943288326263,
    "x2e_entail_prob": 0.21720539033412933
  },
  {
    "id": "covid_fact-000769",
    "statement": "Coronavirus inflicts a short , sharp recession on global economy - cre herald",
    "label": "SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the global economy experienced contraction at a faster pace than during the global financial crisis, indicating a sharp downturn. The zero growth forecast for 2020 also implies a short recession, as it marks a severe economic performance over nearly 50 years. Therefore, the claim of a 'short, sharp recession' is supported by this evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8094092607498169,
    "x2e_entail_prob": 0.004381990991532803
  },
  {
    "id": "covid_fact-000770",
    "statement": "Coronavirus inflicts a world, sharp recession on global economy - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that the global economy contracted sharply in the first quarter of 2020 due to the coronavirus, with further contractions projected for Q2. It indicates that 2020 was expected to be one of the weakest years for the global economy, comparable to the financial crisis of 2009. This supports the claim of a recession inflicted by the coronavirus.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.40629586577415466,
    "x2e_entail_prob": 0.009685732424259186
  },
  {
    "id": "covid_fact-000771",
    "statement": "Coronavirus inflicts a pandemic, sharp recession on global economy - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the global economy faced significant contraction due to the coronavirus pandemic, suggesting a recession. This supports the claim of a pandemic inflicting a recession on the global economy. However, the term 'sharp recession' in the claim could be subjective, which slightly lowers the confidence level.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.007128701079636812,
    "x2e_entail_prob": 0.0029404698871076107
  },
  {
    "id": "covid_fact-000772",
    "statement": "Coronavirus inflicts a short, sharp recession on global health - cre herald",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"In the current (first) quarter of 2020, we expect the global economy to have contracted at a faster pace than during the global financial crisis, with a fall of some 2% in world GDP, and our baseline forecasts then projecting a further quarterly fall of 0.4% in Q2,\" said in the analysis.",
      "The zero growth - Oxford Economics forecasts for 2020 - will mark the second- weakest year for the global economy in almost 50 years of comparable data, with only 2009, in the depths of the financial crisis, worse."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the global economy experienced a sharp contraction due to the coronavirus, with a significant decline in world GDP in early 2020, marking it as one of the weakest years in economic performance over the last 50 years. This supports the claim of a short, sharp recession inflicted by coronavirus on the global economy, which indirectly impacts global health through economic stress factors.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.19603049755096436,
    "x2e_entail_prob": 0.006700492929667234
  },
  {
    "id": "covid_fact-000773",
    "statement": "Onerace , the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19 .",
    "label": "SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention Onerace, a Sydney research team, launching a crowdfunding campaign related to the COVID-19 pandemic. It only references a crowdfunding campaign related to building a border wall, which is unrelated to the pandemic or the research team mentioned in the claim.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.09340007603168488,
    "x2e_entail_prob": 0.02455538883805275
  },
  {
    "id": "covid_fact-000774",
    "statement": "Onerace, the sydney training team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention anything about Onerace, a Sydney training team, launching a crowdfunding campaign related to COVID-19. Instead, the evidence discusses a private group building a border wall using donations from a GoFundMe campaign and also mentions cyclone updates and live coverage of the coronavirus pandemic and USA presidential inauguration. Thus, the claim is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.016090983524918556,
    "x2e_entail_prob": 0.08174825459718704
  },
  {
    "id": "covid_fact-000775",
    "statement": "Irace, the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention the Irace research team or any crowdfunding campaign related to COVID-19. It only includes a reference to a border wall project and GoFundMe. Thus, the claim is not supported by the given evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.016827812418341637,
    "x2e_entail_prob": 0.02899051457643509
  },
  {
    "id": "covid_fact-000776",
    "statement": "Rerace, the sydney research team is launching its crowdfunding campaign to help the world with the current pandemic covid19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "^ \"Private group says it's started building border wall using millions donated in GoFundMe campaign\".",
      "ABC Home Open Sites menu ABC Home News iview TV Radio Kids Shop More Search AustraliaWeather Just In Politics World Business Analysis Sport Science Health Arts Fact Check Other Cyclone warning For latest updates on Cyclone Kimi in Far North Queensland , search on ABC Emergency or find your local ABC radio station Live blog Follow our live coverage for the latest news on the coronavirus pandemic USA Votes Follow our live coverage ahead of the inauguration of Joe Biden as the next US president Email "
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not mention 'Rerace' or any Sydney research team launching a crowdfunding campaign related to COVID-19. It refers to a private group building a border wall with donations from a GoFundMe campaign, which is unrelated to the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.041239090263843536,
    "x2e_entail_prob": 0.237775981426239
  },
  {
    "id": "covid_fact-000777",
    "statement": "Mva vector vaccines inhibit sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that MVA vector vaccines inhibited SARS-CoV-2 replication in the upper and lower respiratory tracts of transgenic mice. It also notes that the vaccines prevented severe and lethal disease in these mice, corroborating the claim fully.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.02607261948287487,
    "x2e_entail_prob": 0.7815151214599609
  },
  {
    "id": "covid_fact-000778",
    "statement": "Mva vector vaccines promote sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that recombinant MVAs expressing modified SARS-CoV-2 spike proteins inhibit virus replication in both the upper and lower respiratory tracts of transgenic mice and prevent severe disease. This directly supports the claim regarding MVA vector vaccines' effectiveness in this context.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.16297225654125214,
    "x2e_entail_prob": 0.5815870761871338
  },
  {
    "id": "covid_fact-000779",
    "statement": "Mva vector vaccines enhance sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that MVA vector vaccines inhibit, rather than enhance, SARS-CoV-2 replication in the respiratory tracts of transgenic mice. The claim that these vaccines enhance replication is contradictory to the evidence, which instead shows they prevent replication and lethal disease.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8053104281425476,
    "x2e_entail_prob": 0.1586451679468155
  },
  {
    "id": "covid_fact-000780",
    "statement": "Mva vector vaccines induce sars cov-2 replication in upper and lower respiratory tracts of transgenic mice and prevent lethal disease.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.",
      "A recent paper, that appeared as a preprint on the bioRxiv server in January 2021, shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.",
      "The researchers found that serum from mice vaccinated with MVA that expressed wildtype S could be given intraperitoneally to transgenic hACE2-expressing mice, producing a high neutralizing titer.",
      "Weight loss and lethality following intranasal infection of transgenic hACE2 mice with CoV-2 was prevented by one or two immunizations with rMVAs or by passive transfer of serum from vaccinated mice."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that recombinant Modified Vaccinia Ankara (MVA) vaccines expressing modified forms of the SARS-CoV-2 spike protein inhibited viral replication in the upper and lower respiratory tracts and prevented severe disease in transgenic mice. The claim specifically states MVA vector vaccines induce SARS-CoV-2 replication and prevent lethal disease. The replication prevention and disease prevention aspects are supported by the evidence, which reports on the success of these MVA vaccines in transgenic mice.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8653526306152344,
    "x2e_entail_prob": 0.3200148046016693
  },
  {
    "id": "covid_fact-000781",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to block stat nuclear import and antagonize interferon signaling",
    "label": "SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the interaction between SARS-CoV-2 Orf6 and Nup98 is critical for blocking STAT nuclear translocation, which disrupts interferon signaling. This supports the claim that SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7505790591239929,
    "x2e_entail_prob": 0.9414106607437134
  },
  {
    "id": "covid_fact-000782",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to promote stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the Orf6 protein from SARS-CoV-2 interacts with Nup98 to block STAT nuclear translocation, which is a mechanism to antagonize interferon signaling, aligning with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.31439530849456787,
    "x2e_entail_prob": 0.7868573665618896
  },
  {
    "id": "covid_fact-000783",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to facilitate stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that the interaction between SARS-CoV-2 Orf6 and Nup98 is involved in blocking STAT nuclear import, which antagonizes interferon signaling. The evidence mentions that Orf6-Nup98 interaction is crucial for preventing STAT1/2 nuclear translocation, thereby interfering with the transcription of IFN-stimulated genes. Therefore, the core claim about hijacking Nup98 to facilitate STAT nuclear import and to antagonize interferon signaling is validated.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7989295125007629,
    "x2e_entail_prob": 0.43349283933639526
  },
  {
    "id": "covid_fact-000784",
    "statement": "Sars-cov-2 orf6 hijacks nup98 to induce stat nuclear import and antagonize interferon signaling",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling.",
      "The Orf6-Nup98 interaction is critical to block STAT nuclear translocation and IFN signaling. Fig.",
      "In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).",
      "We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is supported by the evidence provided, which indicates that SARS-CoV-2 Orf6 interacts with Nup98 to block STAT nuclear translocation and impair interferon (IFN) signaling. This suggests that the viral protein Orf6 indeed hijacks Nup98 to affect STAT nuclear import and interfere with IFN signaling.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4042567014694214,
    "x2e_entail_prob": 0.7276796698570251
  },
  {
    "id": "covid_fact-000785",
    "statement": "Patients are coming in too late for treatment .",
    "label": "SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that late diagnosis can result from patients delaying medical consultation or misjudgment by doctors. This indirectly supports the claim that patients are coming in too late for treatment, as delayed diagnosis implies a late stage of presentation.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.01995147205889225,
    "x2e_entail_prob": 0.002801034599542618
  },
  {
    "id": "covid_fact-000786",
    "statement": "Patients are coming in too short for treatment.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses issues related to late diagnosis, either due to the patient delaying consultation or a doctor's misjudgment, but does not specifically address the claim about patients being too short for treatment. The phrase 'too short for treatment' seems misinterpreted or unsupported by the given evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.006238454952836037,
    "x2e_entail_prob": 0.01298627257347107
  },
  {
    "id": "covid_fact-000787",
    "statement": "Patients are coming in too time for treatment.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Late diagnosis can occur when a patient delays going to see a doctor about symptoms they have developed, or a doctor wrongly judges those signs to be of no concern or believes they indicate another illness, such as irritable bowel syndrome."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses late diagnosis due to patient delay or misjudgment by doctors but does not directly address or confirm that 'patients are coming in too time for treatment.' The claim is about punctuality or timing of patients seeking treatment, which is not covered by the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.010789215564727783,
    "x2e_entail_prob": 0.009233894757926464
  },
  {
    "id": "covid_fact-000788",
    "statement": "Irish-developed kit that confirms covid-19 infection in 15 minutes could be released in seven days",
    "label": "SUPPORTED",
    "evidences": [
      "Photo: PA Laura Lynott March 16 2020 02:30 AM Facebook Twitter Email An Irish company is preparing to release rapid Covid-19 testing kits, which can provide results in 15 minutes and potentially act as a \"clinical weapon\" against coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that an Irish company is preparing to release rapid Covid-19 testing kits with results in 15 minutes. However, there is no confirmation that the kit will be released in seven days, only that they are preparing for release. Thus, the claim is not entirely supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.006275548599660397,
    "x2e_entail_prob": 0.027599139139056206
  },
  {
    "id": "covid_fact-000789",
    "statement": "Irish-developed kit that confirms covid-19 infection in 15 minutes could be released in seven hours",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Photo: PA Laura Lynott March 16 2020 02:30 AM Facebook Twitter Email An Irish company is preparing to release rapid Covid-19 testing kits, which can provide results in 15 minutes and potentially act as a \"clinical weapon\" against coronavirus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that an Irish company is preparing to release rapid Covid-19 testing kits capable of providing results in 15 minutes. However, there is no evidence confirming that these kits could indeed be released in the extremely short timeframe of seven hours. Therefore, the claim is not entirely supported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.012722784653306007,
    "x2e_entail_prob": 0.02490234375
  },
  {
    "id": "covid_fact-000790",
    "statement": "Normally invisible saliva droplets can linger in the air , visualized by researchers using laser technology .",
    "label": "SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that researchers used laser technology to visualize small saliva droplets that can linger in the air. It describes a laser light-scattering experiment where the trajectories of speech-generated droplets were visualized. Therefore, the claim that normally invisible saliva droplets can be visualized using laser technology is supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9110754728317261,
    "x2e_entail_prob": 0.0022505728993564844
  },
  {
    "id": "covid_fact-000791",
    "statement": "Normally invisible saliva droplets can spread in the air, visualized by researchers using laser technology.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that laser technology has been successfully used to visualize and study the behavior of saliva droplets in the air. It mentions laser light-scattering experiments showing speech-generated droplets and their trajectories, supporting the claim that usually invisible droplets can be made visible through laser technology.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.42135173082351685,
    "x2e_entail_prob": 0.0020234910771250725
  },
  {
    "id": "covid_fact-000792",
    "statement": "Normally invisible saliva droplets can increase in the air, visualized by researchers using laser technology.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "He runs a laser lab normally used to study protein structural dynamics, but was able to use that technology to investigate the hunch that normal speaking produces small droplets that can spread disease.",
      "Whereas large droplets fall quickly to the ground, small droplets can dehydrate and linger as droplet nuclei in the air, where they behave like an aerosol and thereby expand the spatial extent of emitted infectious particles.2 We report the results of a laser light-scattering experiment in which speech-generated droplets and their trajectories were visualized.",
      "Laser light is a common technique to visualize and count droplets in the air, says Alex Huffman, an associate professor who studies aerosols in the department of chemistry and biochemistry at the University of Denver.",
      "Image Laser light scattering observations of droplets in the experimental setup.Credit...Valentyn Stadnytskyi; Philip Anfinrud; Christina E. Bax; Adriaan Bax The scientists also found that while droplets start shrinking from dehydration as soon as they leave a persons mouth, they can still float in the air for eight to 14 minutes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes how laser technology was used to visualize droplets emitted during normal speaking. This supports the claim that normally invisible saliva droplets, which can increase in the air, were visualized using laser technology.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.18244437873363495,
    "x2e_entail_prob": 0.00278622773475945
  },
  {
    "id": "covid_fact-000793",
    "statement": "Sex differences in immune responses to sars-cov-2 that underlie disease outcomes",
    "label": "SUPPORTED",
    "evidences": [
      "In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.",
      "Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.",
      "In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence discusses several sex differences in immune responses to SARS-CoV-2, such as differences in viral loads, antibody titers, and cytokine levels, as well as blood cell responses. Specifically, it highlights higher innate immune cytokines in female patients leading to worse disease progression compared to males and stronger T cell activation in females. This supports the claim that there are sex differences in immune responses to SARS-CoV-2 that influence disease outcomes.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.535026490688324,
    "x2e_entail_prob": 0.05558483302593231
  },
  {
    "id": "covid_fact-000794",
    "statement": "Sex differences in immune responses to sars-cov-2 that underlie protection outcomes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this study, we examined sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.",
      "Conversely, higher innate immune cytokines in female patients associated with worse disease progression, but not in male patients.",
      "In contrast, female patients mounted significantly more robust T cell activation than male patients during SARS-CoV-2 infection, which was sustained in old age."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates sex differences in immune responses to SARS-CoV-2, showing variations in viral loads and antibody titers, as well as differences in immune cytokines and T cell activation between male and female patients, which can underlie different protection outcomes.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8425366282463074,
    "x2e_entail_prob": 0.011776510626077652
  },
  {
    "id": "covid_fact-000795",
    "statement": "Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and th17 responses",
    "label": "SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that intranasally administered nanofiber vaccines without exogenous adjuvants elicit robust antigen-specific TH17 responses in the lung. This supports the claim that an adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and TH17 responses.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9411444664001465,
    "x2e_entail_prob": 0.012822553515434265
  },
  {
    "id": "covid_fact-000796",
    "statement": "Adjuvant-free nanofiber vaccine knocks in situ lung dendritic cell activation and th17 responses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that nanofiber vaccines without adjuvants administered intranasally successfully elicit robust antigen-specific TH17 responses in the lung. This supports the claim regarding dendritic cell activation and TH17 response elicitation, which implies in situ lung dendritic cell activation by the adjuvant-free nanofiber vaccine.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8377701044082642,
    "x2e_entail_prob": 0.024787763133645058
  },
  {
    "id": "covid_fact-000797",
    "statement": "Adjuvant-free nanofiber vaccine induces in situ memory dendritic cell activation and th17 responses",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These observations are congruent with the conclusion of independent priming by intranasal E\u03b1Q11 nanofibers of CD4+ T cells in the lung.",
      "Thus, in the absence of exogenous adjuvants, intranasally administered nanofiber vaccines preferentially elicit robust antigen-specific TH17 responses that accumulated in both the LN and lung.",
      "During primary immune responses elicited by pathogens such as Gram-negative bacteria, IL-17 at the lung mucosal surface is produced by natural killer (NK) cells, \u03b3\u03b4 T cells, and group 3 innate lymphoid cells (ILCs) [reviewed in ( 35)]."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that intranasally administered nanofiber vaccines, without exogenous adjuvants, elicit robust antigen-specific TH17 responses. This supports the claim that an adjuvant-free nanofiber vaccine can induce TH17 responses. However, the evidence does not explicitly mention memory dendritic cell activation, though the robust immune response implies some level of immune activation is occurring.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.02216508239507675,
    "x2e_entail_prob": 0.009152054786682129
  },
  {
    "id": "covid_fact-000798",
    "statement": "The fda has canceled emergency use of hydroxychloroquine for covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the FDA has revoked the emergency use authorization for both chloroquine and hydroxychloroquine, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.060895971953868866,
    "x2e_entail_prob": 0.0009699402726255357
  },
  {
    "id": "covid_fact-000799",
    "statement": "The fda has increased emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the FDA has revoked emergency use authorization for hydroxychloroquine and chloroquine for treating COVID-19, not increased it. Furthermore, the FDA has warned against using these drugs in combination with remdesivir.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6516526937484741,
    "x2e_entail_prob": 0.0017177247209474444
  },
  {
    "id": "covid_fact-000800",
    "statement": "The fda has potential emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the FDA revoked the emergency use authorization for hydroxychloroquine in treating COVID-19, thus contradicting the claim of potential emergency use.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.10681840777397156,
    "x2e_entail_prob": 0.0008942941785790026
  },
  {
    "id": "covid_fact-000801",
    "statement": "The fda has good emergency use of hydroxychloroquine for covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, the FDA warned June 15 that hydroxychloroquine and chloroquine shouldnt be given in combination with remdesivir, an antiviral drug that has been shown to shorten recovery time from COVID-19 ( SN: 4/29/20 ).",
      "After reviewing evidence, its no longer reasonable to believe that [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, Hinton wrote.",
      "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the FDA revoked the emergency use authorization for hydroxychloroquine for COVID-19, indicating that it does not have good emergency use. Additionally, the FDA warns against combining it with remdesivir.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.696800947189331,
    "x2e_entail_prob": 0.004179845564067364
  },
  {
    "id": "covid_fact-000802",
    "statement": "Antibody testing will enhance the power and accuracy of covid-19-prevention trials",
    "label": "SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that antibody testing, through seroconversion, can enhance the value and interpretability of COVID-19 prevention trials by providing insights into immunity and optimal outcomes, thereby supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.601017415523529,
    "x2e_entail_prob": 0.0037324896547943354
  },
  {
    "id": "covid_fact-000803",
    "statement": "Antibody testing will reduce the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that antibody testing can enhance the value and interpretability of COVID-19 prevention trials, contrary to the claim that it reduces their power and accuracy.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.05733679234981537,
    "x2e_entail_prob": 0.008737175725400448
  },
  {
    "id": "covid_fact-000804",
    "statement": "Antibody testing will limit the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that serological testing, which is part of antibody testing, actually enhances the value and interpretability of covid-19-prevention trials, rather than limiting their power and accuracy. Therefore, the claim is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.007522939704358578,
    "x2e_entail_prob": 0.008896536193788052
  },
  {
    "id": "covid_fact-000805",
    "statement": "Antibody testing will decrease the power and accuracy of covid-19-prevention trials",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.",
      "Here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that antibody testing will enhance the value and interpretability of covid-19-prevention trials, rather than decrease their power and accuracy. This is contrary to the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.010434482246637344,
    "x2e_entail_prob": 0.006819217465817928
  },
  {
    "id": "covid_fact-000806",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; majority of patients have demonstrated remarkable recoveries",
    "label": "SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim of strong results from COVID-19 patients treated with leronlimab showing remarkable recoveries is supported by evidence from statements by Bruce Patterson, M.D., and Nader Pourhassan, Ph.D. They both describe the patient responses to leronlimab as extremely well and impressive, noting powerful results in nearly all evaluated patients. However, it is important to note that the evidence seems anecdotal and no detailed data is provided, which slightly decreases confidence in the robustness of the claims.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.25642871856689453,
    "x2e_entail_prob": 0.008619756437838078
  },
  {
    "id": "covid_fact-000807",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; none of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided contradicts the claim. The evidence cites that patients are responding extremely well to leronlimab and describes the results as impressive, which is contrary to the claim that none of the patients have demonstrated remarkable recoveries.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.16067038476467133,
    "x2e_entail_prob": 0.0030435812659561634
  },
  {
    "id": "covid_fact-000808",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; few of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that CytoDyn reported positive responses to leronlimab in COVID-19 patients, as described by both executives from associated companies. While the results are described as impressive and anecdotal, the claim that few patients have demonstrated remarkable recoveries is supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.169842928647995,
    "x2e_entail_prob": 0.003971182741224766
  },
  {
    "id": "covid_fact-000809",
    "statement": "Cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; two of patients have demonstrated remarkable recoveries",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing.",
      "All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that strong results were reported for eind COVID-19 patients treated with leronlimab, with two patients demonstrating remarkable recoveries. However, the evidence only mentions that patients are responding well to leronlimab and that results are impressive but anecdotal. No specific mention of two patients with remarkable recoveries is provided in the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.022071760147809982,
    "x2e_entail_prob": 0.006423385813832283
  },
  {
    "id": "covid_fact-000810",
    "statement": "Sars-cov-2 infects brain choroid plexus and disrupts the blood-csf-barrier",
    "label": "SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 has a high viral tropism for the choroid plexus epithelial cells, leading to barrier breakdown of the choroid plexus, which is a part of the blood-CSF barrier. This supports the claim that SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9567493796348572,
    "x2e_entail_prob": 0.0981796607375145
  },
  {
    "id": "covid_fact-000811",
    "statement": "Sars-cov-2 infects intestinal choroid plexus and disrupts the blood-csf-barrier",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence describes that SARS-CoV-2 infects choroid plexus epithelial cells, which represent a subset of epithelial barrier cells, leading to the breakdown of the barrier. This supports the claim that SARS-CoV-2 infects the choroid plexus and disrupts the barrier, in this case, the blood-CSF barrier. While the specifics about the intestinal choroid plexus are not directly addressed, the general mechanism of infection and barrier disruption is supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9523698687553406,
    "x2e_entail_prob": 0.05008816719055176
  },
  {
    "id": "covid_fact-000812",
    "statement": "Sars-cov-2 infects brain choroid plexus and backs the blood-csf-barrier",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We find that infected cells of the choroid plexus are an apolipoprotein and ACE2 expressing subset of epithelial barrier cells.",
      "These findings suggest that neurological complications may result from effects on the choroid plexus, an important barrier that normally prevents entry of immune cells and cytokines into the cerebrospinal fluid (CSF) and brain.",
      "We then challenge organoids with both SARS-CoV-2 spike protein pseudovirus and live virus to demonstrate high viral tropism for choroid plexus epithelial cells but not stromal cells, and little to no infection of neurons or glia.",
      "Here, we use brain organoids to examine SARS-CoV-2 neurotropism.",
      "Finally, we show that infection with live SARS-CoV-2 leads to barrier breakdown of the choroid plexus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infects the choroid plexus brain epithelial cells, leading to barrier breakdown. This supports the claim of its impact on the blood-CSF-barrier.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7832163572311401,
    "x2e_entail_prob": 0.13640645146369934
  },
  {
    "id": "covid_fact-000813",
    "statement": "Coronial autopsies identify the indirect effects of covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that autopsy reports were reviewed to determine the contributions of undiagnosed COVID-19 and lockdown restrictions to deaths. This suggests that coronial autopsies can identify indirect effects of COVID-19. However, the difficulty in pinpointing individual cases influenced by COVID-19 movement restrictions does decrease confidence slightly.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.181757390499115,
    "x2e_entail_prob": 0.004261274356395006
  },
  {
    "id": "covid_fact-000814",
    "statement": "Coronial autopsies identify the therapeutic effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions coronial autopsies being used to determine the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths. However, it does not support the claim that autopsies identify the therapeutic effects of COVID-19. The focus is on identifying causes of death related to COVID-19 and lockdown, not on positive therapeutic effects.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.02663876861333847,
    "x2e_entail_prob": 0.003358063753694296
  },
  {
    "id": "covid_fact-000815",
    "statement": "Coronial autopsies identify the biological effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the assessment of autopsy reports to determine the influence of undiagnosed COVID-19 and lockdown restrictions on deaths. However, it does not specifically confirm that coronial autopsies identify the biological effects of COVID-19 itself. The evidence focuses on undiagnosed cases and lockdown impacts rather than direct biological effects identified through autopsies.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.07372280955314636,
    "x2e_entail_prob": 0.0065393028780817986
  },
  {
    "id": "covid_fact-000816",
    "statement": "Coronial autopsies identify the cytotoxic effects of covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Deaths from drug and alcohol misuse significantly increased during the lockdown period in comparison to the same period in 2018 (appendix), but it was not possible to identify whether individual cases were influenced by COVID-19 movement restrictions.",
      "Review of autopsy reports enabled the determination of the relative contributions of undiagnosed COVID-19 and lockdown restrictions on deaths."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that coronial autopsies can identify contributions of undiagnosed COVID-19 and lockdown restrictions on deaths, but there is no mention of identifying the cytotoxic effects of COVID-19 specifically. Thus, the claim about identifying cytotoxic effects is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.11864849925041199,
    "x2e_entail_prob": 0.006121618673205376
  },
  {
    "id": "covid_fact-000817",
    "statement": "3blue1brown provided detailed simulations of an epidemic",
    "label": "SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly mentions an interactive inspired by 3Blue1Brown's 'Simulating an Epidemic' video, indicating that 3Blue1Brown did indeed provide detailed simulations of an epidemic.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.04715735837817192,
    "x2e_entail_prob": 0.6955527663230896
  },
  {
    "id": "covid_fact-000818",
    "statement": "3blue1brown provided detailed simulations of an algorithm",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions an interactive inspired by 3Blue1Brown's video titled 'Simulating an Epidemic.' However, it does not provide explicit information confirming that 3Blue1Brown themselves provided detailed simulations of an algorithm. Therefore, the claim is not fully supported by the available evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0055342125706374645,
    "x2e_entail_prob": 0.5092875957489014
  },
  {
    "id": "covid_fact-000819",
    "statement": "3blue1brown provided detailed simulations of an equation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions an interactive simulation inspired by 3Blue1Brown's video titled 'Simulating an Epidemic,' which suggests that 3Blue1Brown provided a detailed exploration or simulation related to an equation dealing with epidemics. While the evidence points to a specific video, it aligns with 3Blue1Brown's known content style of providing visual and detailed mathematical explanations.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.043468739837408066,
    "x2e_entail_prob": 0.9065137505531311
  },
  {
    "id": "covid_fact-000820",
    "statement": "3blue1brown provided detailed simulations of an alignment",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Epidemic Simulation An interactive inspired by 3Blue1Brown's \"Simulating an Epidemic\" video."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions an interactive inspired by 3Blue1Brown's 'Simulating an Epidemic' video, but it does not support the specific claim that 3Blue1Brown provided 'detailed simulations of an alignment.' The concept of alignment is not addressed in the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.04984179511666298,
    "x2e_entail_prob": 0.6755427718162537
  },
  {
    "id": "covid_fact-000821",
    "statement": "Delaware medical supplier says fema seized 400,000 n95 masks , now he 's out millions of dollars",
    "label": "SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the Federal Emergency Management Agency (FEMA) did use its authority under the Defense Production Act to 'set aside' masks that Indutex, a Delaware-based medical supplier, possessed during a federal emergency. Furthermore, the owner, George Gianforcaro, stated that FEMA did not pay for the masks, aligning with the claim that he lost out on millions of dollars. However, there is no mention of the exact number of masks being 400,000 in the evidence provided. While the situation described supports the claim, exact details about the number and total financial impact are not fully verified by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6013309955596924,
    "x2e_entail_prob": 0.002583604073151946
  },
  {
    "id": "covid_fact-000822",
    "statement": "Delaware medical supplier and fema seized 400,000 n95 masks, now he's out millions of dollars",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by stating that FEMA, using Defense Production Act authority, seized masks from Indutex USA, a Delaware-based medical supplier. George Gianforcaro, the owner, states that FEMA did not pay for the seized shipments, suggesting a financial loss. While the evidence does not explicitly mention the quantity of 400,000 masks, the overall situation described aligns with the claim's context of a seizure leading to financial loss.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1968446671962738,
    "x2e_entail_prob": 0.0012517641298472881
  },
  {
    "id": "covid_fact-000823",
    "statement": "Delaware medical supplier with fema seized 400,000 n95 masks, now he's out millions of dollars",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Citing Defense Production Act authority, the FEMA document further ordered Indutex to \"set aside\" all N95 or surgical masks it may come to possess during the federal emergency for a potential sale to FEMA.",
      "George Gianforcaro, owner of the small, Newark, Delaware-based Indutex USA, said the Federal Emergency Management Agency did not pay him when it took possession of two imported shipments of masks bound for customers across the United States."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that FEMA exercised its authority under the Defense Production Act to seize masks from Indutex USA, a company based in Newark, Delaware. The owner, George Gianforcaro, claims that FEMA did not pay for these shipments, implying a significant financial loss. While the exact number of masks seized isn't specified in the evidence, the core elements of the claim regarding the seizure and financial loss are supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7423499226570129,
    "x2e_entail_prob": 0.0013665949227288365
  },
  {
    "id": "covid_fact-000824",
    "statement": "Fauci predicts us deaths from coronavirus",
    "label": "SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence specifically indicates that Dr. Anthony Fauci predicted that there might be between 100,000 and 200,000 deaths from COVID-19 in the U.S. based on current modeling. This aligns with the claim about Fauci predicting U.S. deaths from the coronavirus, thus supporting it.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.12377855181694031,
    "x2e_entail_prob": 0.43847572803497314
  },
  {
    "id": "covid_fact-000825",
    "statement": "Fauci predicts us deaths globally coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that Dr. Anthony Fauci predicted a potential death toll of 100,000 to 200,000 in the U.S., not globally. The claim inaccurately extends this prediction to global deaths, which is not supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.052202314138412476,
    "x2e_entail_prob": 0.01477297954261303
  },
  {
    "id": "covid_fact-000826",
    "statement": "Fauci predicts us deaths worldwide coronavirus",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.",
      "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests Fauci predicts worldwide coronavirus deaths, but the evidence specifies that Fauci's prediction is for deaths in the U.S., not worldwide. Therefore, the claim is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.02423267997801304,
    "x2e_entail_prob": 0.024557774886488914
  },
  {
    "id": "covid_fact-000827",
    "statement": "Leronlimab used in seven patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu , removed from icu and extubated with reduced pulmonary inflammation",
    "label": "SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that leronlimab treatment resulted in improved conditions for patients with severe COVID-19, with noted improvements in immune profile and cytokine levels. The specific mention that it gives hope that leronlimab may help patients recover from pulmonary inflammation aligns with the claim, even though it doesn't directly confirm the extubation and ICU removal details mentioned.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.947975754737854,
    "x2e_entail_prob": 0.0032389662228524685
  },
  {
    "id": "covid_fact-000828",
    "statement": "Leronlimab used in two patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that leronlimab shows promise in reducing pulmonary inflammation in COVID-19 patients and hints at positive outcomes in the specific case of two patients in ICU. While detailed specifics about these patients being intubated and subsequently extubated are not explicitly stated, the evidence supports the overarching claim about improvements in severe COVID-19 cases.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.1693325638771057,
    "x2e_entail_prob": 0.0014304156647995114
  },
  {
    "id": "covid_fact-000829",
    "statement": "Leronlimab used in three patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that leronlimab showed promise in improving the immune profile and reducing cytokine levels in patients with severe COVID-19, suggesting it may help reduce pulmonary inflammation and assist in recovery. While the specific details about extubation and removal from ICU for two patients are not directly mentioned, the overall positive response in terms of immune normalization and reduction in inflammation supports the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9528700709342957,
    "x2e_entail_prob": 0.0024160556495189667
  },
  {
    "id": "covid_fact-000830",
    "statement": "Leronlimab used in four patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.",
      "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).",
      "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.",
      "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions preliminary results suggesting hope for leronlimab in treating pulmonary inflammation in COVID-19 patients, but it does not specifically confirm the claim about four NYC patients or detail outcomes such as extubation or removal from ICU. The claim lacks direct evidence linking to these specific outcomes.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0888557881116867,
    "x2e_entail_prob": 0.0022338135167956352
  },
  {
    "id": "covid_fact-000831",
    "statement": "Home testing for coronavirus to track levels of infection in the community",
    "label": "SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the use of home testing kits for health care purposes in general and describes how samples are processed in a laboratory for coronavirus detection. However, the evidence does not explicitly mention the use of home testing for tracking infection levels in the community, nor does it provide details on how these results contribute to community tracking. Thus, the claim is not directly supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.016979986801743507,
    "x2e_entail_prob": 0.0009006455657072365
  },
  {
    "id": "covid_fact-000832",
    "statement": "Laboratory testing for coronavirus to track levels of infection in the community",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only discusses the use of PCR tests in laboratories to detect coronavirus genetic material, but it does not explicitly mention their use to track levels of infection in the community. Thus, while it implies some level of testing, the specific claim about community infection tracking is not directly supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.01137169636785984,
    "x2e_entail_prob": 0.000998755800537765
  },
  {
    "id": "covid_fact-000833",
    "statement": "Studies testing for coronavirus to track levels of infection in the community",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.",
      "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions PCR tests, known as the gold standard for detecting the presence of the coronavirus, which implies that there are studies or testing being conducted to track levels of infection. However, it does not specifically state that these studies are tracking levels of infection in the community, as the claim suggests. The information given highlights the use of PCR tests, but does not directly support the claim about community-level tracking.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.2523272931575775,
    "x2e_entail_prob": 0.0010729487985372543
  },
  {
    "id": "covid_fact-000834",
    "statement": "The sars-cov-2-like virus found in captive pangolins from guangdong should be better sequenced .",
    "label": "SUPPORTED",
    "evidences": [
      "bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.",
      "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.",
      "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that viruses closely related to SARS-CoV-2 were sequenced in Sunda pangolins from Guangdong. The GD/P2S dataset contains reads identical to SARS-CoV-2, implying potential issues such as contamination or the coexistence of two similar viruses. This supports the claim that the sequencing of these viruses should be improved, suggesting a need for better sequencing.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9804988503456116,
    "x2e_entail_prob": 0.08033395558595657
  },
  {
    "id": "covid_fact-000835",
    "statement": "The sars-cov-2-like virus found in captive pangolins from guangdong cannot be better sequenced.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.",
      "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.",
      "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence describes the sequencing of SARS-CoV-2-like viruses found in captive pangolins from Guangdong, using data available in the Sequence Read Archive. It indicates an attempt to assemble genomes from existing data, which suggests that further sequencing was performed and implies potential for additional sequencing efforts. Therefore, the claim that the virus cannot be better sequenced is not supported by the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.9391155242919922,
    "x2e_entail_prob": 0.01990676485002041
  },
  {
    "id": "covid_fact-000836",
    "statement": "High dose vitamin d improves total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence mentions the efficacy and functions of vitamin D in various physiological responses and conditions but does not directly address its impact on total serum antioxidant capacity or specific ICU outcomes in critically ill patients. The claim is not directly supported by detailed findings or results from relevant studies in the provided evidence.",
    "confidence": 0.4,
    "e2x_entail_prob": 0.011592237278819084,
    "x2e_entail_prob": 0.03546220809221268
  },
  {
    "id": "covid_fact-000837",
    "statement": "High dose vitamin d reduces total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly address the claim that high dose vitamin D reduces total serum antioxidant capacity and ICU outcomes in critically ill patients. The evidence mentions various potential effects of vitamin D, such as on immune response and lung function, but it does not specifically link these effects to reductions in antioxidant capacity or ICU outcomes. Thus, the claim is not supported by the evidence given.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.7442404627799988,
    "x2e_entail_prob": 0.10670434683561325
  },
  {
    "id": "covid_fact-000838",
    "statement": "High dose vitamin d decreased total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence does not specifically address the claim that high dose vitamin D decreases total serum antioxidant capacity and ICU outcome in critically ill patients. The evidence only discusses the general efficacy and role of vitamin D on immune response, lung function, muscle function, and cardiac function but does not provide specific findings related to antioxidant capacity or ICU outcomes. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.24995626509189606,
    "x2e_entail_prob": 0.13025961816310883
  },
  {
    "id": "covid_fact-000839",
    "statement": "High dose vitamin d reduced total serum antioxidant capacity and icu outcome in critically ill patients.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.",
      "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.",
      "Vitamin D status in critically ill patients: the evidence is now bioavailable!"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the efficacy of high-dose vitamin D supplementation in critically ill patients and its synergy on various body functions. However, it does not provide specific insight or data on the effect of high-dose vitamin D on reducing total serum antioxidant capacity or improving ICU outcomes. Thus, the claim is not directly supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.044634558260440826,
    "x2e_entail_prob": 0.03507865592837334
  },
  {
    "id": "covid_fact-000840",
    "statement": "Epidemiologic features and clinical course of 1st 18 patients infected with sars-cov-2 in singapore",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that the claim regarding the epidemiologic features and clinical course of the first 18 patients infected with SARS-CoV-2 in Singapore is supported, as it mentions their clinical presentation frequently involved mild respiratory tract infection.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7098087668418884,
    "x2e_entail_prob": 0.9167580008506775
  },
  {
    "id": "covid_fact-000841",
    "statement": "Epidemiologic features and clinical course of 10 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only mentions 18 patients diagnosed with SARS-CoV-2 in Singapore, but the claim refers to 10 18 patients, which seems like a typographical error. It suggests considering more patients than are mentioned in the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0026250858791172504,
    "x2e_entail_prob": 0.0031198663637042046
  },
  {
    "id": "covid_fact-000842",
    "statement": "Epidemiologic features and clinical course of all 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that there was a study or report concerning the first 18 patients diagnosed with SARS-CoV-2 in Singapore, focusing on their epidemiologic features and clinical course. However, it mainly highlights that their clinical presentation was frequently a mild respiratory tract infection. Thus, the claim is largely supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.15321767330169678,
    "x2e_entail_prob": 0.8131387233734131
  },
  {
    "id": "covid_fact-000843",
    "statement": "Epidemiologic features and clinical course of over 18 patients infected with sars-cov-2 in singapore",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim mentions epidemiologic features and clinical course of over 18 patients infected with SARS-CoV-2 in Singapore. The evidence states that there were 18 patients diagnosed with SARS-CoV-2 in Singapore, and it provides information on their clinical presentation, specifically noting mild respiratory tract infection. The number of patients matches, suggesting that it's reasonable to assume epidemiologic features and clinical courses were part of the study, thus supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8685034513473511,
    "x2e_entail_prob": 0.24372237920761108
  },
  {
    "id": "covid_fact-000844",
    "statement": "A bifidobacterial protein that can reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that bifidobacterial proteins can influence immune response by recognizing cytokines, supporting the claim of a bifidobacterial protein reducing inflammation in COVID-19. However, the evidence does not explicitly mention its discovery by a RUDN geneticist. Thus, the core of the claim is supported but with an approximate confidence due to missing details on the discoverer's affiliation.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.002651339629665017,
    "x2e_entail_prob": 0.3304957151412964
  },
  {
    "id": "covid_fact-000845",
    "statement": "A bifidobacterial protein that cannot reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that bifidobacterial proteins have the potential to regulate immune responses and be used as anti-inflammatory treatments. However, it does not directly support the claim that a bifidobacterial protein was found that cannot reduce inflammation in COVID-19. The evidence suggests the opposite\u2014that the protein may have anti-inflammatory properties useful in treating COVID-19.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.03795836120843887,
    "x2e_entail_prob": 0.005743882618844509
  },
  {
    "id": "covid_fact-000846",
    "statement": "A bifidobacterial virus that can reduce inflammation in covid-19 found by a rudn geneticist",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.",
      "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that a virus was found by a geneticist, but the evidence only mentions the potential anti-inflammatory properties of bifidobacterial proteins. There is no mention of a bifidobacterial virus or its discovery by a geneticist.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.004397145938128233,
    "x2e_entail_prob": 0.003682836191728711
  },
  {
    "id": "covid_fact-000847",
    "statement": "Swissmedic begins rolling review of moderna 's mrna vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the rolling review process but does not specifically state that Swissmedic has begun reviewing Moderna's mRNA vaccine against COVID-19. Direct evidence confirming the start of the review for Moderna's vaccine is necessary to support the claim.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.024756543338298798,
    "x2e_entail_prob": 0.0011209301883354783
  },
  {
    "id": "covid_fact-000848",
    "statement": "Swissmedic begins rolling production of moderna's mrna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided indicates that Swissmedic is involved in a rolling review process for ongoing clinical trials of Moderna's mRNA vaccine against COVID-19. This implies regulatory activity, not production. Swissmedic, as a regulatory body, does not engage in the production of vaccines. Thus, the claim that Swissmedic begins rolling production of Moderna's mRNA vaccine is not supported by the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.13420872390270233,
    "x2e_entail_prob": 0.0022909119725227356
  },
  {
    "id": "covid_fact-000849",
    "statement": "Sars-cov-2 spike protein promotes hyper-inflammatory response that can be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro",
    "label": "SUPPORTED",
    "evidences": [
      "We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.",
      "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-\u03baB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that SARS-CoV-2 spike protein subunit 1 induces inflammation via NF-\u03baB activation and pro-inflammatory cytokine production. It also mentions the development of an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced cytokine production. However, the evidence does not confirm the amelioration of hyper-inflammatory response by FDA-approved ER stress and MAP kinase inhibitors in vitro, which is required for full support of the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.004222622606903315,
    "x2e_entail_prob": 0.12278624624013901
  },
  {
    "id": "covid_fact-000850",
    "statement": "Sars-cov-2 spike protein promotes hyper-inflammatory response that cannot be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.",
      "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-\u03baB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only provides support that the spike protein induces a hyper-inflammatory response but does not confirm that this response cannot be ameliorated by the spike-antagonistic peptide or inhibitors. The evidence describes the development of a peptide inhibiting S1-ACE2 interaction and cytokine production, suggesting potential mitigation, contradicting the claim.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.03967972472310066,
    "x2e_entail_prob": 0.1673082560300827
  },
  {
    "id": "covid_fact-000851",
    "statement": "Finding suggests technology can be installed in air conditioning , vacuum , and water systems",
    "label": "SUPPORTED",
    "evidences": [
      "Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.",
      "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.",
      "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that technology for disinfection using LED bulbs can be installed in systems such as air conditioning, vacuum, and water systems. Although the evidence talks about future potential and developments, it supports the claim that such installations are suggested or possible.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7889670133590698,
    "x2e_entail_prob": 0.0072156148962676525
  },
  {
    "id": "covid_fact-000852",
    "statement": "Finding suggests technology cannot be installed in air conditioning, vacuum, and water systems",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.",
      "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.",
      "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that technology, specifically disinfection systems based on LED bulbs, can be installed in air conditioning, vacuum, and water systems, contrary to the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3313513696193695,
    "x2e_entail_prob": 0.009020373225212097
  },
  {
    "id": "covid_fact-000853",
    "statement": "Oxford university vaccine shows 70 % protection - bbc news",
    "label": "SUPPORTED",
    "evidences": [
      "The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that the Oxford university vaccine demonstrated 70% protection. This supports the claim made in the statement.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.07143475115299225,
    "x2e_entail_prob": 0.0016305003082379699
  },
  {
    "id": "covid_fact-000854",
    "statement": "Oxford university vaccine shows 70 % protection -19 news",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the vaccine provides 70% protection, which directly aligns with the claim about the Oxford University vaccine showing 70% protection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0023447456769645214,
    "x2e_entail_prob": 0.0015510877128690481
  },
  {
    "id": "covid_fact-000855",
    "statement": "Mast cells activated by sars-cov-2 release histamine which increases il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that mast cells release histamine, which can play a role in inflammation. However, it does not directly link histamine to increased IL-1 levels or explicitly mention cytokine storms in the context of COVID-19. The connection between mast cells releasing histamine, increased IL-1 levels, and the resulting cytokine storm is not fully supported by the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.6904202103614807,
    "x2e_entail_prob": 0.37853047251701355
  },
  {
    "id": "covid_fact-000856",
    "statement": "Mast cells activated by sars-cov-2 release histamine which reduces il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not explicitly support the claim that mast cells activated by SARS-CoV-2 release histamine, which reduces IL-1 levels and causes a cytokine storm and inflammatory reaction in COVID-19. It does mention mast cells releasing histamine and other substances contributing to inflammation. However, no connection is provided in the evidence regarding histamine's role in reducing IL-1 levels or directly causing a cytokine storm.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.21040835976600647,
    "x2e_entail_prob": 0.46369025111198425
  },
  {
    "id": "covid_fact-000857",
    "statement": "Mast cells activated by sars-cov-2 release histamine which decreases il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence confirms that mast cells release histamine and are involved in inflammation. It also mentions IL-1's role in inflammation and micro-thrombi formation in COVID-19 but does not provide information supporting that histamine release decreases IL-1 levels leading to a cytokine storm. The link between histamine affecting IL-1 levels specifically is also not established.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.27250799536705017,
    "x2e_entail_prob": 0.4016225039958954
  },
  {
    "id": "covid_fact-000858",
    "statement": "Mast cells activated by sars-cov-2 release histamine which inhibits il-1 levels causing cytokine storm and inflammatory reaction in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.",
      "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not confirm that histamine released by mast cells directly inhibits IL-1 levels, nor does it state that this process causes a cytokine storm in COVID-19. The evidence mentions that mast cells release various substances including histamine in COVID-19, and IL-1 is involved in inflammation, but lacks specifics on histamine's role in inhibiting IL-1 or directly causing a cytokine storm.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.6178509593009949,
    "x2e_entail_prob": 0.3689475953578949
  },
  {
    "id": "covid_fact-000859",
    "statement": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells .",
    "label": "SUPPORTED",
    "evidences": [
      "Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.",
      "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission",
      "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.",
      "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the furin cleavage site of the SARS-CoV-2 spike protein is indeed a key determinant for transmission due to its role in virus entry into airway cells. The evidence shows that the polybasic insertion at the S1/S2 site, which is cleaved by furin, provides a selective advantage in human airway epithelial cells, contributing to enhanced viral replication and avoiding antiviral proteins. This supports the claim that the furin cleavage site plays a critical role in the virus's transmission capabilities through enhanced replication in airway cells.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9190503358840942,
    "x2e_entail_prob": 0.0036310304421931505
  },
  {
    "id": "covid_fact-000860",
    "statement": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced infection in airway cells.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.",
      "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission",
      "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.",
      "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the furin cleavage site on the SARS-CoV-2 spike protein is crucial for viral transmission, particularly in airway cells. The cleavage site allows the virus to efficiently enter human airway cells, a key factor for transmission. The selective advantage in airway cells, along with the role of cell surface protease TMPRSS2 in virus entry, supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9030957221984863,
    "x2e_entail_prob": 0.035746168345212936
  },
  {
    "id": "covid_fact-000861",
    "statement": "Is there an airborne component to the transmission of covid-19 ?",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that SARS-CoV-2 virions can be shed in high concentrations from the nasal cavity of individuals and may be transmitted through aerosols in enclosed spaces, indicating an airborne component to COVID-19 transmission.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.940425455570221,
    "x2e_entail_prob": 0.4056606590747833
  },
  {
    "id": "covid_fact-000862",
    "statement": "Is there an airborne component to the entry of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that live SARS-CoV-2 virions are shed from the nasal cavity and can be transmitted via the aerosol route in enclosed spaces. This suggests an airborne component to COVID-19 transmission, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8964980244636536,
    "x2e_entail_prob": 0.3879583179950714
  },
  {
    "id": "covid_fact-000863",
    "statement": "Is there an airborne component to the development of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that COVID-19 can be transmitted via aerosols, supporting the claim that there is an airborne component to the virus's development. The risk of contracting COVID-19 through aerosol transmission in enclosed spaces, as described, implies that airborne factors are significant.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7190352082252502,
    "x2e_entail_prob": 0.07322295010089874
  },
  {
    "id": "covid_fact-000864",
    "statement": "Is there an airborne component to the use of covid-19?",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.",
      "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.",
      "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about the airborne nature of COVID-19 transmission. The provided evidence indicates that SARS-CoV-2, the virus causing COVID-19, can be shed in high concentrations from the nasal cavity, and there's a risk of contracting COVID-19 via aerosols in enclosed spaces. This supports the claim that there is an airborne component to COVID-19 transmission.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9651775360107422,
    "x2e_entail_prob": 0.004985249135643244
  },
  {
    "id": "covid_fact-000865",
    "statement": "Saliva-based antigen testing is better than the pcr swab",
    "label": "SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that saliva-based antigen testing is better than PCR swabs. The evidence provided highlights several advantages of saliva-based antigen testing, such as being cost-effective, convenient, and not requiring specialized equipment or personnel. However, it does not directly compare the overall accuracy, sensitivity, and specificity of saliva-based antigen tests to PCR swabs, which are important factors in determining whether one testing method is 'better' than another. Therefore, without comprehensive evidence comparing both testing methods across all relevant metrics, the claim is not fully supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3669170141220093,
    "x2e_entail_prob": 0.011384613811969757
  },
  {
    "id": "covid_fact-000866",
    "statement": "Saliva-based antigen testing is lower than the pcr swab",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that saliva-based antigen testing is lower than PCR swabs, likely in terms of sensitivity. However, the evidence does not provide a direct comparison in sensitivity or accuracy. It highlights the practical advantages of saliva-based antigen testing over PCR, such as cost, convenience, and speed, but does not establish that it is lower than PCR swabs in sensitivity or other measures.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.028119180351495743,
    "x2e_entail_prob": 0.0057365791872143745
  },
  {
    "id": "covid_fact-000867",
    "statement": "Saliva-based antigen testing is less than the pcr swab",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.",
      "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.",
      "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim by indicating that saliva-based antigen testing is less comprehensive than PCR swab testing in terms of detecting faint signals of lingering viral matter. However, it highlights the practical advantages of saliva antigen tests over PCR in terms of speed, cost, and scalability.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.30340588092803955,
    "x2e_entail_prob": 0.014481556601822376
  },
  {
    "id": "covid_fact-000868",
    "statement": "10 % of stockholmers infected",
    "label": "SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that by the first weeks of April, 10 percent of Stockholm's population had been infected with the coronavirus and developed antibodies. This directly supports the claim that 10% of Stockholmers were infected.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8809930682182312,
    "x2e_entail_prob": 0.0009347205050289631
  },
  {
    "id": "covid_fact-000869",
    "statement": "10 % of authorers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that '10% of authorers were infected' cannot be verified with the provided evidence. The evidence mentions that 10% of Stockholm's population had been infected and developed antibodies by April, but there is no specific information about 'authorers' or a similar group. Additionally, the term 'authorers' seems incorrect or unclear in context.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.22994966804981232,
    "x2e_entail_prob": 0.0016461395425722003
  },
  {
    "id": "covid_fact-000870",
    "statement": "10 % of readers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states '10% of readers infected,' which implies a connection to readers specifically, but the evidence presented refers to the general population of Stockholm in April 2020. Therefore, the evidence does not support the specific wording of 'readers infected,' as it appears to be general population data rather than data about readers.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.2026117593050003,
    "x2e_entail_prob": 0.0010313205420970917
  },
  {
    "id": "covid_fact-000871",
    "statement": "10 % of allers infected",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.",
      "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim that '10% of allers infected' is ambiguous and not directly supported by the evidence provided. The evidence suggests that 10% of Stockholm's population had been infected with the coronavirus and developed antibodies by early April, but it doesn't specify 'allers' nor does it support a broader claim beyond Stockholm. The lack of clarity around 'allers' impacts the confidence and support of this claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6679016351699829,
    "x2e_entail_prob": 0.0019315551035106182
  },
  {
    "id": "covid_fact-000872",
    "statement": "Sars-cov-2 d614g variant exhibits enhanced replication ex vivo and earlier transmission in vivo",
    "label": "SUPPORTED",
    "evidences": [
      "Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.",
      "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that the SARS-CoV-2 D614G variant enhances replication fitness and early transmission. Additionally, the study being referenced is published under a title that strongly aligns with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.09869308769702911,
    "x2e_entail_prob": 0.07363099604845047
  },
  {
    "id": "covid_fact-000873",
    "statement": "Sars-cov-2 d614g variant inhibited enhanced replication ex vivo and earlier transmission in vivo",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.",
      "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the SARS-CoV-2 D614G variant enhances infectivity, replication fitness, and early transmission, which contradicts the claim. Therefore, the claim that it inhibited replication and transmission is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6239446997642517,
    "x2e_entail_prob": 0.02815879136323929
  },
  {
    "id": "covid_fact-000874",
    "statement": "Orf8 and orf3b antibodies are accurate serological markers of early and late sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.",
      "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that ORF8 antibodies are major markers of different stages of SARS-CoV-2 infection, including acute, convalescent, and long-term response. ORF3b is also mentioned among the strongest specific antibody responses. This supports the claim about these being serological markers for early and late SARS-CoV-2 infection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9489793181419373,
    "x2e_entail_prob": 0.5423485636711121
  },
  {
    "id": "covid_fact-000875",
    "statement": "Orf8 and orf3b antibodies are accurate serological markers of early and acute sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.",
      "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that ORF8 is a major marker for acute, convalescent, and long-term antibody response due to its immunodominance and specificity, but it does not explicitly support that ORF8 and ORF3b together are accurate markers of early SARS-CoV-2 infection. While ORF8 is highlighted as significant, the role of ORF3b is not similarly elaborated in the evidence provided, specifically relating to early infection.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.6642429828643799,
    "x2e_entail_prob": 0.08287922292947769
  },
  {
    "id": "covid_fact-000876",
    "statement": "Plasma from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that plasma from recovered COVID-19 subjects with anti-trimer IgGs can inhibit the binding of spike protein to ACE2 in a microsphere-based inhibition assay. Specifically, 22 out of 24 subjects showed this inhibition, correlating with anti-trimer IgG levels, which supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8717265725135803,
    "x2e_entail_prob": 0.026287950575351715
  },
  {
    "id": "covid_fact-000877",
    "statement": "Blood from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that plasma from subjects with anti-trimer IgGs inhibits ACE2-trimer binding significantly more than controls, which supports the claim that blood from recovered COVID-19 subjects can inhibit spike protein binding to ACE2. The evidence directly discusses the use of a microsphere-based assay to measure this inhibition, aligning with the elements of the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6855405569076538,
    "x2e_entail_prob": 0.04135197773575783
  },
  {
    "id": "covid_fact-000878",
    "statement": "Rna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that plasma from subjects with anti-trimer IgGs inhibited ACE2-trimer binding in the context of a microsphere-based assay. Although the claim specifically mentions 'RNA,' the context suggests a focus on plasma and IgG-related inhibition. The evidence supports the main point of inhibiting spike protein binding to ACE2, although it is somewhat indirect about explicit RNA involvement.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5489836931228638,
    "x2e_entail_prob": 0.026469334959983826
  },
  {
    "id": "covid_fact-000879",
    "statement": "Cdna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.",
      "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.",
      "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions plasma from recovered COVID-19 patients inhibiting spike protein binding to ACE2, correlated with anti-trimer IgG levels, in a microsphere-based assay. There is no mention of cDNA being involved in this process.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0049024405889213085,
    "x2e_entail_prob": 0.01894005388021469
  },
  {
    "id": "covid_fact-000880",
    "statement": "Dana-farber to test blood cancer drug in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions that Dana-Farber is collaborating on studies involving the immune system in COVID-19 patients and the potential role of BTK-inhibitors, which are often used in blood cancer treatments. However, there is no direct evidence in the provided information that Dana-Farber is specifically testing a blood cancer drug in COVID-19 patients. The claim is not entirely supported by the evidence given.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.12555424869060516,
    "x2e_entail_prob": 0.02285578101873398
  },
  {
    "id": "covid_fact-000881",
    "statement": "Dana-farber to test breast cancer drug in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a collaboration involving BTK-inhibitors in COVID-19 patients, but it does not specifically mention a breast cancer drug being tested in COVID-19 patients by Dana-Farber. The claim about testing a breast cancer drug in COVID-19 patients is not supported by the given evidence.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.038049306720495224,
    "x2e_entail_prob": 0.0034269425086677074
  },
  {
    "id": "covid_fact-000882",
    "statement": "Dana-farber to test human cancer drug in covid-19 patients",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Dana-Farber is involved in studies using BTK-inhibitors, a type of drug, in the context of COVID-19 patients. This suggests that Dana-Farber is indeed testing a drug, typically used in cancer treatment, on COVID-19 patients, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5367735028266907,
    "x2e_entail_prob": 0.001138156745582819
  },
  {
    "id": "covid_fact-000883",
    "statement": "Hydroxychloroquine improves airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence mentions that hydroxychloroquine is a well-tolerated and safe immunomodulating drug with actions suggesting potential utility in asthma treatment. However, it does not specifically confirm that hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. Therefore, the claim is not directly supported by the evidence given.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.011910073459148407,
    "x2e_entail_prob": 0.5696284770965576
  },
  {
    "id": "covid_fact-000884",
    "statement": "Hydroxychloroquine improves airflow and increases circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only suggests that hydroxychloroquine has potential utility in the treatment of asthma due to its known actions and efficacy in rheumatic diseases. It does not specifically address its effects on airflow or circulating IgE levels in subjects with moderate symptomatic asthma, which are key aspects of the claim.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.004130911082029343,
    "x2e_entail_prob": 0.25882992148399353
  },
  {
    "id": "covid_fact-000885",
    "statement": "Hydroxychloroquine decreases airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specifically address the claim that hydroxychloroquine decreases airflow and lowers circulating IgE levels in individuals with moderate symptomatic asthma. While the evidence suggests hydroxychloroquine has potential utility in asthma treatment due to its immunomodulating properties, it does not confirm the specific effects on airflow and circulating IgE levels as claimed.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.012072799727320671,
    "x2e_entail_prob": 0.1819901317358017
  },
  {
    "id": "covid_fact-000886",
    "statement": "Hydroxychloroquine improves airflow and increased circulating ige levels in subjects with moderate symptomatic asthma",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "While the evidence describes hydroxychloroquine as an immunomodulating drug with potential utility in the treatment of asthma, it does not specifically state that it improves airflow and increases circulating IgE levels in asthmatic subjects. The claim cannot be supported without explicit evidence of these effects.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0028651717584580183,
    "x2e_entail_prob": 0.11841236054897308
  },
  {
    "id": "covid_fact-000887",
    "statement": "Moderna has completed case accrual for first planned interim analysis of its mrna vaccine against covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided offers details about mRNA-1273 as an mRNA vaccine developed by Moderna and co-developed with NIAID, including some timeline details of its early development and testing. However, it does not specifically confirm that Moderna has completed case accrual for the first planned interim analysis of this vaccine. Thus, the claim is not directly supported by the given evidence.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0217916127294302,
    "x2e_entail_prob": 0.07542748749256134
  },
  {
    "id": "covid_fact-000888",
    "statement": "Moderna has no case accrual for first planned interim analysis of its mrna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided offers information regarding mRNA-1273, an mRNA vaccine developed by Moderna and the NIH, including details on production and testing timelines. However, there is no information on case accrual related to the first planned interim analysis, making it impossible to support the claim based on the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0036509637720882893,
    "x2e_entail_prob": 0.18651586771011353
  },
  {
    "id": "covid_fact-000889",
    "statement": "Moderna has completed case accrual for first planned interim analysis of its dna vaccine against covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.",
      "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided describes mRNA-1273 as an mRNA vaccine, not a DNA vaccine as the claim states. Additionally, there is no information regarding the completion of case accrual for a planned interim analysis. Therefore, the claim is not supported by the evidence presented.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.3339312970638275,
    "x2e_entail_prob": 0.5933593511581421
  },
  {
    "id": "covid_fact-000890",
    "statement": "Amplicon contamination in labs masquerades as covid19 in surveillance tests",
    "label": "SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that amplicon contamination is a known issue that can impact COVID-19 surveillance tests. The mention of 'minimizing instances of amplicon contamination' and the development of protocols implies that such contamination can indeed masquerade as positive COVID-19 results, highlighting the need for careful management. Therefore, the claim is supported, although the evidence is not extensive enough for a higher confidence rating.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.19524936378002167,
    "x2e_entail_prob": 0.003798920661211014
  },
  {
    "id": "covid_fact-000891",
    "statement": "Amplicon contamination in human masquerades as covid19 in surveillance tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the importance of minimizing instances of amplicon contamination to avoid misallocating resources from COVID-19 patients. However, it does not explicitly confirm that amplicon contamination in humans masquerades as COVID-19 in surveillance tests. The evidence emphasizes protocol development and research, but does not provide a clear link to the specific claim of misidentification in tests.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.013705382123589516,
    "x2e_entail_prob": 0.10620655864477158
  },
  {
    "id": "covid_fact-000892",
    "statement": "Amplicon contamination in labs masquerades as covid19 in preparation tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that amplicon contamination is an issue that labs need to address to avoid resource diversion, but it does not support the claim that amplicon contamination masquerades as COVID-19 in preparation tests. There is no direct evidence linking amplicon contamination specifically to false positives or misidentification as COVID-19.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.01460670679807663,
    "x2e_entail_prob": 0.12523628771305084
  },
  {
    "id": "covid_fact-000893",
    "statement": "Amplicon contamination in labs masquerades as covid19 in children tests",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence highlights the importance of addressing amplicon contamination to avoid misallocation of resources, but does not directly support the specific claim that amplicon contamination specifically masquerades as COVID-19 in children's test results.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.002947827335447073,
    "x2e_entail_prob": 0.010998471640050411
  },
  {
    "id": "covid_fact-000894",
    "statement": "Male sex hormones appear to help the coronavirus infiltrate human cells",
    "label": "SUPPORTED",
    "evidences": [
      "Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that studies have found male hormones, including testosterone, assist SARS-CoV-2, the virus causing COVID-19, in infiltrating human cells, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.16519103944301605,
    "x2e_entail_prob": 0.0014665968483313918
  },
  {
    "id": "covid_fact-000895",
    "statement": "Male sex hormones fail to help the coronavirus infiltrate human cells",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that androgens, male hormones such as testosterone, actually aid the infiltration of SARS-CoV-2 into human cells, contrary to the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0763329416513443,
    "x2e_entail_prob": 0.0014568263432011008
  },
  {
    "id": "covid_fact-000896",
    "statement": "Il-6 : a novel signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies",
    "label": "SUPPORTED",
    "evidences": [
      "Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.",
      "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that IL-6, when considered as part of the sMIL Index alongside sMAdCAM, is associated with COVID-19 disease progression and the development of anti-SARS-CoV-2 antibodies. This supports the claim that IL-6 is a component of a novel signature related to these conditions.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.818576455116272,
    "x2e_entail_prob": 0.5649279952049255
  },
  {
    "id": "covid_fact-000897",
    "statement": "Il-6 : a common signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.",
      "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about IL-6 being a common signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies. The evidence presents the sMIL index, which combines IL-6 and sMAdCAM, as a novel marker associated with both disease states (early infection and convalescence) and development of antiviral responses. This supports the claim that IL-6 is linked to COVID-19 disease progression and antibody development.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7580687999725342,
    "x2e_entail_prob": 0.9233114123344421
  },
  {
    "id": "covid_fact-000898",
    "statement": "Slovakia to test all adults for sars-cov-2",
    "label": "SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that Slovakia has initiated a massive operation to test its entire adult population for SARS-CoV-2, which directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1127283126115799,
    "x2e_entail_prob": 0.0014358862536028028
  },
  {
    "id": "covid_fact-000899",
    "statement": "He to test all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence refers broadly to Slovakia's efforts to test its entire adult population. However, the claim 'He to test all adults for sars-cov-2' is too vague due to the unidentified 'He' and lacks specificity about who is carrying out the operation, so it is not directly supported by the evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.022290335968136787,
    "x2e_entail_prob": 0.001155179226770997
  },
  {
    "id": "covid_fact-000900",
    "statement": "Slovakia to represent all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that Slovakia is testing its entire adult population for SARS-CoV-2, but it does not indicate that Slovakia is representing all adults globally for SARS-CoV-2. The claim suggests a representation beyond just a national context, which is not supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.07854190468788147,
    "x2e_entail_prob": 0.0010925043607130647
  },
  {
    "id": "covid_fact-000901",
    "statement": "failed to test all adults for sars-cov-2",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Slovakia initiated a program to test its entire adult population for SARS-CoV-2. There is no mention in the evidence of the failure to test all adults. Since the claim specifically mentions a failure, more specific evidence is needed to support this, which is absent here.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.04487738013267517,
    "x2e_entail_prob": 0.0015790811739861965
  },
  {
    "id": "covid_fact-000902",
    "statement": "Extra doses found in pfizer 's coronavirus vaccine.",
    "label": "SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that pharmacists discovered extra doses in vials of Pfizer's coronavirus vaccine, which were initially intended to hold five doses. The FDA has also confirmed that these extra doses can be used, thus supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.22261802852153778,
    "x2e_entail_prob": 0.021260524168610573
  },
  {
    "id": "covid_fact-000903",
    "statement": "No doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence directly contradicts the claim. It indicates that there are actually extra doses found in Pfizer's coronavirus vaccine vials, not that there are no doses found. The claim is therefore not supported by the evidence provided.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.004743690136820078,
    "x2e_entail_prob": 0.027613673359155655
  },
  {
    "id": "covid_fact-000904",
    "statement": "One doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to the number of doses found in Pfizer's coronavirus vaccine. The evidence indicates that pharmacists discovered some vials had extra doses, and the FDA approved using these additional doses. However, the claim suggests a singular dose which is inaccurate in the context of the claim, as the evidence does not specify any instance of just 'one dose' being found in a vial.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.08824601769447327,
    "x2e_entail_prob": 0.0254526287317276
  },
  {
    "id": "covid_fact-000905",
    "statement": "Low doses found in pfizer's coronavirus vaccine.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.",
      "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.",
      "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.",
      "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that 'low doses' are found in Pfizer's coronavirus vaccine. The evidence provided discusses extra doses found in vials of the Pfizer vaccine and how they can be used, but does not support the assertion of 'low doses' within the vaccine itself. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0347420796751976,
    "x2e_entail_prob": 0.031929899007081985
  },
  {
    "id": "covid_fact-000906",
    "statement": "Bradykinin initiates cytokine-mediated inflammatory hyperalgesia",
    "label": "SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that bradykinin can trigger the cascade of cytokine release, which is involved in mediating hyperalgesic responses. Additionally, bradykinin's release of TNF-alpha, a cytokine, plays a crucial role in inflammatory hyperalgesia. Therefore, the claim that bradykinin initiates cytokine-mediated inflammatory hyperalgesia is well-supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9783072471618652,
    "x2e_entail_prob": 0.002628697780892253
  },
  {
    "id": "covid_fact-000907",
    "statement": "Bradykinin initiates cytokine-independent inflammatory hyperalgesia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that bradykinin initiates cytokine release, specifically TNF-alpha, which plays a role in inflammatory hyperalgesia. This implies that the inflammatory hyperalgesia is cytokine-dependent, not independent, as stated in the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0026278910227119923,
    "x2e_entail_prob": 0.0016381419263780117
  },
  {
    "id": "covid_fact-000908",
    "statement": "Bradykinin cans cytokine-mediated inflammatory hyperalgesia",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).",
      "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that bradykinin can initiate a cascade of cytokine release, which is involved in mediating hyperalgesic (increased sensitivity to pain) responses. Therefore, the claim that bradykinin can affect cytokine-mediated inflammatory hyperalgesia is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.585810124874115,
    "x2e_entail_prob": 0.001191588002257049
  },
  {
    "id": "covid_fact-000909",
    "statement": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and protect animals",
    "label": "SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides data on monoclonal antibodies that target the spike protein of SARS-CoV-2 and exhibit potent neutralizing activity. However, there is no specific mention of these antibodies blocking receptor binding or directly protecting animals, which are two key components of the claim. Thus, the claim is not fully supported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.059182822704315186,
    "x2e_entail_prob": 0.01242491602897644
  },
  {
    "id": "covid_fact-000910",
    "statement": "Potently neutralizing mouse antibodies that block sars-cov-2 receptor binding and protect animals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence presents information about mAbs targeting the spike protein from infected human subjects, but it does not specifically mention mouse antibodies or their efficacy in blocking receptor binding or protecting animals from SARS-CoV-2.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.00391387427225709,
    "x2e_entail_prob": 0.014666779898107052
  },
  {
    "id": "covid_fact-000911",
    "statement": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and neutralization animals",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided confirms that the identified monoclonal antibodies exhibit potent neutralizing activity against SARS-CoV-2 in vitro. However, there is no mention of these antibodies blocking receptor binding or protecting animals, which are key components of the claim. Therefore, the claim is not fully supported by the evidence provided.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.05020688474178314,
    "x2e_entail_prob": 0.014122750610113144
  },
  {
    "id": "covid_fact-000912",
    "statement": "Persistence of viral rna , pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim mentions persistence of viral RNA, pneumocyte syncytia, and thrombosis as hallmarks of advanced COVID-19 pathology. The provided evidence consists of studies focusing on the pathological and thrombotic complications of COVID-19, which supports the claim that these factors are significant features of severe or advanced cases. Given that the studies directly address these aspects, the claim is supported by the evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.743220329284668,
    "x2e_entail_prob": 0.18690809607505798
  },
  {
    "id": "covid_fact-000913",
    "statement": "Persistence of viral dna, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that persistence of viral DNA, pneumocyte syncytia, and thrombosis are hallmarks of advanced COVID-19 pathology. The provided evidence titles suggest studies that focus on viral presence, immunopathology, and thrombotic disease related to COVID-19. These topics align with the hallmarks mentioned in the claim. Autopsy studies often reveal detailed postmortem pathology, including viral persistence and syncytial formations, while other studies have linked COVID-19 with thrombosis, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7966790199279785,
    "x2e_entail_prob": 0.30569523572921753
  },
  {
    "id": "covid_fact-000914",
    "statement": "Persistence of viral replication, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.",
      "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that persistent viral replication, pneumocyte syncytia, and thrombosis are key features of advanced COVID-19 pathology. Published studies on COVID-19 autopsies highlight the presence of SARS-CoV-2 in tissues and emphasize thrombotic events as significant in severe cases. Additionally, these studies often describe the formation of multinucleated giant cells (syncytia), which are indicative of cellular infections and are reported in severe COVID-19 cases. Therefore, the claim is well-supported by medical literature.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.38163936138153076,
    "x2e_entail_prob": 0.31424015760421753
  },
  {
    "id": "covid_fact-000915",
    "statement": "The novel severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence directly states that SARS-CoV-2 induces severe tissue damage, including lymph follicle depletion and splenic nodule atrophy, confirming that it decimates human spleens and lymph nodes. The claim is corroborated by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9356251358985901,
    "x2e_entail_prob": 0.9686362743377686
  },
  {
    "id": "covid_fact-000916",
    "statement": "The primary severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided explicitly states that the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. The evidence further supports this by describing the specific types of tissue damage induced by the virus, such as lymph follicle depletion and splenic nodule atrophy, confirming the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.20901703834533691,
    "x2e_entail_prob": 0.9836005568504333
  },
  {
    "id": "covid_fact-000917",
    "statement": "The first severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes",
      "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.",
      "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. The evidence provided confirms this by stating the same claim specifically and describing the kinds of tissue damage SARS-CoV-2 causes, such as lymph follicle depletion and splenic nodule atrophy. Therefore, the claim is supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9288804531097412,
    "x2e_entail_prob": 0.9637633562088013
  },
  {
    "id": "covid_fact-000918",
    "statement": "Researchers discover new variant of covid-19 virus in columbus , ohio.",
    "label": "SUPPORTED",
    "evidences": [
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.",
      "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.",
      "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
      "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.",
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that researchers at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19. Additionally, it is mentioned that this variant was discovered in Columbus. Therefore, the claim is well-supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.019677983596920967,
    "x2e_entail_prob": 0.10661504417657852
  },
  {
    "id": "covid_fact-000919",
    "statement": "Researchers no new variant of covid-19 virus in columbus, ohio.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.",
      "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.",
      "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.",
      "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.",
      "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that researchers at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19 in Columbus, Ohio. This directly supports the claim that a new variant of the virus was found in that location.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.028532136231660843,
    "x2e_entail_prob": 0.10971631109714508
  },
  {
    "id": "covid_fact-000920",
    "statement": "Coronavirus vaccine shows promising early results in china",
    "label": "SUPPORTED",
    "evidences": [
      "Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.",
      "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.",
      "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that a coronavirus vaccine shows promising early results in China is supported by the evidence, which states that a vaccine developed in China appears to be safe and may protect people from the virus. Additionally, the vaccine has entered mid-stage human trials, indicating promising early results.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9565598368644714,
    "x2e_entail_prob": 0.03518858179450035
  },
  {
    "id": "covid_fact-000921",
    "statement": "Coronavirus vaccine shows no early results in china",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.",
      "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.",
      "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that a vaccine developed in China appears to be safe and may protect people from the new coronavirus. It also mentions that the vaccine has entered mid-stage human trials, suggesting progress has been made. Therefore, the claim that the vaccine shows no early results is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.03189416229724884,
    "x2e_entail_prob": 0.028659982606768608
  },
  {
    "id": "covid_fact-000922",
    "statement": "Sars-cov-2 triggers inflammatory responses and cell death through caspase-8 activation",
    "label": "SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection triggers inflammatory responses and cell death through the activation of caspase-8. Multiple sources confirm caspase-8 is involved in mediating pro-inflammatory cytokine processing and inducing apoptosis, supporting the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.11195416748523712,
    "x2e_entail_prob": 0.20352764427661896
  },
  {
    "id": "covid_fact-000923",
    "statement": "Sars-cov-2 suppress inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 infection triggers apoptosis through the activation of caspase-8. It also mentions that caspase-8 activation mediates inflammatory cytokine processing. While the claim states SARS-CoV-2 suppresses inflammatory responses and cell death, the evidence suggests activation of caspase-8 leads to cell death and inflammatory responses. The claim is somewhat supported but may be misinterpreted unless caspase-8 activation is part of a negative feedback to suppress further inflammation and cell death.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.23969914019107819,
    "x2e_entail_prob": 0.11244198679924011
  },
  {
    "id": "covid_fact-000924",
    "statement": "Sars-cov-2 inhibits inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection activates caspase-8, leading to apoptosis (cell death) and inflammatory cytokine processing. However, it does not support the claim that SARS-CoV-2 inhibits inflammatory responses and cell death through caspase-8 activation. Instead, the evidence suggests that caspase-8 activation by SARS-CoV-2 contributes to these processes rather than inhibiting them.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.03677723929286003,
    "x2e_entail_prob": 0.04397192597389221
  },
  {
    "id": "covid_fact-000925",
    "statement": "Sars-cov-2 inhibited inflammatory responses and cell death through caspase-8 activation",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.",
      "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1\u03b2 processing.",
      "2 SARS-CoV-2 infection induces caspase-8 activation Fig.",
      "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.",
      "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that SARS-CoV-2 infection activates caspase-8, which triggers apoptosis and inflammatory cytokine processing, contrary to the claim that it inhibited these processes. The evidence supports activation, not inhibition, of inflammatory responses and cell death.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.875251293182373,
    "x2e_entail_prob": 0.2303004115819931
  },
  {
    "id": "covid_fact-000926",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks.",
    "label": "SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that there was a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks, observing reinfection with SARS-CoV-2. The evidence indicates that 43,044 anti-SARS-CoV-2 positive individuals were followed for a median of 16.3 weeks, with the range up to 34.6 weeks, and 314 individuals (0.7%) experienced PCR-confirmed reinfection. Thus, the evidence supports the claim concerning both cohort size and follow-up duration.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6543631553649902,
    "x2e_entail_prob": 0.9475853443145752
  },
  {
    "id": "covid_fact-000927",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 years.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that 43,044 antibody-positive individuals were followed for a median of 16.3 weeks, not up to 35 years. Therefore, the claim of following individuals for up to 35 years is not supported by the evidence.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.5136866569519043,
    "x2e_entail_prob": 0.8938150405883789
  },
  {
    "id": "covid_fact-000928",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 days.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that the cohort was followed for up to 35 days, but the evidence indicates a follow-up range of up to 34.6 weeks, not days. Therefore, the claim regarding the duration of the follow-up period is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1139448955655098,
    "x2e_entail_prob": 0.802217423915863
  },
  {
    "id": "covid_fact-000929",
    "statement": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 hours.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.",
      "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the cohort was followed for a median of 16.3 weeks, with a range of 0 to 34.6 weeks. The claim of following individuals for up to 35 hours is incorrect as individuals were actually followed for much longer.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.002823776099830866,
    "x2e_entail_prob": 0.7990327477455139
  },
  {
    "id": "covid_fact-000930",
    "statement": "Anakinra to prevent respiratory failure in covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that early suPAR-guided anakinra treatment is associated with a decreased risk of respiratory failure (SRF) in COVID-19 patients. This implies that anakinra might help prevent respiratory failure, thus supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.04699988663196564,
    "x2e_entail_prob": 0.04090401157736778
  },
  {
    "id": "covid_fact-000931",
    "statement": "Anakinra to prevent neurological failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests using Anakinra to prevent neurological failure in COVID-19, but the evidence only shows Anakinra's effects on reducing the risk of severe respiratory failure (SRF) and improving the pro-/anti-inflammatory balance. There is no specific evidence provided about preventing neurological failure in COVID-19 patients.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.007577373646199703,
    "x2e_entail_prob": 0.3525734543800354
  },
  {
    "id": "covid_fact-000932",
    "statement": "Anakinra to cause respiratory failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that Anakinra treatment is associated with a decrease in the risk of respiratory failure in COVID-19 patients, rather than causing it. The evidence points to a reduction in inflammatory markers and severity scores, indicating a positive effect of the treatment.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.6348991394042969,
    "x2e_entail_prob": 0.30534490942955017
  },
  {
    "id": "covid_fact-000933",
    "statement": "Anakinra to causes respiratory failure in covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.",
      "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.",
      "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that anakinra treatment is associated with a decrease in the risk of severe respiratory failure (SRF) in COVID-19 patients, contradicting the claim that it causes respiratory failure.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.17104066908359528,
    "x2e_entail_prob": 0.11643008887767792
  },
  {
    "id": "covid_fact-000934",
    "statement": "Hadassah doctors crack the cause of fatal corona blood clots",
    "label": "SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Hadassah researchers identified increased levels of alpha defensin protein as a cause for the formation of fatal blood clots. This identification substantiates the claim that they have found a cause for fatal corona-related blood clots.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.3881215453147888,
    "x2e_entail_prob": 0.0030837301164865494
  },
  {
    "id": "covid_fact-000935",
    "statement": "Hadassah virus crack the cause of fatal corona blood clots",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Hadassah researchers discovered a link between increased levels of alpha defensin protein and the formation of fatal blood clots. However, the claim states that the Hadassah virus 'crack' the cause of fatal corona blood clots, suggesting a definitive solution or breakthrough regarding coronavirus-related blood clots. The provided evidence only indicates a discovery related to alpha defensin and its role in clot formation, but it does not support the assertion that this discovery is a 'crack' or breakthrough specifically related to coronavirus-caused blood clots.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7403306365013123,
    "x2e_entail_prob": 0.004464178811758757
  },
  {
    "id": "covid_fact-000936",
    "statement": "Hadassah doctors remain the cause of fatal corona blood clots",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.",
      "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that doctors from Hadassah are responsible for causing fatal blood clots related to COVID-19. However, the evidence only indicates that Hadassah researchers identified a protein that increases the risk of blood clot formation. There is no information in the evidence suggesting that the doctors are the cause of these clots. Therefore, the claim that 'Hadassah doctors remain the cause of fatal corona blood clots' is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4049834609031677,
    "x2e_entail_prob": 0.007808451075106859
  },
  {
    "id": "covid_fact-000937",
    "statement": "Virus can infect heart cells in lab dish",
    "label": "SUPPORTED",
    "evidences": [
      "The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.",
      "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence confirms that SARS-CoV-2 can infect heart cells in a lab dish. This directly supports the claim, as the study shows that the virus is capable of infecting human stem cell-derived heart cells and altering their gene expression profile, indicating active infection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9694860577583313,
    "x2e_entail_prob": 0.01275242306292057
  },
  {
    "id": "covid_fact-000938",
    "statement": "Virus cannot infect heart cells in lab dish",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.",
      "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that SARS-CoV-2 can infect heart cells in a lab dish, contradicting the claim that the virus cannot infect these cells.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.7142072916030884,
    "x2e_entail_prob": 0.0009977013105526567
  },
  {
    "id": "covid_fact-000939",
    "statement": "Alpha-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates that alpha-1 antitrypsin (\u03b11-AT) acts as an inhibitor of SARS-CoV-2. It is identified in screenings as a specific inhibitor, targeting the viral spike protein and blocking infection in human airway epithelium. This supports the claim that \u03b11-AT inhibits SARS-CoV-2 infection.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.9432017207145691,
    "x2e_entail_prob": 0.04331756755709648
  },
  {
    "id": "covid_fact-000940",
    "statement": "Cox-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim mentions Cox-1 antitrypsin, but the evidence only discusses \u03b11-antitrypsin (\u03b11-AT), which is shown to inhibit SARS-CoV-2. The specific claim regarding Cox-1 antitrypsin is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.24493885040283203,
    "x2e_entail_prob": 0.1829482913017273
  },
  {
    "id": "covid_fact-000941",
    "statement": "Mcp-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that \u03b11-antitrypsin (\u03b11-AT) inhibits SARS-CoV-2 infection, not MCP-1 antitrypsin. Therefore, the claim that MCP-1 antitrypsin inhibits SARS-CoV-2 infection is not supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.13401848077774048,
    "x2e_entail_prob": 0.020927375182509422
  },
  {
    "id": "covid_fact-000942",
    "statement": "Il-1 antitrypsin inhibits sars-cov-2 infection",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our findings show that endogenous \u03b11-AT restricts SARS-CoV-2 and repurposes \u03b11-AT-based drugs for COVID-19 therapy.",
      "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified \u03b11-antitrypsin (\u03b11-AT) as specific inhibitor of SARS-CoV-2.",
      "\u03b11-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that \u03b11-antitrypsin (\u03b11-AT) is identified as a specific inhibitor of SARS-CoV-2. It targets the viral spike protein and blocks infection at physiological concentrations, which supports the claim that it inhibits SARS-CoV-2 infection.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8747214078903198,
    "x2e_entail_prob": 0.04982093721628189
  },
  {
    "id": "covid_fact-000943",
    "statement": "New study suggests children may carry covid-19 at high levels",
    "label": "SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests a new study about high levels of COVID-19 in children. However, the evidence mentions possible transmission by children without specifying that they carry the virus at high levels. It also contrasts with a South Korean study indicating younger children transmit less than adults and older children at similar rates to adults, but not about viral load levels.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.015914704650640488,
    "x2e_entail_prob": 0.014671031385660172
  },
  {
    "id": "covid_fact-000944",
    "statement": "New study suggests cats may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses the transmission and spread of SARS-CoV-2 by children of different age groups. There is no mention of cats or any indication of a study suggesting cats may carry the virus at high levels, making the claim about cats unsupported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8710132837295532,
    "x2e_entail_prob": 0.0057316855527460575
  },
  {
    "id": "covid_fact-000945",
    "statement": "New study suggests bats may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence deals with the transmission of SARS-CoV-2 among children and their role in spreading the virus but does not mention bats or suggest that they carry COVID-19 at high levels. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.004789835773408413,
    "x2e_entail_prob": 0.003821729449555278
  },
  {
    "id": "covid_fact-000946",
    "statement": "New study suggests coronaviruses may carry covid-19 at high levels",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.",
      "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that coronaviruses may carry COVID-19 at high levels. However, the evidence provided focuses on the transmission of the virus by children of different age groups and does not support the claim that coronaviruses inherently carry high levels of COVID-19. The evidence discusses transmission dynamics, not viral load levels within coronaviruses specifically.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.1717958003282547,
    "x2e_entail_prob": 0.014164339751005173
  },
  {
    "id": "covid_fact-000947",
    "statement": "In the coronavirus pandemic , we 're making decisions without reliable data",
    "label": "SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim states that decisions during the coronavirus pandemic are being made without reliable data. The evidence provided supports this claim by highlighting the absence of reliable data on the real course of the epidemic, suggesting that decision-making is taking place without complete or certain information.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.7969292402267456,
    "x2e_entail_prob": 0.024936240166425705
  },
  {
    "id": "covid_fact-000948",
    "statement": "In the coronavirus pandemic, we're making decisions with reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided explicitly states that decisions during the coronavirus pandemic are being made without reliable data. This directly contradicts the claim that decisions are being made with reliable data, and thus the claim is not supported.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.042692333459854126,
    "x2e_entail_prob": 0.01141931302845478
  },
  {
    "id": "covid_fact-000949",
    "statement": "In the coronavirus pandemic, we're making decisions and reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that decisions during the coronavirus pandemic are being made with reliable data. However, the evidence indicates that decisions are being made without reliable data, directly contradicting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.07503724098205566,
    "x2e_entail_prob": 0.0145511319860816
  },
  {
    "id": "covid_fact-000950",
    "statement": "In the coronavirus pandemic, we're making decisions in reliable data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.",
      "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that decisions during the coronavirus pandemic were made without reliable data. This directly contradicts the claim that decisions were being made based on reliable data. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1912589818239212,
    "x2e_entail_prob": 0.021963397040963173
  },
  {
    "id": "covid_fact-000951",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly decreased mortality",
    "label": "SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided clearly indicates that early transfusion of high titer anti-spike protein RBD IgG convalescent plasma significantly reduces mortality in COVID-19 patients. This supports the claim that there is a 'signal of significantly decreased mortality' with such treatment.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9161219596862793,
    "x2e_entail_prob": 0.43663421273231506
  },
  {
    "id": "covid_fact-000952",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increased mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that early transfusion with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma 'significantly reduces' rather than 'increases' mortality in COVID-19 patients. Therefore, the claim is contrary to the evidence presented.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.019181324169039726,
    "x2e_entail_prob": 0.24254465103149414
  },
  {
    "id": "covid_fact-000953",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increase mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that early transfusion of COVID-19 patients with high titer anti-spike protein IgG convalescent plasma decreases mortality, not increases it. The claim is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.06885337084531784,
    "x2e_entail_prob": 0.20720960199832916
  },
  {
    "id": "covid_fact-000954",
    "statement": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly higher mortality",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.",
      "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).",
      "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.",
      "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that early transfusion of COVID-19 patients with high titer convalescent plasma leads to significantly higher mortality. However, the evidence provided indicates the opposite: that early transfusion significantly reduces mortality. Therefore, the claim is not supported by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0008597979904152453,
    "x2e_entail_prob": 0.03582317754626274
  },
  {
    "id": "covid_fact-000955",
    "statement": "Egyptian doctors are speaking out against health authorities over increasing coronavirus infections and deaths among medical staff across the country .",
    "label": "SUPPORTED",
    "evidences": [
      "Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.",
      "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.",
      "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Egyptian doctors have expressed their discontent with the health authorities over inadequate protection against COVID-19. There are reports of doctors speaking out about their anger and accusations of neglect, as well as arrests of medical professionals who criticized governmental policies, which supports the claim regarding doctors speaking out against health authorities over infections and deaths among medical staff.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.1010865792632103,
    "x2e_entail_prob": 0.0010104847606271505
  },
  {
    "id": "covid_fact-000956",
    "statement": "Egyptian doctors are ruled out against health authorities over increasing coronavirus infections and deaths among medical staff across the country.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.",
      "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.",
      "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that Egyptian doctors have expressed dissatisfaction and anger towards authorities regarding the lack of protective equipment and the handling of coronavirus infections. Additionally, doctors who speak out have faced threats and penalties, which aligns with the claim of conflict between doctors and health authorities due to increasing coronavirus infections and deaths among medical staff.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.234083354473114,
    "x2e_entail_prob": 0.0018513953546062112
  },
  {
    "id": "covid_fact-000957",
    "statement": "High sars-cov-2 viral load is associated with a worse clinical outcome of covid-19 disease",
    "label": "SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provides a statistically significant correlation between high viral load and worse clinical outcomes in COVID-19 disease. It also highlights that this correlation is independent of other risk factors, supporting the claim that high SARS-CoV-2 viral load is associated with worse clinical outcomes.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4776303470134735,
    "x2e_entail_prob": 0.13924287259578705
  },
  {
    "id": "covid_fact-000958",
    "statement": "High sars-cov-2 viral load is associated with a greater clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly indicates a statistically significant correlation between high viral load and worse clinical outcomes in COVID-19 patients. It explicitly states that high viral load is associated with a worse clinical prognosis, independent of other risk factors. Therefore, the claim is well-supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3776978552341461,
    "x2e_entail_prob": 0.3456663489341736
  },
  {
    "id": "covid_fact-000959",
    "statement": "High sars-cov-2 viral load is associated with a better clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that a high SARS-CoV-2 viral load is associated with worse clinical outcomes, not better. Therefore, the claim is not supported.",
    "confidence": 1.0,
    "e2x_entail_prob": 0.028037337586283684,
    "x2e_entail_prob": 0.07448308169841766
  },
  {
    "id": "covid_fact-000960",
    "statement": "High sars-cov-2 viral load is associated with a higher clinical outcome of covid-19 disease",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).",
      "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.",
      "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states a correlation between high viral load and worse clinical prognosis for COVID-19, indicating that higher viral loads are associated with increased severity of the disease. This supports the claim that high SARS-CoV-2 viral load is associated with a higher clinical outcome of COVID-19 disease.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9126785397529602,
    "x2e_entail_prob": 0.02708161249756813
  },
  {
    "id": "covid_fact-000961",
    "statement": "In silico mutagenesis of human ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species",
    "label": "SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is about the explanation of SARS-CoV-2 infectivity in different species through in silico mutagenesis analyzing ACE2 and the S protein, along with translational efficiency. The evidence suggests that genomic variability in ACE2 affects its interaction with SARS-CoV-2, and translational efficiency contributes to infection dynamics. The evidence also mentions that SARS-CoV-2's interaction with ACE2 and its translation efficiency are key factors for infection. Therefore, the claim is supported by the given evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.731097400188446,
    "x2e_entail_prob": 0.23476165533065796
  },
  {
    "id": "covid_fact-000962",
    "statement": "In silico mutagenesis of bat ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim suggests that in silico mutagenesis of bat ACE2 with the S protein and translational efficiency explain SARS-CoV-2 infectivity in different species. The evidence supports this by mentioning that genomic variability, including ACE2 variants, affects recognition by SARS-CoV-2 and that two significant factors for infection are ACE2-mediated entry and viral translation efficiency. Moreover, the interaction and translation efficiency of SARS-CoV-2 vary across species, which aligns with the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9229898452758789,
    "x2e_entail_prob": 0.23861396312713623
  },
  {
    "id": "covid_fact-000963",
    "statement": "In silico mutagenesis of human ace2 with s protein and translational efficiency inhibited sars-cov-2 infectivity in different species",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.",
      "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.",
      "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.",
      "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.",
      "SARS-CoV-2 translational efficiency and ACE2 expression across species."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the role of ACE2 and translational efficiency in SARS-CoV-2 infectivity but does not specifically mention 'in silico mutagenesis' of human ACE2 with the S protein or its effect on translational efficiency and infectivity in various species. Therefore, the claim is not directly supported by the provided evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.004723680671304464,
    "x2e_entail_prob": 0.05652084946632385
  },
  {
    "id": "covid_fact-000964",
    "statement": "Plasmin cascade mediates thrombolytic events in sars-cov-2 infection via complement and platelet-activating systems",
    "label": "SUPPORTED",
    "evidences": [
      "Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that plasmin is a key mediator that influences interactions between the complement and platelet-activating systems in lung epithelial cells during SARS-CoV-2 infection. This supports the claim that the plasmin cascade mediates thrombolytic events via these systems.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0026394540909677744,
    "x2e_entail_prob": 0.06807737797498703
  },
  {
    "id": "covid_fact-000965",
    "statement": "Plasmin cascade mediates thrombolytic events in sars-cov-2 production via complement and platelet-activating systems",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence supports the claim that plasmin cascade mediates thrombolytic events in SARS-CoV-2 production by indicating plasmin's role as a crucial mediator in interactions between complement and platelet-activating systems. However, the specific mention of 'thrombolytic events' isn't directly substantiated by the evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.014425057917833328,
    "x2e_entail_prob": 0.020023643970489502
  },
  {
    "id": "covid_fact-000966",
    "statement": "Private firm running uk ppe stockpile was sold in middle of pandemic .",
    "label": "SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there was a change in the management of the UK PPE stockpile, from a German-owned multinational to an American one, during the pandemic. This supports the claim that the private firm running the UK PPE stockpile was sold in the middle of the pandemic, given that change of management often coincides with a sale or transfer of ownership.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.06438009440898895,
    "x2e_entail_prob": 0.1440744549036026
  },
  {
    "id": "covid_fact-000967",
    "statement": "Private firm running uk ppe stockpile was established in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not confirm the claim that the private firm running the UK's PPE stockpile was established in the middle of the pandemic. The evidence only indicates a change in management of the stock from a German-owned multinational to an American firm but does not specify when the firm was established nor does it mention any new establishment during the pandemic.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.017305215820670128,
    "x2e_entail_prob": 0.08374252170324326
  },
  {
    "id": "covid_fact-000968",
    "statement": "No firm running uk ppe stockpile was sold in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that no firm running the UK PPE stockpile was sold during the pandemic. The evidence indicates a change in management from a German-owned multinational to an American one, which implies a possible sale or transfer of management. However, it does not specify if this occurred during the pandemic, nor does it categorically deny any firm being sold. Thus, the evidence does not conclusively support the claim.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.17221371829509735,
    "x2e_entail_prob": 0.6044049263000488
  },
  {
    "id": "covid_fact-000969",
    "statement": "Private firm running uk ppe stockpile was developed in middle of pandemic.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.",
      "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence talks about the transition of management from a German-owned multinational to an American one, and the potential changes in responsibility for distributing PPE stockpile. However, it does not confirm that a private firm running the UK PPE stockpile was developed in the middle of the pandemic.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.007687355391681194,
    "x2e_entail_prob": 0.26026687026023865
  },
  {
    "id": "covid_fact-000970",
    "statement": "A systematic review uncovers a wide-gap between covid-19 in humans and animal models",
    "label": "SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that severe illness associated with mortality, a significant aspect of COVID-19 in humans, was not observed in animal models. This suggests a wide gap in the similarities between the disease in humans and in animal models, supporting the claim.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9101282358169556,
    "x2e_entail_prob": 0.9744817614555359
  },
  {
    "id": "covid_fact-000971",
    "statement": "A systematic review focuseds a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests a wide gap between COVID-19 in humans and animal models, noting the lack of severe illness associated with mortality in these models. This supports the claim about a gap being identified in a systematic review of COVID-19 and animal models.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7034298777580261,
    "x2e_entail_prob": 0.9670464992523193
  },
  {
    "id": "covid_fact-000972",
    "statement": "A systematic review focusess a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that there is a wide gap between COVID-19 in humans and animal models, as no severe illness with mortality was observed in these models. The systematic review appears to emphasize this gap since it assesses COVID-19 across various animal models. These elements support the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8517395853996277,
    "x2e_entail_prob": 0.960342288017273
  },
  {
    "id": "covid_fact-000973",
    "statement": "A systematic review focuss a wide-gap between covid-19 in humans and animal models",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.",
      "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence provided indicates that a systemic review was conducted using search terms related to COVID-19 in both humans and animal models. It concludes that there is a wide gap between COVID-19 in humans and these animal models based on the observation of no severe illness linked to mortality in the models. This supports the claim of a wide gap identified in the systematic review.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.8730331659317017,
    "x2e_entail_prob": 0.9820146560668945
  },
  {
    "id": "covid_fact-000974",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the heart.",
    "label": "SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that SARS-CoV-2 infection causes distinct transcriptomic changes in the heart, but the evidence provided does not discuss transcriptomic changes specifically. It mentions cardiac replication and effects on heart function, but transcriptomic changes are not explicitly mentioned or supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.1294766515493393,
    "x2e_entail_prob": 0.006744279991835356
  },
  {
    "id": "covid_fact-000975",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lung.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence focuses on cardiac effects of SARS-CoV-2 infection, including replication in the heart and its potential impact on heart function. However, it does not mention transcriptomic changes within the lung associated with cardiac SARS-CoV-2 infection. Thus, the claim lacks support in the provided evidence.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.0023847080301493406,
    "x2e_entail_prob": 0.004510656464844942
  },
  {
    "id": "covid_fact-000976",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lungs.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided discusses cardiac replication of SARS-CoV-2 and its effects on the heart and vascular system. However, it does not mention distinct transcriptomic changes within the lungs associated with cardiac SARS-CoV-2 infection. Therefore, the claim is not supported by the presented evidence.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0029145185835659504,
    "x2e_entail_prob": 0.005406548269093037
  },
  {
    "id": "covid_fact-000977",
    "statement": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the liver.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.",
      "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.",
      "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.",
      "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided primarily discusses the cardiac replication of SARS-CoV-2 and its effects on heart function. There is no mention or evidence of transcriptomic changes within the liver associated with cardiac SARS-CoV-2 infection. Therefore, the claim is not supported by the evidence given.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.007621733471751213,
    "x2e_entail_prob": 0.0060376194305717945
  },
  {
    "id": "covid_fact-000978",
    "statement": "'in a few weeks , we will have coronavirus vaccine '",
    "label": "SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does indicate optimism around the timeline for developing the vaccine, with references to accelerating development and having a vaccine in a few weeks. However, 'in a few weeks' does not align with the noted 90-day safety approval timeline, which suggests a longer period. Therefore, the specific claim of having a vaccine 'in a few weeks' lacks definitive support from the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.16588206589221954,
    "x2e_entail_prob": 0.09161509573459625
  },
  {
    "id": "covid_fact-000979",
    "statement": "'in a few years, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates efforts and an optimistic outlook towards the development of a coronavirus vaccine in a few weeks, rather than a few years as claimed. The information suggests a rapid development and approval process, not aligning with the claim's timeline.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.8066518902778625,
    "x2e_entail_prob": 0.004112958908081055
  },
  {
    "id": "covid_fact-000980",
    "statement": "'in a few hours, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that a coronavirus vaccine will be available in a few hours, but the evidence indicates that the vaccine was expected to undergo safety approval in 90 days and may be available in a few weeks if everything goes accordingly. The timeframe described in the evidence does not match the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4543134868144989,
    "x2e_entail_prob": 0.12276387214660645
  },
  {
    "id": "covid_fact-000981",
    "statement": "'in a few decades, we will have coronavirus vaccine '",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The vaccine could \"achieve safety approval in 90 days,\" he said.",
      "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.",
      "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"",
      "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that a coronavirus vaccine will be available in a few decades, but the evidence points to vaccine development occurring in weeks. This is contradictory, as the timelines do not align with a 'few decades' timeframe.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.26781848073005676,
    "x2e_entail_prob": 0.0042448523454368114
  },
  {
    "id": "covid_fact-000982",
    "statement": "Indiana bans all non-essential gatherings over 250 people",
    "label": "SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence shows that the state of Indiana, under Governor Eric Holcomb's directive, has implemented measures to limit non-essential gatherings to no more than 250 people, effectively banning those over this number. This supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.682330310344696,
    "x2e_entail_prob": 0.06323513388633728
  },
  {
    "id": "covid_fact-000983",
    "statement": "Indiana bans all non-essential gatherings over 15 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Indiana has limited non-essential gatherings to 250 people, not 15. There is no evidence supporting a ban on gatherings over 15 people.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.3007533848285675,
    "x2e_entail_prob": 0.11039070039987564
  },
  {
    "id": "covid_fact-000984",
    "statement": "Indiana bans all non-essential gatherings over 10 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Indiana has banned non-essential gatherings of more than 250 people, not 10 people as claimed. Thus, the claim is not supported by the evidence.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.2821996808052063,
    "x2e_entail_prob": 0.02826075069606304
  },
  {
    "id": "covid_fact-000985",
    "statement": "Indiana bans all non-essential gatherings over 20 people",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.",
      "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.",
      "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.",
      "Non-essential gatherings must be limited to no more than 250 people."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that Indiana bans non-essential gatherings of more than 250 people, not 20 people as claimed. Therefore, the claim is not supported by the provided evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.45902448892593384,
    "x2e_entail_prob": 0.06838009506464005
  },
  {
    "id": "covid_fact-000986",
    "statement": "Evaluation of four commercial , fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a revision of the Siemens SARS-CoV-2 IgG assay is suggested. The impaired sensitivity of the Siemens COV2G assay and the recommendation to switch to the newly filed sCOVG assay support the claim. Additionally, lowering the cut-off index and considering borderline results also imply a need for revision.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8930245041847229,
    "x2e_entail_prob": 0.21856825053691864
  },
  {
    "id": "covid_fact-000987",
    "statement": "Evaluation of two commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that the potentially impaired sensitivity of the Siemens COV2G assay necessitates a switch to a new SARS-CoV-2 IgG assay (sCOVG) and suggests lowering the cut-off index for the Siemens COV2G assay. This supports the claim of a suggested revision to the Siemens SARS-CoV-2 IgG assay.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9327908754348755,
    "x2e_entail_prob": 0.1409105509519577
  },
  {
    "id": "covid_fact-000988",
    "statement": "Evaluation of each commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence notes that the Siemens SARS-CoV-2 IgG assay (COV2G) potentially has impaired sensitivity, suggesting the need for changes such as switching to a newly filed assay (sCOVG) and considering changes in cut-off indices. This supports the claim that a revision of the Siemens SARS-CoV-2 IgG assay is needed.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9001560211181641,
    "x2e_entail_prob": 0.1053922101855278
  },
  {
    "id": "covid_fact-000989",
    "statement": "Evaluation of both commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.",
      "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.",
      "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.",
      "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence mentions a thorough evaluation of serologic tests for SARS-CoV-2 and suggests revising the Siemens SARS-CoV-2 IgG assay due to potentially impaired sensitivity. It discusses the need to switch to a newly filed assay by Siemens and suggests lowering the cut-off index for the existing assay. Therefore, the claim that evaluation of automated SARS-CoV-2 antibody tests suggests a revision of the Siemens IgG assay is supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9207221865653992,
    "x2e_entail_prob": 0.15152408182621002
  },
  {
    "id": "covid_fact-000990",
    "statement": "Global covid-19 cases surpass 75 million.",
    "label": "SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The report from January 2021 confirms that global COVID-19 cases surpassed 75 million and provides specific statistics related to this figure. The information directly supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.006586799863725901,
    "x2e_entail_prob": 0.11297320574522018
  },
  {
    "id": "covid_fact-000991",
    "statement": "Global covid-19 cases surpass 75 days.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim refers to global COVID-19 cases surpassing a number of days, which does not make sense as cases are measured in numbers, not time. The evidence provided mentions cases exceeding 75 million, not 75 days, indicating a misunderstanding of the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.10494276881217957,
    "x2e_entail_prob": 0.09396006166934967
  },
  {
    "id": "covid_fact-000992",
    "statement": "Global covid-19 cases surpass 75 persons.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that global Covid-19 cases have surpassed 75 million, which far exceeds the claim of surpassing 75 persons. The claim is therefore supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.01996130309998989,
    "x2e_entail_prob": 0.17011797428131104
  },
  {
    "id": "covid_fact-000993",
    "statement": "Global covid-19 cases surpass 75 deaths.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence states that global Covid-19 deaths surpass 1.7 million, which far exceeds the claimed number of 75 deaths, therefore supporting the claim.",
    "confidence": 1,
    "e2x_entail_prob": 0.07241325080394745,
    "x2e_entail_prob": 0.48413968086242676
  },
  {
    "id": "covid_fact-000994",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in women.",
    "label": "SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence explicitly states that the claim about COVID-19 vaccines causing infertility is false. This claim is labeled as 'NOT TRUE' by KSAT and clarified through explanations about misconceptions regarding amino acid sequences. Therefore, the false nature of the social media post is supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.0036972982343286276,
    "x2e_entail_prob": 0.0026253897231072187
  },
  {
    "id": "covid_fact-000995",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in dogs.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly labels the claim that COVID-19 vaccines cause infertility as 'NOT TRUE.' The evidence addresses the claim about COVID-19 vaccines causing infertility in humans, not dogs, but it suggests a broader myth about infertility and COVID-19 vaccines. Social media claims often stem from misinterpretations or false information, and the evidence refutes the infertility link, albeit in a human context. There is no support in the evidence provided for the claim related to dogs.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.05377883091568947,
    "x2e_entail_prob": 0.018571797758340836
  },
  {
    "id": "covid_fact-000996",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in children.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the claim of COVID-19 vaccines causing infertility in children, as suggested in a false social media post, is not true. The claim is based on a misunderstanding regarding a shared amino acid sequence between the spike protein of the SARS-CoV-2 virus and a placental protein. Multiple sources confirm that this claim is incorrect.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.0024100898299366236,
    "x2e_entail_prob": 0.038554027676582336
  },
  {
    "id": "covid_fact-000997",
    "statement": "A false post on social media claims covid-19 vaccine causes infertility in adults.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.",
      "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.",
      "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that social media posts falsely assert COVID-19 vaccines cause infertility is supported by evidence. Multiple sources, including KSAT and an Associated Press report, confirm that the claim of COVID-19 vaccines causing infertility due to a shared amino acid sequence is not true.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.04141026735305786,
    "x2e_entail_prob": 0.004493949934840202
  },
  {
    "id": "covid_fact-000998",
    "statement": "Expert reaction to people being re-tested positive for coronavirus after initial recovery",
    "label": "SUPPORTED",
    "evidences": [
      "Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?",
      "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.",
      "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.",
      "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).",
      "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided consists of expert commentary on the need for more research and data regarding patients who test positive for coronavirus after initial recovery. However, it does not contain any direct expert reactions to specific cases, nor does it provide scientifically validated information about why this phenomenon may occur. As such, the claim of 'expert reaction' is not substantiated by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.06861991435289383,
    "x2e_entail_prob": 0.024270672351121902
  },
  {
    "id": "covid_fact-000999",
    "statement": "Expert reaction to people being re-tested positive for coronavirus before initial recovery",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?",
      "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.",
      "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.",
      "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).",
      "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not specifically support the claim of expert reaction to people being re-tested positive for coronavirus before initial recovery. Instead, it discusses the need for more research and information on the virus's behavior and mentions specific concerns regarding testing accuracy and knowledge gaps. No direct expert reactions or opinions on the specific situation of re-testing positive are provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.5129690170288086,
    "x2e_entail_prob": 0.022861944511532784
  },
  {
    "id": "covid_fact-001000",
    "statement": "Il-6 inhibition could be key to covid-19",
    "label": "SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that IL-6 inhibition, such as via Tocilizumab, is expected to be a promising approach for treating severe cases of COVID-19 by blocking the IL-6 signal transduction pathway. This supports the claim as it highlights the potential importance of IL-6 inhibition in COVID-19 treatment.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.9236181974411011,
    "x2e_entail_prob": 0.9722937345504761
  },
  {
    "id": "covid_fact-001001",
    "statement": "Il-6 inhibition could be resistant to covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that IL-6 inhibition, through the blocking of IL-6 signal transduction pathways, may be a potential treatment for severe COVID-19. However, it does not support the claim that IL-6 inhibition leads to resistance to COVID-19. The evidence presents IL-6 inhibitors like Tocilizumab as treatments rather than preventive agents for resistance against the virus.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.8583677411079407,
    "x2e_entail_prob": 0.8371385335922241
  },
  {
    "id": "covid_fact-001002",
    "statement": "Il-6 overexpression could be key to covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that IL-6 plays a significant role in the severity of COVID-19, as blocking its signal transduction pathway with drugs like Tocilizumab could be an effective treatment for severe cases. This implies that IL-6 overexpression might be key to COVID-19's impact, supporting the claim.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.7131850719451904,
    "x2e_entail_prob": 0.6833998560905457
  },
  {
    "id": "covid_fact-001003",
    "statement": "Il-6 expression could be key to covid-19",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.",
      "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that IL-6 expression plays a key role in the pathology of COVID-19, as blocking its signal transduction pathway could become an effective treatment for severe cases. Tocilizumab, an IL-6 receptor blocker, is mentioned as a potential therapeutic option, supporting the claim that IL-6 is important in addressing severe COVID-19.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.8743895888328552,
    "x2e_entail_prob": 0.9478698372840881
  },
  {
    "id": "covid_fact-001004",
    "statement": "Pompeo saying that chinese labs created covid-19 .",
    "label": "SUPPORTED",
    "evidences": [
      "ANDREW HARNIK/POOL/AFP via Getty Images Secretary of State Mike Pompeo on Sunday said there was \"enormous evidence\" that COVID-19 originated in a Chinese lab.",
      "Secretary of State Mike Pompeo on Sunday claimed there was \"enormous evidence\" that COVID-19, the disease caused by the novel coronavirus, originated in a laboratory in Wuhan, China, though there has been so far no public evidence to support such a theory."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Mike Pompeo claimed there was 'enormous evidence' that COVID-19 originated in a Chinese lab. However, it also states that there has been no public evidence presented to support the theory that Chinese labs created COVID-19. Therefore, the claim is not supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.5255398750305176,
    "x2e_entail_prob": 0.3383367657661438
  },
  {
    "id": "covid_fact-001005",
    "statement": "Pompeo saying that our labs created covid-19.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "ANDREW HARNIK/POOL/AFP via Getty Images Secretary of State Mike Pompeo on Sunday said there was \"enormous evidence\" that COVID-19 originated in a Chinese lab.",
      "Secretary of State Mike Pompeo on Sunday claimed there was \"enormous evidence\" that COVID-19, the disease caused by the novel coronavirus, originated in a laboratory in Wuhan, China, though there has been so far no public evidence to support such a theory."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that Mike Pompeo claimed there is 'enormous evidence' that COVID-19 originated in a Chinese lab. However, there is no public evidence provided or mentioned to support the specific claim that any labs 'created' COVID-19.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8488613963127136,
    "x2e_entail_prob": 0.18972603976726532
  },
  {
    "id": "covid_fact-001006",
    "statement": "Interferons and viruses induce a novel truncated ace2 isoform and not the full-length sars-cov-2 receptor",
    "label": "SUPPORTED",
    "evidences": [
      "We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.",
      "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence clearly states that it is the truncated version of ACE2, known as dACE2, and not the full-length ACE2, that is induced by interferons and viruses, including SARS-CoV-2. This directly supports the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8503969311714172,
    "x2e_entail_prob": 0.002051105722784996
  },
  {
    "id": "covid_fact-001007",
    "statement": "Interferons and viruses induce a novel truncated ace2 isoform and produce the full-length sars-cov-2 receptor",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.",
      "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that a truncated ACE2 isoform (dACE2) is induced by interferons and viruses, but it does not mention the induction of a 'novel truncated ace2 isoform' nor does it support the production of the full-length SARS-CoV-2 receptor by these factors. The claim requires additional evidence to be considered supported.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.040671203285455704,
    "x2e_entail_prob": 0.015142901800572872
  },
  {
    "id": "covid_fact-001008",
    "statement": "Interferons and viruses induce a novel truncated ace2 isoform and induce the full-length sars-cov-2 receptor",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.",
      "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence clearly states that it is the truncated dACE2 isoform that is induced by interferons and viruses, not the full-length ACE2 that acts as the SARS-CoV-2 receptor. Therefore, the claim that both a novel truncated isoform and the full-length receptor are induced by interferons and viruses is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6357625126838684,
    "x2e_entail_prob": 0.014784288592636585
  },
  {
    "id": "covid_fact-001009",
    "statement": "Interferons and viruses induce a novel truncated ace2 isoform and form the full-length sars-cov-2 receptor",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.",
      "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that a novel truncated ACE2 isoform, dACE2, is induced by interferons (IFNs) and viruses. However, it does not directly mention the full-length ACE2 being the SARS-CoV-2 receptor. It is a well-established fact that the full-length ACE2 acts as a receptor for SARS-CoV-2, and the evidence specifies that dACE2 is the isoform induced by IFNs and viruses. Thus, the claim is mostly supported, especially the part about interferons and viruses inducing a truncated ACE2.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.10906915366649628,
    "x2e_entail_prob": 0.10918018966913223
  },
  {
    "id": "covid_fact-001010",
    "statement": "Neutralizing antibodies correlate with protection from sars-cov-2 in humans during a fishery vessel outbreak with high attack rate",
    "label": "SUPPORTED",
    "evidences": [
      "This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim is directly supported by the provided evidence, which states that an article with the same title as the claim has been published in J Clin Microbiol. This suggests that there is indeed a study or report linking neutralizing antibodies with protection from SARS-CoV-2 during a specific outbreak.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.4065011441707611,
    "x2e_entail_prob": 0.011734172701835632
  },
  {
    "id": "covid_fact-001011",
    "statement": "Neutralizing antibodies correlate with protection from sars-cov-2 in pigs during a fishery vessel outbreak with high attack rate",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to a study about humans, not pigs, in the context of a fishery vessel outbreak. Therefore, it does not support the claim that neutralizing antibodies correlate with protection from SARS-CoV-2 in pigs.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.007211634889245033,
    "x2e_entail_prob": 0.0020669358782470226
  },
  {
    "id": "covid_fact-001012",
    "statement": "Neutralizing antibodies correlate with protection from sars-cov-2 in mice during a fishery vessel outbreak with high attack rate",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses neutralizing antibodies correlating with protection from SARS-CoV-2 in humans during a fishery vessel outbreak, not in mice. Therefore, this evidence does not support the claim about mice.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.009497718885540962,
    "x2e_entail_prob": 0.0015427711186930537
  },
  {
    "id": "covid_fact-001013",
    "statement": "Neutralizing antibodies correlate with protection from sars-cov-2 in animals during a fishery vessel outbreak with high attack rate",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided refers to a study involving humans, not animals, indicating a misinterpretation of the original claim regarding animals. Therefore, the claim is not supported by the given evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.015382494777441025,
    "x2e_entail_prob": 0.003257362637668848
  },
  {
    "id": "covid_fact-001014",
    "statement": "Covid-19 infections leave an impact on the heart",
    "label": "SUPPORTED",
    "evidences": [
      "If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.",
      "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.",
      "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "Multiple pieces of evidence indicate that Covid-19 infections have a significant likelihood of impacting cardiovascular health, including risks of heart failure and chronic complications. The presence of heart-related symptoms such as blood clots, strokes, and heart attacks has been associated with Covid-19, supporting the claim.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9626393914222717,
    "x2e_entail_prob": 0.0010000155307352543
  },
  {
    "id": "covid_fact-001015",
    "statement": "Covid-19 infections leave an impact on the pandemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.",
      "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.",
      "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Covid-19 infections have a long-term impact on individuals' health, contributing to serious cardiovascular issues such as heart failure, blood clots, and strokes. These complications imply that Covid-19 leads to enduring health consequences, thus impacting the pandemic by potentially increasing healthcare burdens and influencing pandemic management and response strategies.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5104073286056519,
    "x2e_entail_prob": 0.003634043736383319
  },
  {
    "id": "covid_fact-001016",
    "statement": "Covid-19 infections leave an impact on the epidemic",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.",
      "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.",
      "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Covid-19 infections have significant potential to lead to chronic health complications such as heart failure, and the association with cardiovascular events like blood clots, strokes, and heart attacks demonstrates the lasting impact of infections. These chronic health issues contribute to the ongoing nature of the epidemic by increasing the burden of related health problems.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.6327747702598572,
    "x2e_entail_prob": 0.003132626647129655
  },
  {
    "id": "covid_fact-001017",
    "statement": "Covid-19 infections leave an impact on the future",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.",
      "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.",
      "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that Covid-19 infections are associated with long-term health impacts, particularly related to heart health and cardiovascular complications. This supports the claim that Covid-19 infections leave an impact on the future by potentially increasing the incidence of chronic conditions like heart failure and blood clots.",
    "confidence": 0.85,
    "e2x_entail_prob": 0.9375882744789124,
    "x2e_entail_prob": 0.002175870118662715
  },
  {
    "id": "covid_fact-001018",
    "statement": "Sars-cov1 frequent mask use in public venues , frequent hand washing , and disinfecting the living quarters were significant protective factors",
    "label": "SUPPORTED",
    "evidences": [
      "In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).",
      "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.",
      "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.",
      "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence consistently shows that frequent mask use in public venues, frequent hand washing, and disinfecting living quarters were significant protective factors, as indicated by the reported odds ratios and p-values. These protective factors were statistically significant, and the frequent mention of these measures across multiple pieces of evidence supports the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8178080320358276,
    "x2e_entail_prob": 0.8601454496383667
  },
  {
    "id": "covid_fact-001019",
    "statement": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were not protective factors",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).",
      "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.",
      "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.",
      "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that frequent mask use in public venues, frequent hand washing, and disinfecting living quarters were not protective factors for SARS-CoV-1, but the evidence clearly shows that these measures were significant protective factors, as indicated by the given odds ratios and p-values.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.1851455271244049,
    "x2e_entail_prob": 0.6226235032081604
  },
  {
    "id": "covid_fact-001020",
    "statement": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were no protective factors",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).",
      "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.",
      "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.",
      "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The available evidence indicates that frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors with strong statistical support, contrary to the claim.",
    "confidence": 0.97,
    "e2x_entail_prob": 0.649326741695404,
    "x2e_entail_prob": 0.834854006767273
  },
  {
    "id": "covid_fact-001021",
    "statement": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were less protective factors",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).",
      "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.",
      "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.",
      "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence demonstrates that frequent mask use, frequent hand washing, and disinfecting the living quarters were actually significant protective factors against SARS-CoV-1, not less protective as the claim suggests. All described odds ratios indicate these measures significantly reduced risk.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.8318735361099243,
    "x2e_entail_prob": 0.8753581643104553
  },
  {
    "id": "covid_fact-001022",
    "statement": "Major new lineages of sars-cov-2 emerge and spread in south africa during lockdown .",
    "label": "SUPPORTED",
    "evidences": [
      "We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.",
      "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates the emergence and spread of several SARS-CoV-2 lineages in South Africa, which constituted a significant portion of infections (~42%). This supports the claim of major new lineages emerging and spreading during lockdown periods.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.09614592045545578,
    "x2e_entail_prob": 0.002648592460900545
  },
  {
    "id": "covid_fact-001023",
    "statement": "Major new lineages of sars-cov-2 emerge and spread in south china during lockdown.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.",
      "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided only discusses the spread of SARS-CoV-2 lineages in South Africa, not in South China. Therefore, it does not support the claim about the emergence and spread of new lineages in South China during lockdown.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.0028321011923253536,
    "x2e_entail_prob": 0.0017283062916249037
  },
  {
    "id": "covid_fact-001024",
    "statement": "Major new lineages of sars-cov-2 emerge and spread in south asia during lockdown.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.",
      "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provides information about the spread of SARS-CoV-2 lineages in South Africa, not South Asia. There is no evidence supporting the emergence and spread of new lineages in South Asia during lockdown as per the claim.",
    "confidence": 0.95,
    "e2x_entail_prob": 0.007882479578256607,
    "x2e_entail_prob": 0.0011297541204839945
  },
  {
    "id": "covid_fact-001025",
    "statement": "Researchers race to develop in-home testing for covid-19 , a potential game changer",
    "label": "SUPPORTED",
    "evidences": [
      "The company has already developed a lab-based test thats handheld and gives results in 15 minutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided mentions the development of a lab-based test that is handheld and gives results in 15 minutes, but it does not specify whether it is specifically for in-home use. While the claim suggests a focus on in-home testing, the evidence does not confirm this aspect. Thus, the evidence does not fully support the claim about the development of in-home COVID-19 testing.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.03218421712517738,
    "x2e_entail_prob": 0.8869713544845581
  },
  {
    "id": "covid_fact-001026",
    "statement": "Researchers race to develop in-hospital testing for covid-19, a potential game changer",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The company has already developed a lab-based test thats handheld and gives results in 15 minutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions a lab-based test that is handheld and provides results in 15 minutes, but it does not specify if this is for in-hospital testing or if researchers are racing to develop it. Thus, the claim lacks sufficient evidence for full support.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.004432684276252985,
    "x2e_entail_prob": 0.147971510887146
  },
  {
    "id": "covid_fact-001027",
    "statement": "Researchers race to develop in-line testing for covid-19, a potential game changer",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The company has already developed a lab-based test thats handheld and gives results in 15 minutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the company has developed a lab-based test that is handheld and gives results in 15 minutes. However, this does not specifically confirm the development of in-line testing for COVID-19, nor does it establish that such testing is a potential game changer as claimed. The term 'in-line testing' implies real-time testing in actual use situations, which is not explicitly supported by the evidence provided.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.005051755346357822,
    "x2e_entail_prob": 0.9906243681907654
  },
  {
    "id": "covid_fact-001028",
    "statement": "Researchers race to develop in-site testing for covid-19, a potential game changer",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "The company has already developed a lab-based test thats handheld and gives results in 15 minutes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the existence of a lab-based test that is handheld and provides quick results in 15 minutes. However, it does not confirm that this test is specifically being developed for in-site COVID-19 testing, nor does it discuss the broader context of researchers racing to develop such testing as a potential 'game changer.'",
    "confidence": 0.75,
    "e2x_entail_prob": 0.0018771161558106542,
    "x2e_entail_prob": 0.9503138065338135
  },
  {
    "id": "covid_fact-001029",
    "statement": "Estimating the generation interval for covid-19 based on symptom onset data",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim involves estimating the generation interval for COVID-19 based on symptom onset data. The evidence provided discusses the importance of investigating transmission networks when estimating generation and serial interval distributions but does not specifically address or support the process or outcome of estimating the generation interval from symptom onset data.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.0072450051084160805,
    "x2e_entail_prob": 0.5401590466499329
  },
  {
    "id": "covid_fact-001030",
    "statement": "Estimating the survival interval for covid-19 based on symptom onset data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The provided evidence discusses estimating generation and serial interval distributions from outbreak data and emphasizes the need for careful investigation of the underlying transmission network. However, this evidence does not specifically address estimating the survival interval for COVID-19 based on symptom onset data, which is the main aspect of the claim. Thus, the claim is not supported by the evidence provided.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.006142343394458294,
    "x2e_entail_prob": 0.3620873987674713
  },
  {
    "id": "covid_fact-001031",
    "statement": "Estimating the time interval for covid-19 based on symptom onset data",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided does not directly support or mention estimating the time interval for COVID-19 based on symptom onset data. The evidence discusses the importance of investigating the underlying transmission network for estimating intervals, but it doesn't specifically address using symptom onset data for this purpose.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.011179747991263866,
    "x2e_entail_prob": 0.4018157422542572
  },
  {
    "id": "covid_fact-001032",
    "statement": "Inactivated rabies virus vectored sars-cov-2 vaccine prevents disease in a syrian hamster model .",
    "label": "SUPPORTED",
    "evidences": [
      "Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.",
      "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the evaluation of an inactivated rabies virus vectored SARS-CoV-2 vaccine in a Syrian hamster model, but does not explicitly confirm that it prevents disease in this model. The evidence lacks specific details on outcomes related to disease prevention in Syrian hamsters.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.0535905696451664,
    "x2e_entail_prob": 0.06649012118577957
  },
  {
    "id": "covid_fact-001033",
    "statement": "Inactivated rabies virus vectored sars-cov-2 vaccine causes disease in a syrian hamster model.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.",
      "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence discusses the evaluation of an inactivated rabies vectored SARS-CoV-2 vaccine in a Syrian hamster model but provides no information indicating that the vaccine causes disease in this model. Thus, it does not support the claim that the vaccine causes disease in a Syrian hamster model.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.02833058126270771,
    "x2e_entail_prob": 0.041472405195236206
  },
  {
    "id": "covid_fact-001034",
    "statement": "Inactivated rabies virus vectored sars-cov-2 vaccine induces disease in a syrian hamster model.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.",
      "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence mentions the evaluation of an inactivated rabies vectored SARS-CoV-2 vaccine called CORAVAX in a Syrian hamster model. However, there is no information provided on whether this vaccine induces disease in the hamsters. The evidence does not specifically support or refute the claim that the vaccine induces disease, merely that it was evaluated in that model.",
    "confidence": 0.6,
    "e2x_entail_prob": 0.23669573664665222,
    "x2e_entail_prob": 0.6505830883979797
  },
  {
    "id": "covid_fact-001035",
    "statement": "Inactivated rabies virus vectored sars-cov-2 vaccine causing disease in a syrian hamster model.",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.",
      "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence only mentions evaluation of an inactivated rabies vectored SARS-CoV-2 vaccine (CORAVAX) in a Syrian hamster model, and not that it caused disease in this model. There is no direct evidence supporting the claim that the inactivated rabies vectored vaccine caused disease in Syrian hamsters.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.035436928272247314,
    "x2e_entail_prob": 0.2290770560503006
  },
  {
    "id": "covid_fact-001036",
    "statement": "100 percent of regular icu beds in texas medical center occupied , but hospitals have space for surge",
    "label": "SUPPORTED",
    "evidences": [
      "Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.",
      "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence states that the average ICU occupancy rate is 70 to 80 percent, which contradicts the claim that 100 percent of regular ICU beds are occupied. Additionally, hospitals are moving some ICU patients to beds not normally used for critical care, indicating they have space for surge patients, further contradicting the claim of full occupancy.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.47090259194374084,
    "x2e_entail_prob": 0.0016069228295236826
  },
  {
    "id": "covid_fact-001037",
    "statement": "Two percent of regular icu beds in texas medical center occupied, but hospitals have space for surge",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.",
      "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim suggests that only two percent of regular ICU beds at the Texas Medical Center are occupied, yet the evidence does not indicate this specific figure. Instead, it mentions an average ICU occupancy rate of 70 to 80 percent at the medical center. Additionally, it suggests hospitals have additional capacity. Without concrete evidence to support the 'two percent' figure, the claim is not fully supported.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.40401723980903625,
    "x2e_entail_prob": 0.005615521688014269
  },
  {
    "id": "covid_fact-001038",
    "statement": "One percent of regular icu beds in texas medical center occupied, but hospitals have space for surge",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.",
      "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not support the claim that only one percent of regular ICU beds in Texas Medical Center are occupied. The evidence mentions an average ICU occupancy rate of 70 to 80 percent, which contradicts the claim of only one percent occupancy. Additionally, hospitals are moving ICU patients to beds not normally used for critical care, indicating that regular ICU beds are likely highly occupied.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.9659210443496704,
    "x2e_entail_prob": 0.003341031027957797
  },
  {
    "id": "covid_fact-001039",
    "statement": "Five percent of regular icu beds in texas medical center occupied, but hospitals have space for surge",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.",
      "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence does not provide information that specifically confirms or denies the claim that five percent of regular ICU beds in Texas Medical Center are occupied. The evidence does mention that the average ICU occupancy rate is 70 to 80 percent, but does not specify the current percentage occupancy of regular ICU beds or confirm the five percent figure in the claim. Therefore, the claim is not sufficiently supported by the provided evidence.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.37623777985572815,
    "x2e_entail_prob": 0.004231539089232683
  },
  {
    "id": "covid_fact-001040",
    "statement": "U.s. to suspend visa services in virus-hit countries including japan",
    "label": "SUPPORTED",
    "evidences": [
      "(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.",
      "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.",
      "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.",
      "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that the U.S. will suspend routine nonimmigrant visa services in countries affected by COVID-19, including Japan, as mentioned in the claim. The U.S. Embassy in Tokyo confirmed the suspension of these services starting Thursday, aligning with the claim, thus supporting the suspension of visa services in virus-hit countries like Japan.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.7281786799430847,
    "x2e_entail_prob": 0.12207910418510437
  },
  {
    "id": "covid_fact-001041",
    "statement": "U.s. to provide visa services in virus-hit countries including japan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.",
      "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.",
      "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.",
      "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that the U.S. will suspend, not provide, routine nonimmigrant visa services in Japan due to COVID-19 challenges. This contradicts the claim that the U.S. is providing visa services in Japan. The claim is not supported by the given evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.19301770627498627,
    "x2e_entail_prob": 0.097012959420681
  },
  {
    "id": "covid_fact-001042",
    "statement": "U.s. to include visa services in virus-hit countries including japan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.",
      "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.",
      "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.",
      "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence shows that the U.S. is suspending visa services in Japan, contrary to the claim that the U.S. will include visa services in Japan. Visa services are being suspended in response to COVID-19, with Japan being subject to a Level 2 travel advisory. Thus, the claim is not supported by the evidence.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.5074946880340576,
    "x2e_entail_prob": 0.5813311338424683
  },
  {
    "id": "covid_fact-001043",
    "statement": "U.s. to create visa services in virus-hit countries including japan",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.",
      "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.",
      "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.",
      "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The claim states that the U.S. will create visa services in virus-hit countries, including Japan. However, the evidence indicates the opposite: the U.S. is suspending routine visa services in Japan and other countries due to COVID-19 challenges. This directly contradicts the claim that visa services are being created.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.029498914256691933,
    "x2e_entail_prob": 0.1043078675866127
  },
  {
    "id": "covid_fact-001044",
    "statement": "Chloroquine inhibits hmgb1 inflammatory signaling and protects mice from lethal sepsis",
    "label": "SUPPORTED",
    "evidences": [
      "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal Figure 3.",
      "Here, we show that chloroquine, an anti-malarial drug, prevents lethality in mice with established endotoxemia or sepsis.",
      "The protective effects of chloroquine were mediated through inhibition of HMGB1 release in macrophages, monocytes, and endothelial cells, thereby preventing its cytokine-like activities.",
      "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal ligation and puncture technique was used to induce intraabdominal sepsis in mice (n = 20 per group)."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The claim that chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis is well supported by the evidence. The provided evidence specifically states that chloroquine protects mice against lethal sepsis by mediating through the inhibition of HMGB1 release, which prevents its cytokine-like activities. Thus, both components of the claim are supported.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.8172467350959778,
    "x2e_entail_prob": 0.012195167131721973
  },
  {
    "id": "covid_fact-001045",
    "statement": "Chloroquine inhibits hmgb1 inflammatory signaling and protects humans from lethal sepsis",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal Figure 3.",
      "Here, we show that chloroquine, an anti-malarial drug, prevents lethality in mice with established endotoxemia or sepsis.",
      "The protective effects of chloroquine were mediated through inhibition of HMGB1 release in macrophages, monocytes, and endothelial cells, thereby preventing its cytokine-like activities.",
      "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal ligation and puncture technique was used to induce intraabdominal sepsis in mice (n = 20 per group)."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence provided shows that chloroquine inhibits HMGB1 release and protects mice from lethal sepsis, but it does not extend this finding to humans. Therefore, the claim that chloroquine protects humans from lethal sepsis is not supported by the evidence, which is based on mouse models.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.05073196813464165,
    "x2e_entail_prob": 0.014696599915623665
  },
  {
    "id": "covid_fact-001046",
    "statement": "Significant expression of furin and ace2 on oral epithelial cells may facilitate the efficiency of 2019-ncov entry",
    "label": "SUPPORTED",
    "evidences": [
      "Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.",
      "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.",
      "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.",
      "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence suggests that 2019-nCov could effectively invade oral mucosal cells through binding to the ACE2 receptor and membrane fusion activated by the FURIN protease. The differential expression of ACE2 and FURIN on epithelial cells, with a higher proportion of FURIN-positive cells, supports the claim that the expression of these proteins on oral epithelial cells may facilitate viral entry.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.9586169719696045,
    "x2e_entail_prob": 0.3443615734577179
  },
  {
    "id": "covid_fact-001047",
    "statement": "Significant expression of furin and ace2 on oral epithelial cells may reduce the efficiency of 2019-ncov entry",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.",
      "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.",
      "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.",
      "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that ACE2 and FURIN expression on oral epithelial cells facilitates, rather than reduces, 2019-nCov entry. High expression levels of these proteins on oral cells are posited to make them susceptible to infection, enabling entry of the virus. Therefore, the claim about these expressions reducing viral entry is not supported.",
    "confidence": 0.75,
    "e2x_entail_prob": 0.3412938416004181,
    "x2e_entail_prob": 0.07637359946966171
  },
  {
    "id": "covid_fact-001048",
    "statement": "Significant expression of furin and ace2 on oral epithelial cells may decrease the efficiency of 2019-ncov entry",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.",
      "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.",
      "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.",
      "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence suggests that ACE2 and FURIN are crucial for the entry of 2019-nCov into oral epithelial cells. However, it does not support the claim that significant expression of these proteins may decrease the efficiency of viral entry. In fact, the presence of ACE2 and FURIN appears to facilitate the virus entry rather than decrease its efficiency.",
    "confidence": 0.7,
    "e2x_entail_prob": 0.025253407657146454,
    "x2e_entail_prob": 0.09224547445774078
  },
  {
    "id": "covid_fact-001049",
    "statement": "Significant expression of furin and ace2 on oral epithelial cells may limit the efficiency of 2019-ncov entry",
    "label": "NOT_SUPPORTED",
    "evidences": [
      "Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.",
      "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.",
      "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.",
      "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."
    ],
    "model_verdict": "NOT_SUPPORTED",
    "explanation": "The evidence indicates that ACE2 and FURIN are expressed on oral epithelial cells and suggests that these cells are susceptible to 2019-nCov entry through these pathways. However, there is no direct evidence provided that this expression limits the efficiency of virus entry, only that it facilitates it. Thus, the claim is not supported by the evidence provided.",
    "confidence": 0.8,
    "e2x_entail_prob": 0.027711383998394012,
    "x2e_entail_prob": 0.051724765449762344
  },
  {
    "id": "covid_fact-001050",
    "statement": "High expression of angiotensin-converting enzyme-2 on tissue macrophages that may be targeted by virus sars-cov-2 in covid-19 patients",
    "label": "SUPPORTED",
    "evidences": [
      "Consequently, this broad expression of ACE2 associated with TMPRSS2 and FURIN may explain the high pathogenic potential of SARS-CoV-2 described in some COVID-19 patients with severe multi-organ dysfunction.",
      "Share High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 Share This Article: Copy Citation Tools High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 ",
      "These data indicate that alveolar macrophages, as the frontline immune cells, may be directly targeted by the SARS-CoV-2 infection and therefore need to be considered for the prevention and treatment of COVID-19.",
      "To better understand the pathogenesis of COVID-19 and build up the host anti-viral immunity, we examined the levels of ACE2 expression on different types of immune cells including tissue macrophages.",
      "Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin- converting enzyme 2."
    ],
    "model_verdict": "SUPPORTED",
    "explanation": "The evidence indicates that angiotensin-converting enzyme-2 (ACE2) is highly expressed on tissue macrophages, which may be targeted by SARS-CoV-2 in COVID-19 patients, as described in the study cited. This supports the claim that macrophages could be directly targeted during infection.",
    "confidence": 0.9,
    "e2x_entail_prob": 0.6747788190841675,
    "x2e_entail_prob": 0.011516135185956955
  }
]